No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 4e4nB, 1.0000, 0.00, 1.000, 280, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
2, 4ei4B, 0.9976, 0.30, 1.000, 280, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
3, 4ivdB, 0.9975, 0.31, 1.000, 280, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
4, 4k77B, 0.9967, 0.37, 1.000, 280, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
5, 4k77A, 0.9955, 0.47, 0.996, 282, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
6, 5wo4A, 0.9949, 0.51, 1.000, 292, 280, JAK1 COMPLEXED WITH COMPOUND 28
7, 5hx8A, 0.9947, 0.52, 1.000, 291, 280, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
8, 4ehzB, 0.9946, 0.46, 1.000, 280, 280, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
9, 4ivcB, 0.9944, 0.49, 1.000, 280, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
10, 4ivbB, 0.9943, 0.52, 1.000, 280, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
11, 4e4nA, 0.9940, 0.37, 0.996, 291, 279, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
12, 5wo4B, 0.9935, 0.57, 1.000, 280, 280, JAK1 COMPLEXED WITH COMPOUND 28
13, 4i5cA, 0.9933, 0.35, 1.000, 279, 279, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
14, 4ehzD, 0.9922, 0.56, 1.000, 280, 280, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
15, 4fk6B, 0.9913, 0.58, 1.000, 284, 280, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
16, 4ehzA, 0.9911, 0.46, 1.000, 290, 279, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
17, 5hx8B, 0.9910, 0.50, 0.996, 279, 279, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
18, 5e1eB, 0.9908, 0.51, 1.000, 280, 279, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
19, 5e1eA, 0.9908, 0.51, 1.000, 279, 279, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
20, 4ivdA, 0.9905, 0.30, 1.000, 290, 278, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
21, 4e4lE, 0.9901, 0.50, 1.000, 280, 279, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
22, 4i5cB, 0.9897, 0.62, 0.996, 291, 279, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
23, 4ivcA, 0.9895, 0.59, 0.996, 291, 279, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
24, 4ivbA, 0.9890, 0.64, 0.996, 291, 279, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
25, 4ehzC, 0.9878, 0.44, 1.000, 278, 278, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
26, 4e4lB, 0.9873, 0.47, 1.000, 279, 278, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
27, 4ei4A, 0.9870, 0.29, 1.000, 289, 277, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
28, 4e5wA, 0.9870, 0.69, 1.000, 292, 279, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
29, 4e4lD, 0.9869, 0.49, 1.000, 281, 278, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
30, 4fk6A, 0.9848, 0.56, 1.000, 285, 278, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
31, 4e4lA, 0.9826, 0.52, 1.000, 277, 277, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
32, 4k6zA, 0.9824, 0.81, 0.996, 279, 279, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
33, 6bbuA, 0.9801, 0.76, 1.000, 279, 278, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH COMPOUND 25
34, 4e5wB, 0.9798, 0.69, 1.000, 278, 277, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
35, 3q32B, 0.9769, 0.99, 0.554, 294, 280, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
36, 3krrA, 0.9766, 1.00, 0.554, 291, 280, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
37, 5cf4B, 0.9760, 1.01, 0.557, 291, 280, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
38, 4zimB, 0.9758, 1.01, 0.557, 294, 280, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
39, 4aqcB, 0.9755, 1.06, 0.557, 295, 280, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
40, 3e64A, 0.9750, 1.03, 0.554, 291, 280, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
41, 5cf5B, 0.9747, 1.03, 0.557, 294, 280, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
42, 4ji9B, 0.9746, 1.10, 0.557, 288, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
43, 4e6qB, 0.9746, 1.04, 0.568, 296, 280, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
44, 4d0xA, 0.9741, 1.05, 0.554, 291, 280, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
45, 3tjdB, 0.9738, 1.03, 0.559, 287, 279, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
46, 5cf6B, 0.9737, 1.05, 0.554, 290, 280, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
47, 3e62A, 0.9735, 1.08, 0.554, 291, 280, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
48, 4e6qA, 0.9734, 1.06, 0.568, 296, 280, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
49, 3tjcB, 0.9732, 1.05, 0.559, 287, 279, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
50, 4hgeB, 0.9731, 1.15, 0.554, 288, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
51, 3q32A, 0.9730, 1.00, 0.552, 291, 279, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
52, 5cf8B, 0.9725, 1.01, 0.559, 288, 279, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
53, 4e6dB, 0.9711, 0.99, 0.572, 286, 278, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
54, 4d0wA, 0.9711, 1.04, 0.556, 289, 279, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
55, 3fupB, 0.9707, 1.11, 0.559, 287, 279, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
56, 5aepA, 0.9705, 1.05, 0.556, 287, 279, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
57, 2b7aB, 0.9701, 1.11, 0.559, 287, 279, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
58, 4gfmA, 0.9687, 1.13, 0.556, 289, 279, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
59, 3eygA, 0.9687, 1.20, 1.000, 280, 279, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
60, 4p7eB, 0.9683, 1.09, 0.558, 285, 278, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
61, 3e63A, 0.9682, 1.14, 0.556, 290, 279, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
62, 3eyhA, 0.9680, 1.31, 0.996, 285, 280, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
63, 4bbfA, 0.9679, 1.03, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
64, 4e4mA, 0.9678, 1.24, 0.554, 296, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
65, 4bbfD, 0.9678, 1.03, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
66, 4e4mE, 0.9677, 1.24, 0.554, 296, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
67, 4e6dA, 0.9674, 1.09, 0.572, 286, 278, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
68, 4zimA, 0.9667, 0.98, 0.549, 285, 277, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
69, 4ivaA, 0.9657, 1.10, 0.550, 290, 278, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
70, 5khwB, 0.9654, 0.85, 0.996, 276, 275, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
71, 4f08A, 0.9653, 0.95, 0.551, 288, 276, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
72, 4aqcA, 0.9647, 1.07, 0.552, 289, 277, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
73, 5cf6A, 0.9645, 1.03, 0.556, 285, 277, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
74, 4f08B, 0.9644, 1.00, 0.551, 288, 276, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
75, 3tjdA, 0.9640, 1.02, 0.554, 284, 276, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
76, 5cf5A, 0.9636, 1.05, 0.556, 287, 277, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
77, 3lpbB, 0.9634, 0.97, 0.562, 284, 276, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
78, 4e4mD, 0.9631, 1.31, 0.550, 296, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
79, 4e4mB, 0.9625, 1.32, 0.550, 296, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
80, 4ytiA, 0.9624, 1.09, 0.549, 284, 277, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
81, 4f09A, 0.9621, 1.01, 0.554, 288, 276, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
82, 5tq8A, 0.9619, 1.28, 0.554, 291, 278, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
83, 3tjcA, 0.9615, 1.09, 0.554, 284, 276, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
84, 5tq5A, 0.9603, 1.34, 0.554, 291, 278, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
85, 5cf8A, 0.9602, 1.07, 0.558, 285, 276, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
86, 4ji9A, 0.9601, 1.10, 0.551, 284, 276, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
87, 4gmyA, 0.9599, 1.32, 0.550, 298, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
88, 3fupA, 0.9596, 1.13, 0.554, 284, 276, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
89, 4hgeA, 0.9592, 1.15, 0.551, 284, 276, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
90, 5khxA, 0.9591, 0.76, 1.000, 276, 272, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
91, 4ythA, 0.9591, 1.15, 0.552, 287, 277, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
92, 2b7aA, 0.9591, 1.15, 0.554, 284, 276, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
93, 4jiaA, 0.9586, 1.34, 0.557, 298, 280, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
94, 5cf4A, 0.9585, 1.12, 0.551, 283, 276, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
95, 4p7eA, 0.9579, 1.00, 0.558, 281, 274, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
96, 4bbeC, 0.9570, 1.25, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
97, 6bbvA, 0.9569, 1.24, 0.554, 289, 276, CRYSTAL STRUCTURE OF JAK2 IN COMPLEX WITH COMPOUND 25
98, 3io7A, 0.9568, 1.05, 0.549, 282, 275, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
99, 4bbeB, 0.9567, 1.25, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
100, 4ytcA, 0.9566, 1.05, 0.549, 284, 275, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
101, 4py1A, 0.9563, 1.19, 0.594, 289, 276, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
102, 4bbfB, 0.9558, 1.26, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
103, 4bbfC, 0.9555, 1.26, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
104, 4ytfA, 0.9550, 1.09, 0.549, 283, 275, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
105, 4gvjA, 0.9549, 1.22, 0.591, 290, 276, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
106, 5khwA, 0.9546, 1.11, 1.000, 276, 275, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
107, 3iokA, 0.9546, 1.09, 0.549, 285, 275, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
108, 6gl9B, 0.9541, 1.40, 0.522, 291, 278, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
109, 4gl9D, 0.9541, 1.23, 0.551, 282, 276, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
110, 6gl9A, 0.9537, 1.45, 0.520, 292, 279, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
111, 2w1iA, 0.9537, 1.25, 0.551, 284, 276, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
112, 4bbeD, 0.9535, 1.30, 0.543, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
113, 5l3aA, 0.9534, 1.31, 0.558, 290, 278, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
114, 4bbeA, 0.9533, 1.31, 0.547, 288, 278, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
115, 3kckA, 0.9533, 1.12, 0.549, 285, 275, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
116, 3jy9A, 0.9532, 1.11, 0.549, 282, 275, JANUS KINASE 2 INHIBITORS
117, 2w1iB, 0.9528, 1.26, 0.547, 284, 276, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
118, 3rvgA, 0.9515, 1.03, 0.560, 285, 273, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
119, 4rioA, 0.9514, 1.43, 0.522, 285, 276, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
120, 4gihA, 0.9507, 1.24, 0.589, 288, 275, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
121, 4gj2A, 0.9500, 1.25, 0.589, 288, 275, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
122, 5lwnA, 0.9495, 1.43, 0.520, 290, 277, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
123, 3zc6B, 0.9495, 1.11, 0.535, 276, 273, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
124, 4gl9C, 0.9490, 1.33, 0.547, 282, 276, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
125, 4gj3A, 0.9489, 1.26, 0.589, 288, 275, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
126, 4giiA, 0.9489, 1.27, 0.589, 289, 275, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
127, 5wevA, 0.9487, 1.34, 0.556, 293, 277, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
128, 3zc6A, 0.9481, 1.29, 0.529, 277, 274, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
129, 5lwmA, 0.9479, 1.46, 0.520, 290, 277, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
130, 3lxnA, 0.9479, 1.35, 0.596, 287, 275, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
131, 4e1zA, 0.9477, 1.40, 0.574, 288, 277, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
132, 3lpbA, 0.9476, 1.06, 0.562, 278, 272, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
133, 5tq3B, 0.9475, 1.25, 0.555, 285, 274, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
134, 4gl9A, 0.9473, 1.36, 0.547, 282, 276, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
135, 1yvjA, 0.9458, 1.74, 0.522, 288, 278, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
136, 3zc6C, 0.9453, 1.12, 0.533, 275, 272, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
137, 4gl9B, 0.9451, 1.29, 0.558, 280, 274, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
138, 5usyA, 0.9450, 1.45, 0.558, 287, 276, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
139, 3pjcA, 0.9446, 1.64, 0.520, 286, 277, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
140, 6glaA, 0.9444, 1.46, 0.525, 288, 276, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
141, 6glbB, 0.9443, 1.44, 0.525, 288, 276, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
142, 3lxlA, 0.9443, 1.15, 0.533, 281, 272, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
143, 5tozA, 0.9438, 1.33, 0.524, 278, 273, JAK3 WITH COVALENT INHIBITOR PF-06651600
144, 6glbA, 0.9432, 1.45, 0.525, 288, 276, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
145, 6glaB, 0.9431, 1.34, 0.524, 286, 275, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
146, 6c7yA, 0.9428, 1.20, 0.993, 273, 272, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS1 IN COMPLEX WITH JAK1 KINASE DOMAIN 
147, 5walA, 0.9424, 1.34, 0.588, 286, 274, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
148, 4hvgA, 0.9423, 1.28, 0.527, 281, 273, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
149, 5ttvA, 0.9416, 1.60, 0.529, 280, 274, JAK3 WITH COVALENT INHIBITOR 6
150, 4e20A, 0.9412, 1.30, 0.593, 282, 273, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
151, 5ttsA, 0.9405, 1.23, 0.531, 274, 271, JAK3 WITH COVALENT INHIBITOR 4
152, 5tq3A, 0.9398, 1.17, 0.557, 282, 271, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
153, 4hvhA, 0.9391, 1.15, 0.531, 278, 271, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
154, 5tq7A, 0.9389, 1.00, 0.565, 275, 269, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
155, 4c61B, 0.9387, 1.08, 0.559, 274, 270, INHIBITORS OF JAK2 KINASE DOMAIN
156, 3lxkA, 0.9386, 1.14, 0.530, 279, 270, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
157, 4i6qA, 0.9385, 1.09, 0.530, 277, 270, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
158, 2xa4A, 0.9384, 1.13, 0.552, 276, 270, INHIBITORS OF JAK2 KINASE DOMAIN
159, 5usyB, 0.9382, 1.64, 0.558, 287, 276, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
160, 2xa4B, 0.9379, 1.17, 0.557, 275, 271, INHIBITORS OF JAK2 KINASE DOMAIN
161, 5tq4A, 0.9377, 1.72, 0.550, 290, 278, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
162, 3zmmB, 0.9375, 1.10, 0.559, 274, 270, INHIBITORS OF JAK2 KINASE DOMAIN
163, 3zepC, 0.9370, 1.21, 0.528, 276, 271, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
164, 4hviA, 0.9360, 1.20, 0.530, 274, 270, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
165, 4hvdA, 0.9360, 1.14, 0.530, 276, 270, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
166, 6drwA, 0.9349, 1.53, 0.562, 289, 274, JAK2 JH1 IN COMPLEX WITH JNJ-7706621 (CRYSTAL FORM 2) 
167, 4qt1A, 0.9342, 1.16, 0.533, 277, 270, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
168, 5tq6A, 0.9331, 0.99, 0.562, 274, 267, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
169, 3nz0A, 0.9330, 1.30, 0.594, 285, 271, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
170, 4d1sA, 0.9317, 1.19, 0.567, 280, 270, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
171, 3zepA, 0.9315, 1.33, 0.535, 274, 271, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
172, 5f1zA, 0.9313, 1.59, 0.595, 281, 274, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
173, 4z16B, 0.9311, 1.20, 0.533, 276, 270, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
174, 3zmmA, 0.9305, 1.00, 0.554, 273, 267, INHIBITORS OF JAK2 KINASE DOMAIN
175, 4c62B, 0.9301, 1.01, 0.558, 271, 267, INHIBITORS OF JAK2 KINASE DOMAIN
176, 4c62A, 0.9297, 1.02, 0.554, 273, 267, INHIBITORS OF JAK2 KINASE DOMAIN
177, 5tq6B, 0.9290, 1.02, 0.564, 271, 266, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
178, 5w86D, 0.9286, 1.46, 0.528, 272, 271, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
179, 3zepD, 0.9276, 1.28, 0.539, 272, 269, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
180, 5ttuA, 0.9275, 1.02, 0.530, 271, 266, JAK3 WITH COVALENT INHIBITOR 7
181, 4c61A, 0.9268, 1.01, 0.556, 272, 266, INHIBITORS OF JAK2 KINASE DOMAIN
182, 5tq7B, 0.9263, 0.93, 0.558, 269, 265, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
183, 3zc6D, 0.9254, 0.90, 0.542, 267, 264, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
184, 4qpsC, 0.9241, 1.36, 0.537, 276, 268, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
185, 5f20A, 0.9226, 1.49, 0.604, 274, 270, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
186, 5w86C, 0.9224, 1.66, 0.537, 273, 270, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
187, 3zepB, 0.9209, 1.06, 0.540, 268, 265, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
188, 4v0gB, 0.9207, 1.41, 0.528, 272, 269, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
189, 3lxpA, 0.9171, 1.71, 0.585, 285, 272, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
190, 4qpsA, 0.9167, 1.53, 0.528, 270, 269, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
191, 4oliA, 0.9167, 1.29, 0.605, 539, 266, THE PSEUDOKINASE/KINASE PROTEIN FROM JAK-FAMILY MEMBER TYK2
192, 4z16A, 0.9160, 1.15, 0.540, 271, 265, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
193, 4z16C, 0.9155, 1.16, 0.540, 271, 265, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
194, 5vo6A, 0.9138, 1.11, 0.536, 271, 263, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
195, 5w86A, 0.9133, 1.40, 0.530, 269, 266, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
196, 4z16D, 0.9126, 1.22, 0.540, 271, 265, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
197, 4gfoA, 0.9098, 1.46, 0.605, 272, 266, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
198, 5wfjA, 0.9072, 1.62, 0.534, 265, 264, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
199, 4v0gA, 0.9072, 1.30, 0.534, 267, 264, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
200, 5w86B, 0.9035, 1.61, 0.534, 267, 264, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
201, 3nyxA, 0.9031, 2.07, 0.568, 287, 273, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
202, 3ugcA, 0.8868, 1.75, 0.557, 274, 262, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
203, 4g5pA, 0.8843, 2.02, 0.360, 299, 264, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
204, 2jitA, 0.8811, 2.10, 0.355, 299, 265, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
205, 5xgnA, 0.8808, 1.90, 0.363, 302, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
206, 5hezD, 0.8808, 1.92, 0.533, 289, 261, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
207, 5hezC, 0.8805, 1.95, 0.536, 289, 261, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
208, 4lrmE, 0.8803, 2.01, 0.356, 290, 264, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
209, 4lrmC, 0.8802, 2.13, 0.358, 293, 265, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
210, 2jiuA, 0.8778, 2.07, 0.360, 303, 264, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
211, 5hezB, 0.8777, 2.10, 0.534, 289, 262, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
212, 4rixD, 0.8774, 1.88, 0.360, 297, 261, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
213, 3ikaA, 0.8772, 2.04, 0.361, 310, 263, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
214, 5hezA, 0.8768, 2.01, 0.533, 287, 261, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
215, 4riyD, 0.8768, 2.00, 0.359, 297, 262, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
216, 4lrmD, 0.8766, 2.19, 0.356, 289, 264, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
217, 4lrmA, 0.8766, 2.21, 0.355, 307, 265, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
218, 5jebA, 0.8731, 2.20, 0.361, 299, 263, CRYSTAL STRUCTURE OF EGFR TYROSINE KINASE DOMAIN WITH NOVEL INHIBITOR OF ACTIVE STATE OF HER2
219, 4riwD, 0.8723, 2.08, 0.359, 297, 262, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
220, 4lrmB, 0.8713, 2.31, 0.356, 293, 264, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
221, 5cy3A, 0.8706, 2.17, 0.359, 276, 262, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
222, 2ivuA, 0.8676, 2.02, 0.359, 288, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
223, 4ckjA, 0.8675, 2.04, 0.359, 292, 262, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
224, 4li5A, 0.8660, 2.07, 0.356, 306, 261, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
225, 4wd5A, 0.8640, 2.18, 0.359, 307, 262, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
226, 2x2kA, 0.8639, 2.11, 0.363, 289, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
227, 2ivtA, 0.8638, 2.11, 0.363, 288, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
228, 3gqiA, 0.8635, 2.02, 0.387, 304, 261, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
229, 2x2lA, 0.8632, 2.11, 0.363, 287, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
230, 4ckiA, 0.8631, 2.19, 0.363, 293, 262, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
231, 4ewhA, 0.8628, 2.08, 0.360, 274, 261, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
232, 5amnA, 0.8624, 2.07, 0.360, 287, 261, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
233, 3pp0B, 0.8622, 2.23, 0.338, 296, 263, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
234, 4ewhB, 0.8621, 2.09, 0.360, 273, 261, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
235, 5eg3A, 0.8620, 1.99, 0.379, 301, 261, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
236, 3bkbA, 0.8616, 2.15, 0.340, 373, 262, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)
237, 3bceB, 0.8616, 2.20, 0.387, 286, 261, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
238, 2ivsA, 0.8607, 2.05, 0.364, 284, 261, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
239, 4riyB, 0.8606, 1.96, 0.364, 293, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
240, 4rixB, 0.8604, 2.00, 0.364, 293, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
241, 4jq8A, 0.8594, 2.16, 0.356, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
242, 3bceC, 0.8593, 2.26, 0.393, 286, 262, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
243, 5cxzA, 0.8591, 2.03, 0.364, 269, 258, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
244, 2qohB, 0.8587, 2.07, 0.362, 281, 260, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
245, 1pkgA, 0.8582, 2.25, 0.355, 290, 262, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
246, 2x2mA, 0.8577, 2.04, 0.359, 286, 259, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
247, 2ivvA, 0.8577, 2.03, 0.367, 282, 259, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
248, 3eqrA, 0.8576, 2.21, 0.360, 270, 261, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
249, 4wnmA, 0.8573, 2.12, 0.363, 273, 259, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
250, 2z60A, 0.8573, 2.12, 0.362, 281, 260, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
251, 3cblA, 0.8571, 2.20, 0.340, 356, 262, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
252, 5lmbA, 0.8569, 2.02, 0.366, 264, 257, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
253, 3pp0A, 0.8568, 2.21, 0.337, 286, 261, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
254, 4jq7A, 0.8567, 2.21, 0.356, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
255, 6fekA, 0.8566, 2.16, 0.360, 294, 261, ONCOGENIC POINT MUTATION OF RET RECEPTOR TYROSINE KINASE
256, 4jr3A, 0.8563, 2.22, 0.356, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
257, 5y5uA, 0.8560, 2.16, 0.367, 266, 259, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
258, 3kulB, 0.8559, 2.08, 0.335, 271, 260, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
259, 3dqwC, 0.8559, 1.85, 0.345, 275, 258, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
260, 3dqwD, 0.8558, 1.97, 0.347, 276, 259, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
261, 3bceA, 0.8558, 2.30, 0.387, 285, 261, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
262, 2g2hB, 0.8558, 2.06, 0.362, 272, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
263, 5flfD, 0.8556, 2.19, 0.385, 290, 262, DISEASE LINKED MUTATION IN FGFR
264, 4riwB, 0.8554, 2.07, 0.364, 293, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
265, 2qohA, 0.8552, 2.13, 0.362, 271, 260, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
266, 2j6mA, 0.8552, 2.31, 0.359, 306, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
267, 4jrvA, 0.8549, 2.24, 0.356, 300, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
268, 5tr6A, 0.8548, 2.19, 0.363, 272, 259, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
269, 2itpA, 0.8548, 2.28, 0.356, 305, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
270, 3srvB, 0.8546, 2.12, 0.364, 263, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
271, 5flfA, 0.8542, 2.24, 0.385, 296, 262, DISEASE LINKED MUTATION IN FGFR
272, 5cxhA, 0.8542, 2.17, 0.363, 277, 259, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
273, 1m17A, 0.8541, 2.23, 0.360, 312, 261, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
274, 4rx7A, 0.8538, 2.16, 0.363, 272, 259, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
275, 5ugbA, 0.8537, 2.25, 0.356, 307, 261, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
276, 5ui0B, 0.8536, 2.15, 0.379, 304, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
277, 4tksA, 0.8535, 2.25, 0.360, 307, 261, NATIVE-SAD PHASING FOR HUMAN EGFR KINASE DOMAIN.
278, 1u59A, 0.8535, 2.18, 0.350, 282, 260, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
279, 4k33A, 0.8533, 2.14, 0.372, 293, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
280, 3srvA, 0.8529, 1.91, 0.365, 262, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
281, 5cavA, 0.8527, 2.30, 0.356, 306, 261, EGFR KINASE DOMAIN WITH COMPOUND 41A
282, 3vf8A, 0.8527, 2.18, 0.364, 265, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
283, 3eqrB, 0.8525, 2.16, 0.363, 271, 259, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
284, 1m14A, 0.8525, 2.25, 0.350, 307, 260, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
285, 4j98B, 0.8524, 2.17, 0.379, 304, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
286, 4j96B, 0.8524, 2.16, 0.383, 305, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
287, 4gfgA, 0.8524, 2.16, 0.363, 277, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
288, 3clyA, 0.8524, 2.23, 0.369, 289, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
289, 2f4jA, 0.8524, 2.30, 0.366, 287, 262, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
290, 3r7oA, 0.8522, 2.16, 0.333, 299, 258, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
291, 3cd3A, 0.8522, 2.22, 0.345, 352, 261, CRYSTAL STRUCTURE OF PHOSPHORYLATED HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V-FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
292, 1xbaA, 0.8520, 2.18, 0.364, 266, 258, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
293, 2j5eA, 0.8519, 2.22, 0.340, 309, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
294, 1xbcA, 0.8518, 2.19, 0.364, 268, 258, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
295, 3eqpB, 0.8515, 2.27, 0.354, 270, 260, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
296, 4id7A, 0.8513, 2.09, 0.337, 268, 258, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
297, 2itqA, 0.8513, 2.31, 0.356, 300, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
298, 2g2fA, 0.8513, 2.21, 0.364, 275, 261, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
299, 2dq7X, 0.8512, 2.03, 0.337, 262, 258, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
300, 5lmaA, 0.8511, 2.11, 0.366, 267, 257, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
301, 5hg7A, 0.8510, 2.39, 0.364, 280, 261, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-{(3R4R)-3-[5-CHLORO-2- (1-METHYL-1H-PYRAZOL-4-YLAMINO)-7H-PYRROLO[23-D]PYRIMIDIN-4- YLOXYMETHYL]-4-METHOXY-PYRROLIDIN-1-YL}PROPENONE (PF-06459988)
302, 5ugaA, 0.8509, 2.33, 0.359, 283, 262, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH 4-(4-{[2-{[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9- (PROPAN-2-YL)-9H-PURIN-6-YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
303, 2v7aA, 0.8509, 2.10, 0.351, 269, 259, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
304, 2fo0A, 0.8509, 2.20, 0.360, 465, 261, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
305, 4ll0A, 0.8508, 1.76, 0.372, 291, 253, EGFR L858R/T790M IN COMPLEX WITH PD168393
306, 3q6wA, 0.8507, 2.20, 0.333, 297, 258, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
307, 4xg3B, 0.8505, 2.02, 0.367, 267, 256, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
308, 1m52A, 0.8505, 2.26, 0.356, 271, 261, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
309, 2gqgB, 0.8504, 2.18, 0.354, 276, 260, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
310, 5c26A, 0.8503, 2.21, 0.363, 272, 259, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
311, 1u4dB, 0.8503, 2.09, 0.359, 262, 256, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
312, 5ui0A, 0.8500, 2.18, 0.379, 301, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
313, 1qpjA, 0.8500, 1.97, 0.364, 265, 258, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
314, 5u6bB, 0.8499, 2.09, 0.314, 291, 258, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
315, 2gs6A, 0.8498, 2.30, 0.342, 311, 260, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
316, 4twpB, 0.8497, 2.19, 0.365, 271, 260, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
317, 3ue4A, 0.8497, 2.11, 0.369, 270, 260, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
318, 6bl8A, 0.8496, 2.17, 0.362, 270, 260, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
319, 5hg5A, 0.8495, 2.36, 0.359, 302, 262, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
320, 5u8lA, 0.8492, 2.36, 0.363, 289, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH A SULFONYL FLUORIDE PROBE XO44
321, 5u6bD, 0.8492, 2.11, 0.314, 291, 258, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
322, 3lcdA, 0.8490, 2.16, 0.332, 290, 259, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
323, 3eqpA, 0.8490, 2.30, 0.354, 268, 260, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
324, 2hz4B, 0.8489, 1.97, 0.367, 261, 256, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
325, 5c27A, 0.8488, 2.26, 0.363, 272, 259, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
326, 1oplB, 0.8484, 2.21, 0.362, 365, 260, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
327, 3hmiA, 0.8483, 2.09, 0.351, 268, 259, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
328, 4rx8A, 0.8482, 2.16, 0.370, 269, 257, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
329, 3vf9A, 0.8482, 2.15, 0.366, 265, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
330, 5ugcA, 0.8481, 2.55, 0.363, 280, 262, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-METHYL-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
331, 5hg9A, 0.8480, 2.58, 0.365, 280, 263, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-[(3R4R)-3-[({2-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY) METHYL]-4-(TRIFLUOROMETHYL)PYRROLIDIN-1-YL]PROP-2-EN-1-ONE
332, 4puzB, 0.8480, 1.97, 0.373, 265, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
333, 2x2mB, 0.8480, 2.05, 0.359, 279, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
334, 4zogB, 0.8479, 1.97, 0.358, 268, 257, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
335, 2hziB, 0.8479, 2.07, 0.364, 264, 258, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
336, 5hg8A, 0.8478, 2.39, 0.359, 300, 262, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
337, 5flfB, 0.8478, 2.32, 0.385, 292, 262, DISEASE LINKED MUTATION IN FGFR
338, 4xg3A, 0.8478, 1.98, 0.362, 262, 254, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
339, 2pvfA, 0.8478, 2.17, 0.386, 285, 259, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
340, 5tt7A, 0.8477, 2.23, 0.362, 274, 257, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
341, 4zjvA, 0.8477, 2.40, 0.355, 282, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH MITOGEN- INDUCIBLE GENE 6 PROTEIN
342, 1m52B, 0.8476, 2.31, 0.356, 272, 261, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
343, 5ug9A, 0.8475, 2.46, 0.360, 280, 261, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
344, 3dk7B, 0.8475, 2.04, 0.362, 268, 257, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
345, 5xdkA, 0.8473, 2.38, 0.360, 307, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
346, 2itwA, 0.8473, 2.36, 0.350, 300, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
347, 4ll0B, 0.8469, 1.77, 0.373, 281, 252, EGFR L858R/T790M IN COMPLEX WITH PD168393
348, 4i23A, 0.8468, 2.24, 0.357, 304, 258, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
349, 2xynA, 0.8466, 2.26, 0.346, 264, 260, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
350, 1opkA, 0.8466, 2.30, 0.352, 449, 261, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
351, 4xg6A, 0.8465, 1.96, 0.369, 271, 255, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
352, 2jitB, 0.8464, 2.28, 0.309, 312, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
353, 3kulA, 0.8463, 2.00, 0.336, 267, 256, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
354, 2hz0A, 0.8463, 2.14, 0.358, 265, 257, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
355, 4rssA, 0.8462, 2.19, 0.364, 269, 258, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
356, 3dk3B, 0.8462, 2.03, 0.362, 269, 257, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
357, 5ug8A, 0.8461, 2.48, 0.360, 280, 261, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
358, 2jiuB, 0.8461, 2.30, 0.305, 309, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
359, 4xliA, 0.8460, 2.20, 0.359, 264, 259, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
360, 4j98A, 0.8458, 2.25, 0.379, 304, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
361, 2ofuA, 0.8458, 2.20, 0.365, 272, 260, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
362, 5hibA, 0.8457, 2.26, 0.364, 314, 258, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
363, 1oplA, 0.8456, 2.31, 0.364, 451, 261, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
364, 4xg9B, 0.8455, 2.00, 0.369, 265, 255, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
365, 1qpdA, 0.8455, 2.20, 0.365, 270, 260, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
366, 4pv0A, 0.8454, 2.31, 0.364, 268, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
367, 4j96A, 0.8454, 2.25, 0.379, 302, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
368, 2g2hA, 0.8452, 2.30, 0.350, 272, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
369, 1u54B, 0.8450, 1.99, 0.354, 261, 254, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
370, 4iwdA, 0.8449, 2.30, 0.333, 299, 258, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
371, 5lmbB, 0.8448, 1.96, 0.372, 261, 253, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
372, 4puzA, 0.8447, 2.13, 0.371, 263, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
373, 5j9yA, 0.8444, 2.33, 0.377, 300, 260, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
374, 4xg4A, 0.8444, 2.15, 0.371, 264, 256, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
375, 2j0lA, 0.8441, 2.21, 0.358, 274, 260, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
376, 3fqhA, 0.8440, 1.96, 0.364, 262, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
377, 2g2fB, 0.8440, 1.86, 0.350, 264, 254, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
378, 2gs2A, 0.8439, 2.41, 0.342, 305, 260, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
379, 4dfnA, 0.8438, 2.29, 0.357, 269, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
380, 3kxzA, 0.8438, 1.99, 0.370, 263, 257, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
381, 3kxxA, 0.8438, 2.28, 0.383, 305, 261, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
382, 5em8A, 0.8437, 2.46, 0.356, 303, 261, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
383, 3vjnA, 0.8437, 2.27, 0.353, 297, 258, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
384, 3bymA, 0.8435, 2.23, 0.365, 271, 260, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
385, 2gqgA, 0.8433, 2.27, 0.358, 277, 260, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
386, 4twpA, 0.8432, 2.18, 0.366, 266, 257, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
387, 4r3pA, 0.8432, 2.46, 0.341, 310, 261, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
388, 4i21B, 0.8432, 2.52, 0.357, 302, 263, CRYSTAL STRUCTURE OF L858R + T790M EGFR KINASE DOMAIN IN COMPLEX WITH MIG6 PEPTIDE
389, 2of4A, 0.8432, 2.30, 0.360, 271, 261, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
390, 4i21A, 0.8431, 2.52, 0.357, 290, 263, CRYSTAL STRUCTURE OF L858R + T790M EGFR KINASE DOMAIN IN COMPLEX WITH MIG6 PEPTIDE
391, 2g2iB, 0.8430, 2.24, 0.364, 265, 258, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
392, 2g2iA, 0.8430, 2.22, 0.371, 271, 259, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
393, 2hziA, 0.8428, 2.25, 0.362, 268, 260, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
394, 3fqeA, 0.8427, 2.21, 0.371, 269, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
395, 1qpcA, 0.8427, 2.24, 0.369, 270, 260, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
396, 5ghvB, 0.8426, 2.15, 0.367, 265, 256, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
397, 5ghvA, 0.8426, 2.14, 0.367, 265, 256, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
398, 2v7aB, 0.8425, 2.24, 0.355, 268, 259, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
399, 4wa9B, 0.8424, 2.17, 0.355, 276, 259, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
400, 3kmmA, 0.8424, 2.25, 0.369, 270, 260, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
401, 3dqwA, 0.8423, 2.19, 0.347, 278, 259, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
402, 1y57A, 0.8423, 2.24, 0.344, 452, 259, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
403, 3w2oA, 0.8422, 2.45, 0.331, 305, 260, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
404, 3ac1A, 0.8419, 2.25, 0.369, 270, 260, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
405, 4xliB, 0.8416, 2.17, 0.362, 264, 257, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
406, 4j95B, 0.8416, 2.35, 0.379, 282, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
407, 4px6A, 0.8415, 2.16, 0.373, 262, 255, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
408, 4zogA, 0.8414, 2.25, 0.363, 269, 259, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
409, 4wkqA, 0.8413, 2.28, 0.355, 296, 256, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
410, 5ugxA, 0.8412, 2.36, 0.375, 297, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
411, 5y9tA, 0.8410, 2.48, 0.364, 300, 261, CRYSTAL STRUCTURE OF EGFR T790M MUTANT IN COMPLEX WITH NAQUOTINIB 
412, 3ac5A, 0.8409, 2.27, 0.369, 270, 260, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
413, 5y5tA, 0.8408, 2.21, 0.357, 263, 255, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
414, 3kxxB, 0.8406, 2.32, 0.383, 305, 261, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
415, 1k9aB, 0.8406, 1.71, 0.348, 441, 250, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
416, 6bl8B, 0.8405, 2.04, 0.348, 268, 256, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
417, 2of2A, 0.8405, 2.34, 0.360, 271, 261, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
418, 4j97C, 0.8404, 2.20, 0.376, 283, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
419, 5czhA, 0.8403, 2.53, 0.345, 311, 261, EGFR L858R MUTANT IN COMPLEX WITH AN OPTIMAL PEPTIDE SUBSTRATE
420, 4j99D, 0.8403, 2.20, 0.391, 281, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
421, 3dqwB, 0.8403, 2.21, 0.347, 278, 259, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
422, 3w2qA, 0.8401, 2.46, 0.360, 307, 261, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
423, 2zm4A, 0.8401, 2.28, 0.365, 270, 260, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
424, 2zm1A, 0.8401, 2.29, 0.369, 270, 260, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
425, 4hzrA, 0.8399, 2.07, 0.354, 261, 254, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
426, 2xynC, 0.8399, 2.29, 0.351, 262, 259, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
427, 4fl1A, 0.8398, 2.42, 0.367, 268, 259, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
428, 3ackA, 0.8398, 2.29, 0.365, 270, 260, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
429, 3ac3A, 0.8398, 2.29, 0.365, 270, 260, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
430, 3ac2A, 0.8398, 2.28, 0.369, 270, 260, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
431, 3ad4A, 0.8396, 2.29, 0.369, 270, 260, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
432, 3acjA, 0.8396, 2.29, 0.369, 270, 260, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
433, 4xeyA, 0.8395, 2.18, 0.354, 269, 257, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
434, 4j99B, 0.8394, 2.40, 0.379, 291, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
435, 3ue4B, 0.8393, 2.17, 0.372, 268, 258, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
436, 3lckA, 0.8393, 2.30, 0.365, 270, 260, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
437, 3kf4A, 0.8393, 2.41, 0.363, 281, 259, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
438, 6d8eA, 0.8392, 2.33, 0.368, 304, 258, DISCOVERY OF A HIGHLY POTENT AND BROADLY EFFECTIVE EGFR AND HER2 EXON 20 INSERTION MUTANT INHIBITOR 
439, 3ad6A, 0.8392, 2.30, 0.369, 272, 260, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
440, 3ac4A, 0.8392, 2.29, 0.365, 270, 260, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
441, 1qpeA, 0.8392, 2.29, 0.369, 270, 260, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
442, 5flfC, 0.8390, 2.48, 0.368, 283, 261, DISEASE LINKED MUTATION IN FGFR
443, 3vjoA, 0.8390, 2.43, 0.351, 298, 259, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
444, 1u54A, 0.8390, 2.08, 0.354, 262, 254, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
445, 4zjvB, 0.8388, 2.32, 0.355, 273, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH MITOGEN- INDUCIBLE GENE 6 PROTEIN
446, 3b2tA, 0.8388, 2.35, 0.373, 288, 260, STRUCTURE OF PHOSPHOTRANSFERASE
447, 3ad5A, 0.8388, 2.30, 0.369, 270, 260, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
448, 2zybA, 0.8388, 2.30, 0.369, 270, 260, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
449, 5cziA, 0.8387, 2.49, 0.324, 310, 259, EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE
450, 4rx9A, 0.8386, 2.25, 0.369, 268, 255, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
451, 3dk7A, 0.8386, 2.17, 0.362, 265, 257, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
452, 3ac8A, 0.8386, 2.30, 0.369, 270, 260, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
453, 1u4dA, 0.8385, 2.11, 0.364, 258, 253, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
454, 4hzrB, 0.8382, 1.90, 0.351, 258, 251, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
455, 3ug1A, 0.8382, 2.37, 0.354, 296, 257, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
456, 3kf4B, 0.8381, 2.37, 0.351, 270, 259, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
457, 3dk3A, 0.8380, 2.18, 0.358, 266, 257, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
458, 4yjoA, 0.8378, 2.31, 0.366, 267, 257, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
459, 3ikaB, 0.8378, 2.40, 0.310, 310, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
460, 3fqsA, 0.8378, 2.32, 0.371, 268, 256, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
461, 4i0sA, 0.8377, 2.25, 0.369, 267, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
462, 3w2pA, 0.8377, 2.48, 0.328, 308, 259, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
463, 1oecA, 0.8377, 2.35, 0.381, 280, 260, FGFR2 KINASE DOMAIN
464, 2eb2A, 0.8376, 2.35, 0.360, 305, 258, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
465, 1xbbA, 0.8376, 2.32, 0.371, 268, 256, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
466, 2xynB, 0.8375, 2.42, 0.346, 264, 260, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
467, 4j97A, 0.8374, 2.26, 0.376, 282, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
468, 5gtzA, 0.8373, 2.30, 0.375, 317, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
469, 4r3rA, 0.8372, 2.52, 0.324, 309, 259, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
470, 1k9aA, 0.8372, 1.78, 0.348, 439, 250, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
471, 4fyoA, 0.8371, 2.25, 0.369, 267, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
472, 4dflA, 0.8370, 2.25, 0.361, 263, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
473, 2itxA, 0.8369, 2.43, 0.367, 307, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
474, 1u46B, 0.8369, 2.06, 0.355, 257, 251, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
475, 4j97B, 0.8368, 2.27, 0.376, 283, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
476, 4f4pA, 0.8366, 2.03, 0.375, 262, 253, SYK IN COMPLEX WITH LIGAND LASW836
477, 4xg7A, 0.8365, 2.09, 0.360, 266, 253, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
478, 4j99C, 0.8365, 2.53, 0.356, 291, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
479, 3byoA, 0.8365, 2.33, 0.365, 270, 260, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
480, 5uhnA, 0.8361, 2.40, 0.375, 282, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
481, 2pwlA, 0.8361, 2.50, 0.381, 284, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
482, 4fynA, 0.8358, 2.27, 0.369, 267, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
483, 2hz4A, 0.8358, 2.08, 0.369, 262, 255, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
484, 4xg9A, 0.8355, 2.20, 0.374, 259, 254, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
485, 2z8cA, 0.8355, 2.40, 0.324, 297, 259, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
486, 4yjuA, 0.8353, 2.15, 0.370, 262, 254, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
487, 5tiuA, 0.8350, 2.16, 0.360, 266, 253, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
488, 1gjoA, 0.8348, 2.39, 0.381, 280, 260, THE FGFR2 TYROSINE KINASE DOMAIN
489, 4j95C, 0.8344, 2.39, 0.381, 281, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
490, 3faaD, 0.8342, 2.74, 0.229, 330, 266, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
491, 1iasD, 0.8342, 2.75, 0.229, 330, 266, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
492, 5y5uB, 0.8341, 2.09, 0.373, 257, 252, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
493, 4lqmA, 0.8341, 2.36, 0.359, 305, 256, EGFR L858R IN COMPLEX WITH PD168393
494, 4i0tA, 0.8340, 2.26, 0.370, 266, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
495, 4yjtA, 0.8337, 2.36, 0.366, 268, 257, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
496, 2pwlB, 0.8337, 2.51, 0.381, 286, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
497, 5t68B, 0.8332, 2.33, 0.371, 264, 256, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
498, 3faaE, 0.8332, 2.69, 0.230, 330, 265, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
499, 5feqA, 0.8331, 2.43, 0.370, 290, 257, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE
500, 4j97D, 0.8330, 2.22, 0.371, 285, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
501, 2r4bA, 0.8330, 2.44, 0.383, 292, 256, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
502, 3dk6A, 0.8329, 2.13, 0.361, 262, 255, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
503, 3fqhB, 0.8327, 2.16, 0.365, 258, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
504, 4i20A, 0.8326, 2.60, 0.354, 287, 263, CRYSTAL STRUCTURE OF MONOMERIC (V948R) PRIMARY ONCOGENIC MUTANT L858R EGFR KINASE DOMAIN
505, 3mdyC, 0.8326, 2.72, 0.245, 320, 261, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
506, 2py3B, 0.8326, 2.36, 0.371, 284, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
507, 2rf9A, 0.8325, 2.75, 0.357, 280, 263, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
508, 4i0rA, 0.8324, 2.12, 0.369, 264, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
509, 1iasE, 0.8324, 2.77, 0.229, 330, 266, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
510, 5x26A, 0.8323, 2.28, 0.366, 302, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(3)
511, 3kcfE, 0.8323, 2.77, 0.229, 330, 266, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
512, 1iasA, 0.8320, 2.77, 0.229, 330, 266, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
513, 5t68A, 0.8319, 2.35, 0.371, 266, 256, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
514, 3mdyA, 0.8319, 2.65, 0.246, 320, 260, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
515, 3kcfD, 0.8319, 2.79, 0.229, 330, 266, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
516, 1iasC, 0.8319, 2.78, 0.229, 330, 266, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
517, 3kcfC, 0.8318, 2.77, 0.226, 330, 266, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
518, 5x27A, 0.8317, 2.29, 0.362, 302, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(5)
519, 2j5fA, 0.8317, 2.32, 0.369, 308, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
520, 5x28A, 0.8315, 2.29, 0.366, 310, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(6)
521, 2b4sD, 0.8313, 2.53, 0.319, 294, 260, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
522, 3ug2A, 0.8311, 2.49, 0.358, 299, 257, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
523, 4xeyB, 0.8309, 2.22, 0.354, 359, 254, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
524, 2psqA, 0.8309, 2.64, 0.358, 287, 260, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
525, 2ivsB, 0.8309, 1.99, 0.378, 277, 251, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
526, 4yjpA, 0.8308, 2.35, 0.367, 263, 256, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
527, 2r4bB, 0.8308, 2.40, 0.384, 291, 255, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
528, 3faaB, 0.8305, 2.73, 0.231, 324, 264, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
529, 4fz6A, 0.8304, 2.32, 0.370, 266, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
530, 3emgA, 0.8302, 2.21, 0.368, 255, 253, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
531, 5x2kA, 0.8301, 2.44, 0.370, 314, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH WZ4003
532, 3kcfB, 0.8300, 2.81, 0.226, 324, 265, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
533, 4g5jA, 0.8298, 2.38, 0.356, 307, 253, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
534, 3faaC, 0.8298, 2.73, 0.234, 330, 265, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
535, 2py3A, 0.8298, 2.52, 0.374, 282, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
536, 3ri1A, 0.8297, 2.65, 0.358, 285, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
537, 1iasB, 0.8297, 2.79, 0.223, 324, 265, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
538, 2pvyA, 0.8296, 2.22, 0.369, 288, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
539, 5e8uA, 0.8293, 2.72, 0.236, 306, 263, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
540, 3bu6A, 0.8293, 2.49, 0.320, 294, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
541, 3kxxD, 0.8292, 2.39, 0.374, 288, 257, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
542, 3zewA, 0.8291, 2.40, 0.316, 269, 256, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
543, 3d7uC, 0.8290, 1.74, 0.356, 257, 247, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
544, 3d7uA, 0.8290, 1.74, 0.356, 257, 247, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
545, 3kcfA, 0.8288, 2.77, 0.226, 328, 265, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
546, 5uglA, 0.8287, 2.51, 0.379, 285, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
547, 4i1zA, 0.8287, 2.66, 0.357, 287, 263, CRYSTAL STRUCTURE OF THE MONOMERIC (V948R) FORM OF THE GEFITINIB/ERLOTINIB RESISTANT EGFR KINASE DOMAIN L858R+T790M
548, 4hjoA, 0.8287, 2.24, 0.358, 278, 254, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
549, 5xgnB, 0.8286, 2.32, 0.323, 308, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
550, 4trlA, 0.8286, 2.38, 0.323, 268, 257, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
551, 2b4sB, 0.8286, 2.50, 0.317, 294, 259, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
552, 3w2rA, 0.8284, 2.16, 0.369, 297, 252, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
553, 3lcsA, 0.8284, 2.62, 0.314, 304, 261, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
554, 2x7oB, 0.8284, 2.82, 0.229, 330, 266, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
555, 3b2tB, 0.8283, 2.31, 0.371, 287, 256, STRUCTURE OF PHOSPHOTRANSFERASE
556, 4cnhB, 0.8282, 2.19, 0.321, 293, 252, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
557, 4uxlA, 0.8281, 2.23, 0.358, 288, 254, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
558, 1k9aE, 0.8281, 1.94, 0.347, 440, 251, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
559, 5fedA, 0.8280, 2.40, 0.357, 288, 255, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
560, 4wd5B, 0.8280, 2.39, 0.306, 304, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
561, 3bu3A, 0.8279, 2.51, 0.320, 294, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
562, 2x7oC, 0.8279, 2.82, 0.229, 330, 266, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
563, 2itoA, 0.8279, 2.33, 0.366, 303, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH IRESSA
564, 3faaA, 0.8278, 2.80, 0.234, 328, 265, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
565, 2x7oD, 0.8278, 2.83, 0.229, 330, 266, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
566, 2hk5A, 0.8278, 2.21, 0.363, 269, 256, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
567, 4fz7A, 0.8277, 2.30, 0.368, 265, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
568, 3sxsA, 0.8274, 2.39, 0.320, 264, 259, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
569, 2x7oA, 0.8271, 2.84, 0.229, 330, 266, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
570, 3kxxC, 0.8270, 2.31, 0.389, 286, 257, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
571, 2x7oE, 0.8269, 2.84, 0.229, 330, 266, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
572, 5mjbA, 0.8268, 2.48, 0.307, 276, 257, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
573, 4u5jA, 0.8265, 1.93, 0.343, 267, 251, C-SRC IN COMPLEX WITH RUXOLITINIB
574, 2pvyD, 0.8265, 2.27, 0.369, 283, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
575, 1u46A, 0.8265, 2.14, 0.364, 255, 250, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
576, 2hz4C, 0.8264, 2.12, 0.368, 259, 253, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
577, 2qu5A, 0.8263, 2.30, 0.386, 292, 251, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
578, 4j99A, 0.8262, 2.54, 0.364, 280, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
579, 5e90A, 0.8261, 2.73, 0.236, 303, 263, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
580, 2pz5B, 0.8261, 2.37, 0.370, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
581, 3ppzA, 0.8260, 2.31, 0.328, 264, 256, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
582, 3dk6B, 0.8260, 1.87, 0.353, 259, 249, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
583, 4g5pB, 0.8259, 2.25, 0.314, 303, 255, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
584, 5e8tA, 0.8258, 2.76, 0.224, 302, 263, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
585, 2q0bB, 0.8257, 2.41, 0.369, 282, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
586, 5e8zA, 0.8255, 2.73, 0.232, 303, 263, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
587, 4xg8A, 0.8252, 2.22, 0.371, 258, 251, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
588, 2pzpB, 0.8252, 2.38, 0.370, 282, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
589, 2itzA, 0.8250, 2.35, 0.368, 302, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
590, 2q0bA, 0.8249, 2.42, 0.369, 280, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
591, 2psqB, 0.8249, 2.73, 0.358, 286, 260, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
592, 2ittA, 0.8246, 2.41, 0.366, 302, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
593, 3lctA, 0.8245, 2.72, 0.318, 308, 261, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
594, 4j95A, 0.8244, 2.58, 0.364, 279, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
595, 1pkgB, 0.8244, 2.19, 0.359, 277, 251, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
596, 2itnA, 0.8243, 2.40, 0.366, 304, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
597, 5friA, 0.8239, 2.82, 0.221, 301, 263, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
598, 5x2fD, 0.8237, 2.45, 0.355, 309, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
599, 4bkjB, 0.8237, 2.61, 0.359, 297, 256, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
600, 4xlvA, 0.8236, 2.65, 0.319, 307, 260, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
601, 4yjqA, 0.8235, 2.46, 0.362, 264, 254, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
602, 3ri1B, 0.8235, 2.75, 0.358, 283, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
603, 6b8yA, 0.8234, 2.72, 0.233, 304, 262, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3- FLUOROPYRIDIN-4-YL)-2-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-7H-PYRROLO[2 3-D]PYRIMIDIN-4-AMINE
604, 4u5jB, 0.8234, 1.96, 0.343, 267, 251, C-SRC IN COMPLEX WITH RUXOLITINIB
605, 3wzeA, 0.8231, 2.27, 0.382, 298, 251, KDR IN COMPLEX WITH LIGAND SORAFENIB
606, 2pz5A, 0.8231, 2.42, 0.374, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
607, 5t8pA, 0.8230, 2.49, 0.221, 327, 258, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
608, 5e8wA, 0.8230, 2.72, 0.234, 303, 261, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
609, 1rqqB, 0.8230, 2.58, 0.324, 294, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
610, 5xp5A, 0.8229, 2.00, 0.343, 267, 251, C-SRC IN COMPLEX WITH ATP-CHF
611, 5x2aB, 0.8227, 2.58, 0.366, 322, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
612, 4e93A, 0.8227, 2.08, 0.353, 361, 249, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)IN COMPLEX WITH TAE684
613, 3q4tB, 0.8226, 2.72, 0.241, 308, 261, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
614, 5xp7B, 0.8225, 1.97, 0.345, 267, 249, C-SRC IN COMPLEX WITH ATP-CHCL
615, 2ityA, 0.8224, 2.36, 0.372, 300, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
616, 1rqqA, 0.8224, 2.57, 0.302, 294, 258, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
617, 3geqB, 0.8223, 1.93, 0.351, 273, 248, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
618, 4xg8C, 0.8222, 2.13, 0.378, 254, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
619, 1t46A, 0.8222, 2.26, 0.355, 297, 251, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
620, 4yc8B, 0.8220, 2.24, 0.366, 264, 254, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
621, 3zosB, 0.8219, 2.62, 0.355, 303, 256, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
622, 3b2wA, 0.8219, 2.09, 0.359, 261, 251, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
623, 2pzpA, 0.8219, 2.43, 0.374, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
624, 5gmpA, 0.8218, 2.33, 0.373, 305, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
625, 4xg2A, 0.8218, 2.09, 0.361, 259, 249, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
626, 4mkcA, 0.8218, 2.53, 0.320, 303, 256, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
627, 3q4uD, 0.8218, 2.93, 0.243, 299, 263, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
628, 5ugxB, 0.8217, 2.20, 0.389, 282, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
629, 5t8pB, 0.8215, 2.49, 0.221, 328, 258, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
630, 5feeA, 0.8215, 2.42, 0.360, 287, 253, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
631, 4asxA, 0.8215, 2.81, 0.237, 310, 262, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
632, 4yjvA, 0.8214, 2.44, 0.360, 263, 253, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
633, 4j95D, 0.8213, 2.08, 0.400, 271, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
634, 3socB, 0.8213, 2.75, 0.241, 309, 261, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
635, 3dqxB, 0.8213, 2.08, 0.341, 268, 252, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
636, 2j0jA, 0.8212, 2.21, 0.361, 611, 252, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
637, 3bu5A, 0.8211, 2.47, 0.316, 291, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
638, 2pzrB, 0.8211, 2.43, 0.370, 282, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
639, 5e8sA, 0.8210, 2.83, 0.229, 301, 262, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
640, 2itvA, 0.8210, 2.47, 0.366, 303, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
641, 2gs7A, 0.8208, 2.64, 0.366, 281, 257, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
642, 4wrgA, 0.8207, 2.30, 0.355, 289, 251, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
643, 4asxB, 0.8205, 2.80, 0.237, 307, 262, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
644, 4u0iA, 0.8204, 2.41, 0.357, 297, 252, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
645, 2rf9B, 0.8204, 2.36, 0.370, 269, 254, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
646, 2r2pA, 0.8204, 2.64, 0.320, 283, 259, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
647, 1yi6B, 0.8204, 2.46, 0.300, 274, 257, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
648, 1b6cD, 0.8204, 2.93, 0.233, 326, 266, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
649, 6g4yB, 0.8203, 2.52, 0.213, 328, 258, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
650, 4ag8A, 0.8203, 2.40, 0.389, 296, 252, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
651, 4zauA, 0.8202, 2.39, 0.375, 283, 253, AZD9291 COMPLEX WITH WILD TYPE EGFR
652, 4yc8A, 0.8202, 2.17, 0.361, 259, 252, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
653, 2gs7B, 0.8202, 2.53, 0.363, 288, 256, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
654, 3a4oX, 0.8201, 2.15, 0.339, 259, 251, LYN KINASE DOMAIN
655, 2xirA, 0.8201, 2.40, 0.389, 296, 252, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH PF-00337210 (N2-DIMETHYL-6-(7-(2-MORPHOLINOETHOXY) QUINOLIN-4-YLOXY)BENZOFURAN-3-CARBOXAMIDE)
656, 2pzrA, 0.8201, 2.44, 0.370, 280, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
657, 5xp5B, 0.8200, 2.01, 0.343, 267, 251, C-SRC IN COMPLEX WITH ATP-CHF
658, 2bdjA, 0.8200, 2.02, 0.345, 254, 249, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
659, 5grnA, 0.8199, 2.40, 0.393, 285, 252, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
660, 2wotA, 0.8199, 2.83, 0.229, 303, 262, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
661, 5gtyH, 0.8197, 2.56, 0.374, 300, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
662, 5x2cA, 0.8196, 2.38, 0.375, 304, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(5)
663, 5hcyA, 0.8196, 2.24, 0.372, 302, 250, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
664, 4y85B, 0.8196, 2.69, 0.222, 306, 261, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
665, 4g3cB, 0.8196, 2.57, 0.216, 327, 259, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
666, 3zfxH, 0.8196, 2.18, 0.328, 266, 250, CRYSTAL STRUCTURE OF EPHB1
667, 5x2aD, 0.8195, 2.65, 0.375, 297, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
668, 3socA, 0.8195, 2.81, 0.237, 307, 262, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
669, 1b6cH, 0.8195, 3.02, 0.228, 326, 267, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
670, 6eixA, 0.8194, 3.05, 0.243, 312, 267, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
671, 4x2fA, 0.8194, 2.80, 0.230, 303, 261, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
672, 3q4tA, 0.8194, 2.82, 0.237, 305, 262, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
673, 3bbtB, 0.8192, 2.50, 0.397, 274, 252, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
674, 4zseA, 0.8190, 2.51, 0.378, 297, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
675, 4i24B, 0.8189, 2.60, 0.373, 304, 255, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
676, 3w32A, 0.8189, 2.63, 0.368, 317, 258, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
677, 2pvyB, 0.8189, 2.12, 0.376, 286, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
678, 4qrcA, 0.8188, 2.58, 0.391, 297, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
679, 3zfxA, 0.8188, 2.22, 0.328, 267, 250, CRYSTAL STRUCTURE OF EPHB1
680, 5mjbB, 0.8187, 2.80, 0.312, 278, 260, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
681, 4x0mA, 0.8187, 2.78, 0.230, 303, 261, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
682, 3zfxD, 0.8187, 2.26, 0.328, 265, 250, CRYSTAL STRUCTURE OF EPHB1
683, 3q4uC, 0.8187, 2.78, 0.242, 296, 260, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
684, 3bbwA, 0.8187, 2.50, 0.397, 268, 252, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN ITS INACTIVE CONFORMATION
685, 4yjrA, 0.8186, 2.50, 0.356, 263, 253, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
686, 4bkjA, 0.8186, 2.58, 0.357, 295, 255, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
687, 3geqA, 0.8185, 1.94, 0.348, 272, 247, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
688, 3bbwB, 0.8185, 2.51, 0.397, 275, 252, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN ITS INACTIVE CONFORMATION
689, 4x2nA, 0.8184, 2.77, 0.230, 303, 261, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
690, 5usqA, 0.8183, 2.74, 0.231, 299, 260, ALK-5 KINASE INHIBITOR COMPLEX
691, 5t8qB, 0.8183, 2.55, 0.217, 328, 258, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
692, 3c0gB, 0.8182, 2.36, 0.231, 320, 255, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
693, 5gtyA, 0.8181, 2.61, 0.373, 300, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
694, 4x2kA, 0.8181, 2.79, 0.230, 303, 261, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
695, 4x2jA, 0.8181, 2.79, 0.230, 303, 261, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
696, 6gi6A, 0.8180, 2.90, 0.240, 298, 262, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 5-METHYL CORE. 
697, 5d41B, 0.8180, 2.50, 0.382, 302, 254, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
698, 4x2gA, 0.8180, 2.86, 0.221, 303, 262, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
699, 4zseC, 0.8178, 2.40, 0.369, 301, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
700, 4yjsA, 0.8178, 2.34, 0.359, 257, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
701, 3zfxI, 0.8178, 2.28, 0.328, 263, 250, CRYSTAL STRUCTURE OF EPHB1
702, 5cnnB, 0.8177, 2.48, 0.366, 304, 254, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
703, 3fzrA, 0.8177, 2.06, 0.348, 261, 247, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
704, 4zseB, 0.8176, 2.53, 0.378, 313, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
705, 2zvaA, 0.8176, 2.36, 0.345, 261, 255, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
706, 5hcxA, 0.8175, 2.24, 0.378, 298, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
707, 3ppzB, 0.8175, 2.25, 0.321, 264, 252, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
708, 1yi6A, 0.8174, 2.51, 0.315, 274, 257, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
709, 4ueuA, 0.8173, 2.16, 0.364, 256, 250, TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL
710, 1xkkA, 0.8173, 2.55, 0.364, 289, 253, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
711, 1ir3A, 0.8173, 2.73, 0.319, 300, 260, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
712, 1gagA, 0.8173, 2.75, 0.319, 300, 260, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
713, 5x2fA, 0.8172, 2.54, 0.382, 301, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
714, 4y85A, 0.8172, 2.72, 0.222, 307, 261, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
715, 5oxgC, 0.8171, 3.14, 0.238, 301, 265, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
716, 4z55A, 0.8171, 2.61, 0.322, 294, 255, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
717, 4rwkA, 0.8171, 2.56, 0.391, 308, 256, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
718, 3vntA, 0.8171, 2.33, 0.386, 301, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
719, 2wouA, 0.8171, 2.80, 0.230, 299, 261, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
720, 2pvyC, 0.8171, 2.21, 0.375, 285, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
721, 1rw8A, 0.8171, 2.81, 0.234, 301, 261, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
722, 5x2fB, 0.8170, 2.54, 0.359, 312, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
723, 5hczA, 0.8170, 2.22, 0.355, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
724, 4bggA, 0.8170, 2.83, 0.242, 296, 260, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
725, 5x2cB, 0.8169, 2.43, 0.364, 303, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(5)
726, 3vrzB, 0.8169, 2.01, 0.347, 430, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
727, 5uwdA, 0.8168, 2.57, 0.361, 271, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH THE COVALENT INHIBITOR CO-1686
728, 3sxrA, 0.8168, 2.39, 0.314, 260, 255, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
729, 3q4uA, 0.8168, 2.83, 0.235, 298, 260, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
730, 4bggB, 0.8167, 2.82, 0.242, 293, 260, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
731, 5fm3A, 0.8166, 2.46, 0.370, 276, 254, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
732, 2ituA, 0.8166, 2.44, 0.353, 304, 252, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
733, 5t8oB, 0.8165, 2.56, 0.213, 328, 258, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
734, 4zseD, 0.8165, 2.60, 0.382, 297, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
735, 4rwiA, 0.8165, 2.58, 0.391, 305, 256, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
736, 3vhkA, 0.8165, 2.27, 0.384, 297, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BACK POCKET BINDER
737, 5hicA, 0.8164, 2.24, 0.373, 302, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
738, 4cd0A, 0.8164, 2.46, 0.324, 295, 253, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
739, 1b6cB, 0.8164, 2.98, 0.233, 326, 266, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
740, 5h0bA, 0.8163, 2.49, 0.346, 446, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
741, 5fm2A, 0.8163, 2.47, 0.370, 273, 254, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
742, 3l9pA, 0.8163, 2.62, 0.319, 303, 257, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
743, 3en4B, 0.8163, 2.09, 0.341, 266, 249, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
744, 2g1tC, 0.8163, 2.36, 0.360, 276, 253, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
745, 5x2fC, 0.8161, 2.54, 0.379, 302, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
746, 5gtyB, 0.8161, 2.59, 0.374, 299, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
747, 3mtfB, 0.8161, 2.93, 0.238, 298, 261, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
748, 5h0hA, 0.8160, 2.49, 0.346, 446, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
749, 4idvB, 0.8160, 2.56, 0.221, 335, 258, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
750, 4idvD, 0.8159, 2.58, 0.225, 335, 258, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
751, 5h09A, 0.8158, 2.49, 0.346, 446, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
752, 4idvC, 0.8158, 2.58, 0.217, 335, 258, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
753, 4asdA, 0.8158, 2.35, 0.386, 305, 251, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
754, 3vs1A, 0.8158, 2.10, 0.355, 424, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
755, 1qcfA, 0.8158, 2.26, 0.332, 449, 253, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
756, 2h8hA, 0.8157, 2.26, 0.324, 444, 253, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
757, 5iu2B, 0.8156, 2.71, 0.212, 313, 260, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
758, 6aywB, 0.8155, 2.35, 0.236, 293, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
759, 3c0iA, 0.8155, 2.43, 0.239, 298, 255, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
760, 1b6cF, 0.8155, 2.96, 0.233, 326, 266, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
761, 4y85C, 0.8154, 2.74, 0.222, 303, 261, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
762, 5casA, 0.8153, 2.37, 0.380, 299, 250, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
763, 3vs3B, 0.8153, 2.26, 0.355, 431, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
764, 3dqxA, 0.8152, 2.11, 0.343, 267, 251, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
765, 5vloB, 0.8151, 2.36, 0.236, 293, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
766, 3et7A, 0.8151, 2.04, 0.368, 261, 247, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
767, 5yu9D, 0.8150, 2.52, 0.375, 300, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
768, 5h0eA, 0.8150, 2.49, 0.346, 446, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
769, 3vo3A, 0.8150, 2.38, 0.382, 303, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
770, 2hckA, 0.8150, 2.22, 0.351, 437, 251, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
771, 2g1tB, 0.8149, 2.37, 0.360, 273, 253, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
772, 5iu2A, 0.8148, 2.72, 0.212, 312, 260, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
773, 5cnoA, 0.8148, 2.52, 0.364, 300, 253, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
774, 5cnnA, 0.8148, 2.31, 0.367, 300, 251, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
775, 4c02A, 0.8147, 3.00, 0.246, 313, 264, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
776, 3c0gA, 0.8146, 2.34, 0.232, 309, 254, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
777, 1py5A, 0.8146, 2.81, 0.234, 301, 261, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
778, 3mfrA, 0.8144, 2.41, 0.243, 302, 255, CASK-4M CAM KINASE DOMAIN NATIVE
779, 3c0hB, 0.8144, 2.41, 0.231, 300, 255, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
780, 5zj6B, 0.8143, 2.53, 0.346, 270, 254, CRYSTAL STRUCTURE OF HCK KINASE COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4- PHENOXYPHENYL)-7H-PYRROLO[2;3-D]PYRIMIDIN-4-AMINE 
781, 5x2aC, 0.8143, 2.44, 0.381, 303, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
782, 3f6xD, 0.8143, 2.12, 0.348, 267, 250, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
783, 5zj6A, 0.8142, 2.54, 0.346, 271, 254, CRYSTAL STRUCTURE OF HCK KINASE COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4- PHENOXYPHENYL)-7H-PYRROLO[2;3-D]PYRIMIDIN-4-AMINE 
784, 5gtyG, 0.8142, 2.61, 0.375, 299, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
785, 4mxzA, 0.8142, 2.13, 0.353, 266, 249, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
786, 4mxyA, 0.8142, 2.13, 0.353, 266, 249, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
787, 4i22A, 0.8142, 2.45, 0.371, 297, 251, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
788, 4aseA, 0.8142, 2.36, 0.386, 305, 251, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
789, 3my0M, 0.8142, 3.00, 0.253, 298, 265, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
790, 2jivB, 0.8142, 2.66, 0.369, 272, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPEX WITH HKI-272
791, 5x2aA, 0.8141, 2.55, 0.379, 297, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
792, 5e8yA, 0.8141, 2.86, 0.254, 298, 260, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
793, 3mfuA, 0.8140, 2.41, 0.239, 302, 255, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
794, 2rgpA, 0.8140, 2.57, 0.365, 284, 252, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
795, 2jivA, 0.8140, 2.60, 0.375, 270, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPEX WITH HKI-272
796, 5zwjA, 0.8139, 2.21, 0.385, 267, 247, CRYSTAL STRUCTURE OF EGFR 675-1022 T790M/C797S/V948R IN COMPLEX WITH EAI045 
797, 5em6A, 0.8139, 2.26, 0.359, 301, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
798, 5cnoB, 0.8139, 2.54, 0.375, 302, 253, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
799, 4idvA, 0.8139, 2.60, 0.221, 335, 258, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
800, 5yu9C, 0.8138, 2.64, 0.374, 306, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
801, 3mfsA, 0.8138, 2.52, 0.250, 303, 256, CASK-4M CAM KINASE DOMAIN AMPPNP
802, 3c0hA, 0.8137, 2.41, 0.231, 300, 255, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
803, 2c0tA, 0.8137, 2.01, 0.348, 427, 247, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
804, 3vs4A, 0.8136, 2.22, 0.356, 429, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
805, 5gtyE, 0.8135, 2.47, 0.365, 297, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
806, 4k11A, 0.8135, 2.31, 0.320, 447, 253, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
807, 4agcA, 0.8135, 2.36, 0.386, 304, 251, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
808, 3vs6A, 0.8135, 2.14, 0.357, 434, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
809, 2p2iA, 0.8135, 2.25, 0.383, 289, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
810, 2hckB, 0.8135, 2.25, 0.347, 437, 251, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
811, 1vjyA, 0.8134, 2.86, 0.224, 299, 259, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
812, 4d58B, 0.8133, 2.41, 0.365, 261, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
813, 5ng0B, 0.8132, 2.44, 0.256, 282, 254, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
814, 5h0gA, 0.8132, 2.53, 0.346, 446, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
815, 5canA, 0.8132, 2.25, 0.373, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
816, 2c0oA, 0.8132, 2.02, 0.348, 433, 247, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
817, 4g3dA, 0.8131, 2.60, 0.218, 324, 257, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
818, 3g6hA, 0.8131, 2.04, 0.345, 266, 249, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
819, 2c0iA, 0.8131, 2.02, 0.348, 433, 247, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
820, 1fpuB, 0.8131, 2.49, 0.367, 270, 251, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
821, 3vryA, 0.8130, 2.15, 0.357, 428, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
822, 3f6xC, 0.8129, 2.11, 0.359, 265, 248, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
823, 5yu9A, 0.8128, 2.63, 0.374, 302, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
824, 5ew3A, 0.8127, 2.05, 0.386, 274, 246, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
825, 5e92A, 0.8126, 2.97, 0.253, 298, 261, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
826, 5caqA, 0.8126, 2.29, 0.378, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
827, 3vs6B, 0.8126, 2.16, 0.357, 434, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
828, 1ad5B, 0.8126, 2.26, 0.347, 437, 251, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
829, 5winA, 0.8125, 2.39, 0.275, 274, 251, JAK2 PSEUDOKINASE IN COMPLEX WITH JNJ7706621 
830, 5gnkA, 0.8125, 2.66, 0.375, 277, 253, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
831, 5wijA, 0.8124, 2.40, 0.275, 274, 251, JAK2 PSEUDOKINASE IN COMPLEX WITH NU6140 
832, 5cauA, 0.8124, 2.36, 0.382, 297, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
833, 3zosA, 0.8124, 2.58, 0.358, 301, 254, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
834, 3w2sA, 0.8124, 2.67, 0.378, 307, 254, EGFR KINASE DOMAIN WITH COMPOUND4
835, 2g1tD, 0.8124, 2.41, 0.364, 277, 253, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
836, 5xy1A, 0.8123, 1.97, 0.344, 253, 247, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
837, 4g3eB, 0.8123, 2.50, 0.220, 325, 255, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
838, 3vs1B, 0.8123, 2.13, 0.359, 433, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
839, 3vs0B, 0.8123, 2.12, 0.359, 433, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
840, 2rfdA, 0.8123, 2.70, 0.358, 288, 254, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
841, 1ql6A, 0.8123, 2.50, 0.240, 281, 254, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
842, 5gtyD, 0.8122, 2.58, 0.372, 297, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
843, 3g2fA, 0.8122, 2.91, 0.243, 302, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II (BMPR2) AT 2.35 A RESOLUTION
844, 3my0E, 0.8121, 2.98, 0.254, 294, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
845, 4ogrI, 0.8120, 2.80, 0.243, 318, 259, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
846, 2rfeA, 0.8120, 2.56, 0.356, 286, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
847, 5oxgB, 0.8119, 2.87, 0.242, 296, 260, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
848, 5gtyF, 0.8119, 2.38, 0.359, 297, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
849, 5aaaA, 0.8119, 2.47, 0.325, 294, 252, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
850, 3vryB, 0.8119, 2.15, 0.353, 434, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
851, 3vs4B, 0.8118, 2.15, 0.353, 434, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
852, 3pozA, 0.8118, 2.42, 0.367, 293, 251, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
853, 3my0N, 0.8118, 2.99, 0.250, 300, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
854, 3my0L, 0.8118, 2.98, 0.254, 296, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
855, 3my0G, 0.8117, 2.98, 0.254, 294, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
856, 3mtfA, 0.8117, 2.89, 0.239, 296, 259, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
857, 5em7A, 0.8116, 2.33, 0.373, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
858, 5e91A, 0.8116, 2.87, 0.255, 297, 259, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
859, 3vrzA, 0.8116, 2.16, 0.355, 429, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
860, 3mftA, 0.8116, 2.43, 0.231, 302, 255, CASK-4M CAM KINASE DOMAIN MN2+
861, 4ludB, 0.8115, 2.12, 0.359, 409, 248, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
862, 4fobA, 0.8115, 2.66, 0.291, 295, 254, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
863, 3vheA, 0.8115, 2.32, 0.380, 303, 250, CRYSTAL STRUCTURE OF HUMAN VEGFR2 KINASE DOMAIN WITH A NOVEL PYRROLOPYRIMIDINE INHIBITOR.
864, 3tzmA, 0.8115, 2.74, 0.233, 295, 258, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
865, 3ky2A, 0.8115, 2.56, 0.386, 307, 254, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
866, 2g1tA, 0.8115, 2.47, 0.360, 271, 253, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
867, 1ad5A, 0.8115, 2.27, 0.351, 437, 251, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
868, 6gipA, 0.8114, 2.88, 0.242, 296, 260, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 2; 5-DIMETHYL CORE. 
869, 6ginA, 0.8114, 2.87, 0.243, 296, 259, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH AN QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 4-MORPHOLINOPHENYL SOLVENT ACCESSIBLE GROUP. 
870, 4d4sB, 0.8114, 2.37, 0.363, 260, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN
871, 5c8nA, 0.8113, 2.31, 0.378, 300, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
872, 4d55A, 0.8113, 2.15, 0.361, 260, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN
873, 3my0F, 0.8113, 3.02, 0.254, 294, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
874, 5d41A, 0.8112, 2.18, 0.367, 300, 248, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
875, 2srcA, 0.8112, 2.47, 0.327, 449, 254, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
876, 2qluA, 0.8112, 2.77, 0.230, 297, 257, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
877, 1opjA, 0.8112, 2.33, 0.372, 287, 250, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
878, 3oomA, 0.8111, 2.92, 0.238, 297, 260, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
879, 1iepB, 0.8111, 2.31, 0.368, 274, 250, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
880, 5wikB, 0.8110, 2.43, 0.275, 274, 251, JAK2 PSEUDOKINASE IN COMPLEX WITH BI-D1870 
881, 3my0R, 0.8110, 3.01, 0.250, 294, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
882, 2c0tB, 0.8110, 2.18, 0.355, 429, 248, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
883, 2c0iB, 0.8110, 2.18, 0.355, 433, 248, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
884, 6g4zB, 0.8109, 2.51, 0.212, 325, 255, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
885, 5wilA, 0.8109, 2.43, 0.275, 274, 251, JAK2 PSEUDOKINASE IN COMPLEX WITH AZD7762 
886, 5ut4A, 0.8109, 2.41, 0.275, 273, 251, JAK2 JH2 IN COMPLEX WITH NVP-BSK805
887, 5oy6B, 0.8109, 2.84, 0.243, 292, 259, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
888, 3vs7A, 0.8109, 2.08, 0.356, 432, 247, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
889, 3vs3A, 0.8109, 2.17, 0.357, 434, 249, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
890, 3bbtD, 0.8109, 2.28, 0.405, 259, 247, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
891, 5t8qA, 0.8108, 2.60, 0.215, 323, 256, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
892, 5ew8A, 0.8108, 2.65, 0.391, 291, 256, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
893, 4l7sA, 0.8108, 1.84, 0.317, 250, 243, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
894, 3belA, 0.8108, 2.59, 0.367, 280, 251, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
895, 4qqtA, 0.8107, 2.56, 0.391, 283, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
896, 1kswA, 0.8107, 2.46, 0.327, 449, 254, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
897, 5oxgA, 0.8106, 2.90, 0.242, 293, 260, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
898, 5i4nA, 0.8106, 2.43, 0.271, 275, 251, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
899, 4ogrA, 0.8106, 2.80, 0.243, 314, 259, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
900, 4fvrA, 0.8106, 2.41, 0.271, 274, 251, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
901, 3f6xA, 0.8106, 2.06, 0.344, 264, 247, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
902, 2zv8A, 0.8106, 2.23, 0.343, 257, 251, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
903, 5mjaB, 0.8105, 2.71, 0.277, 274, 256, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
904, 3my0U, 0.8105, 3.04, 0.250, 285, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
905, 3my0A, 0.8105, 3.01, 0.254, 296, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
906, 3hngA, 0.8105, 2.31, 0.365, 288, 249, CRYSTAL STRUCTURE OF VEGFR1 IN COMPLEX WITH N-(4-CHLOROPHENYL)-2- ((PYRIDIN-4-YLMETHYL)AMINO)BENZAMIDE
907, 2bdfB, 0.8105, 2.25, 0.347, 265, 251, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
908, 5j7hA, 0.8104, 2.24, 0.325, 291, 249, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
909, 3zfxE, 0.8104, 2.18, 0.328, 262, 247, CRYSTAL STRUCTURE OF EPHB1
910, 3pxkB, 0.8104, 2.06, 0.376, 258, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
911, 5e8xA, 0.8103, 2.86, 0.234, 304, 261, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
912, 4mneB, 0.8103, 2.36, 0.253, 270, 253, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
913, 4fvqA, 0.8103, 2.32, 0.276, 274, 250, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
914, 3vs2A, 0.8102, 2.16, 0.359, 430, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
915, 3js2B, 0.8101, 2.64, 0.391, 291, 256, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
916, 1phkA, 0.8101, 2.37, 0.238, 277, 252, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
917, 1k2pA, 0.8101, 2.37, 0.324, 258, 253, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
918, 5aa9A, 0.8100, 2.49, 0.325, 295, 252, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
919, 4uwcB, 0.8100, 2.66, 0.391, 301, 256, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
920, 4mxzB, 0.8100, 2.08, 0.351, 264, 248, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
921, 4mxyB, 0.8100, 2.08, 0.351, 264, 248, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
922, 4ec8A, 0.8100, 2.82, 0.246, 325, 260, STRUCTURE OF FULL LENGTH CDK9 IN COMPLEX WITH CYCLINT AND DRB
923, 3vs5A, 0.8100, 2.15, 0.359, 429, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
924, 5yu9B, 0.8098, 2.59, 0.377, 295, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
925, 5uhnB, 0.8098, 2.39, 0.376, 269, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
926, 5calA, 0.8098, 2.29, 0.375, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
927, 3vs0A, 0.8098, 2.20, 0.355, 428, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
928, 5capA, 0.8097, 2.24, 0.379, 303, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
929, 4rj8A, 0.8097, 2.38, 0.378, 298, 249, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
930, 4rj7A, 0.8097, 2.34, 0.375, 295, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
931, 3my0I, 0.8097, 2.98, 0.255, 293, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
932, 3gvuA, 0.8097, 2.34, 0.369, 271, 249, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
933, 2c0oB, 0.8097, 2.19, 0.355, 433, 248, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
934, 1opjB, 0.8097, 2.42, 0.375, 288, 251, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
935, 5hu9A, 0.8096, 2.59, 0.371, 266, 251, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
936, 3kfaA, 0.8096, 2.47, 0.371, 284, 251, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
937, 2j0kA, 0.8096, 2.11, 0.360, 598, 247, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
938, 3my0B, 0.8095, 3.02, 0.250, 295, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
939, 3kfaB, 0.8095, 2.46, 0.375, 284, 251, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
940, 2rfeD, 0.8095, 2.64, 0.373, 278, 252, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
941, 5mjaA, 0.8094, 2.51, 0.317, 271, 252, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
942, 5kz0A, 0.8094, 2.45, 0.323, 293, 251, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
943, 3zzeA, 0.8094, 2.83, 0.331, 286, 254, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
944, 2hznA, 0.8094, 2.26, 0.367, 272, 248, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
945, 4d4yB, 0.8093, 2.39, 0.363, 260, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN
946, 4cmoA, 0.8092, 2.51, 0.321, 295, 252, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
947, 4aoiA, 0.8091, 2.56, 0.335, 289, 251, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
948, 2eb3A, 0.8091, 2.33, 0.371, 294, 248, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
949, 3hmmA, 0.8090, 2.76, 0.234, 293, 256, STRUCTURE OF ALK5 + GW855857
950, 2zv9A, 0.8089, 2.29, 0.343, 256, 251, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
951, 6g4yA, 0.8088, 2.59, 0.208, 322, 255, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
952, 6f3fA, 0.8088, 2.46, 0.331, 448, 254, AUTOINHIBITED SRC KINASE BOUND TO ADP
953, 5oxgD, 0.8088, 2.91, 0.242, 293, 260, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
954, 5aabA, 0.8088, 2.46, 0.324, 293, 250, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
955, 4yhfB, 0.8088, 2.38, 0.311, 269, 251, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
956, 4d5hB, 0.8088, 2.42, 0.363, 260, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN
957, 3my0Q, 0.8088, 3.04, 0.254, 294, 264, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
958, 3gt8C, 0.8088, 2.49, 0.373, 296, 252, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
959, 2oiqB, 0.8088, 2.05, 0.347, 265, 248, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
960, 2j0kB, 0.8088, 2.17, 0.367, 612, 248, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
961, 5wimA, 0.8087, 2.45, 0.275, 274, 251, JAK2 PSEUDOKINASE IN COMPLEX WITH AT9283 
962, 5e8vA, 0.8087, 2.87, 0.256, 296, 258, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
963, 5c8kA, 0.8087, 2.30, 0.379, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
964, 4ccuA, 0.8087, 2.40, 0.317, 292, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
965, 3vs5B, 0.8087, 2.17, 0.359, 427, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
966, 2biyA, 0.8087, 2.72, 0.205, 287, 259, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
967, 3vs7B, 0.8086, 2.01, 0.358, 426, 246, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
968, 4wnkA, 0.8085, 2.91, 0.207, 499, 261, CRYSTAL STRUCTURE OF BOVINE G PROTEIN COUPLED-RECEPTOR KINASE 5 IN COMPLEX WITH CCG215022
969, 4l7sB, 0.8085, 1.86, 0.317, 250, 243, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
970, 4focA, 0.8085, 2.57, 0.290, 296, 252, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
971, 3zclA, 0.8085, 2.57, 0.335, 289, 251, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
972, 3c4fB, 0.8085, 2.72, 0.391, 290, 256, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
973, 4cliA, 0.8084, 2.52, 0.321, 294, 252, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
974, 3w33A, 0.8084, 2.72, 0.372, 297, 253, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
975, 5c8mA, 0.8083, 2.32, 0.373, 302, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
976, 4i24A, 0.8083, 2.52, 0.380, 295, 250, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
977, 3qgyB, 0.8083, 1.79, 0.328, 245, 241, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
978, 3kexA, 0.8083, 2.74, 0.328, 292, 256, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
979, 5t0pA, 0.8082, 2.10, 0.348, 264, 247, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
980, 5bmmA, 0.8082, 2.40, 0.329, 275, 252, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC25B
981, 4ccbA, 0.8082, 2.40, 0.325, 287, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
982, 5a46B, 0.8081, 2.62, 0.392, 297, 255, FGFR1 IN COMPLEX WITH DOVITINIB
983, 4rwjA, 0.8081, 2.72, 0.387, 307, 256, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
984, 4mxoA, 0.8081, 2.20, 0.345, 266, 249, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
985, 4cmuA, 0.8081, 2.52, 0.321, 294, 252, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
986, 4ap7A, 0.8081, 2.57, 0.335, 289, 251, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
987, 3sxrB, 0.8081, 2.41, 0.312, 258, 253, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
988, 3kexB, 0.8081, 2.75, 0.328, 283, 256, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
989, 3f6xB, 0.8081, 2.10, 0.343, 267, 248, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
990, 5t8oA, 0.8080, 2.60, 0.211, 324, 256, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
991, 5oy6A, 0.8080, 2.85, 0.244, 291, 258, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
992, 4rj4A, 0.8080, 2.39, 0.373, 299, 249, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
993, 3k5vA, 0.8080, 2.42, 0.360, 286, 250, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
994, 1iepA, 0.8080, 2.41, 0.356, 274, 250, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
995, 4zsaA, 0.8079, 2.70, 0.391, 289, 256, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
996, 2x9fA, 0.8079, 2.46, 0.311, 265, 251, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
997, 1mqbB, 0.8079, 2.27, 0.337, 265, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
998, 4uwbA, 0.8078, 2.61, 0.392, 299, 255, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
999, 4tt7A, 0.8078, 2.55, 0.319, 291, 251, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
1000, 3vs2B, 0.8078, 2.18, 0.359, 433, 248, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
1001, 3oy3B, 0.8078, 2.48, 0.375, 284, 251, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
1002, 3h3cA, 0.8078, 2.15, 0.352, 263, 247, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
1003, 2wgjA, 0.8078, 2.58, 0.335, 289, 251, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
1004, 2j0mB, 0.8078, 2.02, 0.376, 257, 245, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
1005, 3zbxA, 0.8077, 2.58, 0.335, 282, 251, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
1006, 3tt0A, 0.8077, 2.66, 0.387, 305, 256, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
1007, 5ut5A, 0.8076, 2.41, 0.276, 272, 250, JAK2 JH2 IN COMPLEX WITH GLPG0634
1008, 4qqjA, 0.8076, 2.57, 0.391, 282, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
1009, 4g3dB, 0.8076, 2.73, 0.218, 318, 257, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
1010, 3my0S, 0.8076, 3.00, 0.251, 294, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1011, 5vndB, 0.8075, 2.66, 0.391, 295, 256, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
1012, 3my1A, 0.8075, 2.85, 0.246, 314, 260, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
1013, 3my0T, 0.8075, 2.98, 0.256, 292, 262, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1014, 3my0H, 0.8075, 3.00, 0.251, 294, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1015, 6c0tA, 0.8074, 2.71, 0.240, 334, 258, CRYSTAL STRUCTURE OF CGMP-DEPENDENT PROTEIN KINASE IALPHA (PKG IALPHA) CATALYTIC DOMAIN BOUND WITH N46 
1016, 5o49A, 0.8074, 2.68, 0.391, 289, 256, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
1017, 5j9zA, 0.8074, 2.33, 0.379, 291, 248, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
1018, 4rj6A, 0.8074, 2.44, 0.373, 297, 249, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
1019, 4r7hA, 0.8074, 2.41, 0.332, 308, 250, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
1020, 4fvpA, 0.8074, 2.36, 0.276, 274, 250, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (APO FORM)
1021, 3q4uB, 0.8074, 3.02, 0.246, 300, 260, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
1022, 3ik3A, 0.8073, 2.44, 0.368, 280, 250, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
1023, 1k3aA, 0.8073, 2.83, 0.300, 288, 257, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
1024, 5bmmB, 0.8072, 2.42, 0.329, 275, 252, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC25B
1025, 4kioC, 0.8072, 1.94, 0.316, 251, 244, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1026, 3c4fA, 0.8072, 2.73, 0.391, 290, 256, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
1027, 3js2A, 0.8070, 2.69, 0.391, 295, 256, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
1028, 4gu6A, 0.8069, 2.58, 0.369, 271, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
1029, 4aw2A, 0.8069, 2.86, 0.193, 398, 259, CRYSTAL STRUCTURE OF CDC42 BINDING PROTEIN KINASE ALPHA (MRCK ALPHA)
1030, 5ut1A, 0.8068, 2.43, 0.276, 272, 250, JAK2 JH2 IN COMPLEX WITH BI-D1870
1031, 6g4zA, 0.8067, 2.62, 0.212, 322, 255, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
1032, 5ut2A, 0.8067, 2.43, 0.276, 273, 250, JAK2 JH2 IN COMPLEX WITH PRT062607
1033, 3oy3A, 0.8067, 2.50, 0.375, 284, 251, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
1034, 3my0C, 0.8067, 3.01, 0.251, 299, 263, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1035, 2rfdB, 0.8067, 2.85, 0.352, 286, 256, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
1036, 3gt8D, 0.8066, 2.51, 0.382, 295, 251, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1037, 4uwcA, 0.8065, 2.74, 0.391, 300, 256, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
1038, 4r5sA, 0.8065, 2.62, 0.366, 299, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
1039, 4mxoB, 0.8065, 2.12, 0.343, 264, 248, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
1040, 3zxzA, 0.8065, 2.60, 0.335, 289, 251, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
1041, 3l8pA, 0.8065, 2.36, 0.363, 292, 248, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
1042, 4uxqA, 0.8064, 2.63, 0.395, 286, 253, FGFR4 IN COMPLEX WITH PONATINIB
1043, 4cljA, 0.8064, 2.58, 0.324, 295, 253, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
1044, 3k5vB, 0.8064, 2.35, 0.369, 283, 249, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
1045, 2rfeB, 0.8064, 2.50, 0.371, 273, 251, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
1046, 5uszA, 0.8063, 2.43, 0.276, 272, 250, JAK2 JH2 IN COMPLEX WITH JNJ-7706621
1047, 5o4aA, 0.8063, 2.69, 0.391, 290, 256, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
1048, 5am7A, 0.8063, 2.59, 0.391, 294, 253, FGFR1 MUTANT WITH AN INHIBITOR
1049, 3rhxA, 0.8063, 2.68, 0.391, 289, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
1050, 5ng2B, 0.8062, 2.26, 0.261, 278, 249, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
1051, 5gtyC, 0.8062, 2.42, 0.372, 295, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
1052, 4mxxA, 0.8062, 2.22, 0.345, 266, 249, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1053, 3v8sD, 0.8062, 2.70, 0.187, 397, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
1054, 4fl2A, 0.8061, 2.66, 0.370, 555, 254, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
1055, 2hyyB, 0.8061, 2.34, 0.373, 265, 249, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
1056, 4fodA, 0.8060, 2.65, 0.289, 308, 253, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
1057, 2oiqA, 0.8060, 2.23, 0.343, 265, 248, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
1058, 5ut3A, 0.8059, 2.45, 0.276, 272, 250, JAK2 JH2 IN COMPLEX WITH IKK-2 INHIBITOR VI
1059, 5iuiA, 0.8058, 2.83, 0.289, 303, 256, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
1060, 4agdA, 0.8058, 2.46, 0.386, 303, 251, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
1061, 3b8qA, 0.8058, 2.10, 0.380, 292, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1062, 5am6A, 0.8057, 2.59, 0.387, 295, 253, NATIVE FGFR1 WITH AN INHIBITOR
1063, 4e26A, 0.8057, 2.53, 0.260, 270, 254, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
1064, 4idtB, 0.8056, 2.59, 0.227, 335, 255, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
1065, 4hvsA, 0.8056, 2.50, 0.363, 326, 251, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
1066, 3eflA, 0.8056, 2.00, 0.387, 286, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
1067, 3nynB, 0.8055, 2.91, 0.220, 553, 259, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
1068, 3my0D, 0.8055, 3.00, 0.252, 298, 262, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1069, 5ut0A, 0.8054, 2.45, 0.276, 272, 250, JAK2 JH2 IN COMPLEX WITH AT9283
1070, 4d4vA, 0.8054, 2.01, 0.361, 256, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1071, 2hiwA, 0.8054, 2.53, 0.375, 274, 251, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
1072, 1fpuA, 0.8053, 2.34, 0.369, 275, 249, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1073, 5xdlA, 0.8052, 2.38, 0.371, 292, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
1074, 3my0V, 0.8052, 2.87, 0.251, 282, 259, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1075, 3g2fB, 0.8052, 2.68, 0.248, 300, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II (BMPR2) AT 2.35 A RESOLUTION
1076, 2hyyA, 0.8052, 2.36, 0.363, 263, 248, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
1077, 5ut6A, 0.8051, 2.46, 0.276, 272, 250, JAK2 JH2 IN COMPLEX WITH A DIAMINOPYRIMIDINE
1078, 3beaA, 0.8051, 2.54, 0.327, 310, 251, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
1079, 4bcgA, 0.8049, 2.87, 0.242, 312, 260, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1080, 3lvpC, 0.8049, 2.82, 0.302, 293, 258, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1081, 5ng2A, 0.8048, 2.15, 0.259, 274, 247, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
1082, 2e2bA, 0.8048, 2.38, 0.359, 270, 248, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
1083, 6ginB, 0.8047, 2.97, 0.246, 296, 260, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH AN QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 4-MORPHOLINOPHENYL SOLVENT ACCESSIBLE GROUP. 
1084, 4d5kB, 0.8046, 2.06, 0.369, 256, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1085, 4ckrA, 0.8046, 2.65, 0.358, 295, 254, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
1086, 2xvdA, 0.8046, 2.79, 0.299, 270, 254, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1087, 6babD, 0.8045, 2.36, 0.238, 291, 252, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1088, 4rt7A, 0.8045, 2.43, 0.368, 274, 250, CRYSTAL STRUCTURE OF FLT3 WITH A SMALL MOLECULE INHIBITOR
1089, 4anqA, 0.8045, 2.49, 0.316, 293, 250, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1090, 1k2pB, 0.8045, 2.47, 0.300, 258, 253, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
1091, 4bcjA, 0.8044, 2.90, 0.238, 309, 260, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1092, 3s95B, 0.8044, 2.46, 0.272, 290, 250, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1093, 5oy6C, 0.8043, 2.90, 0.244, 291, 258, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1094, 5ew8B, 0.8043, 2.63, 0.394, 290, 254, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
1095, 2hyyD, 0.8043, 2.54, 0.360, 264, 250, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
1096, 4bggD, 0.8042, 2.92, 0.243, 286, 259, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
1097, 3rwqA, 0.8042, 2.63, 0.208, 283, 255, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1098, 2pl0A, 0.8042, 2.36, 0.361, 268, 249, LCK BOUND TO IMATINIB
1099, 2i1mA, 0.8042, 2.55, 0.327, 311, 251, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
1100, 1fgiA, 0.8042, 2.75, 0.387, 283, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
1101, 3nynA, 0.8041, 2.91, 0.216, 553, 259, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
1102, 3gt8B, 0.8041, 2.55, 0.382, 292, 251, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1103, 3gt8A, 0.8041, 2.57, 0.382, 300, 251, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1104, 1t45A, 0.8041, 2.43, 0.352, 331, 250, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
1105, 3v8sB, 0.8040, 2.75, 0.183, 397, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
1106, 3ik3B, 0.8040, 2.47, 0.368, 286, 250, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
1107, 2vz6A, 0.8040, 2.35, 0.239, 291, 251, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1108, 3cs9A, 0.8039, 2.44, 0.367, 264, 248, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
1109, 5ftoA, 0.8038, 2.85, 0.286, 298, 255, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
1110, 5a46A, 0.8038, 2.58, 0.399, 289, 253, FGFR1 IN COMPLEX WITH DOVITINIB
1111, 4uwyA, 0.8038, 2.56, 0.378, 296, 251, FGFR1 APO STRUCTURE
1112, 3ms9B, 0.8038, 2.40, 0.365, 272, 249, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
1113, 2xb7A, 0.8038, 2.19, 0.329, 286, 246, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
1114, 5xp7A, 0.8037, 2.16, 0.347, 265, 248, C-SRC IN COMPLEX WITH ATP-CHCL
1115, 5a9uA, 0.8037, 2.47, 0.317, 292, 249, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
1116, 4otwA, 0.8037, 2.88, 0.329, 272, 255, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
1117, 3zc5A, 0.8037, 2.64, 0.335, 289, 251, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
1118, 5l6wL, 0.8036, 2.60, 0.269, 290, 253, STRUCTURE OF THE LIMK1-ATPGAMMAS-CFL1 COMPLEX
1119, 4bcfA, 0.8036, 2.86, 0.239, 307, 259, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1120, 3g0fA, 0.8036, 2.43, 0.356, 291, 250, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
1121, 4qmpA, 0.8035, 2.64, 0.260, 289, 254, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
1122, 3orxC, 0.8035, 2.57, 0.205, 283, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1123, 3my0P, 0.8035, 3.00, 0.256, 290, 262, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1124, 5i9vA, 0.8034, 2.48, 0.317, 279, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
1125, 3lq5A, 0.8033, 2.77, 0.238, 307, 256, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
1126, 4yznA, 0.8032, 2.61, 0.278, 269, 255, HUMANIZED ROCO4 BOUND TO COMPOUND 19
1127, 3uqgA, 0.8032, 2.01, 0.341, 263, 246, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
1128, 3orxA, 0.8032, 2.58, 0.205, 283, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1129, 3lvpB, 0.8032, 2.76, 0.309, 295, 256, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1130, 4uakA, 0.8031, 2.90, 0.208, 404, 259, MRCK BETA IN COMPLEX WITH ADP
1131, 4idtA, 0.8031, 2.64, 0.224, 334, 255, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
1132, 4bggC, 0.8031, 2.87, 0.250, 279, 256, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
1133, 2zv7A, 0.8031, 2.32, 0.343, 257, 251, LYN TYROSINE KINASE DOMAIN APO FORM
1134, 3lmgB, 0.8030, 2.77, 0.331, 268, 254, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1135, 3cp9B, 0.8030, 2.26, 0.384, 269, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
1136, 4ib5A, 0.8029, 2.65, 0.227, 331, 256, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1137, 5aa8A, 0.8028, 2.48, 0.321, 292, 249, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
1138, 4bciA, 0.8028, 2.91, 0.242, 308, 260, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1139, 3tv7B, 0.8028, 2.75, 0.186, 397, 258, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
1140, 2rfeC, 0.8028, 2.39, 0.364, 262, 247, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
1141, 2jkmA, 0.8028, 2.29, 0.363, 260, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1142, 2f2uB, 0.8028, 2.73, 0.179, 383, 257, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
1143, 4y95B, 0.8027, 2.37, 0.328, 266, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1144, 4nw6A, 0.8027, 2.91, 0.256, 302, 258, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
1145, 4ctcA, 0.8027, 2.37, 0.320, 288, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
1146, 3zbfA, 0.8027, 2.28, 0.360, 281, 247, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
1147, 3my0O, 0.8027, 2.98, 0.253, 297, 261, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1148, 3cc6A, 0.8027, 2.62, 0.374, 269, 254, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
1149, 6aywA, 0.8026, 2.52, 0.244, 293, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1150, 5x02A, 0.8026, 2.48, 0.364, 305, 250, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
1151, 5vndA, 0.8026, 2.66, 0.392, 302, 255, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
1152, 5oteA, 0.8026, 2.90, 0.212, 407, 259, MRCK BETA IN COMPLEX WITH BDP-00008900
1153, 4uwbB, 0.8026, 2.65, 0.398, 299, 254, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
1154, 4ansA, 0.8026, 2.51, 0.320, 293, 250, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1155, 3tv7D, 0.8026, 2.73, 0.183, 397, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
1156, 2auhA, 0.8026, 2.88, 0.298, 297, 258, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
1157, 4y95C, 0.8025, 2.38, 0.328, 266, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1158, 4d4yA, 0.8025, 2.01, 0.358, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1159, 3l8vA, 0.8025, 2.64, 0.327, 293, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
1160, 5zv2A, 0.8024, 2.66, 0.386, 284, 254, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
1161, 3lzbC, 0.8024, 2.41, 0.383, 259, 248, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1162, 5kksB, 0.8023, 2.75, 0.191, 395, 257, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
1163, 5k9iB, 0.8023, 2.04, 0.341, 262, 246, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
1164, 4nw5A, 0.8023, 2.92, 0.256, 302, 258, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
1165, 4d5kA, 0.8023, 2.02, 0.358, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1166, 3rcdB, 0.8023, 2.37, 0.346, 271, 246, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
1167, 2yfxA, 0.8023, 2.52, 0.320, 292, 250, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1168, 2phkA, 0.8023, 2.50, 0.230, 277, 252, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
1169, 4ogrE, 0.8022, 2.77, 0.238, 310, 256, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1170, 4hw7A, 0.8022, 2.56, 0.336, 289, 250, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
1171, 3twjA, 0.8022, 2.66, 0.184, 396, 256, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
1172, 3rcdD, 0.8022, 2.37, 0.346, 271, 246, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
1173, 2zm3C, 0.8022, 2.82, 0.304, 296, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1174, 4y95A, 0.8021, 2.45, 0.300, 266, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1175, 3qfvA, 0.8021, 2.73, 0.218, 395, 257, MRCK BETA IN COMPLEX WITH TPCA-1
1176, 3lmgA, 0.8021, 2.96, 0.336, 268, 256, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
1177, 2bdfA, 0.8021, 2.32, 0.337, 261, 249, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
1178, 4y93A, 0.8020, 2.44, 0.325, 429, 252, CRYSTAL STRUCTURE OF THE PH-TH-KINASE CONSTRUCT OF BRUTON S TYROSINE KINASE (BTK)
1179, 4r7iA, 0.8020, 2.44, 0.333, 290, 249, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
1180, 4d4vB, 0.8020, 2.04, 0.366, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1181, 2xp2A, 0.8020, 2.39, 0.324, 285, 247, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
1182, 4pp9B, 0.8019, 1.82, 0.315, 247, 241, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
1183, 2hyyC, 0.8019, 2.59, 0.360, 262, 250, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
1184, 5bmlB, 0.8018, 2.77, 0.191, 395, 257, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
1185, 4qmoA, 0.8018, 2.66, 0.260, 288, 254, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
1186, 2i0yA, 0.8018, 2.46, 0.329, 289, 249, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
1187, 1k9aF, 0.8018, 2.28, 0.296, 436, 247, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
1188, 5t0pB, 0.8017, 2.15, 0.348, 263, 247, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1189, 5caoA, 0.8017, 2.33, 0.377, 300, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
1190, 3v8sC, 0.8017, 2.79, 0.191, 395, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
1191, 3plsA, 0.8017, 2.71, 0.354, 298, 254, RON IN COMPLEX WITH LIGAND AMP-PNP
1192, 3krjA, 0.8017, 2.49, 0.325, 304, 249, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
1193, 3h9rA, 0.8017, 2.79, 0.246, 312, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
1194, 1lufA, 0.8017, 2.36, 0.359, 275, 248, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
1195, 5bvkA, 0.8016, 2.42, 0.372, 278, 250, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
1196, 4d5hA, 0.8016, 2.03, 0.358, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1197, 2etmA, 0.8016, 2.35, 0.365, 262, 249, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
1198, 5uglB, 0.8015, 2.54, 0.372, 271, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
1199, 5u7qB, 0.8015, 2.79, 0.175, 385, 257, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1200, 4qmqA, 0.8015, 2.66, 0.260, 289, 254, MST3 IN COMPLEX WITH CP-673451
1201, 4mxcA, 0.8015, 2.61, 0.328, 290, 250, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1202, 3v8sA, 0.8015, 2.79, 0.191, 395, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
1203, 5hznE, 0.8014, 2.76, 0.331, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1204, 3lcoA, 0.8014, 2.46, 0.329, 293, 249, INHIBITOR BOUND TO A DFG-OUT STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
1205, 3eflB, 0.8014, 2.16, 0.381, 263, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
1206, 2qu6B, 0.8014, 1.95, 0.373, 260, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
1207, 2hiwB, 0.8014, 2.38, 0.378, 274, 249, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
1208, 5hznA, 0.8013, 2.76, 0.331, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1209, 5fg8A, 0.8013, 2.59, 0.229, 269, 253, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1210, 3nyoA, 0.8013, 2.96, 0.216, 553, 259, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
1211, 3my0W, 0.8013, 2.93, 0.251, 281, 259, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
1212, 6c0uA, 0.8012, 2.59, 0.236, 338, 254, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CALPHA SUBUNIT BOUND WITH N46 
1213, 4nkaB, 0.8012, 2.48, 0.392, 287, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
1214, 4bchA, 0.8012, 2.89, 0.239, 308, 259, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1215, 2vz6B, 0.8012, 2.48, 0.245, 294, 253, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1216, 4w7pC, 0.8011, 2.78, 0.195, 383, 257, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
1217, 3orxD, 0.8011, 2.57, 0.206, 282, 253, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1218, 3lzbB, 0.8011, 2.57, 0.380, 265, 250, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1219, 3gxlA, 0.8011, 2.84, 0.220, 285, 255, ALK-5 KINASE COMPLEX WITH GW857175
1220, 4o2pB, 0.8010, 2.18, 0.313, 265, 246, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
1221, 4imyE, 0.8010, 2.76, 0.242, 313, 256, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1222, 4d58A, 0.8010, 2.05, 0.362, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1223, 3u6jA, 0.8010, 2.53, 0.386, 308, 251, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
1224, 3tv7C, 0.8010, 2.79, 0.187, 394, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
1225, 3nyoB, 0.8010, 2.96, 0.220, 553, 259, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
1226, 6babA, 0.8009, 2.36, 0.239, 290, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1227, 5l1zA, 0.8009, 2.79, 0.238, 310, 256, TAR COMPLEX WITH HIV-1 TAT-AFF4-P-TEFB
1228, 5imxA, 0.8009, 1.99, 0.329, 266, 243, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
1229, 5am7B, 0.8009, 2.50, 0.400, 287, 250, FGFR1 MUTANT WITH AN INHIBITOR
1230, 4l00B, 0.8009, 2.65, 0.240, 278, 254, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
1231, 2etkB, 0.8009, 2.89, 0.190, 398, 258, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
1232, 5am6B, 0.8008, 2.57, 0.400, 280, 250, NATIVE FGFR1 WITH AN INHIBITOR
1233, 4xufB, 0.8008, 2.52, 0.365, 274, 249, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR QUIZARTINIB (AC220)
1234, 4wboC, 0.8008, 3.08, 0.218, 481, 262, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1235, 4kabB, 0.8008, 2.43, 0.369, 258, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
1236, 3g0fB, 0.8008, 2.56, 0.355, 293, 251, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
1237, 2ckeA, 0.8008, 2.79, 0.226, 301, 257, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1238, 5htiA, 0.8007, 2.75, 0.331, 290, 251, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
1239, 5h9bA, 0.8007, 2.65, 0.228, 269, 254, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
1240, 4w7pB, 0.8007, 2.82, 0.187, 387, 257, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
1241, 4or5A, 0.8007, 2.96, 0.247, 319, 259, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1242, 4eolC, 0.8007, 2.67, 0.256, 299, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1243, 4qmmA, 0.8006, 2.68, 0.260, 288, 254, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
1244, 3twjC, 0.8006, 2.77, 0.195, 396, 257, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
1245, 2wkmA, 0.8006, 2.88, 0.332, 286, 253, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
1246, 5hvkA, 0.8005, 2.70, 0.264, 297, 254, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
1247, 4l00A, 0.8005, 2.42, 0.243, 277, 251, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
1248, 5u7rC, 0.8004, 2.78, 0.179, 387, 257, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1249, 5dg5B, 0.8004, 2.62, 0.328, 297, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
1250, 4or5F, 0.8004, 3.08, 0.249, 324, 261, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1251, 3tv7A, 0.8004, 2.81, 0.187, 394, 257, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
1252, 1xo2B, 0.8004, 2.72, 0.256, 289, 254, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
1253, 5vilC, 0.8003, 2.76, 0.281, 271, 253, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
1254, 5kktB, 0.8003, 2.80, 0.187, 394, 257, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
1255, 5edqA, 0.8003, 2.33, 0.377, 298, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
1256, 1h1wA, 0.8003, 2.67, 0.208, 284, 255, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
1257, 5xs2A, 0.8002, 3.19, 0.194, 366, 263, CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-CHLORO-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
1258, 5kksA, 0.8002, 2.83, 0.187, 395, 257, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
1259, 4y95D, 0.8001, 2.43, 0.301, 265, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1260, 4w8dA, 0.8001, 2.69, 0.260, 289, 254, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
1261, 5hznC, 0.8000, 2.78, 0.331, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1262, 4g3fA, 0.8000, 2.52, 0.218, 312, 252, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 2-(AMINOTHIAZOLY)PHENOL (CMP2)
1263, 3b8qB, 0.8000, 2.16, 0.385, 271, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1264, 5y25A, 0.7999, 2.36, 0.377, 292, 247, EGFR KINASE DOMAIN MUTANT (T790M/L858R) WITH COVALENT LIGAND NS-062 
1265, 5hznG, 0.7999, 2.78, 0.331, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1266, 5aacA, 0.7999, 2.52, 0.317, 292, 249, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1267, 4u8zA, 0.7999, 2.68, 0.260, 289, 254, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
1268, 4g3gA, 0.7999, 2.53, 0.222, 312, 252, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) V408L BOUND TO A 2-(AMINOTHIAZOLYL)PHENOL (CMP3)
1269, 3qfvB, 0.7999, 2.76, 0.218, 396, 257, MRCK BETA IN COMPLEX WITH TPCA-1
1270, 2etmB, 0.7999, 2.47, 0.363, 263, 248, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
1271, 4hctA, 0.7998, 2.46, 0.304, 265, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
1272, 3svvA, 0.7998, 2.05, 0.340, 261, 244, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
1273, 3mvjE, 0.7998, 2.59, 0.237, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1274, 2etrB, 0.7998, 2.79, 0.187, 398, 257, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
1275, 5hznF, 0.7997, 2.79, 0.331, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1276, 5hznB, 0.7997, 2.79, 0.331, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1277, 5ar2B, 0.7997, 2.44, 0.264, 285, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
1278, 4w7pA, 0.7997, 2.79, 0.187, 388, 257, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
1279, 3lzbD, 0.7997, 2.58, 0.380, 261, 250, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1280, 3lzbA, 0.7997, 2.60, 0.380, 265, 250, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
1281, 1uvrA, 0.7997, 2.68, 0.208, 284, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1282, 5o49B, 0.7996, 2.53, 0.398, 286, 251, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
1283, 4yhfA, 0.7996, 2.70, 0.316, 268, 253, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
1284, 4pmmA, 0.7996, 2.61, 0.380, 285, 250, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
1285, 3qhwA, 0.7996, 2.77, 0.254, 297, 256, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1286, 2a2aA, 0.7996, 2.79, 0.233, 304, 257, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1287, 4qmvA, 0.7995, 2.70, 0.260, 288, 254, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
1288, 3tn8A, 0.7995, 2.99, 0.238, 304, 260, CDK9/CYCLIN T IN COMPLEX WITH CAN508
1289, 3tkuB, 0.7995, 2.76, 0.218, 395, 257, MRCK BETA IN COMPLEX WITH FASUDIL
1290, 4yvcB, 0.7994, 2.71, 0.184, 392, 256, ROCK 1 BOUND TO THIAZOLE INHIBITOR
1291, 4w7pD, 0.7994, 2.88, 0.190, 387, 258, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
1292, 4bb4A, 0.7994, 2.63, 0.300, 265, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1293, 3tkuA, 0.7994, 2.77, 0.218, 395, 257, MRCK BETA IN COMPLEX WITH FASUDIL
1294, 3g6gB, 0.7994, 2.10, 0.335, 263, 245, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
1295, 3el8A, 0.7994, 2.07, 0.341, 263, 246, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1296, 4z3vA, 0.7993, 2.54, 0.306, 271, 252, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
1297, 4ctbA, 0.7993, 2.51, 0.321, 292, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
1298, 3qhwC, 0.7993, 2.77, 0.254, 297, 256, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1299, 5vjaB, 0.7992, 2.52, 0.241, 266, 253, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
1300, 5ci7A, 0.7992, 2.63, 0.252, 276, 254, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
1301, 4dglD, 0.7992, 2.70, 0.227, 328, 256, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1302, 2zm3D, 0.7992, 2.92, 0.329, 293, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1303, 2zm3B, 0.7992, 2.97, 0.328, 296, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1304, 2vd5B, 0.7992, 2.81, 0.200, 380, 255, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
1305, 5p9kA, 0.7991, 2.52, 0.295, 271, 251, CRYSTAL STRUCTURE OF BTK WITH CNX 774
1306, 4eokC, 0.7991, 2.66, 0.252, 299, 254, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1307, 3blrA, 0.7991, 2.88, 0.233, 300, 257, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
1308, 2zm3A, 0.7991, 2.90, 0.328, 300, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
1309, 5hvkC, 0.7990, 2.77, 0.268, 291, 254, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
1310, 3iw4A, 0.7990, 2.69, 0.251, 330, 255, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1311, 2xuuA, 0.7990, 2.82, 0.242, 301, 256, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
1312, 1h1pC, 0.7990, 2.78, 0.255, 296, 255, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1313, 5xvfA, 0.7989, 2.85, 0.210, 289, 257, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH062
1314, 5vioC, 0.7989, 2.80, 0.276, 271, 254, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
1315, 4l6qA, 0.7989, 2.82, 0.179, 388, 257, ROCK2 IN COMPLEX WITH BENZOXABOROLE
1316, 3b8rB, 0.7989, 2.17, 0.381, 267, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1317, 2wtkB, 0.7989, 2.47, 0.223, 311, 251, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
1318, 2ckeC, 0.7989, 2.84, 0.230, 300, 257, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1319, 5ng0A, 0.7988, 2.20, 0.260, 274, 246, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
1320, 4o2pA, 0.7988, 2.57, 0.343, 265, 251, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
1321, 3oxzA, 0.7988, 2.19, 0.373, 268, 244, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
1322, 5oy6D, 0.7987, 2.99, 0.236, 292, 259, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
1323, 6fd3A, 0.7986, 2.72, 0.235, 296, 255, THIOPHOSPHORYLATED PAK3 KINASE DOMAIN
1324, 5nkeA, 0.7986, 2.79, 0.328, 292, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
1325, 5d7vC, 0.7986, 2.38, 0.333, 264, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1326, 4rqvA, 0.7986, 2.78, 0.206, 288, 257, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
1327, 3orxB, 0.7986, 2.51, 0.207, 280, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1328, 5dh3B, 0.7985, 2.95, 0.226, 283, 257, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1329, 4v05B, 0.7985, 2.64, 0.397, 286, 252, FGFR1 IN COMPLEX WITH AZD4547.
1330, 4rj5A, 0.7985, 2.49, 0.377, 296, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
1331, 4mneG, 0.7985, 2.19, 0.252, 259, 246, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1332, 4md7H, 0.7985, 2.70, 0.223, 330, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1333, 3aglA, 0.7985, 2.63, 0.237, 338, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1334, 5vfiA, 0.7984, 2.51, 0.321, 271, 252, BRUTON S TYROSINE KINASE (BTK) WITH GDC-0853
1335, 4yveB, 0.7984, 2.73, 0.184, 393, 256, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
1336, 4rwlB, 0.7984, 2.57, 0.402, 285, 251, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
1337, 2q0nA, 0.7984, 2.83, 0.203, 293, 256, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
1338, 1re8A, 0.7984, 2.67, 0.229, 337, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
1339, 6g33B, 0.7983, 2.85, 0.246, 337, 252, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1340, 5i9uA, 0.7983, 2.57, 0.325, 281, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
1341, 4zlyA, 0.7983, 2.53, 0.295, 270, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
1342, 3aglB, 0.7983, 2.69, 0.233, 335, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1343, 5vilA, 0.7982, 2.90, 0.283, 271, 254, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
1344, 4l6qB, 0.7982, 2.82, 0.179, 388, 257, ROCK2 IN COMPLEX WITH BENZOXABOROLE
1345, 4l01B, 0.7982, 2.49, 0.243, 274, 251, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
1346, 3byuA, 0.7982, 2.30, 0.370, 256, 246, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
1347, 2ckeB, 0.7982, 2.84, 0.226, 300, 257, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1348, 4eonA, 0.7981, 2.67, 0.257, 299, 253, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1349, 3v5lD, 0.7981, 2.12, 0.314, 246, 242, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1350, 3uodA, 0.7981, 2.70, 0.231, 266, 255, AURORA A IN COMPLEX WITH RPM1693
1351, 3c4zA, 0.7981, 3.08, 0.199, 493, 261, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 1.84A
1352, 2e2bB, 0.7981, 2.34, 0.378, 262, 246, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
1353, 1bkxA, 0.7981, 2.67, 0.233, 337, 253, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
1354, 5wngA, 0.7980, 2.82, 0.182, 395, 258, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1355, 5p9fA, 0.7980, 2.41, 0.324, 266, 250, BTK IN COMPLEX WITH GDC-0834
1356, 4md7G, 0.7980, 2.70, 0.223, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1357, 4c7tA, 0.7980, 2.43, 0.361, 259, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
1358, 3en4A, 0.7980, 1.90, 0.343, 257, 242, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
1359, 2vd5A, 0.7980, 2.79, 0.203, 390, 256, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
1360, 2ckeD, 0.7980, 2.87, 0.222, 300, 257, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1361, 1okyA, 0.7980, 2.61, 0.209, 281, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1362, 5wneA, 0.7979, 2.80, 0.187, 384, 257, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1363, 5otfA, 0.7979, 2.96, 0.212, 411, 259, MRCK BETA IN COMPLEX WITH BDP-00009066
1364, 5ig1A, 0.7979, 2.72, 0.247, 300, 255, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1365, 5ftqA, 0.7979, 2.62, 0.288, 293, 250, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
1366, 4zlzA, 0.7979, 2.52, 0.321, 270, 252, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
1367, 4xx9A, 0.7979, 2.81, 0.202, 288, 257, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
1368, 4md7F, 0.7979, 2.70, 0.223, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1369, 4hcuA, 0.7979, 2.62, 0.280, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
1370, 4d4sA, 0.7979, 2.07, 0.358, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1371, 3qhrA, 0.7979, 2.80, 0.254, 297, 256, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1372, 3lq8A, 0.7979, 2.64, 0.333, 278, 249, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
1373, 3c51A, 0.7979, 3.07, 0.218, 487, 262, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
1374, 2ptkA, 0.7979, 1.97, 0.354, 425, 243, CHICKEN SRC TYROSINE KINASE
1375, 5ar5A, 0.7978, 2.32, 0.266, 284, 248, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
1376, 4gg5A, 0.7978, 2.81, 0.333, 274, 252, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1377, 3zfxF, 0.7978, 1.84, 0.333, 254, 240, CRYSTAL STRUCTURE OF EPHB1
1378, 2ijmA, 0.7978, 2.17, 0.374, 260, 246, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
1379, 1z9xB, 0.7978, 2.84, 0.230, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
1380, 4wboD, 0.7977, 3.11, 0.218, 491, 262, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1381, 3qhrC, 0.7977, 2.81, 0.254, 297, 256, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
1382, 1z9xA, 0.7977, 2.84, 0.230, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
1383, 5p9jA, 0.7976, 2.66, 0.295, 263, 251, BTK1 COCRYSTALLIZED WITH IBRUTINIB
1384, 4fnyA, 0.7976, 2.12, 0.318, 273, 242, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
1385, 3lvpA, 0.7976, 2.68, 0.308, 289, 253, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
1386, 5nkhA, 0.7975, 2.88, 0.327, 295, 257, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
1387, 5j87B, 0.7975, 2.50, 0.315, 274, 251, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1388, 5ia2A, 0.7975, 2.68, 0.331, 287, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
1389, 4pp9A, 0.7975, 1.85, 0.317, 246, 240, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
1390, 4ot6A, 0.7975, 2.46, 0.316, 265, 250, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
1391, 3v8tB, 0.7975, 1.94, 0.317, 244, 240, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
1392, 3qgwB, 0.7975, 1.52, 0.328, 240, 235, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
1393, 3ndmB, 0.7975, 2.82, 0.183, 396, 257, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
1394, 2i0vA, 0.7974, 2.53, 0.325, 303, 249, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
1395, 2esmB, 0.7974, 2.73, 0.184, 398, 256, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
1396, 5wnhA, 0.7973, 2.79, 0.187, 394, 257, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1397, 5vilB, 0.7973, 2.84, 0.281, 271, 253, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
1398, 5lxmA, 0.7973, 2.56, 0.230, 266, 252, CRYSTAL STRUCTURE OF AURORA-A BOUND TO A HYDROCARBON-STAPLED PROTEOMIMETIC OF TPX2
1399, 4pniA, 0.7973, 3.11, 0.218, 492, 262, BOVINE G PROTEIN-COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH GSK2163632A
1400, 4anlA, 0.7973, 2.58, 0.289, 292, 249, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
1401, 3dtwA, 0.7973, 2.14, 0.379, 288, 243, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
1402, 5lvlA, 0.7972, 2.69, 0.204, 285, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
1403, 5edpA, 0.7972, 2.44, 0.371, 295, 248, EGFR KINASE (T790M/L858R) APO
1404, 4mxxB, 0.7972, 2.07, 0.336, 260, 244, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1405, 4md9H, 0.7972, 2.73, 0.227, 328, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1406, 4mcvB, 0.7972, 2.32, 0.315, 265, 248, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1407, 4brxA, 0.7972, 2.45, 0.357, 259, 249, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
1408, 5d7vB, 0.7971, 2.39, 0.333, 264, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1409, 4xi2A, 0.7971, 2.43, 0.304, 421, 250, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
1410, 4deeA, 0.7971, 2.73, 0.231, 271, 255, AURORA A IN COMPLEX WITH ADP
1411, 1uu7A, 0.7971, 2.55, 0.206, 280, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
1412, 1smhA, 0.7971, 2.70, 0.237, 348, 253, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
1413, 5n3oA, 0.7970, 2.64, 0.234, 335, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-(13-OXAZOL-5-YL)ANILINE
1414, 5n3lA, 0.7970, 2.65, 0.234, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1 2-DIOL
1415, 4g3cA, 0.7970, 2.44, 0.217, 315, 249, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
1416, 3uo5A, 0.7970, 2.70, 0.231, 267, 255, AURORA A IN COMPLEX WITH YL1-038-31
1417, 3q9xB, 0.7970, 2.72, 0.223, 330, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1418, 2wd1A, 0.7970, 2.97, 0.331, 289, 254, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
1419, 2a2aD, 0.7970, 2.87, 0.222, 303, 257, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1420, 5bpyA, 0.7969, 2.48, 0.305, 263, 249, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
1421, 4wotC, 0.7969, 2.73, 0.180, 392, 256, ROCK2 IN COMPLEX WITH 1426382-07-1
1422, 4md7E, 0.7969, 2.72, 0.223, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1423, 4gu9B, 0.7969, 2.51, 0.340, 255, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
1424, 1rejA, 0.7969, 2.69, 0.233, 333, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
1425, 1bx6A, 0.7969, 2.68, 0.237, 337, 253, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1426, 5kktA, 0.7968, 2.86, 0.187, 389, 257, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
1427, 4rx5A, 0.7968, 2.50, 0.316, 265, 250, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
1428, 4k8aB, 0.7968, 2.39, 0.379, 258, 248, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
1429, 2f7xE, 0.7968, 2.73, 0.236, 336, 254, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
1430, 3ndmD, 0.7967, 2.83, 0.183, 396, 257, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
1431, 3iw4C, 0.7967, 2.76, 0.246, 332, 256, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1432, 3c50A, 0.7967, 3.06, 0.203, 499, 261, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
1433, 2ojfE, 0.7967, 2.75, 0.232, 336, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1434, 2jkkA, 0.7967, 2.39, 0.359, 258, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1435, 5osdA, 0.7966, 2.63, 0.229, 266, 253, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1436, 4zsaB, 0.7966, 2.60, 0.402, 282, 251, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
1437, 4mcvA, 0.7966, 2.43, 0.297, 267, 249, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1438, 4hcvA, 0.7966, 2.46, 0.305, 263, 249, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
1439, 4eomC, 0.7966, 2.78, 0.251, 275, 255, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
1440, 4dgoA, 0.7966, 2.73, 0.215, 325, 256, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
1441, 2f7zE, 0.7966, 2.75, 0.232, 336, 254, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
1442, 1unlB, 0.7966, 2.91, 0.219, 292, 256, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
1443, 1lp4A, 0.7966, 2.74, 0.215, 327, 256, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
1444, 5j1vA, 0.7965, 2.88, 0.250, 338, 252, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1445, 5a4cB, 0.7965, 2.64, 0.401, 286, 252, FGFR1 LIGAND COMPLEX
1446, 4l01A, 0.7965, 2.47, 0.247, 274, 251, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
1447, 6ft9C, 0.7964, 2.82, 0.250, 337, 252, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1448, 6fnkA, 0.7964, 2.68, 0.287, 274, 251, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
1449, 5wnlA, 0.7964, 2.36, 0.259, 262, 247, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO STAUROSPORINE 
1450, 5p9gA, 0.7964, 2.45, 0.316, 265, 250, STRUCTURE OF BTK WITH RN486
1451, 5d12A, 0.7964, 2.17, 0.343, 260, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
1452, 5bmlA, 0.7964, 2.82, 0.191, 393, 256, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
1453, 4eojC, 0.7964, 2.79, 0.255, 282, 255, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
1454, 4b4lA, 0.7964, 2.84, 0.245, 299, 257, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
1455, 3f82A, 0.7964, 2.18, 0.333, 278, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
1456, 2yabA, 0.7964, 2.65, 0.236, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
1457, 5j1wC, 0.7963, 2.83, 0.250, 316, 252, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1458, 5hznH, 0.7963, 2.85, 0.335, 303, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1459, 5hznD, 0.7963, 2.85, 0.335, 304, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
1460, 4wnoA, 0.7963, 2.73, 0.247, 272, 255, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
1461, 4tyiA, 0.7963, 2.54, 0.404, 277, 250, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4
1462, 4mf1A, 0.7963, 1.89, 0.322, 243, 239, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
1463, 4imyA, 0.7963, 2.96, 0.245, 314, 257, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1464, 2uztA, 0.7963, 2.77, 0.232, 336, 254, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
1465, 1dawA, 0.7963, 2.73, 0.215, 327, 256, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
1466, 1agwB, 0.7963, 2.65, 0.398, 272, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
1467, 5k5xA, 0.7962, 2.65, 0.390, 345, 251, CRYSTAL STRUCTURE OF HUMAN PDGFRA
1468, 5hvuA, 0.7962, 2.85, 0.183, 394, 257, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
1469, 5dg5A, 0.7962, 2.60, 0.329, 297, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
1470, 4md9G, 0.7962, 2.74, 0.227, 329, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1471, 4md8H, 0.7962, 2.74, 0.223, 331, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1472, 4ludA, 0.7962, 2.14, 0.366, 421, 243, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1473, 4f1oA, 0.7962, 2.84, 0.267, 276, 255, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
1474, 3idcA, 0.7962, 2.72, 0.225, 341, 253, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1475, 2f7eE, 0.7962, 2.76, 0.232, 336, 254, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
1476, 5upkB, 0.7961, 2.76, 0.204, 288, 255, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTERFACE - 3 PEPTIDE: PAK4CAT PAK4-N45 CDC42
1477, 5m56A, 0.7961, 2.75, 0.215, 331, 256, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1478, 4lueA, 0.7961, 2.15, 0.365, 422, 244, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
1479, 3wilA, 0.7961, 2.78, 0.207, 331, 256, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
1480, 3qlgB, 0.7961, 2.11, 0.332, 260, 244, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
1481, 3ocsA, 0.7961, 2.48, 0.305, 264, 249, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
1482, 3at4A, 0.7961, 2.77, 0.219, 331, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
1483, 2a2aC, 0.7961, 2.88, 0.222, 303, 257, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1484, 5h8eA, 0.7960, 2.73, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1485, 4wboA, 0.7960, 3.13, 0.218, 497, 262, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1486, 4md8F, 0.7960, 2.74, 0.223, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1487, 3fy2A, 0.7960, 2.70, 0.311, 285, 251, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYEFIW
1488, 5wnoA, 0.7959, 2.74, 0.359, 302, 251, CRYSTAL STRUCTURE OF C. ELEGANS LET-23 KINASE DOMAIN COMPLEXED WITH AMP-PNP
1489, 4v04B, 0.7959, 2.52, 0.394, 287, 249, FGFR1 IN COMPLEX WITH PONATINIB.
1490, 4md8G, 0.7959, 2.74, 0.223, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1491, 4dgnA, 0.7959, 2.73, 0.215, 325, 256, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
1492, 3qa0B, 0.7959, 2.74, 0.223, 330, 256, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1493, 3ms9A, 0.7959, 2.33, 0.370, 265, 246, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
1494, 3d4qB, 0.7959, 2.38, 0.270, 264, 248, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1495, 2yaaA, 0.7959, 2.71, 0.235, 300, 255, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
1496, 2uzvA, 0.7959, 2.77, 0.232, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1497, 2jkqA, 0.7959, 2.26, 0.370, 258, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1498, 2f2uA, 0.7959, 2.85, 0.179, 386, 257, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
1499, 5kvtA, 0.7958, 2.74, 0.348, 287, 250, THE STRUCTURE OF TRKA KINASE DOMAIN BOUND TO THE INHIBITOR ENTRECTINIB
1500, 5ku8B, 0.7958, 2.78, 0.223, 331, 256, CRYSTAL STRUCTURE OF CK2
1501, 5d7vD, 0.7958, 2.42, 0.333, 264, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1502, 4nh1B, 0.7958, 2.76, 0.223, 332, 256, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1503, 4l9iB, 0.7958, 3.09, 0.199, 493, 261, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
1504, 4ks8A, 0.7958, 2.83, 0.238, 286, 256, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1505, 3fxxA, 0.7958, 2.65, 0.311, 288, 251, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYE[PTYR]IW
1506, 2yhvA, 0.7958, 2.59, 0.309, 291, 249, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
1507, 5wngD, 0.7957, 2.84, 0.183, 396, 257, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1508, 5wnfA, 0.7957, 2.81, 0.187, 395, 257, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1509, 5vjaA, 0.7957, 2.53, 0.242, 266, 252, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
1510, 5ew3B, 0.7957, 2.13, 0.384, 266, 242, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
1511, 5ackA, 0.7957, 2.76, 0.199, 286, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
1512, 4otqA, 0.7957, 2.42, 0.306, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
1513, 3zfxB, 0.7957, 2.02, 0.332, 254, 241, CRYSTAL STRUCTURE OF EPHB1
1514, 3tnhA, 0.7957, 2.82, 0.244, 288, 254, CDK9/CYCLIN T IN COMPLEX WITH CAN508
1515, 3qc9D, 0.7957, 3.14, 0.199, 486, 261, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1516, 3qc9B, 0.7957, 3.14, 0.199, 481, 261, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1517, 3iw4B, 0.7957, 2.70, 0.248, 325, 254, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1518, 3e8eA, 0.7957, 2.73, 0.233, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1519, 3d4qA, 0.7957, 2.39, 0.270, 264, 248, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1520, 2pvnA, 0.7957, 2.73, 0.207, 327, 256, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1521, 1q61A, 0.7957, 2.74, 0.237, 335, 253, PKA TRIPLE MUTANT MODEL OF PKB
1522, 6fyvA, 0.7956, 2.84, 0.230, 329, 252, X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A 
1523, 5u7rA, 0.7956, 2.68, 0.176, 387, 255, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1524, 5u7qD, 0.7956, 2.79, 0.176, 383, 255, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1525, 5os5A, 0.7956, 2.64, 0.229, 267, 253, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1526, 4xufA, 0.7956, 2.51, 0.371, 270, 248, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR QUIZARTINIB (AC220)
1527, 4wnpA, 0.7956, 2.72, 0.247, 273, 255, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1528, 3qc9C, 0.7956, 3.14, 0.199, 482, 261, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1529, 3oxtA, 0.7956, 2.74, 0.233, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1530, 3f3tB, 0.7956, 2.12, 0.337, 259, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
1531, 3c4wB, 0.7956, 3.10, 0.199, 518, 261, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
1532, 1xhaA, 0.7956, 2.71, 0.241, 348, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1533, 1xh8A, 0.7956, 2.71, 0.237, 337, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1534, 1fvrB, 0.7956, 2.82, 0.343, 300, 254, TIE2 KINASE DOMAIN
1535, 5vjaC, 0.7955, 2.57, 0.235, 265, 251, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
1536, 5vioA, 0.7955, 2.79, 0.277, 271, 253, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
1537, 5m75A, 0.7955, 2.69, 0.233, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A (S)-METHYL SUBSTITUED FASUDIL-DERIVATIVE 
1538, 5i9yA, 0.7955, 2.92, 0.335, 287, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
1539, 4r1vA, 0.7955, 3.01, 0.331, 289, 254, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
1540, 4nh1A, 0.7955, 2.77, 0.223, 330, 256, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1541, 4md9M, 0.7955, 2.75, 0.223, 331, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1542, 3qc9A, 0.7955, 3.15, 0.199, 486, 261, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1543, 3mssB, 0.7955, 2.45, 0.358, 264, 246, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
1544, 3fzpA, 0.7955, 2.13, 0.362, 259, 243, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
1545, 5hq0A, 0.7954, 2.90, 0.255, 292, 255, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
1546, 5eycA, 0.7954, 2.90, 0.333, 288, 252, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
1547, 4z83E, 0.7954, 2.73, 0.237, 335, 253, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 47A
1548, 4yveA, 0.7954, 2.86, 0.187, 390, 257, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
1549, 4y72A, 0.7954, 2.90, 0.255, 292, 255, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
1550, 3zfxG, 0.7954, 1.91, 0.333, 253, 240, CRYSTAL STRUCTURE OF EPHB1
1551, 3warA, 0.7954, 2.76, 0.227, 334, 256, CRYSTAL STRUCTURE OF HUMAN CK2A
1552, 3up2A, 0.7954, 2.74, 0.212, 266, 255, AURORA A IN COMPLEX WITH RPM1686
1553, 3u9cB, 0.7954, 2.76, 0.227, 331, 256, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1554, 3mssA, 0.7954, 2.40, 0.358, 264, 246, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
1555, 1h1pA, 0.7954, 2.82, 0.255, 296, 255, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1556, 5x8iB, 0.7953, 2.86, 0.258, 327, 252, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
1557, 5x8iA, 0.7953, 2.86, 0.258, 328, 252, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
1558, 5os7A, 0.7953, 2.81, 0.219, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
1559, 5d7vA, 0.7953, 2.41, 0.329, 268, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
1560, 5b7vA, 0.7953, 2.52, 0.390, 282, 249, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
1561, 4wotB, 0.7953, 2.85, 0.183, 394, 257, ROCK2 IN COMPLEX WITH 1426382-07-1
1562, 4wnpD, 0.7953, 2.74, 0.247, 272, 255, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1563, 4rqkA, 0.7953, 2.71, 0.200, 285, 255, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
1564, 4rfyA, 0.7953, 2.43, 0.306, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
1565, 4dgmA, 0.7953, 2.74, 0.215, 326, 256, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
1566, 4deaA, 0.7953, 2.74, 0.212, 266, 255, AURORA A IN COMPLEX WITH YL1-038-18
1567, 3ppjB, 0.7953, 2.38, 0.270, 264, 248, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
1568, 3mssD, 0.7953, 2.43, 0.362, 264, 246, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
1569, 1snuB, 0.7953, 1.70, 0.321, 241, 237, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1570, 1sm2A, 0.7953, 1.81, 0.318, 245, 239, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1571, 5u9dA, 0.7952, 2.56, 0.313, 271, 252, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
1572, 5p9iA, 0.7952, 2.55, 0.303, 271, 251, BTK1 SOAKED WITH IBRUTINIB-REV
1573, 5n3sA, 0.7952, 2.67, 0.234, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-HYDROXYBENZAMIDE
1574, 5n3kA, 0.7952, 2.66, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE O-GUANIDINO-L-HOMOSERINE
1575, 5ar3A, 0.7952, 2.26, 0.268, 279, 246, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
1576, 4mf1B, 0.7952, 2.07, 0.318, 246, 242, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
1577, 4md9F, 0.7952, 2.78, 0.219, 327, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1578, 3mssC, 0.7952, 2.41, 0.358, 264, 246, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
1579, 3fhiA, 0.7952, 2.71, 0.233, 336, 253, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
1580, 3c4xB, 0.7952, 3.09, 0.195, 475, 261, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
1581, 2yabB, 0.7952, 2.63, 0.232, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
1582, 1stcE, 0.7952, 2.70, 0.245, 334, 253, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1583, 1jwhB, 0.7952, 2.75, 0.227, 335, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1584, 1dayA, 0.7952, 2.75, 0.215, 327, 256, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
1585, 6gmdB, 0.7951, 2.82, 0.219, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
1586, 5n9nA, 0.7951, 2.76, 0.219, 329, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
1587, 5n3nA, 0.7951, 2.66, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE [(2R)-24-DIHYDROXY-4-OXOBUTYL]- TRIMETHYLAZANIUM
1588, 5hu3A, 0.7951, 2.61, 0.227, 266, 251, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1589, 4xcuA, 0.7951, 2.78, 0.387, 288, 253, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
1590, 4uj2A, 0.7951, 2.74, 0.233, 335, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1591, 4o27B, 0.7951, 2.62, 0.257, 281, 253, CRYSTAL STRUCTURE OF MST3-MO25 COMPLEX WITH WIF MOTIF
1592, 4o0vA, 0.7951, 2.81, 0.215, 290, 256, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1593, 3v5lC, 0.7951, 1.96, 0.312, 244, 240, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
1594, 3u9cA, 0.7951, 2.78, 0.227, 331, 256, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1595, 3ppkB, 0.7951, 2.38, 0.270, 264, 248, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1596, 2uzuE, 0.7951, 2.77, 0.232, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1597, 2helA, 0.7951, 2.51, 0.312, 256, 247, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
1598, 1q62A, 0.7951, 2.74, 0.237, 336, 253, PKA DOUBLE MUTANT MODEL OF PKB
1599, 5n3tA, 0.7950, 2.68, 0.234, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 5-CHLOROTHIOPHENE-2-SULFONAMIDE
1600, 4ujbA, 0.7950, 2.73, 0.233, 344, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1601, 3mpmA, 0.7950, 2.23, 0.354, 257, 246, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
1602, 2xikA, 0.7950, 2.67, 0.253, 288, 253, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
1603, 2oh0E, 0.7950, 2.76, 0.240, 336, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
1604, 2cchC, 0.7950, 2.66, 0.258, 296, 252, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
1605, 5otyA, 0.7949, 2.80, 0.227, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
1606, 5n3pA, 0.7949, 2.67, 0.234, 336, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 1H-INDOL-5-OL
1607, 5mohA, 0.7949, 2.79, 0.227, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
1608, 5j87A, 0.7949, 2.43, 0.306, 263, 248, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1609, 5j1wA, 0.7949, 2.90, 0.254, 338, 252, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1610, 5h2uC, 0.7949, 2.44, 0.333, 264, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1611, 4jdiA, 0.7949, 2.83, 0.215, 289, 256, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1612, 4cmtA, 0.7949, 2.45, 0.321, 284, 246, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
1613, 3s95A, 0.7949, 2.58, 0.268, 290, 250, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1614, 3a4pA, 0.7949, 2.74, 0.332, 285, 250, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
1615, 1vebA, 0.7949, 2.73, 0.237, 338, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
1616, 1sm2B, 0.7949, 1.62, 0.322, 241, 236, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1617, 5nkgA, 0.7948, 2.85, 0.328, 292, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
1618, 5n3hA, 0.7948, 2.67, 0.234, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE PYRIDINE-3-CARBOXAMIDE
1619, 5m0lA, 0.7948, 2.73, 0.237, 338, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE METHYLATED FASUDIL-DERIVED FRAGMENT N-METHYLISOQUINOLINE-5- SULFONAMIDE (LIGAND 02) 
1620, 5ku8A, 0.7948, 2.78, 0.223, 328, 256, CRYSTAL STRUCTURE OF CK2
1621, 5j5xA, 0.7948, 2.72, 0.233, 340, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1416
1622, 4uj1A, 0.7948, 2.73, 0.233, 335, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1623, 4oh4A, 0.7948, 2.65, 0.228, 299, 250, CRYSTAL STRUCTURE OF BRI1 IN COMPLEX WITH BKI1
1624, 4md9L, 0.7948, 2.66, 0.213, 328, 253, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1625, 4f64B, 0.7948, 2.67, 0.398, 272, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
1626, 3uqfA, 0.7948, 1.99, 0.342, 260, 243, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
1627, 3rhxB, 0.7948, 2.67, 0.398, 275, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
1628, 3dtwB, 0.7948, 2.37, 0.380, 269, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
1629, 3c4xA, 0.7948, 3.11, 0.199, 496, 261, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
1630, 3at3A, 0.7948, 2.79, 0.219, 332, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
1631, 2uzwE, 0.7948, 2.78, 0.232, 336, 254, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
1632, 2oxdA, 0.7948, 2.74, 0.215, 325, 256, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
1633, 2a2aB, 0.7948, 2.87, 0.226, 303, 257, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1634, 5n3mA, 0.7947, 2.68, 0.234, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE D-ARGININE
1635, 5h2uA, 0.7947, 2.43, 0.333, 265, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1636, 5bmsA, 0.7947, 2.87, 0.207, 290, 256, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1637, 4ujaA, 0.7947, 2.74, 0.233, 336, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1638, 4uj9A, 0.7947, 2.74, 0.233, 339, 253, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1639, 3thbA, 0.7947, 2.81, 0.264, 287, 254, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1640, 3psdB, 0.7947, 2.39, 0.270, 264, 248, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
1641, 2eufB, 0.7947, 2.84, 0.255, 282, 255, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
1642, 1fgkB, 0.7947, 2.66, 0.398, 272, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
1643, 5otiA, 0.7946, 2.84, 0.227, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 27
1644, 5edrA, 0.7946, 2.41, 0.377, 299, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
1645, 5cu3B, 0.7946, 2.84, 0.219, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1646, 4yxrA, 0.7946, 2.74, 0.233, 334, 253, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1647, 4md8E, 0.7946, 2.78, 0.223, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1648, 4ij9A, 0.7946, 2.75, 0.241, 335, 253, BOVINE PKA C-ALPHA IN COMPLEX WITH 2-[[5-(4-PYRIDYL)-1H-124-TRIAZOL- 3-YL]SULFANYL]-1-(2-THIOPHENYL)ETHANONE
1649, 4f1mA, 0.7946, 2.91, 0.250, 278, 256, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
1650, 3vqhA, 0.7946, 2.74, 0.233, 344, 253, BROMINE SAD PARTIALLY RESOLVES MULTIPLE BINDING MODES FOR PKA INHIBITOR H-89
1651, 3tacA, 0.7946, 2.83, 0.218, 324, 257, CRYSTAL STRUCTURE OF THE LIPRIN-ALPHA/CASK COMPLEX
1652, 3pxkA, 0.7946, 2.18, 0.343, 256, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
1653, 3oogA, 0.7946, 2.74, 0.233, 333, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
1654, 1jluE, 0.7946, 2.74, 0.229, 337, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
1655, 5h8eB, 0.7945, 2.78, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1656, 4wotD, 0.7945, 2.84, 0.180, 389, 256, ROCK2 IN COMPLEX WITH 1426382-07-1
1657, 4dymA, 0.7945, 3.00, 0.245, 293, 257, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
1658, 3zo4A, 0.7945, 2.74, 0.233, 335, 253, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
1659, 3u87A, 0.7945, 2.79, 0.227, 329, 256, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1660, 3psbB, 0.7945, 2.38, 0.266, 264, 248, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
1661, 3priA, 0.7945, 2.40, 0.270, 264, 248, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1662, 3e8eP, 0.7945, 2.73, 0.233, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1663, 3e8cA, 0.7945, 2.72, 0.233, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1664, 2y7jA, 0.7945, 2.62, 0.217, 284, 253, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1665, 1zogA, 0.7945, 2.74, 0.215, 325, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
1666, 1svgA, 0.7945, 2.74, 0.237, 338, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
1667, 5vgoA, 0.7944, 2.62, 0.304, 265, 250, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
1668, 5u7rB, 0.7944, 2.88, 0.179, 387, 257, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1669, 5owlB, 0.7944, 2.75, 0.227, 332, 256, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1670, 5motA, 0.7944, 2.79, 0.223, 328, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
1671, 5mo8A, 0.7944, 2.84, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1672, 5eydA, 0.7944, 2.85, 0.339, 289, 251, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
1673, 4riyC, 0.7944, 2.84, 0.335, 275, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
1674, 4mneC, 0.7944, 2.34, 0.255, 260, 247, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1675, 4md9P, 0.7944, 2.79, 0.223, 328, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1676, 4h58A, 0.7944, 2.42, 0.266, 263, 248, BRAF IN COMPLEX WITH COMPOUND 3
1677, 3priB, 0.7944, 2.40, 0.270, 264, 248, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1678, 3e8eL, 0.7944, 2.73, 0.233, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1679, 3e8cC, 0.7944, 2.72, 0.233, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1680, 2ijmB, 0.7944, 2.36, 0.370, 261, 246, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
1681, 2esmA, 0.7944, 2.88, 0.187, 400, 257, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
1682, 1wvxA, 0.7944, 2.67, 0.249, 275, 253, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1683, 4ubaA, 0.7943, 2.78, 0.227, 333, 256, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1684, 4rixC, 0.7943, 2.84, 0.335, 275, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
1685, 3wowA, 0.7943, 2.80, 0.219, 334, 256, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
1686, 3v8wB, 0.7943, 1.87, 0.315, 242, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
1687, 3miaA, 0.7943, 3.05, 0.243, 324, 259, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
1688, 3e8eB, 0.7943, 2.64, 0.234, 337, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1689, 2p2iB, 0.7943, 2.18, 0.373, 263, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
1690, 2oxyA, 0.7943, 2.64, 0.209, 327, 253, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1691, 1sveA, 0.7943, 2.74, 0.237, 341, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
1692, 5o4aB, 0.7942, 2.59, 0.398, 291, 251, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
1693, 5kupA, 0.7942, 2.64, 0.296, 265, 250, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
1694, 4ymjA, 0.7942, 2.51, 0.399, 270, 248, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1695, 4degA, 0.7942, 2.89, 0.335, 286, 251, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
1696, 3e8cF, 0.7942, 2.73, 0.233, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1697, 3dneA, 0.7942, 2.73, 0.241, 336, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
1698, 3c50B, 0.7942, 3.12, 0.202, 496, 262, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
1699, 2yaaB, 0.7942, 2.66, 0.236, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
1700, 2v55C, 0.7942, 2.81, 0.191, 396, 257, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
1701, 1svhA, 0.7942, 2.74, 0.237, 335, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
1702, 1snuA, 0.7942, 1.82, 0.318, 245, 239, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1703, 5n3qA, 0.7941, 2.68, 0.238, 336, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINOBENZAMIDE
1704, 5n3iA, 0.7941, 2.69, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL (2S)-2-AMINO-3-PHENYLPROPANOATE
1705, 5mo7A, 0.7941, 2.82, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1706, 5m0cA, 0.7941, 2.75, 0.233, 336, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE FASUDIL-FRAGMENT ISOQUINOLINE-5-SULFONAMIDE 
1707, 5ig1B, 0.7941, 2.79, 0.247, 304, 255, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1708, 5h2uB, 0.7941, 2.45, 0.333, 263, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1709, 5bvwA, 0.7941, 2.40, 0.369, 274, 249, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
1710, 4v05A, 0.7941, 2.70, 0.397, 287, 252, FGFR1 IN COMPLEX WITH AZD4547.
1711, 4md9K, 0.7941, 2.77, 0.219, 328, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1712, 4deiA, 0.7941, 2.87, 0.333, 287, 252, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
1713, 3e8cE, 0.7941, 2.73, 0.233, 336, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1714, 2vx0A, 0.7941, 2.90, 0.304, 273, 253, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1715, 1jamA, 0.7941, 2.78, 0.211, 327, 256, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
1716, 5ts8A, 0.7940, 2.77, 0.219, 332, 256, Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 56-DIBROMOBENZOTRIAZOLE
1717, 5tehB, 0.7940, 2.16, 0.344, 262, 244, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
1718, 5n9kA, 0.7940, 2.77, 0.219, 329, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
1719, 5mo7B, 0.7940, 2.81, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1720, 5kwhB, 0.7940, 2.78, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2
1721, 5h8bB, 0.7940, 2.80, 0.223, 331, 256, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1722, 5cu3A, 0.7940, 2.85, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1723, 5cu2A, 0.7940, 2.84, 0.219, 328, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1724, 4ymjB, 0.7940, 2.50, 0.399, 275, 248, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1725, 4riwC, 0.7940, 2.85, 0.327, 275, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
1726, 4o22A, 0.7940, 2.69, 0.234, 336, 252, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
1727, 3e8cD, 0.7940, 2.73, 0.233, 344, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1728, 2y7jC, 0.7940, 2.72, 0.197, 284, 254, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1729, 2qu6A, 0.7940, 2.05, 0.383, 283, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
1730, 2ogvA, 0.7940, 2.73, 0.331, 317, 251, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
1731, 1snxA, 0.7940, 1.82, 0.318, 245, 239, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1732, 1rekA, 0.7940, 2.73, 0.229, 336, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
1733, 1qmzC, 0.7940, 2.67, 0.254, 296, 252, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1734, 1oguC, 0.7940, 2.77, 0.252, 272, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1735, 6ft9A, 0.7939, 2.93, 0.250, 336, 252, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1736, 5vioB, 0.7939, 2.75, 0.282, 271, 252, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
1737, 5h2uD, 0.7939, 2.46, 0.333, 263, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1738, 4otrA, 0.7939, 2.46, 0.306, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
1739, 4o0yA, 0.7939, 2.94, 0.214, 290, 257, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1740, 4md9E, 0.7939, 2.80, 0.215, 329, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1741, 4c3fA, 0.7939, 2.24, 0.354, 257, 246, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
1742, 3e8cB, 0.7939, 2.73, 0.233, 344, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1743, 2y7jB, 0.7939, 2.70, 0.213, 281, 253, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1744, 2vx1A, 0.7939, 2.82, 0.290, 274, 252, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1745, 2rfsA, 0.7939, 2.66, 0.335, 264, 248, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
1746, 5wnhD, 0.7938, 2.87, 0.183, 397, 257, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1747, 5n3gA, 0.7938, 2.68, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (R)-14-OXAZEPAN-6-OL
1748, 5mmrA, 0.7938, 2.82, 0.219, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1749, 5hngA, 0.7938, 2.58, 0.211, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1750, 4wnpC, 0.7938, 2.71, 0.252, 271, 254, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
1751, 4o0xA, 0.7938, 2.89, 0.218, 290, 257, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1752, 4nksB, 0.7938, 2.62, 0.396, 271, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
1753, 3u87B, 0.7938, 2.77, 0.227, 329, 256, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1754, 3tnpF, 0.7938, 2.69, 0.230, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1755, 3tnpC, 0.7938, 2.69, 0.230, 334, 252, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1756, 3pvbA, 0.7938, 2.58, 0.231, 341, 251, CRYSTAL STRUCTURE OF (73-244)RIA:C HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
1757, 3kxmA, 0.7938, 2.75, 0.215, 326, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
1758, 3g0eA, 0.7938, 2.55, 0.348, 332, 250, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1759, 3b8rA, 0.7938, 2.13, 0.384, 289, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1760, 2vwyA, 0.7938, 2.83, 0.304, 274, 253, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1761, 1jbpE, 0.7938, 2.74, 0.229, 339, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
1762, 6ehkA, 0.7937, 2.82, 0.227, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712 AND COMPOUND 37
1763, 5u6yL, 0.7937, 2.37, 0.249, 459, 249, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1764, 5u6yK, 0.7937, 2.37, 0.249, 459, 249, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1765, 5u6yJ, 0.7937, 2.37, 0.249, 459, 249, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1766, 5u6yI, 0.7937, 2.37, 0.249, 459, 249, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1767, 5u6yH, 0.7937, 2.37, 0.249, 459, 249, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1768, 5u6yG, 0.7937, 2.37, 0.249, 459, 249, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1769, 5u6yF, 0.7937, 2.37, 0.249, 459, 249, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1770, 5u6yE, 0.7937, 2.37, 0.249, 459, 249, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1771, 5u6yD, 0.7937, 2.37, 0.249, 459, 249, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1772, 5u6yC, 0.7937, 2.37, 0.249, 459, 249, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1773, 5u6yB, 0.7937, 2.37, 0.249, 459, 249, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1774, 5u6yA, 0.7937, 2.37, 0.249, 459, 249, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1775, 4v01B, 0.7937, 2.39, 0.390, 275, 246, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
1776, 4hptE, 0.7937, 2.75, 0.229, 335, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING COMPLETE PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
1777, 3wikA, 0.7937, 2.80, 0.211, 334, 256, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
1778, 3v8wA, 0.7937, 1.87, 0.315, 243, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
1779, 3ow3A, 0.7937, 2.75, 0.233, 334, 253, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1780, 6fnhB, 0.7936, 2.97, 0.312, 271, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
1781, 5zv2B, 0.7936, 2.69, 0.402, 282, 251, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
1782, 5lcpA, 0.7936, 2.70, 0.245, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH FASUDIL (M77)
1783, 5j87D, 0.7936, 2.43, 0.306, 263, 248, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1784, 4jajA, 0.7936, 2.69, 0.228, 265, 254, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
1785, 4ii5C, 0.7936, 2.62, 0.255, 295, 251, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
1786, 4fl3A, 0.7936, 2.66, 0.372, 538, 250, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
1787, 3g5dB, 0.7936, 2.09, 0.333, 257, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1788, 3el8B, 0.7936, 2.12, 0.346, 259, 243, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1789, 3e8eE, 0.7936, 2.73, 0.233, 341, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1790, 3cpcB, 0.7936, 2.15, 0.378, 262, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
1791, 2vo7A, 0.7936, 2.76, 0.237, 335, 253, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
1792, 2gnfA, 0.7936, 2.74, 0.241, 339, 253, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
1793, 6fyoA, 0.7935, 2.88, 0.258, 331, 252, X-RAY STRUCTURE OF CLK1-KD(148-484)/CPD-2 AT 2.32A 
1794, 6d20A, 0.7935, 2.69, 0.376, 296, 250, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE AND 5-{[2;4- DICHLORO-5-(PYRIDIN-2-YL)BENZENE-1-CARBONYL]AMINO}-N-(2-HYDROXY-2- METHYLPROPYL)-1-PHENYL-1H-PYRAZOLE-3-CARBOXAMIDE INHIBITORS 
1795, 5wr7A, 0.7935, 2.67, 0.382, 301, 249, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
1796, 5wneD, 0.7935, 2.87, 0.187, 396, 257, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1797, 5vioD, 0.7935, 2.85, 0.276, 271, 254, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
1798, 5vedA, 0.7935, 2.80, 0.215, 289, 256, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1799, 5nk5A, 0.7935, 2.73, 0.328, 287, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
1800, 5j1vB, 0.7935, 2.93, 0.250, 337, 252, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1801, 5h8bA, 0.7935, 2.76, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1802, 5b7vB, 0.7935, 2.45, 0.395, 277, 248, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
1803, 4yzmB, 0.7935, 2.58, 0.277, 262, 249, HUMANIZED ROCO4 BOUND TO LRRK2-IN1
1804, 4nwmB, 0.7935, 2.34, 0.320, 261, 247, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
1805, 3pe1A, 0.7935, 2.79, 0.219, 327, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
1806, 3owpA, 0.7935, 2.76, 0.233, 334, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1807, 3mi9A, 0.7935, 3.04, 0.243, 328, 259, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
1808, 3fjqE, 0.7935, 2.76, 0.229, 334, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
1809, 3eknA, 0.7935, 2.96, 0.316, 297, 256, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
1810, 2zjwA, 0.7935, 2.68, 0.213, 332, 253, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
1811, 2vwzA, 0.7935, 2.83, 0.290, 274, 252, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1812, 1qmzA, 0.7935, 2.68, 0.254, 296, 252, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
1813, 5n3jA, 0.7934, 2.70, 0.234, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-NITROBENZOIC ACID
1814, 5n1dA, 0.7934, 2.53, 0.235, 348, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-METHYL-1-(5-PYRIDIN-3-YLOXYFURAN-2-YL) METHANAMINE
1815, 5j79A, 0.7934, 2.36, 0.267, 283, 247, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1816, 4wboB, 0.7934, 3.17, 0.218, 495, 262, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1817, 4ot5A, 0.7934, 2.50, 0.298, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
1818, 4kioD, 0.7934, 1.90, 0.322, 242, 239, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1819, 4i3zC, 0.7934, 2.63, 0.255, 295, 251, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
1820, 4i3zA, 0.7934, 2.63, 0.255, 295, 251, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
1821, 3qamE, 0.7934, 2.75, 0.225, 348, 253, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1822, 3mb6A, 0.7934, 2.82, 0.223, 329, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
1823, 3gqlA, 0.7934, 2.69, 0.393, 287, 252, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
1824, 3axwA, 0.7934, 2.80, 0.215, 329, 256, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
1825, 2vn9B, 0.7934, 2.59, 0.225, 301, 253, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1826, 2v55A, 0.7934, 2.84, 0.191, 393, 257, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
1827, 2jdtA, 0.7934, 2.75, 0.237, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1828, 5oumA, 0.7933, 2.85, 0.219, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
1829, 5orhB, 0.7933, 2.84, 0.219, 325, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
1830, 5n1hA, 0.7933, 2.70, 0.234, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL 4-(AMINOMETHYL)BENZOATE
1831, 5lcqA, 0.7933, 2.76, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH LONG-CHAIN FASUDIL-DERIVATIVE (LIGAND 05)
1832, 5cu4A, 0.7933, 2.74, 0.213, 327, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1833, 5clpB, 0.7933, 2.83, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1834, 5bx7A, 0.7933, 2.76, 0.233, 343, 253, PKA IN COMPLEX WITH A BENZOTHIOPHENE FRAGMENT COMPOUND.
1835, 4x6qC, 0.7933, 2.69, 0.230, 334, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1836, 4o21A, 0.7933, 2.70, 0.234, 333, 252, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
1837, 4gubA, 0.7933, 2.81, 0.219, 329, 256, CASEIN KINASE II BOUND TO INHIBITOR
1838, 3oezA, 0.7933, 2.26, 0.335, 261, 245, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
1839, 3at2A, 0.7933, 2.78, 0.227, 334, 256, CRYSTAL STRUCTURE OF CK2ALPHA
1840, 2wtkE, 0.7933, 2.50, 0.225, 308, 249, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
1841, 2gngA, 0.7933, 2.74, 0.237, 338, 253, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
1842, 1agwA, 0.7933, 2.67, 0.378, 278, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
1843, 5vilD, 0.7932, 2.87, 0.276, 271, 254, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
1844, 5n9lA, 0.7932, 2.81, 0.215, 329, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
1845, 5m0bA, 0.7932, 2.76, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A SHORT-CHAINED N-(2-AMINOETHYL)ISOQUINOLINE-5-SULFONAMIDE) FASUDIL-DERIVATIVE (LIGAND 03) 
1846, 5izfA, 0.7932, 2.70, 0.233, 336, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1408
1847, 4yo4A, 0.7932, 2.64, 0.250, 280, 252, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
1848, 4eoqC, 0.7932, 2.81, 0.251, 275, 255, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
1849, 4axaA, 0.7932, 2.76, 0.233, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1S)-2-AMINO-1-( 4-CHLOROPHENYL)-1-(4-(1H-PYRAZOL-4-YL)PHENYL)ETHAN-1-OL
1850, 3x2wA, 0.7932, 2.70, 0.234, 336, 252, MICHAELIS COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1851, 3d9vB, 0.7932, 2.78, 0.184, 398, 256, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
1852, 3bhhB, 0.7932, 2.46, 0.220, 289, 250, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1853, 2c1aA, 0.7932, 2.75, 0.237, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
1854, 1snxB, 0.7932, 1.83, 0.318, 245, 239, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1855, 1m2rA, 0.7932, 2.77, 0.211, 327, 256, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
1856, 5wnfD, 0.7931, 2.86, 0.187, 396, 257, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1857, 5nkfA, 0.7931, 2.80, 0.329, 291, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
1858, 5m4cA, 0.7931, 2.66, 0.217, 329, 253, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
1859, 4xyfA, 0.7931, 2.82, 0.323, 290, 251, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
1860, 4rwlA, 0.7931, 2.56, 0.394, 282, 249, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
1861, 4rg0A, 0.7931, 2.51, 0.298, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
1862, 4eolA, 0.7931, 2.71, 0.258, 294, 252, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1863, 3nczA, 0.7931, 2.90, 0.182, 399, 258, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
1864, 3mj2A, 0.7931, 2.33, 0.309, 259, 246, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
1865, 2vn9A, 0.7931, 2.59, 0.225, 301, 253, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1866, 2uvxA, 0.7931, 2.76, 0.237, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
1867, 2gcdB, 0.7931, 2.79, 0.241, 308, 253, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1868, 2etkA, 0.7931, 2.88, 0.187, 400, 257, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
1869, 1apmE, 0.7931, 2.77, 0.229, 338, 253, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
1870, 6g33A, 0.7930, 2.80, 0.252, 335, 250, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1871, 5xvgA, 0.7930, 2.86, 0.215, 292, 256, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH226
1872, 5mmfA, 0.7930, 2.86, 0.219, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1873, 5kwhA, 0.7930, 2.79, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2
1874, 5b0xA, 0.7930, 2.80, 0.211, 329, 256, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
1875, 4wihA, 0.7930, 2.71, 0.229, 350, 253, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS
1876, 4g3eA, 0.7930, 2.46, 0.214, 314, 248, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
1877, 4eopA, 0.7930, 2.74, 0.252, 297, 254, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1878, 3u4wA, 0.7930, 2.72, 0.310, 275, 252, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
1879, 3pe2A, 0.7930, 2.80, 0.215, 327, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
1880, 3idbA, 0.7930, 2.77, 0.225, 341, 253, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1881, 3gopA, 0.7930, 2.12, 0.328, 300, 241, CRYSTAL STRUCTURE OF THE EGF RECEPTOR JUXTAMEMBRANE AND KINASE DOMAINS
1882, 1rjbA, 0.7930, 2.60, 0.367, 298, 248, CRYSTAL STRUCTURE OF FLT3
1883, 1ds5A, 0.7930, 2.78, 0.211, 328, 256, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1884, 6eiiA, 0.7929, 2.83, 0.219, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
1885, 5u7qC, 0.7929, 2.71, 0.176, 390, 255, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1886, 5t1hB, 0.7929, 2.82, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2
1887, 4ypdA, 0.7929, 2.65, 0.250, 281, 252, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
1888, 4yhtB, 0.7929, 2.35, 0.271, 258, 247, BRAF COMPLEXED WITH AN INHIBITOR
1889, 4fnwA, 0.7929, 2.64, 0.317, 304, 249, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1890, 4f63A, 0.7929, 2.68, 0.378, 278, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
1891, 4dehA, 0.7929, 2.76, 0.336, 286, 250, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
1892, 3q9zB, 0.7929, 2.78, 0.223, 332, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1893, 2qc6A, 0.7929, 2.77, 0.211, 326, 256, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
1894, 1fvrA, 0.7929, 2.80, 0.344, 299, 253, TIE2 KINASE DOMAIN
1895, 6g33C, 0.7928, 2.90, 0.254, 336, 252, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1896, 5nk7A, 0.7928, 2.67, 0.332, 284, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
1897, 5n3rA, 0.7928, 2.70, 0.238, 336, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(CARBAMOYLAMINO)-4- METHYLSULFANYLBUTANOIC ACID
1898, 5lpvA, 0.7928, 2.59, 0.229, 282, 249, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
1899, 5jrsA, 0.7928, 2.26, 0.322, 258, 245, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
1900, 5ct0A, 0.7928, 2.85, 0.219, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1901, 4rfzA, 0.7928, 2.51, 0.298, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
1902, 4l9iA, 0.7928, 3.11, 0.203, 504, 261, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
1903, 4ie9A, 0.7928, 2.76, 0.233, 335, 253, BOVINE PKA C-ALPHA IN COMPLEX WITH 3-PYRIDYLMETHYL-5-METHYL-1H- PYRAZOLE-3-CARBOXYLATE
1904, 4ib5C, 0.7928, 2.82, 0.223, 332, 256, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1905, 4eokA, 0.7928, 2.69, 0.254, 293, 252, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1906, 4b6lA, 0.7928, 2.83, 0.248, 281, 254, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
1907, 3rcdC, 0.7928, 2.42, 0.351, 281, 245, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
1908, 3l9nA, 0.7928, 2.73, 0.241, 332, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
1909, 3kxgA, 0.7928, 2.77, 0.215, 326, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
1910, 2c1bA, 0.7928, 2.77, 0.237, 335, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
1911, 1rdqE, 0.7928, 2.77, 0.229, 340, 253, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1912, 1m2qA, 0.7928, 2.79, 0.211, 327, 256, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
1913, 1ds5C, 0.7928, 2.79, 0.211, 328, 256, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1914, 5vefA, 0.7927, 2.81, 0.204, 289, 255, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
1915, 5u7qA, 0.7927, 2.71, 0.176, 388, 255, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1916, 5n1gA, 0.7927, 2.71, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(2-AMINO-13-THIAZOL-4-YL)-1- OXASPIRO[4.5]DECAN-2-ONE
1917, 5cu0A, 0.7927, 2.85, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1918, 4yvcA, 0.7927, 2.95, 0.183, 388, 257, ROCK 1 BOUND TO THIAZOLE INHIBITOR
1919, 4wotA, 0.7927, 2.71, 0.181, 389, 254, ROCK2 IN COMPLEX WITH 1426382-07-1
1920, 4fr4F, 0.7927, 2.98, 0.224, 346, 259, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1921, 3rcdA, 0.7927, 2.42, 0.351, 281, 245, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
1922, 3ngaA, 0.7927, 2.79, 0.227, 331, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1923, 3bysA, 0.7927, 2.28, 0.369, 255, 244, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
1924, 2pvhA, 0.7927, 2.78, 0.211, 327, 256, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1925, 1xh5A, 0.7927, 2.76, 0.241, 335, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1926, 1fgkA, 0.7927, 2.68, 0.378, 278, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
1927, 5lcuA, 0.7926, 2.71, 0.245, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A S-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 01)
1928, 5cx9A, 0.7926, 2.86, 0.219, 328, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1929, 4xw5A, 0.7926, 2.70, 0.234, 334, 252, X-RAY STRUCTURE OF PKAC WITH ATP CP20 CALCIUM IONS
1930, 4rlkA, 0.7926, 2.78, 0.211, 327, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1931, 4cfuC, 0.7926, 2.77, 0.252, 272, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1932, 4aojA, 0.7926, 2.34, 0.355, 260, 245, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
1933, 3ngaB, 0.7926, 2.79, 0.227, 331, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1934, 3be9A, 0.7926, 2.79, 0.211, 327, 256, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
1935, 3agmA, 0.7926, 2.74, 0.237, 337, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
1936, 2uw8A, 0.7926, 2.72, 0.238, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
1937, 1ydsE, 0.7926, 2.76, 0.229, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
1938, 1xh9A, 0.7926, 2.77, 0.245, 336, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1939, 6ft8A, 0.7925, 2.84, 0.255, 338, 251, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 8G 
1940, 5vibA, 0.7925, 2.74, 0.237, 308, 253, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
1941, 5uzkA, 0.7925, 2.77, 0.233, 335, 253, CRYSTAL STRUCTURE OF PKA BOUND TO AN PYRROLO PYRIDINE INHIBITOR
1942, 5n1fA, 0.7925, 2.71, 0.238, 337, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-QUINOLIN-5-YLPYRIDINE-3-CARBOXAMIDE
1943, 5mo8B, 0.7925, 2.84, 0.219, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1944, 5mo5A, 0.7925, 2.86, 0.219, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1945, 5jr7A, 0.7925, 2.70, 0.230, 335, 252, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
1946, 5dr2A, 0.7925, 2.63, 0.230, 264, 252, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
1947, 5bx6A, 0.7925, 2.77, 0.233, 343, 253, PKA IN COMPLEX WITH A HALOGENATED PHTHALAZINONE FRAGMENT COMPOUND.
1948, 4ualA, 0.7925, 2.96, 0.210, 403, 257, MRCK BETA IN COMPLEX WITH BDP00005290
1949, 4c37A, 0.7925, 2.71, 0.238, 335, 252, PKA-S6K1 CHIMERA WITH COMPOUND 21A (CCT196539) BOUND
1950, 3nrmA, 0.7925, 2.67, 0.229, 263, 253, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
1951, 1ydrE, 0.7925, 2.75, 0.229, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
1952, 1q24A, 0.7925, 2.78, 0.229, 335, 253, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1953, 4tyjA, 0.7924, 2.59, 0.398, 278, 246, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
1954, 4f64A, 0.7924, 2.69, 0.378, 278, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
1955, 2vwxA, 0.7924, 2.84, 0.290, 274, 252, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1956, 2fgiA, 0.7924, 2.63, 0.380, 274, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
1957, 1ydtE, 0.7924, 2.78, 0.229, 334, 253, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
1958, 6b3eA, 0.7923, 2.92, 0.241, 309, 257, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
1959, 5xvaA, 0.7923, 2.85, 0.204, 292, 255, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH216
1960, 5t1hA, 0.7923, 2.80, 0.227, 331, 256, CRYSTAL STRUCTURE OF CK2
1961, 5bq0A, 0.7923, 2.74, 0.313, 265, 252, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
1962, 4f63B, 0.7923, 2.67, 0.396, 271, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
1963, 4dh7A, 0.7923, 2.74, 0.230, 333, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20 
1964, 2erzE, 0.7923, 2.76, 0.229, 334, 253, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
1965, 5otrA, 0.7922, 2.75, 0.217, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 14
1966, 5ot6A, 0.7922, 2.85, 0.219, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
1967, 5n7pA, 0.7922, 2.76, 0.233, 350, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(PYRROLIDIN-1-YL)-1H-PYRAZOLE- 4-CARBONITRILE
1968, 5l2qB, 0.7922, 2.61, 0.206, 282, 252, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
1969, 5ek7B, 0.7922, 2.60, 0.332, 286, 250, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
1970, 5dh3A, 0.7922, 3.00, 0.223, 287, 256, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1971, 4z84A, 0.7922, 2.78, 0.233, 335, 253, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 34A
1972, 4f1tA, 0.7922, 2.96, 0.258, 269, 256, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
1973, 4f0fA, 0.7922, 2.95, 0.254, 276, 256, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
1974, 3e3bX, 0.7922, 2.86, 0.211, 334, 256, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
1975, 2etrA, 0.7922, 2.89, 0.187, 400, 257, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
1976, 2cdzA, 0.7922, 2.76, 0.206, 289, 253, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
1977, 1u5qB, 0.7922, 2.82, 0.241, 308, 253, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1978, 6ehuB, 0.7921, 2.83, 0.230, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1979, 5oueA, 0.7921, 2.87, 0.219, 328, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
1980, 5oryA, 0.7921, 2.59, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
1981, 5nk1A, 0.7921, 2.68, 0.332, 284, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
1982, 4xw6A, 0.7921, 2.71, 0.230, 334, 252, X-RAY STRUCTURE OF PKAC WITH ADP FREE PHOSPHATE ION CP20 MAGNESIUM IONS
1983, 4w9xA, 0.7921, 2.60, 0.215, 300, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
1984, 4rllA, 0.7921, 2.82, 0.219, 329, 256, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1985, 4dh1A, 0.7921, 2.73, 0.226, 333, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH LOW MG2+ ATP AND IP20
1986, 4dg2E, 0.7921, 2.72, 0.230, 347, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
1987, 3v5jA, 0.7921, 1.90, 0.315, 241, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
1988, 3r0tA, 0.7921, 2.81, 0.219, 327, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
1989, 3q9wA, 0.7921, 2.82, 0.219, 328, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
1990, 3pzhA, 0.7921, 2.79, 0.211, 327, 256, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
1991, 3omvA, 0.7921, 2.42, 0.274, 264, 248, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
1992, 2y7jD, 0.7921, 2.67, 0.222, 281, 252, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1993, 2oxxA, 0.7921, 2.78, 0.211, 325, 256, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1994, 1zohA, 0.7921, 2.78, 0.215, 326, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
1995, 1fmoE, 0.7921, 2.80, 0.225, 336, 253, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
1996, 1atpE, 0.7921, 2.78, 0.225, 334, 253, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
1997, 5otlB, 0.7920, 2.85, 0.219, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
1998, 5oslA, 0.7920, 2.73, 0.217, 328, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 7
1999, 5n7uA, 0.7920, 2.78, 0.233, 350, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-BROMO-35-DIMETHYL-1H-PYRAZOLE
2000, 5modA, 0.7920, 2.86, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2001, 5jr7C, 0.7920, 2.71, 0.230, 335, 252, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
2002, 4yxsA, 0.7920, 2.77, 0.237, 335, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2003, 4x6rA, 0.7920, 2.72, 0.230, 347, 252, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2004, 4wb6B, 0.7920, 2.70, 0.233, 340, 253, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2005, 4fiiA, 0.7920, 2.84, 0.204, 291, 255, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2006, 4dn5B, 0.7920, 2.58, 0.227, 330, 251, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
2007, 4debA, 0.7920, 2.73, 0.213, 264, 254, AURORA A IN COMPLEX WITH RK2-17-01
2008, 3qalE, 0.7920, 2.77, 0.225, 339, 253, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2009, 3nunA, 0.7920, 2.58, 0.212, 278, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
2010, 3mvjA, 0.7920, 2.78, 0.237, 334, 253, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2011, 3gniB, 0.7920, 2.54, 0.225, 304, 249, STRUCTURE OF STRAD AND MO25
2012, 3dgkA, 0.7920, 2.65, 0.250, 278, 252, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
2013, 3bwjA, 0.7920, 2.71, 0.234, 338, 252, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
2014, 2gnjA, 0.7920, 2.78, 0.237, 335, 253, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
2015, 2fgiB, 0.7920, 2.70, 0.398, 272, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
2016, 1z57A, 0.7920, 2.86, 0.255, 333, 251, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH 10Z-HYMENIALDISINE
2017, 1lr4A, 0.7920, 2.78, 0.211, 327, 256, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
2018, 1ds5B, 0.7920, 2.80, 0.211, 328, 256, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2019, 1cdkA, 0.7920, 2.77, 0.229, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2020, 5uzjA, 0.7919, 2.91, 0.187, 387, 257, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
2021, 5orpA, 0.7919, 2.59, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2022, 4ib0A, 0.7919, 2.73, 0.230, 334, 252, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH NA+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2023, 4iadA, 0.7919, 2.73, 0.230, 334, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2024, 4dc2A, 0.7919, 2.79, 0.192, 328, 255, STRUCTURE OF PKC IN COMPLEX WITH A SUBSTRATE PEPTIDE FROM PAR-3
2025, 4cfnC, 0.7919, 2.77, 0.252, 296, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2026, 3sc1A, 0.7919, 2.56, 0.208, 278, 250, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
2027, 3q9xA, 0.7919, 2.81, 0.223, 330, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
2028, 3kb7A, 0.7919, 2.85, 0.268, 289, 254, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2029, 2qocA, 0.7919, 2.71, 0.312, 283, 250, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
2030, 5lcrA, 0.7918, 2.72, 0.245, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH OPEN-CHAIN FASUDIL-DERIVATIVE (LIGAND 04)
2031, 5cqwB, 0.7918, 2.80, 0.227, 331, 256, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
2032, 4fr4A, 0.7918, 3.00, 0.224, 350, 259, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2033, 4eopC, 0.7918, 2.73, 0.254, 296, 252, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2034, 4dh3A, 0.7918, 2.73, 0.226, 333, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ATP AND IP20
2035, 3qrjB, 0.7918, 2.39, 0.382, 265, 246, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
2036, 2uw7A, 0.7918, 2.77, 0.237, 335, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
2037, 2uw5A, 0.7918, 2.74, 0.234, 333, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2038, 2uw3A, 0.7918, 2.73, 0.238, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
2039, 2h9vA, 0.7918, 2.89, 0.183, 383, 257, STRUCTURAL BASIS FOR INDUCED-FIT BINDING OF RHO-KINASE TO THE INHIBITOR Y27632
2040, 1ds5D, 0.7918, 2.78, 0.211, 328, 256, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2041, 6gmdA, 0.7917, 2.85, 0.223, 325, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
2042, 5wnkA, 0.7917, 2.31, 0.253, 263, 245, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO TG100-115 
2043, 5orvA, 0.7917, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2044, 5orrA, 0.7917, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2045, 5n37A, 0.7917, 2.72, 0.234, 347, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YLMETHYL) CYCLOPENTANAMINE
2046, 5l2qD, 0.7917, 2.75, 0.200, 294, 255, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
2047, 4ubaB, 0.7917, 2.79, 0.223, 333, 256, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
2048, 4otdA, 0.7917, 2.82, 0.267, 334, 255, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
2049, 4h1jA, 0.7917, 2.56, 0.376, 263, 250, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
2050, 4g3dD, 0.7917, 2.46, 0.218, 290, 248, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
2051, 3pwdA, 0.7917, 2.79, 0.211, 327, 256, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
2052, 3c13A, 0.7917, 2.82, 0.223, 328, 256, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2053, 3bqcA, 0.7917, 2.83, 0.219, 328, 256, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2054, 1xh7A, 0.7917, 2.73, 0.238, 337, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2055, 1cdkB, 0.7917, 2.78, 0.229, 342, 253, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2056, 6fnmA, 0.7916, 2.67, 0.288, 270, 250, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH DASATINIB 
2057, 5wnjA, 0.7916, 2.31, 0.249, 264, 245, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN KINASE 4 (RIPK4) D143N IN COMPLEX WITH LESTAURTINIB 
2058, 5veeA, 0.7916, 2.93, 0.206, 289, 257, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
2059, 5oseA, 0.7916, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2060, 5orzA, 0.7916, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2061, 5nk2A, 0.7916, 2.69, 0.332, 290, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
2062, 5mhiA, 0.7916, 2.59, 0.235, 348, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
2063, 4ib3A, 0.7916, 2.72, 0.234, 336, 252, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH ADP PHOSPHORYLATED PEPTIDE PSP20 AND NO METAL
2064, 4ib1A, 0.7916, 2.74, 0.230, 335, 252, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH K+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2065, 4iaiA, 0.7916, 2.74, 0.230, 333, 252, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH CA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2066, 4iacA, 0.7916, 2.72, 0.234, 333, 252, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION AMP-PCP AND PSEUDO-SUBSTRATE PEPTIDE SP20
2067, 4dg3E, 0.7916, 2.75, 0.230, 335, 252, CRYSTAL STRUCTURE OF R336A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED TURN MOTIF.
2068, 3t9tA, 0.7916, 2.64, 0.289, 263, 249, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
2069, 3qlfB, 0.7916, 2.18, 0.332, 258, 244, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
2070, 5osfA, 0.7915, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2071, 5l2wA, 0.7915, 2.71, 0.254, 297, 252, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
2072, 5i0bA, 0.7915, 2.88, 0.215, 288, 256, STRUCTURE OF PAK4
2073, 5cspA, 0.7915, 2.83, 0.223, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
2074, 4hpuE, 0.7915, 2.74, 0.230, 336, 252, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING PARTIAL PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
2075, 4ec9A, 0.7915, 2.91, 0.234, 306, 256, CRYSTAL STRUCTURE OF FULL-LENGTH CDK9 IN COMPLEX WITH CYCLIN T
2076, 3mb7A, 0.7915, 2.85, 0.215, 330, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
2077, 2w4kA, 0.7915, 2.87, 0.246, 301, 256, X-RAY STRUCTURE OF A DAP-KINASE 2-302
2078, 2cpkE, 0.7915, 2.74, 0.230, 333, 252, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
2079, 1q8tA, 0.7915, 2.77, 0.233, 338, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
2080, 5p9hA, 0.7914, 2.47, 0.317, 264, 249, BTK1 COCRYSTALLIZED WITH RN983
2081, 5os4A, 0.7914, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2082, 5ornA, 0.7914, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2083, 5iugA, 0.7914, 2.37, 0.324, 285, 244, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
2084, 5ho7A, 0.7914, 2.62, 0.211, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2085, 5cu2B, 0.7914, 2.86, 0.223, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
2086, 5ctpB, 0.7914, 2.88, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2087, 4xw4A, 0.7914, 2.71, 0.234, 334, 252, X-RAY STRUCTURE OF PKAC WITH AMPPNP SP20 CALCIUM IONS
2088, 4rixA, 0.7914, 2.74, 0.335, 269, 251, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2089, 4ib5B, 0.7914, 2.84, 0.211, 329, 256, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2090, 4dfzE, 0.7914, 2.73, 0.230, 347, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
2091, 4c38A, 0.7914, 2.72, 0.238, 334, 252, PKA-S6K1 CHIMERA WITH COMPOUND 21E (CCT239066) BOUND
2092, 4a06A, 0.7914, 2.69, 0.202, 282, 253, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
2093, 3vw8A, 0.7914, 2.55, 0.335, 303, 245, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
2094, 3pvgA, 0.7914, 2.80, 0.211, 326, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
2095, 3pooA, 0.7914, 2.78, 0.233, 331, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2096, 3l9lB, 0.7914, 2.77, 0.237, 337, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2097, 3gu8A, 0.7914, 2.65, 0.250, 278, 252, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
2098, 3c4wA, 0.7914, 3.06, 0.215, 494, 261, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
2099, 3bhtC, 0.7914, 2.71, 0.254, 270, 252, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
2100, 2fb8A, 0.7914, 2.33, 0.272, 259, 246, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
2101, 2acxA, 0.7914, 3.23, 0.195, 495, 261, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
2102, 1lpuA, 0.7914, 2.80, 0.211, 327, 256, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
2103, 6eiiB, 0.7913, 2.85, 0.219, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
2104, 6d1zA, 0.7913, 2.53, 0.379, 290, 248, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE INHIBITOR 
2105, 5uzjB, 0.7913, 2.76, 0.189, 386, 254, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
2106, 5u6cA, 0.7913, 2.42, 0.351, 272, 245, CRYSTAL STRUCTURE OF THE MER KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2107, 5othB, 0.7913, 2.88, 0.219, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
2108, 5os6A, 0.7913, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2109, 5os1A, 0.7913, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2110, 5orxA, 0.7913, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2111, 5orwA, 0.7913, 2.60, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2112, 5m6vA, 0.7913, 2.74, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A DOUBLE METHYLATED FASUDIL-DERIVATIVE 
2113, 5ar3B, 0.7913, 2.21, 0.270, 276, 244, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
2114, 4pmpA, 0.7913, 2.54, 0.381, 280, 247, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
2115, 4p2kA, 0.7913, 2.42, 0.312, 259, 247, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2116, 4lfiB, 0.7913, 2.83, 0.207, 371, 256, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
2117, 4ii5A, 0.7913, 2.80, 0.256, 295, 254, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
2118, 4fihA, 0.7913, 2.86, 0.215, 291, 256, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
2119, 4dh5A, 0.7913, 2.72, 0.230, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ADP PHOSPHATE AND IP20
2120, 3qa0A, 0.7913, 2.83, 0.223, 330, 256, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
2121, 3dkcA, 0.7913, 2.82, 0.320, 312, 253, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
2122, 3amaA, 0.7913, 2.77, 0.233, 342, 253, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
2123, 2w4jA, 0.7913, 2.65, 0.250, 276, 252, X-RAY STRUCTURE OF A DAP-KINASE 2-277
2124, 1uu8A, 0.7913, 2.62, 0.211, 277, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
2125, 5othA, 0.7912, 2.85, 0.219, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
2126, 5os7B, 0.7912, 2.86, 0.219, 325, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
2127, 5os0A, 0.7912, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2128, 5i9xA, 0.7912, 2.71, 0.332, 284, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
2129, 4wb6A, 0.7912, 2.66, 0.230, 336, 252, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2130, 4riyA, 0.7912, 2.74, 0.335, 269, 251, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2131, 4m0yA, 0.7912, 2.77, 0.288, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
2132, 4fr4D, 0.7912, 3.00, 0.224, 346, 259, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2133, 3uo4A, 0.7912, 2.74, 0.197, 266, 254, AURORA A IN COMPLEX WITH RPM1680
2134, 3q9yA, 0.7912, 2.83, 0.223, 327, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
2135, 3nczD, 0.7912, 2.89, 0.187, 397, 257, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2136, 2gnhA, 0.7912, 2.77, 0.237, 338, 253, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
2137, 5uplA, 0.7911, 2.88, 0.196, 290, 255, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTEFACE - 2 PEPTIDE: PAK4FL CDC42 - UNREFINED
2138, 5ot5B, 0.7911, 2.88, 0.219, 325, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
2139, 5lvoA, 0.7911, 2.76, 0.192, 285, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
2140, 5li1A, 0.7911, 2.65, 0.198, 331, 252, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
2141, 5eobA, 0.7911, 3.00, 0.328, 288, 253, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
2142, 5cu0B, 0.7911, 2.87, 0.223, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2143, 4yhtA, 0.7911, 2.33, 0.272, 256, 246, BRAF COMPLEXED WITH AN INHIBITOR
2144, 4lfiA, 0.7911, 2.83, 0.207, 370, 256, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
2145, 4iakA, 0.7911, 2.73, 0.234, 334, 252, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2146, 4eosA, 0.7911, 2.77, 0.256, 296, 254, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2147, 3zo2A, 0.7911, 2.73, 0.238, 340, 252, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2148, 3tl8D, 0.7911, 2.69, 0.258, 306, 252, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2149, 3qgyA, 0.7911, 2.07, 0.320, 246, 241, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
2150, 3ovvA, 0.7911, 2.79, 0.233, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2151, 2qcsA, 0.7911, 2.74, 0.230, 335, 252, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
2152, 5ot6B, 0.7910, 2.88, 0.219, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
2153, 5o0eA, 0.7910, 2.68, 0.246, 349, 252, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND FASUDIL 
2154, 5mpjA, 0.7910, 2.84, 0.223, 326, 256, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
2155, 5mo6A, 0.7910, 2.88, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2156, 5m71A, 0.7910, 2.73, 0.245, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH AN (R)-METHYL SUBSTITUED FASUDIL-DERIVATIVE. 
2157, 4gk3A, 0.7910, 2.65, 0.327, 275, 248, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
2158, 3x2vA, 0.7910, 2.75, 0.230, 331, 252, MICHAELIS-LIKE COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2159, 3t8oA, 0.7910, 3.20, 0.202, 493, 262, RHODOPSIN KINASE (GRK1) L166K MUTANT AT 2.5A RESOLUTION
2160, 3qd3A, 0.7910, 2.59, 0.212, 278, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
2161, 3gu6A, 0.7910, 2.67, 0.250, 280, 252, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
2162, 3aoxA, 0.7910, 2.66, 0.309, 298, 249, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
2163, 2wxvA, 0.7910, 2.93, 0.246, 302, 256, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2164, 2pvlA, 0.7910, 2.80, 0.211, 327, 256, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2165, 1xh6A, 0.7910, 2.80, 0.237, 331, 253, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2166, 1xh4A, 0.7910, 2.73, 0.234, 334, 252, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2167, 6ehuA, 0.7909, 2.84, 0.230, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
2168, 6dkiA, 0.7909, 2.46, 0.381, 279, 247, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 19. 
2169, 5vloA, 0.7909, 2.56, 0.239, 290, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2170, 5p9mA, 0.7909, 2.79, 0.310, 271, 252, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
2171, 5os3A, 0.7909, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2172, 5nk6A, 0.7909, 2.59, 0.333, 284, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
2173, 5n3cA, 0.7909, 2.64, 0.235, 348, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE THIOPHENE-3-CARBOXIMIDAMIDE
2174, 5cu6A, 0.7909, 2.84, 0.223, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA
2175, 5csvA, 0.7909, 2.84, 0.223, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
2176, 4y83B, 0.7909, 2.81, 0.227, 302, 255, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
2177, 4xmoA, 0.7909, 2.79, 0.324, 289, 250, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
2178, 4iafA, 0.7909, 2.73, 0.230, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2179, 4gk4A, 0.7909, 2.69, 0.325, 275, 249, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
2180, 4dn5A, 0.7909, 2.60, 0.227, 331, 251, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
2181, 3qlgA, 0.7909, 2.12, 0.337, 259, 243, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
2182, 3l9mB, 0.7909, 2.77, 0.241, 336, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2183, 3e8eI, 0.7909, 2.77, 0.233, 345, 253, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2184, 5ouuB, 0.7908, 2.89, 0.219, 325, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
2185, 5oquA, 0.7908, 2.87, 0.219, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
2186, 4yhjB, 0.7908, 3.01, 0.189, 490, 259, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
2187, 4xbrA, 0.7908, 2.92, 0.207, 315, 256, IN CELLULO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA
2188, 4o0sA, 0.7908, 2.65, 0.230, 265, 252, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2189, 4nk9A, 0.7908, 2.66, 0.392, 281, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
2190, 4m15A, 0.7908, 2.71, 0.288, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
2191, 4jdhA, 0.7908, 2.78, 0.197, 289, 254, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
2192, 4j8nC, 0.7908, 2.72, 0.198, 266, 253, AURORA A KINASE APO
2193, 4fieB, 0.7908, 2.89, 0.196, 300, 255, FULL-LENGTH HUMAN PAK4
2194, 4fieA, 0.7908, 2.89, 0.196, 300, 255, FULL-LENGTH HUMAN PAK4
2195, 4eonC, 0.7908, 2.93, 0.258, 298, 256, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2196, 4eoiC, 0.7908, 2.74, 0.254, 296, 252, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2197, 4c34A, 0.7908, 2.72, 0.238, 336, 252, PKA-S6K1 CHIMERA WITH STAUROSPORINE BOUND
2198, 3w8lB, 0.7908, 2.85, 0.223, 326, 256, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
2199, 5oroA, 0.7907, 2.61, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2200, 5oniB, 0.7907, 2.80, 0.223, 334, 256, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2201, 5n33A, 0.7907, 2.55, 0.236, 347, 250, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(TRIFLUOROMETHYL)-1H-PYRIDIN-2- ONE
2202, 5cqwA, 0.7907, 2.82, 0.227, 331, 256, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
2203, 4wb7B, 0.7907, 2.75, 0.230, 402, 252, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2204, 4anmA, 0.7907, 2.80, 0.211, 328, 256, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
2205, 3kxnA, 0.7907, 2.80, 0.215, 327, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
2206, 3bhvC, 0.7907, 2.75, 0.253, 271, 253, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
2207, 2uw4A, 0.7907, 2.75, 0.234, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2208, 2pvrA, 0.7907, 2.84, 0.223, 328, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
2209, 2hy81, 0.7907, 2.90, 0.218, 293, 257, PAK1 COMPLEX WITH ST2001
2210, 2gfcA, 0.7907, 2.81, 0.237, 335, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2211, 1u5qA, 0.7907, 2.83, 0.241, 308, 253, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2212, 5n1eA, 0.7906, 2.65, 0.235, 347, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YL)-2-PIPERIDIN-1- YLACETAMIDE
2213, 4imyC, 0.7906, 2.82, 0.241, 310, 253, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
2214, 4dfxE, 0.7906, 2.74, 0.230, 347, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
2215, 3up7A, 0.7906, 2.79, 0.197, 264, 254, AURORA A IN COMPLEX WITH YL1-038-09
2216, 3qcqA, 0.7906, 2.54, 0.209, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
2217, 3ofmA, 0.7906, 2.85, 0.215, 325, 256, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
2218, 3l9lA, 0.7906, 2.77, 0.245, 338, 253, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2219, 3gu5A, 0.7906, 2.66, 0.250, 280, 252, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
2220, 2og8A, 0.7906, 2.09, 0.368, 246, 242, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
2221, 1m2pA, 0.7906, 2.81, 0.211, 325, 256, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
2222, 5orsA, 0.7905, 2.62, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2223, 5mowA, 0.7905, 2.88, 0.223, 328, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2224, 5j1wB, 0.7905, 2.96, 0.250, 337, 252, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
2225, 4j8nB, 0.7905, 2.73, 0.198, 266, 253, AURORA A KINASE APO
2226, 4fx3A, 0.7905, 2.72, 0.250, 298, 252, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
2227, 4ekkB, 0.7905, 2.67, 0.246, 318, 252, AKT1 WITH AMP-PNP
2228, 4a4oA, 0.7905, 2.85, 0.264, 290, 254, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
2229, 3hgkA, 0.7905, 2.86, 0.249, 286, 253, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
2230, 2gniA, 0.7905, 2.79, 0.237, 338, 253, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
2231, 2a27B, 0.7905, 2.77, 0.217, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2232, 5u7rD, 0.7904, 2.73, 0.182, 382, 253, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2233, 5ho8A, 0.7904, 2.59, 0.212, 278, 250, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2234, 4otfA, 0.7904, 2.46, 0.308, 262, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
2235, 4nk9B, 0.7904, 2.71, 0.396, 282, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
2236, 4j8nA, 0.7904, 2.73, 0.198, 266, 253, AURORA A KINASE APO
2237, 3qcsA, 0.7904, 2.54, 0.209, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
2238, 3pwyA, 0.7904, 2.66, 0.210, 281, 252, CRYSTAL STRUCTURE OF AN EXTENDER (SPD28345)-MODIFIED HUMAN PDK1 COMPLEX 2
2239, 2gu8A, 0.7904, 2.79, 0.229, 335, 253, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
2240, 2a27G, 0.7904, 2.77, 0.217, 303, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2241, 1om1A, 0.7904, 2.81, 0.211, 325, 256, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
2242, 5vhbA, 0.7903, 2.73, 0.242, 325, 252, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITOR
2243, 5ooiA, 0.7903, 2.82, 0.219, 329, 256, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2244, 5nkcA, 0.7903, 2.70, 0.332, 286, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
2245, 5moeA, 0.7903, 2.87, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2246, 5l2qA, 0.7903, 2.57, 0.211, 293, 251, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
2247, 4rzvB, 0.7903, 3.04, 0.267, 271, 255, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
2248, 4knbC, 0.7903, 2.81, 0.335, 271, 248, C-MET IN COMPLEX WITH OSI LIGAND
2249, 4gg7A, 0.7903, 2.95, 0.324, 278, 253, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
2250, 4a4lA, 0.7903, 2.85, 0.264, 290, 254, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
2251, 3omvB, 0.7903, 2.45, 0.270, 264, 248, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
2252, 3kkvA, 0.7903, 2.73, 0.238, 335, 252, STRUCTURE OF PKA WITH A PROTEIN KINASE B-SELECTIVE INHIBITOR.
2253, 3bhuC, 0.7903, 2.80, 0.253, 271, 253, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2254, 2vo6A, 0.7903, 2.76, 0.234, 335, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
2255, 2qkwB, 0.7903, 2.83, 0.249, 290, 253, STRUCTURAL BASIS FOR ACTIVATION OF PLANT IMMUNITY BY BACTERIAL EFFECTOR PROTEIN AVRPTO
2256, 2gcdA, 0.7903, 2.83, 0.241, 308, 253, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
2257, 1fgiB, 0.7903, 2.75, 0.398, 272, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
2258, 5orjA, 0.7902, 2.86, 0.219, 325, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
2259, 5nw8A, 0.7902, 2.71, 0.242, 337, 252, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP032 AND FASUDIL 
2260, 5n3bA, 0.7902, 2.66, 0.235, 342, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(PYRIDIN-3-YL)ETHANAMINE
2261, 5m6yA, 0.7902, 2.74, 0.241, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A METHYLISOQUINOLINE FASUDIL-DERIVATIVE 
2262, 5f9eA, 0.7902, 2.72, 0.233, 334, 253, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
2263, 4xbuA, 0.7902, 2.92, 0.215, 292, 256, IN VITRO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA PEPTIDE
2264, 4fr4C, 0.7902, 3.02, 0.224, 344, 259, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2265, 3kxhA, 0.7902, 2.81, 0.215, 326, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
2266, 3hrfA, 0.7902, 2.76, 0.201, 284, 254, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
2267, 3gubA, 0.7902, 2.68, 0.250, 278, 252, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
2268, 3g5dA, 0.7902, 2.07, 0.332, 256, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
2269, 2vnyA, 0.7902, 2.75, 0.234, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
2270, 5orhA, 0.7901, 2.87, 0.223, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
2271, 5n1nA, 0.7901, 2.66, 0.235, 348, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-9-PROPAN-2-YLPURINE
2272, 5cx9B, 0.7901, 2.88, 0.223, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
2273, 5cvhA, 0.7901, 2.85, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA
2274, 4neuA, 0.7901, 2.56, 0.293, 286, 249, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
2275, 4ks7A, 0.7901, 2.97, 0.207, 286, 256, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
2276, 4fx3C, 0.7901, 2.72, 0.250, 298, 252, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
2277, 4c33A, 0.7901, 2.73, 0.238, 335, 252, PKA-S6K1 CHIMERA APO
2278, 2uw6A, 0.7901, 2.74, 0.238, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2279, 5n32A, 0.7900, 2.57, 0.232, 345, 250, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-CHLOROBENZYL CARBAMIMIDOTHIOATE
2280, 5fbnC, 0.7900, 2.66, 0.308, 256, 250, BTK KINASE DOMAIN WITH INHIBITOR 1
2281, 5ct0B, 0.7900, 2.88, 0.223, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
2282, 4wb8A, 0.7900, 2.77, 0.230, 334, 252, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT) EXON 1 DELETION
2283, 4eosC, 0.7900, 2.75, 0.254, 296, 252, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2284, 4dh8A, 0.7900, 2.76, 0.230, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20
2285, 4cegA, 0.7900, 2.62, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
2286, 3qriA, 0.7900, 2.59, 0.382, 275, 249, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
2287, 3p0mA, 0.7900, 2.79, 0.233, 335, 253, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2288, 2xchA, 0.7900, 2.57, 0.208, 278, 250, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2289, 2oxyB, 0.7900, 2.84, 0.215, 327, 256, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2290, 2cchA, 0.7900, 2.73, 0.262, 296, 252, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
2291, 2a27E, 0.7900, 2.78, 0.231, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2292, 5oniA, 0.7899, 2.85, 0.223, 334, 256, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2293, 5n3eA, 0.7899, 2.66, 0.235, 348, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 6-DIMETHYLAMINOPYRIDINE-3-CARBOXYLIC ACID
2294, 4jdjA, 0.7899, 2.83, 0.216, 288, 255, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
2295, 4hzsA, 0.7899, 2.66, 0.375, 319, 248, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
2296, 4fijA, 0.7899, 2.89, 0.215, 291, 256, CATALYTIC DOMAIN OF HUMAN PAK4
2297, 3cp9A, 0.7899, 2.11, 0.379, 288, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
2298, 2a27D, 0.7899, 2.77, 0.217, 304, 254, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2299, 2a27C, 0.7899, 2.82, 0.216, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2300, 5n3aA, 0.7898, 2.75, 0.234, 349, 252, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-METHYL-5-(1-METHYLIMIDAZOL-2-YL)-13- THIAZOL-2-AMINE
2301, 5n39A, 0.7898, 2.57, 0.236, 347, 250, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(23-DIHYDROBENZO[B][14]DIOXIN-6-YL) PYRROLIDINE
2302, 5lctA, 0.7898, 2.74, 0.237, 350, 253, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A R-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 02)
2303, 5a4cA, 0.7898, 2.60, 0.402, 294, 249, FGFR1 LIGAND COMPLEX
2304, 4nwmA, 0.7898, 2.45, 0.304, 261, 247, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
2305, 4jboA, 0.7898, 2.70, 0.233, 266, 253, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2306, 4hzsD, 0.7898, 2.67, 0.375, 319, 248, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
2307, 4hzsC, 0.7898, 2.67, 0.375, 319, 248, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
2308, 4fifB, 0.7898, 2.90, 0.196, 292, 255, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2309, 4dggA, 0.7898, 2.12, 0.337, 261, 243, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
2310, 3owkA, 0.7898, 2.89, 0.219, 330, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
2311, 2x39A, 0.7898, 2.68, 0.246, 316, 252, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
2312, 2g9xC, 0.7898, 2.75, 0.258, 274, 252, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2313, 1zwsD, 0.7898, 2.77, 0.227, 278, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2314, 1o6kA, 0.7898, 2.71, 0.238, 317, 252, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
2315, 5w5oO, 0.7897, 2.19, 0.267, 276, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2316, 5oumB, 0.7897, 2.87, 0.223, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
2317, 5nk9A, 0.7897, 2.62, 0.333, 285, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
2318, 4wbbB, 0.7897, 2.73, 0.230, 334, 252, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
2319, 4wb7A, 0.7897, 2.74, 0.234, 402, 252, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2320, 4txcA, 0.7897, 2.76, 0.244, 276, 254, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2321, 4riwA, 0.7897, 2.78, 0.335, 269, 251, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2322, 4hzsB, 0.7897, 2.67, 0.375, 319, 248, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
2323, 3v5lA, 0.7897, 1.93, 0.319, 240, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2324, 3q4cA, 0.7897, 2.37, 0.271, 264, 247, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
2325, 3genA, 0.7897, 2.59, 0.305, 264, 249, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
2326, 2vo0A, 0.7897, 2.80, 0.237, 340, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2327, 2pvmA, 0.7897, 2.82, 0.211, 327, 256, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2328, 2jdsA, 0.7897, 2.75, 0.238, 334, 252, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
2329, 2a27A, 0.7897, 2.82, 0.216, 304, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2330, 1jklA, 0.7897, 2.71, 0.250, 280, 252, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2331, 5otdA, 0.7896, 2.90, 0.219, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
2332, 5dn3A, 0.7896, 2.73, 0.229, 264, 253, AURORA A IN COMPLEX WITH ATP AND AA35.
2333, 5cquA, 0.7896, 2.87, 0.223, 328, 256, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
2334, 4yhjA, 0.7896, 3.03, 0.189, 501, 259, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
2335, 4jqeA, 0.7896, 2.85, 0.207, 369, 256, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
2336, 4fifA, 0.7896, 2.90, 0.192, 293, 255, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2337, 3lvpD, 0.7896, 2.69, 0.308, 282, 250, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2338, 3d7tB, 0.7896, 2.45, 0.290, 265, 248, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
2339, 2uvzA, 0.7896, 2.75, 0.238, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
2340, 1yrpB, 0.7896, 2.76, 0.241, 275, 253, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2341, 1yrpA, 0.7896, 2.76, 0.241, 275, 253, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2342, 5orlA, 0.7895, 2.59, 0.235, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2343, 5ooiB, 0.7895, 2.82, 0.219, 325, 256, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2344, 5iuhA, 0.7895, 2.32, 0.321, 285, 243, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
2345, 4yuqA, 0.7895, 2.89, 0.267, 462, 255, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
2346, 4utdA, 0.7895, 2.62, 0.231, 266, 251, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2347, 4njdA, 0.7895, 2.92, 0.215, 290, 256, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
2348, 4m13A, 0.7895, 2.74, 0.288, 264, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
2349, 4eooC, 0.7895, 2.77, 0.253, 297, 253, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2350, 3uqgB, 0.7895, 2.08, 0.340, 257, 241, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
2351, 5nk4A, 0.7894, 2.77, 0.332, 290, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
2352, 5mmfB, 0.7894, 2.87, 0.223, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
2353, 4krcA, 0.7894, 2.89, 0.247, 297, 255, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
2354, 4j8nD, 0.7894, 2.70, 0.198, 265, 252, AURORA A KINASE APO
2355, 4dg0E, 0.7894, 2.75, 0.234, 338, 252, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
2356, 4c36A, 0.7894, 2.75, 0.238, 335, 252, PKA-S6K1 CHIMERA WITH COMPOUND 15E (CCT147581) BOUND
2357, 2ya9A, 0.7894, 2.78, 0.235, 299, 255, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2358, 5ot5A, 0.7893, 2.88, 0.219, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
2359, 5orkA, 0.7893, 2.89, 0.219, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
2360, 5n36A, 0.7893, 2.57, 0.236, 347, 250, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3H-ISOINDOL-2-IUM-1-AMINE
2361, 5mmrB, 0.7893, 2.87, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
2362, 5j87C, 0.7893, 2.53, 0.306, 261, 248, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2363, 4l67A, 0.7893, 2.91, 0.211, 289, 256, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
2364, 4gv1A, 0.7893, 2.74, 0.241, 329, 253, PKB ALPHA IN COMPLEX WITH AZD5363
2365, 3qcxA, 0.7893, 2.55, 0.209, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
2366, 3hgkB, 0.7893, 2.86, 0.249, 286, 253, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
2367, 3dndA, 0.7893, 2.80, 0.237, 334, 253, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2368, 2pvkA, 0.7893, 2.82, 0.211, 327, 256, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2369, 2a27H, 0.7893, 2.79, 0.231, 304, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2370, 1fvvA, 0.7893, 2.71, 0.254, 298, 252, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
2371, 5orjB, 0.7892, 2.89, 0.223, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
2372, 5n1vA, 0.7892, 2.74, 0.217, 331, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
2373, 5mo6B, 0.7892, 2.90, 0.219, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2374, 5dt3A, 0.7892, 2.63, 0.231, 263, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2375, 4m0zA, 0.7892, 2.73, 0.288, 264, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
2376, 4kwpA, 0.7892, 2.84, 0.219, 329, 256, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
2377, 4fr4E, 0.7892, 3.06, 0.201, 342, 259, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2378, 4cfxC, 0.7892, 2.72, 0.258, 298, 252, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2379, 4c35A, 0.7892, 2.74, 0.238, 337, 252, PKA-S6K1 CHIMERA WITH COMPOUND 1 (NU1085) BOUND
2380, 3ppkA, 0.7892, 2.39, 0.272, 262, 246, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
2381, 3l9mA, 0.7892, 2.78, 0.245, 338, 253, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2382, 3bhhA, 0.7892, 2.52, 0.220, 289, 250, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2383, 5ok3A, 0.7891, 2.71, 0.246, 349, 252, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP241 AND FASUDIL 
2384, 5mpjB, 0.7891, 2.88, 0.223, 324, 256, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
2385, 5j1vC, 0.7891, 2.82, 0.253, 314, 249, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
2386, 4wsqA, 0.7891, 2.79, 0.225, 317, 249, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2387, 4rwkB, 0.7891, 2.63, 0.382, 282, 249, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
2388, 3ppjA, 0.7891, 2.38, 0.272, 262, 246, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
2389, 3f5pT, 0.7891, 3.18, 0.298, 295, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2390, 3ewhA, 0.7891, 2.73, 0.382, 300, 251, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
2391, 3cjgA, 0.7891, 2.42, 0.378, 280, 246, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
2392, 2uvyA, 0.7891, 2.76, 0.238, 333, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
2393, 1q8wA, 0.7891, 2.73, 0.234, 334, 252, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
2394, 1l3rE, 0.7891, 2.77, 0.226, 338, 252, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2395, 5vjaD, 0.7890, 2.58, 0.237, 261, 249, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2396, 5ortA, 0.7890, 2.63, 0.231, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2397, 5oquB, 0.7890, 2.89, 0.223, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
2398, 5n1mA, 0.7890, 2.58, 0.236, 347, 250, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
2399, 4wb5A, 0.7890, 2.76, 0.234, 335, 252, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2400, 4bcnC, 0.7890, 2.78, 0.253, 295, 253, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2401, 3u51A, 0.7890, 1.94, 0.342, 256, 240, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
2402, 3rawA, 0.7890, 2.95, 0.226, 351, 252, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
2403, 2vo3A, 0.7890, 2.76, 0.234, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2404, 1zwsB, 0.7890, 2.78, 0.224, 278, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2405, 1o6lA, 0.7890, 2.70, 0.238, 316, 252, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
2406, 6fnhA, 0.7889, 2.62, 0.332, 277, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
2407, 5swhB, 0.7889, 2.14, 0.343, 261, 242, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
2408, 5otoA, 0.7889, 2.89, 0.219, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
2409, 5nkdA, 0.7889, 2.67, 0.333, 287, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
2410, 5n1kA, 0.7889, 2.60, 0.232, 341, 250, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-AMINO-1-(4-FLUOROPHENYL)ETHANOL
2411, 5ek7A, 0.7889, 2.64, 0.332, 286, 250, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
2412, 5cyiC, 0.7889, 2.74, 0.254, 296, 252, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
2413, 5cs6A, 0.7889, 2.88, 0.219, 327, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
2414, 4tl0A, 0.7889, 2.89, 0.246, 300, 256, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
2415, 4otgA, 0.7889, 2.85, 0.267, 322, 255, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
2416, 3owlA, 0.7889, 2.91, 0.219, 330, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
2417, 3nusA, 0.7889, 2.57, 0.209, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
2418, 3cpbA, 0.7889, 2.06, 0.372, 285, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
2419, 2g15A, 0.7889, 3.03, 0.304, 301, 253, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
2420, 2c4gA, 0.7889, 2.95, 0.246, 301, 256, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2421, 2a27F, 0.7889, 2.83, 0.216, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
2422, 6d1yA, 0.7888, 2.58, 0.379, 300, 248, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 2;4-DICHLORO-N-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)BENZAMIDE INHIBITOR 
2423, 5os8A, 0.7888, 2.89, 0.227, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
2424, 5n3dA, 0.7888, 2.58, 0.236, 346, 250, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(TRIFLUOROMETHYL)BENZENECARBOXIMIDAMIDE
2425, 5n1lA, 0.7888, 2.58, 0.236, 347, 250, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 25-DIMETHYL-N-PYRIDIN-4-YLFURAN-3- CARBOXAMIDE
2426, 5dnrA, 0.7888, 2.68, 0.230, 264, 252, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
2427, 4fr4B, 0.7888, 3.07, 0.201, 350, 259, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2428, 3zo1A, 0.7888, 2.75, 0.238, 339, 252, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2429, 3d9vA, 0.7888, 2.94, 0.187, 400, 257, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
2430, 2vnwA, 0.7888, 2.77, 0.234, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
2431, 1j91A, 0.7888, 2.89, 0.207, 327, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
2432, 5movA, 0.7887, 2.87, 0.223, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
2433, 5ia3A, 0.7887, 2.47, 0.337, 275, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
2434, 4rwiB, 0.7887, 2.54, 0.395, 280, 248, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
2435, 4m12A, 0.7887, 2.75, 0.288, 264, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
2436, 4fzaB, 0.7887, 2.74, 0.254, 281, 252, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
2437, 4aojC, 0.7887, 2.43, 0.385, 261, 247, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
2438, 3gu7A, 0.7887, 2.72, 0.250, 280, 252, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
2439, 3blhA, 0.7887, 3.06, 0.238, 291, 256, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
2440, 1vywA, 0.7887, 2.96, 0.246, 302, 256, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2441, 6b3eC, 0.7886, 2.85, 0.243, 307, 255, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
2442, 5oulA, 0.7886, 2.87, 0.223, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
2443, 4figB, 0.7886, 2.94, 0.203, 292, 256, CATALYTIC DOMAIN OF HUMAN PAK4
2444, 3mv5A, 0.7886, 2.72, 0.242, 315, 252, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
2445, 3hgkD, 0.7886, 3.00, 0.244, 286, 254, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
2446, 3gu4A, 0.7886, 2.69, 0.250, 280, 252, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
2447, 2gnlA, 0.7886, 2.80, 0.233, 338, 253, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
2448, 1na7A, 0.7886, 2.87, 0.223, 326, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
2449, 6fypA, 0.7885, 2.96, 0.222, 348, 252, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CX-4945 AT 2.29A 
2450, 5tobA, 0.7885, 2.10, 0.389, 245, 239, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
2451, 4ebvA, 0.7885, 2.59, 0.370, 262, 246, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
2452, 3x2uA, 0.7885, 2.76, 0.234, 336, 252, MICHAELIS-LIKE INITIAL COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT.
2453, 3v5lB, 0.7885, 1.90, 0.312, 241, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2454, 3pyyB, 0.7885, 2.30, 0.364, 257, 242, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
2455, 3pyyA, 0.7885, 2.74, 0.363, 265, 248, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
2456, 3fbvD, 0.7885, 2.56, 0.205, 422, 249, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2457, 3d94A, 0.7885, 2.69, 0.341, 288, 249, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
2458, 3ambA, 0.7885, 2.80, 0.237, 340, 253, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
2459, 2yjrA, 0.7885, 2.30, 0.336, 278, 244, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
2460, 2uzdA, 0.7885, 2.85, 0.256, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2461, 2uzbC, 0.7885, 2.71, 0.255, 292, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2462, 1zwsC, 0.7885, 2.84, 0.223, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2463, 5oueB, 0.7884, 2.91, 0.219, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
2464, 5n23A, 0.7884, 2.76, 0.238, 333, 252, PROTEIN KINASE A MUTANTS AS SURROGATE MODEL FOR AURORA B WITH AT9283 INHIBITOR
2465, 4ybkA, 0.7884, 2.51, 0.339, 266, 248, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
2466, 4k8aA, 0.7884, 2.37, 0.350, 251, 243, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
2467, 4aw1A, 0.7884, 2.64, 0.200, 283, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
2468, 3psdA, 0.7884, 2.39, 0.272, 262, 246, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
2469, 3juhB, 0.7884, 2.72, 0.221, 334, 253, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
2470, 3fbvK, 0.7884, 2.56, 0.205, 422, 249, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2471, 3bz3A, 0.7884, 2.44, 0.370, 259, 246, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
2472, 2yacA, 0.7884, 2.88, 0.264, 290, 254, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
2473, 1fq1B, 0.7884, 2.67, 0.256, 295, 250, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
2474, 4ysjB, 0.7883, 2.80, 0.277, 462, 253, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
2475, 4y83A, 0.7883, 2.75, 0.221, 299, 253, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
2476, 4pf4A, 0.7883, 2.68, 0.250, 278, 252, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2477, 4jdkA, 0.7883, 2.86, 0.212, 288, 255, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
2478, 4f0iB, 0.7883, 2.68, 0.378, 294, 249, CRYSTAL STRUCTURE OF APO TRKA
2479, 4euuB, 0.7883, 2.90, 0.241, 307, 257, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
2480, 3rwpA, 0.7883, 2.56, 0.209, 277, 249, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2481, 3qgwA, 0.7883, 1.91, 0.322, 244, 239, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
2482, 3q9zA, 0.7883, 2.87, 0.227, 332, 256, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
2483, 3q04A, 0.7883, 2.86, 0.223, 328, 256, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
2484, 1oiuA, 0.7883, 2.82, 0.252, 296, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2485, 5otzA, 0.7882, 2.90, 0.227, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
2486, 4ysjA, 0.7882, 2.74, 0.278, 459, 252, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
2487, 4iazA, 0.7882, 2.76, 0.234, 334, 252, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH BA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2488, 4fnxA, 0.7882, 2.59, 0.308, 292, 247, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
2489, 4at5A, 0.7882, 2.78, 0.386, 294, 249, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
2490, 3of0A, 0.7882, 2.27, 0.340, 260, 244, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
2491, 3nuyA, 0.7882, 2.57, 0.209, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
2492, 3fbvN, 0.7882, 2.55, 0.209, 415, 249, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2493, 3fbvH, 0.7882, 2.55, 0.209, 415, 249, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2494, 3ddpC, 0.7882, 2.75, 0.254, 298, 252, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
2495, 3cthA, 0.7882, 2.73, 0.317, 295, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
2496, 2yakA, 0.7882, 2.79, 0.248, 277, 254, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
2497, 1u5rB, 0.7882, 2.87, 0.241, 308, 253, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2498, 1q8uA, 0.7882, 2.80, 0.233, 341, 253, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
2499, 6fykB, 0.7881, 2.98, 0.210, 349, 252, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
2500, 5o5mA, 0.7881, 2.73, 0.242, 336, 252, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND RKP117 
2501, 5em5A, 0.7881, 2.61, 0.372, 298, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
2502, 4tnbA, 0.7881, 3.14, 0.188, 529, 260, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH SANGIVAMYCIN
2503, 4mwhA, 0.7881, 2.87, 0.207, 371, 256, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
2504, 3zh8C, 0.7881, 2.74, 0.194, 312, 253, A NOVEL SMALL MOLECULE APKC INHIBITOR
2505, 3sdjK, 0.7881, 2.56, 0.205, 422, 249, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2506, 3sdjD, 0.7881, 2.56, 0.205, 422, 249, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2507, 3o17B, 0.7881, 2.84, 0.198, 357, 253, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
2508, 3fbvM, 0.7881, 2.55, 0.209, 415, 249, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2509, 3fbvF, 0.7881, 2.55, 0.209, 415, 249, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2510, 3fbvE, 0.7881, 2.55, 0.209, 415, 249, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2511, 3fbvC, 0.7881, 2.55, 0.209, 415, 249, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2512, 3fbvA, 0.7881, 2.55, 0.209, 415, 249, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2513, 2j0iA, 0.7881, 2.94, 0.219, 289, 256, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2514, 1oguA, 0.7881, 2.82, 0.252, 296, 254, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
2515, 5wngC, 0.7880, 2.76, 0.190, 387, 253, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2516, 5njzA, 0.7880, 2.54, 0.336, 273, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
2517, 5mp8A, 0.7880, 2.90, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2518, 5ikwA, 0.7880, 2.53, 0.215, 297, 246, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2519, 5cvhB, 0.7880, 2.89, 0.219, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA
2520, 4mnfB, 0.7880, 2.28, 0.270, 257, 244, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
2521, 4m14A, 0.7880, 2.76, 0.288, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
2522, 4figA, 0.7880, 2.95, 0.203, 292, 256, CATALYTIC DOMAIN OF HUMAN PAK4
2523, 4fi1A, 0.7880, 2.87, 0.207, 371, 256, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
2524, 4dedA, 0.7880, 2.88, 0.212, 265, 255, AURORA A IN COMPLEX WITH YL1-038-21
2525, 3v5jB, 0.7880, 1.85, 0.318, 241, 236, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
2526, 3rcjA, 0.7880, 2.70, 0.202, 281, 252, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
2527, 3owjA, 0.7880, 2.92, 0.223, 328, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
2528, 3fbvG, 0.7880, 2.55, 0.209, 415, 249, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2529, 3d0eB, 0.7880, 2.70, 0.238, 322, 252, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
2530, 3cpbB, 0.7880, 2.22, 0.369, 263, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
2531, 2uw0A, 0.7880, 2.77, 0.234, 334, 252, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
2532, 2acxB, 0.7880, 3.00, 0.195, 492, 257, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
2533, 1xjdA, 0.7880, 2.63, 0.257, 280, 249, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
2534, 5wnhC, 0.7879, 2.76, 0.185, 388, 254, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2535, 5wnfC, 0.7879, 2.73, 0.190, 386, 253, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2536, 5da3A, 0.7879, 2.60, 0.341, 263, 249, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
2537, 3prfA, 0.7879, 2.41, 0.268, 262, 246, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
2538, 3fbvL, 0.7879, 2.56, 0.209, 415, 249, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2539, 3cquA, 0.7879, 2.69, 0.246, 318, 252, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
2540, 2yjsA, 0.7879, 2.51, 0.314, 286, 245, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
2541, 2ofvB, 0.7879, 1.97, 0.377, 244, 236, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
2542, 1ig1A, 0.7879, 2.72, 0.250, 280, 252, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2543, 6gihA, 0.7878, 2.76, 0.225, 324, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
2544, 5xfjA, 0.7878, 2.49, 0.397, 266, 247, CRYSTAL STRUCTURE OF LY2874455 IN COMPLEX OF FGFR4 GATEKEEPER MUTATION (V550M) 
2545, 5otdB, 0.7878, 2.92, 0.219, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
2546, 4wnpB, 0.7878, 2.85, 0.247, 272, 255, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2547, 4w9wA, 0.7878, 2.65, 0.211, 306, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
2548, 3zo3A, 0.7878, 2.77, 0.238, 337, 252, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2549, 3zh8A, 0.7878, 2.76, 0.190, 318, 253, A NOVEL SMALL MOLECULE APKC INHIBITOR
2550, 3fc2A, 0.7878, 2.98, 0.267, 293, 255, PLK1 IN COMPLEX WITH BI6727
2551, 3f3uB, 0.7878, 2.29, 0.340, 259, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
2552, 3d0eA, 0.7878, 2.70, 0.238, 322, 252, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
2553, 2pvjA, 0.7878, 2.84, 0.211, 326, 256, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2554, 2pmnX, 0.7878, 2.92, 0.199, 340, 256, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP-SITE INHIBITOR
2555, 2pmlX, 0.7878, 2.93, 0.191, 340, 256, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP ANALOGUE
2556, 2hz0B, 0.7878, 1.94, 0.373, 243, 236, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
2557, 2fb8B, 0.7878, 2.41, 0.272, 259, 246, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
2558, 1uu9A, 0.7878, 2.62, 0.212, 276, 250, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2559, 1jksA, 0.7878, 2.74, 0.250, 280, 252, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2560, 1h1sC, 0.7878, 2.74, 0.254, 296, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
2561, 1fmkA, 0.7878, 2.35, 0.336, 437, 247, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
2562, 5wnmA, 0.7877, 2.32, 0.254, 263, 244, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO TOZASERTIB (VX-680) 
2563, 5w5oK, 0.7877, 2.19, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2564, 5k9iA, 0.7877, 2.10, 0.343, 258, 242, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
2565, 4yuqB, 0.7877, 2.86, 0.268, 462, 254, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
2566, 4iayA, 0.7877, 2.77, 0.230, 333, 252, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2567, 4dinA, 0.7877, 2.80, 0.229, 340, 253, NOVEL LOCALIZATION AND QUATERNARY STRUCTURE OF THE PKA RI BETA HOLOENZYME
2568, 4ct2A, 0.7877, 2.76, 0.209, 277, 253, HUMAN PDK1-PKCZETA KINASE CHIMERA
2569, 4cfuA, 0.7877, 2.86, 0.255, 299, 255, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2570, 3tz8B, 0.7877, 2.31, 0.339, 263, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
2571, 3miyA, 0.7877, 1.78, 0.323, 239, 235, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
2572, 2pmoX, 0.7877, 2.94, 0.199, 340, 256, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH HYMENIALDISINE
2573, 2jdrA, 0.7877, 2.71, 0.242, 316, 252, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
2574, 5w5oM, 0.7876, 2.23, 0.267, 276, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2575, 5cvgA, 0.7876, 2.67, 0.211, 326, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
2576, 4j52A, 0.7876, 2.90, 0.268, 293, 254, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
2577, 4h58B, 0.7876, 2.46, 0.271, 262, 247, BRAF IN COMPLEX WITH COMPOUND 3
2578, 3svvB, 0.7876, 2.07, 0.346, 257, 240, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
2579, 3bhuA, 0.7876, 2.79, 0.253, 297, 253, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2580, 1ol7A, 0.7876, 2.62, 0.232, 261, 250, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
2581, 1oiyC, 0.7876, 2.76, 0.254, 296, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2582, 1mq4A, 0.7876, 2.65, 0.231, 261, 251, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
2583, 5w5oJ, 0.7875, 2.19, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2584, 5n1vB, 0.7875, 2.85, 0.223, 331, 256, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
2585, 5m56B, 0.7875, 2.87, 0.219, 328, 256, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2586, 5av1A, 0.7875, 2.65, 0.251, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2587, 5av0A, 0.7875, 2.65, 0.251, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2588, 4au8A, 0.7875, 2.53, 0.232, 276, 246, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
2589, 3psbA, 0.7875, 2.40, 0.272, 262, 246, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
2590, 2ya9B, 0.7875, 2.77, 0.232, 299, 254, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
2591, 2wmbC, 0.7875, 2.65, 0.256, 266, 250, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2592, 2v7oA, 0.7875, 2.74, 0.217, 305, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
2593, 1zoeA, 0.7875, 2.85, 0.211, 325, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
2594, 1okzA, 0.7875, 2.57, 0.209, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
2595, 6cd6C, 0.7874, 2.69, 0.245, 265, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2596, 5w5oD, 0.7874, 2.18, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2597, 5otoB, 0.7874, 2.93, 0.219, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
2598, 5nkbA, 0.7874, 2.65, 0.333, 285, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
2599, 5mowB, 0.7874, 2.93, 0.223, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2600, 5moeB, 0.7874, 2.84, 0.220, 323, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2601, 5lvnA, 0.7874, 2.75, 0.202, 283, 253, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
2602, 5h8gA, 0.7874, 2.79, 0.209, 324, 254, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
2603, 4w8eA, 0.7874, 2.82, 0.261, 290, 253, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
2604, 4tndA, 0.7874, 3.15, 0.188, 529, 260, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH AMP-PNP
2605, 4qmyA, 0.7874, 2.84, 0.265, 287, 253, MST3 IN COMPLEX WITH STAUROSPORINE
2606, 4fbxA, 0.7874, 2.83, 0.227, 333, 256, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
2607, 4cfwC, 0.7874, 2.82, 0.253, 297, 253, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2608, 4cfhA, 0.7874, 2.66, 0.275, 401, 251, STRUCTURE OF AN ACTIVE FORM OF MAMMALIAN AMPK
2609, 3u4uA, 0.7874, 2.91, 0.223, 327, 256, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
2610, 3sdjH, 0.7874, 2.55, 0.209, 415, 249, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2611, 3sdjC, 0.7874, 2.55, 0.209, 415, 249, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2612, 3sdjB, 0.7874, 2.55, 0.209, 415, 249, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2613, 2uw9A, 0.7874, 2.69, 0.242, 316, 252, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
2614, 2pe0A, 0.7874, 2.47, 0.211, 275, 247, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2615, 5fbnD, 0.7873, 2.63, 0.305, 255, 249, BTK KINASE DOMAIN WITH INHIBITOR 1
2616, 4yzbA, 0.7873, 2.94, 0.272, 466, 257, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
2617, 4eklA, 0.7873, 2.69, 0.242, 329, 252, AKT1 WITH GDC0068
2618, 4cxaA, 0.7873, 2.87, 0.239, 329, 255, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
2619, 3zh8B, 0.7873, 2.77, 0.190, 317, 253, A NOVEL SMALL MOLECULE APKC INHIBITOR
2620, 3sdjA, 0.7873, 2.55, 0.209, 415, 249, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2621, 3nx8A, 0.7873, 2.85, 0.237, 333, 253, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
2622, 3e88B, 0.7873, 2.71, 0.242, 319, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2623, 3e88A, 0.7873, 2.71, 0.242, 319, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2624, 2uzbA, 0.7873, 2.72, 0.255, 295, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2625, 2jdoA, 0.7873, 2.70, 0.246, 314, 252, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
2626, 1zwsG, 0.7873, 2.79, 0.224, 278, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2627, 1jkkA, 0.7873, 2.79, 0.249, 277, 253, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2628, 1j91B, 0.7873, 2.90, 0.207, 327, 256, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
2629, 1bygA, 0.7873, 2.07, 0.361, 246, 241, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
2630, 5wneC, 0.7872, 2.75, 0.190, 384, 253, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2631, 5uoxA, 0.7872, 2.65, 0.291, 263, 247, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2632, 4bn1A, 0.7872, 2.66, 0.231, 261, 251, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
2633, 3tnqB, 0.7872, 2.67, 0.231, 331, 251, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2634, 3sdjG, 0.7872, 2.55, 0.209, 415, 249, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2635, 3sdjF, 0.7872, 2.55, 0.209, 415, 249, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2636, 3sdjE, 0.7872, 2.56, 0.209, 415, 249, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2637, 3nr9C, 0.7872, 3.01, 0.210, 347, 252, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
2638, 3nczC, 0.7872, 2.87, 0.185, 389, 254, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2639, 3f5pA, 0.7872, 3.20, 0.298, 299, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2640, 3cpcA, 0.7872, 2.10, 0.372, 284, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
2641, 2wihA, 0.7872, 2.96, 0.246, 302, 256, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2642, 1zwsH, 0.7872, 2.86, 0.227, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2643, 5v62A, 0.7871, 2.85, 0.233, 349, 253, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
2644, 5mo5B, 0.7871, 2.93, 0.219, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2645, 4g2fA, 0.7871, 2.66, 0.328, 275, 247, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
2646, 4csvA, 0.7871, 2.07, 0.362, 244, 240, TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL BOUND TO GLEEVEC
2647, 3sdjN, 0.7871, 2.56, 0.209, 415, 249, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2648, 3sdjL, 0.7871, 2.55, 0.209, 415, 249, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2649, 3prfB, 0.7871, 2.41, 0.272, 262, 246, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
2650, 3hgkC, 0.7871, 2.82, 0.230, 284, 252, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
2651, 3g6gA, 0.7871, 2.31, 0.337, 264, 246, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
2652, 1zwsF, 0.7871, 2.80, 0.227, 278, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2653, 1oi9C, 0.7871, 2.78, 0.254, 296, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2654, 1h1rC, 0.7871, 2.77, 0.254, 296, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
2655, 5cshA, 0.7870, 2.92, 0.223, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
2656, 4appA, 0.7870, 2.86, 0.189, 291, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
2657, 3f5gA, 0.7870, 2.66, 0.251, 279, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2658, 3f3uA, 0.7870, 2.23, 0.340, 261, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
2659, 2x4fB, 0.7870, 2.80, 0.213, 288, 254, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
2660, 2v5qA, 0.7870, 2.88, 0.248, 285, 254, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
2661, 5oyfA, 0.7869, 2.89, 0.230, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 31
2662, 5i9zA, 0.7869, 2.59, 0.332, 273, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
2663, 5hvuB, 0.7869, 2.82, 0.182, 394, 253, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
2664, 4kabA, 0.7869, 2.35, 0.343, 255, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
2665, 3sdmG, 0.7869, 2.61, 0.212, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
2666, 3sdmF, 0.7869, 2.61, 0.212, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
2667, 3sdmE, 0.7869, 2.61, 0.212, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
2668, 3sdmD, 0.7869, 2.61, 0.212, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
2669, 3sdmC, 0.7869, 2.61, 0.212, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
2670, 3sdmB, 0.7869, 2.61, 0.212, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
2671, 3sdmA, 0.7869, 2.61, 0.212, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
2672, 3fbvB, 0.7869, 2.61, 0.212, 415, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2673, 3dfcB, 0.7869, 2.73, 0.250, 280, 252, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2674, 2owbA, 0.7869, 2.89, 0.268, 294, 254, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2675, 1h1qC, 0.7869, 2.76, 0.254, 296, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
2676, 4rerA, 0.7868, 2.68, 0.279, 458, 251, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX BOUND TO AMP AND CYCLODEXTRIN
2677, 4q9zA, 0.7868, 2.71, 0.234, 331, 252, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
2678, 4mneF, 0.7868, 2.26, 0.254, 258, 244, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2679, 4ekkA, 0.7868, 2.74, 0.242, 318, 252, AKT1 WITH AMP-PNP
2680, 3zewB, 0.7868, 2.25, 0.324, 252, 241, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
2681, 3q6uA, 0.7868, 2.44, 0.332, 287, 244, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
2682, 3o2mB, 0.7868, 2.89, 0.198, 358, 253, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
2683, 3f5pI, 0.7868, 3.19, 0.298, 294, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2684, 2jedA, 0.7868, 2.73, 0.254, 324, 252, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
2685, 1wmkD, 0.7868, 2.94, 0.227, 314, 256, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2686, 5ta6A, 0.7867, 3.02, 0.255, 294, 255, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
2687, 5nk3A, 0.7867, 2.89, 0.329, 281, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
2688, 5ia4A, 0.7867, 2.77, 0.309, 269, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
2689, 4ra4A, 0.7867, 2.74, 0.217, 317, 253, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2690, 4fzfB, 0.7867, 2.61, 0.253, 279, 249, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH DKI
2691, 4bcoC, 0.7867, 2.81, 0.258, 269, 252, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2692, 3juhA, 0.7867, 2.76, 0.221, 334, 253, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
2693, 2qo9A, 0.7867, 2.70, 0.310, 277, 248, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
2694, 1wmkB, 0.7867, 2.94, 0.227, 314, 256, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2695, 5w5oG, 0.7866, 2.20, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2696, 5ta8A, 0.7866, 2.93, 0.252, 294, 254, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
2697, 5owlA, 0.7866, 2.90, 0.227, 331, 256, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
2698, 5owhA, 0.7866, 2.81, 0.212, 334, 255, HIGH SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3-AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
2699, 5ouuA, 0.7866, 2.79, 0.221, 324, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
2700, 5nqcA, 0.7866, 2.76, 0.213, 331, 253, CK2ALPHA IN COMPLEX WITH NMR154
2701, 4bcmA, 0.7866, 2.83, 0.256, 295, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2702, 3e87B, 0.7866, 2.72, 0.242, 321, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2703, 3e87A, 0.7866, 2.72, 0.242, 321, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2704, 3d7uB, 0.7866, 2.08, 0.340, 258, 241, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
2705, 3bhtA, 0.7866, 2.80, 0.253, 297, 253, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
2706, 2iw8A, 0.7866, 2.76, 0.246, 297, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2707, 1pjkA, 0.7866, 2.93, 0.219, 331, 256, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
2708, 5xvuA, 0.7865, 2.82, 0.229, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2709, 5u6bC, 0.7865, 2.56, 0.332, 270, 247, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2710, 5sysA, 0.7865, 2.05, 0.332, 258, 241, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
2711, 5i3oA, 0.7865, 2.75, 0.214, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2712, 4gu9A, 0.7865, 2.37, 0.343, 252, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
2713, 3orzD, 0.7865, 2.64, 0.208, 278, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2714, 3h9oA, 0.7865, 2.49, 0.211, 275, 247, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
2715, 3f5pK, 0.7865, 3.16, 0.300, 293, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2716, 3f5pB, 0.7865, 3.21, 0.298, 298, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2717, 3eh9A, 0.7865, 2.67, 0.251, 278, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2718, 2ofvA, 0.7865, 2.11, 0.374, 244, 238, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
2719, 1wmkH, 0.7865, 2.95, 0.227, 304, 256, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2720, 1wmkC, 0.7865, 2.95, 0.227, 303, 256, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2721, 5wniA, 0.7864, 2.35, 0.246, 263, 244, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN KINASE 4 (RIPK4) D143N IN COMPLEX WITH ATP 
2722, 4krdA, 0.7864, 2.82, 0.246, 294, 252, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
2723, 4j53A, 0.7864, 2.90, 0.260, 293, 254, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
2724, 4dceB, 0.7864, 2.27, 0.314, 284, 242, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
2725, 3orzB, 0.7864, 2.64, 0.208, 278, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2726, 3f5pD, 0.7864, 3.22, 0.298, 297, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2727, 3blqA, 0.7864, 2.94, 0.236, 295, 254, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
2728, 2uzlA, 0.7864, 2.73, 0.255, 295, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2729, 2qurA, 0.7864, 2.83, 0.233, 338, 253, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2730, 2c6tA, 0.7864, 2.87, 0.256, 295, 254, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
2731, 1z5mA, 0.7864, 2.48, 0.211, 275, 247, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2732, 1wmkG, 0.7864, 2.95, 0.227, 313, 256, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2733, 1wmkF, 0.7864, 2.94, 0.227, 303, 256, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2734, 1wmkE, 0.7864, 2.95, 0.227, 313, 256, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2735, 5xgmA, 0.7863, 2.55, 0.378, 288, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
2736, 5auwA, 0.7863, 2.61, 0.256, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2737, 4yneA, 0.7863, 2.48, 0.382, 281, 246, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
2738, 4ct1A, 0.7863, 2.74, 0.209, 283, 253, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
2739, 3fl5A, 0.7863, 2.89, 0.207, 324, 256, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
2740, 3dpkA, 0.7863, 2.34, 0.333, 279, 243, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
2741, 1wmkA, 0.7863, 2.94, 0.227, 303, 256, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2742, 6ccyA, 0.7862, 2.83, 0.247, 325, 255, CRYSTAL STRUCTURE OF AKT1 IN COMPLEX WITH A SELECTIVE INHIBITOR 
2743, 5v24B, 0.7862, 2.54, 0.289, 263, 246, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2744, 5modB, 0.7862, 2.93, 0.219, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2745, 4qmsA, 0.7862, 3.01, 0.260, 283, 254, MST3 IN COMPLEX WITH DASATINIB
2746, 4gu6B, 0.7862, 2.47, 0.374, 258, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
2747, 4f65A, 0.7862, 2.82, 0.382, 279, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
2748, 3f5pG, 0.7862, 3.22, 0.298, 299, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2749, 3f5pC, 0.7862, 3.21, 0.298, 301, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2750, 2rkuA, 0.7862, 3.02, 0.255, 294, 255, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
2751, 2iw9C, 0.7862, 2.71, 0.256, 268, 250, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2752, 2h96B, 0.7862, 2.90, 0.198, 357, 253, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
2753, 2c4gC, 0.7862, 2.86, 0.248, 300, 254, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2754, 2bkzA, 0.7862, 3.00, 0.246, 302, 256, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
2755, 1ol5A, 0.7862, 2.88, 0.209, 263, 253, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
2756, 5xvuB, 0.7861, 2.83, 0.229, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2757, 4wsqB, 0.7861, 2.75, 0.226, 310, 248, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2758, 4ra5A, 0.7861, 2.79, 0.237, 332, 253, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2759, 4r1yA, 0.7861, 2.53, 0.317, 265, 243, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
2760, 3u51B, 0.7861, 1.93, 0.343, 255, 239, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
2761, 3tl8G, 0.7861, 2.81, 0.257, 301, 253, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2762, 3nuuA, 0.7861, 2.59, 0.209, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
2763, 1h26C, 0.7861, 2.72, 0.256, 267, 250, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
2764, 1f0qA, 0.7861, 2.89, 0.211, 329, 256, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
2765, 6dkgA, 0.7860, 2.52, 0.381, 276, 247, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 13B. 
2766, 6b1uA, 0.7860, 2.62, 0.264, 441, 250, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
2767, 5i3rA, 0.7860, 2.77, 0.214, 302, 248, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2768, 5av3A, 0.7860, 2.66, 0.251, 275, 251, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2769, 3sdjM, 0.7860, 2.61, 0.212, 415, 250, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2770, 3qd4A, 0.7860, 2.58, 0.214, 276, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2771, 3o2mA, 0.7860, 2.79, 0.198, 358, 252, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
2772, 2jdvA, 0.7860, 2.84, 0.237, 334, 253, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
2773, 2cciC, 0.7860, 2.94, 0.255, 296, 255, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
2774, 1yomA, 0.7860, 2.08, 0.336, 260, 241, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
2775, 6ft9B, 0.7859, 2.92, 0.251, 337, 251, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
2776, 5auvA, 0.7859, 2.68, 0.251, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2777, 4rrvA, 0.7859, 2.76, 0.202, 283, 253, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND PIFTIDE
2778, 4at3A, 0.7859, 2.93, 0.344, 289, 250, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
2779, 3rawB, 0.7859, 3.00, 0.226, 349, 252, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
2780, 3qrjA, 0.7859, 2.21, 0.382, 258, 241, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
2781, 3lm0A, 0.7859, 2.51, 0.219, 278, 247, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2782, 3a7fA, 0.7859, 2.66, 0.265, 283, 249, HUMAN MST3 KINASE
2783, 5j79B, 0.7858, 2.34, 0.270, 277, 244, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2784, 5auxA, 0.7858, 2.70, 0.255, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2785, 4qmxA, 0.7858, 2.88, 0.257, 287, 253, MST3 IN COMPLEX WITH SARACATINIB
2786, 4kioA, 0.7858, 1.88, 0.318, 240, 236, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
2787, 4bcmC, 0.7858, 2.78, 0.254, 294, 252, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2788, 3q5iA, 0.7858, 2.94, 0.247, 470, 255, CRYSTAL STRUCTURE OF PBANKA_031420
2789, 3oezB, 0.7858, 2.22, 0.342, 261, 243, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
2790, 3f5pS, 0.7858, 3.20, 0.298, 295, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2791, 6fykC, 0.7857, 3.00, 0.214, 349, 252, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
2792, 5xvuC, 0.7857, 2.83, 0.229, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2793, 5omyA, 0.7857, 2.87, 0.227, 332, 256, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2794, 5m4fA, 0.7857, 2.94, 0.227, 330, 256, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
2795, 4qmzA, 0.7857, 2.88, 0.257, 286, 253, MST3 IN COMPLEX WITH SUNITINIB
2796, 3f5pM, 0.7857, 3.11, 0.300, 295, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2797, 3e8dB, 0.7857, 2.72, 0.242, 317, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2798, 3e8dA, 0.7857, 2.72, 0.242, 315, 252, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2799, 1jktA, 0.7857, 2.87, 0.249, 276, 253, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2800, 5ctpA, 0.7856, 2.95, 0.219, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2801, 3bprA, 0.7856, 2.45, 0.352, 261, 244, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
2802, 2pe1A, 0.7856, 2.48, 0.211, 275, 247, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2803, 5w5oE, 0.7855, 2.21, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2804, 5u6bA, 0.7855, 2.58, 0.332, 270, 247, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2805, 5t18A, 0.7855, 2.60, 0.297, 261, 246, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
2806, 5av4A, 0.7855, 2.63, 0.252, 274, 250, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2807, 4uv0A, 0.7855, 2.87, 0.243, 300, 255, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
2808, 3f5pH, 0.7855, 3.24, 0.298, 299, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2809, 3ej1A, 0.7855, 2.78, 0.250, 295, 252, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
2810, 2ou7A, 0.7855, 2.99, 0.263, 292, 255, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2811, 5av2A, 0.7854, 2.68, 0.251, 275, 251, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2812, 4rewA, 0.7854, 2.73, 0.278, 411, 252, CRYSTAL STRUCTURE OF THE NON-PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX
2813, 4qnaA, 0.7854, 3.03, 0.260, 284, 254, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
2814, 4iw0A, 0.7854, 2.91, 0.237, 647, 257, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
2815, 3qkmA, 0.7854, 2.71, 0.242, 329, 252, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
2816, 3f5pL, 0.7854, 3.17, 0.300, 293, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2817, 3a7iA, 0.7854, 2.88, 0.253, 286, 253, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
2818, 2uzlC, 0.7854, 2.75, 0.255, 295, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2819, 5orkB, 0.7853, 2.90, 0.220, 323, 255, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
2820, 5auyA, 0.7853, 2.68, 0.251, 275, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2821, 4qmuA, 0.7853, 2.90, 0.253, 286, 253, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
2822, 4mnfA, 0.7853, 2.33, 0.270, 257, 244, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
2823, 4e26B, 0.7853, 2.52, 0.262, 264, 248, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
2824, 3wzdA, 0.7853, 2.35, 0.385, 278, 244, KDR IN COMPLEX WITH LIGAND LENVATINIB
2825, 3nr9A, 0.7853, 3.02, 0.218, 341, 252, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
2826, 3ddpA, 0.7853, 2.77, 0.254, 297, 252, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
2827, 2wpaA, 0.7853, 3.00, 0.246, 302, 256, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
2828, 5w5oA, 0.7852, 2.22, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2829, 5swhA, 0.7852, 2.05, 0.336, 258, 241, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
2830, 5ia0C, 0.7852, 2.44, 0.339, 269, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2831, 4nusA, 0.7852, 3.03, 0.262, 301, 256, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
2832, 4l53A, 0.7852, 2.42, 0.279, 296, 244, CRYSTAL STRUCTURE OF (1R4R)-4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7- YL)-3-CHLOROFURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}CYCLOHEXAN-1-OL BOUND TO TAK1-TAB1
2833, 3q53A, 0.7852, 3.06, 0.210, 291, 257, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
2834, 3ocbB, 0.7852, 2.73, 0.250, 319, 252, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
2835, 3nr9B, 0.7852, 3.02, 0.206, 347, 252, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
2836, 3ehaA, 0.7852, 2.69, 0.251, 279, 251, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2837, 3cd8A, 0.7852, 2.76, 0.339, 278, 248, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
2838, 5lqfA, 0.7851, 2.93, 0.258, 287, 252, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2839, 5i3oB, 0.7851, 2.89, 0.217, 302, 249, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2840, 4cfvA, 0.7851, 2.85, 0.252, 300, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2841, 3o17A, 0.7851, 2.86, 0.198, 357, 253, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
2842, 3my5C, 0.7851, 2.71, 0.256, 266, 250, CDK2/CYCLINA IN COMPLEX WITH DRB
2843, 2iw6C, 0.7851, 2.81, 0.254, 295, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2844, 1wvyA, 0.7851, 2.93, 0.248, 273, 254, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2845, 1jwhA, 0.7851, 2.74, 0.217, 336, 253, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
2846, 6fnfA, 0.7850, 2.27, 0.342, 267, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH NVP-BHG712 
2847, 6c9dA, 0.7850, 2.66, 0.271, 425, 251, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
2848, 5w5oH, 0.7850, 2.23, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2849, 5uq1C, 0.7850, 2.82, 0.254, 289, 252, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
2850, 5lxdA, 0.7850, 3.17, 0.240, 385, 254, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
2851, 5ezvA, 0.7850, 2.63, 0.264, 441, 250, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
2852, 5dzcA, 0.7850, 2.93, 0.230, 816, 257, CRYSTAL STRUCTURE OF PVX_084705 IN COMPLEX WITH AMP-PNP
2853, 3qcyA, 0.7850, 2.57, 0.210, 275, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2854, 3q4cB, 0.7850, 2.46, 0.263, 264, 247, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
2855, 1zwsA, 0.7850, 2.86, 0.227, 278, 255, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2856, 5oszA, 0.7849, 2.92, 0.230, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 23
2857, 4oh4B, 0.7849, 2.90, 0.240, 289, 250, CRYSTAL STRUCTURE OF BRI1 IN COMPLEX WITH BKI1
2858, 4o0tA, 0.7849, 2.91, 0.208, 292, 255, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2859, 3en5B, 0.7849, 2.26, 0.350, 261, 243, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
2860, 1h28C, 0.7849, 2.80, 0.254, 296, 252, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
2861, 5n3fA, 0.7848, 2.58, 0.230, 318, 248, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-[3-(AMINOMETHYL)PHENYL]ACETAMIDE
2862, 4yzbB, 0.7848, 3.03, 0.268, 464, 257, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
2863, 4eoiA, 0.7848, 2.77, 0.258, 294, 252, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2864, 3e5aA, 0.7848, 2.85, 0.198, 264, 253, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
2865, 3cqwA, 0.7848, 2.77, 0.246, 318, 252, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
2866, 2wu7A, 0.7848, 2.99, 0.222, 348, 252, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH V25
2867, 2nruA, 0.7848, 2.95, 0.239, 293, 251, CRYSTAL STRUCTURE OF IRAK-4
2868, 5lpbA, 0.7847, 2.65, 0.231, 280, 247, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
2869, 4f0iA, 0.7847, 2.70, 0.379, 284, 248, CRYSTAL STRUCTURE OF APO TRKA
2870, 4euuA, 0.7847, 3.09, 0.242, 307, 260, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
2871, 3g6hB, 0.7847, 2.13, 0.339, 259, 242, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
2872, 3f5pF, 0.7847, 3.23, 0.298, 299, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2873, 3ckxA, 0.7847, 2.64, 0.264, 276, 250, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
2874, 5lxdB, 0.7846, 3.17, 0.244, 385, 254, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
2875, 5lmkC, 0.7846, 2.70, 0.257, 265, 249, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2876, 4qmnA, 0.7846, 3.03, 0.260, 283, 254, MST3 IN COMPLEX WITH BOSUTINIB
2877, 3rhkA, 0.7846, 2.91, 0.304, 298, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
2878, 3iopA, 0.7846, 2.52, 0.211, 275, 247, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
2879, 3fbvJ, 0.7846, 2.51, 0.206, 413, 247, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2880, 2uzeA, 0.7846, 2.76, 0.255, 295, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2881, 2r7iB, 0.7846, 2.77, 0.221, 322, 253, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2882, 5n1oA, 0.7845, 2.55, 0.230, 335, 248, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-4-(CHLOROMETHYL)-5- HYDROXYPHENYL)ETHAN-1-ONE
2883, 5ar5B, 0.7845, 2.27, 0.272, 279, 243, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
2884, 4zhxA, 0.7845, 2.63, 0.264, 408, 250, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
2885, 4v01A, 0.7845, 2.52, 0.388, 273, 245, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
2886, 3tv6B, 0.7845, 2.77, 0.267, 276, 251, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
2887, 3fbvI, 0.7845, 2.51, 0.206, 413, 247, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
2888, 2uzeC, 0.7845, 2.75, 0.255, 295, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2889, 1gy3C, 0.7845, 2.75, 0.255, 295, 251, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2890, 5v60A, 0.7844, 2.94, 0.232, 347, 254, PHOSPHO-ERK2 BOUND TO AMP-PCP
2891, 5nhjA, 0.7844, 3.11, 0.230, 345, 256, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2892, 2w1cA, 0.7844, 2.66, 0.212, 261, 250, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2893, 5jkgA, 0.7843, 2.54, 0.393, 266, 247, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
2894, 5ia0B, 0.7843, 2.63, 0.333, 266, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2895, 5auuA, 0.7843, 2.65, 0.252, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
2896, 4eojA, 0.7843, 2.85, 0.257, 295, 253, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2897, 4cfxA, 0.7843, 2.78, 0.262, 298, 252, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2898, 1jstC, 0.7843, 2.75, 0.255, 297, 251, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
2899, 1h1sA, 0.7843, 2.79, 0.254, 296, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
2900, 6babB, 0.7842, 2.33, 0.241, 285, 245, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2901, 5ztnA, 0.7842, 2.95, 0.242, 395, 252, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
2902, 5efqA, 0.7842, 2.97, 0.258, 321, 256, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
2903, 4qmtA, 0.7842, 2.91, 0.257, 284, 253, MST3 IN COMPLEX WITH HESPERADIN
2904, 4q9zB, 0.7842, 2.88, 0.213, 308, 254, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
2905, 4knbA, 0.7842, 2.99, 0.336, 273, 250, C-MET IN COMPLEX WITH OSI LIGAND
2906, 3tudA, 0.7842, 2.42, 0.361, 256, 244, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
2907, 3ky2B, 0.7842, 2.68, 0.395, 280, 248, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
2908, 3gqlB, 0.7842, 2.60, 0.399, 276, 248, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2909, 5ztnB, 0.7841, 2.95, 0.242, 395, 252, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
2910, 4wo5A, 0.7841, 3.04, 0.268, 266, 254, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
2911, 4uwyB, 0.7841, 2.53, 0.394, 273, 246, FGFR1 APO STRUCTURE
2912, 4dceA, 0.7841, 2.51, 0.314, 288, 245, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
2913, 4aw0A, 0.7841, 2.79, 0.202, 283, 253, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
2914, 3qklA, 0.7841, 2.76, 0.242, 317, 252, SPIROCHROMANE AKT INHIBITORS
2915, 3mvhA, 0.7841, 2.71, 0.247, 311, 251, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
2916, 3fzoA, 0.7841, 2.75, 0.378, 262, 249, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
2917, 2r7iD, 0.7841, 2.81, 0.221, 322, 253, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2918, 2pe2A, 0.7841, 2.52, 0.211, 275, 247, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2919, 2c5nA, 0.7841, 2.79, 0.250, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2920, 1h1rA, 0.7841, 2.80, 0.254, 296, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
2921, 1gy3A, 0.7841, 2.76, 0.255, 295, 251, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
2922, 5jfsA, 0.7840, 2.45, 0.389, 277, 244, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
2923, 4ix4B, 0.7840, 3.25, 0.154, 350, 259, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
2924, 4dggB, 0.7840, 2.34, 0.354, 259, 243, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
2925, 3rpsA, 0.7840, 2.76, 0.202, 334, 252, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
2926, 3h30A, 0.7840, 2.79, 0.213, 333, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
2927, 3f5pJ, 0.7840, 3.18, 0.300, 293, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2928, 2clqA, 0.7840, 2.70, 0.285, 263, 249, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2929, 1p5eC, 0.7840, 2.81, 0.254, 296, 252, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
2930, 1e9hC, 0.7840, 2.82, 0.258, 296, 252, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2931, 5m0uA, 0.7839, 2.70, 0.237, 346, 249, APOSTRUCTURE STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) FROM CHO CELLS WITH A PEPTIDIC INHIBITOR FRAGMENT 
2932, 5jfxA, 0.7839, 2.44, 0.389, 277, 244, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
2933, 5auzA, 0.7839, 2.66, 0.252, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
2934, 4grbA, 0.7839, 2.95, 0.223, 327, 256, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
2935, 4eomA, 0.7839, 2.85, 0.257, 296, 253, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2936, 4dawA, 0.7839, 3.09, 0.206, 293, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2937, 4au8B, 0.7839, 2.56, 0.229, 277, 245, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
2938, 3rpsB, 0.7839, 2.84, 0.212, 334, 255, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
2939, 3f66B, 0.7839, 2.75, 0.335, 269, 248, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
2940, 3f5uA, 0.7839, 2.74, 0.251, 279, 251, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2941, 3f5pR, 0.7839, 3.24, 0.298, 294, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2942, 3bhvA, 0.7839, 2.84, 0.253, 297, 253, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
2943, 2iw6A, 0.7839, 2.81, 0.254, 292, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2944, 1w98A, 0.7839, 2.77, 0.258, 297, 252, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
2945, 1ol1C, 0.7839, 2.82, 0.250, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
2946, 6fykA, 0.7838, 3.04, 0.214, 349, 252, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
2947, 6bqpA, 0.7838, 2.77, 0.225, 263, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
2948, 5i3rB, 0.7838, 2.90, 0.217, 302, 249, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2949, 4qmlA, 0.7838, 2.74, 0.255, 280, 251, MST3 IN COMPLEX WITH AMP-PNP
2950, 3sdjI, 0.7838, 2.51, 0.206, 413, 247, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
2951, 2jedB, 0.7838, 2.77, 0.226, 320, 252, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
2952, 2iw8C, 0.7838, 2.69, 0.249, 265, 249, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2953, 5lpzA, 0.7837, 2.64, 0.235, 283, 247, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
2954, 5kmnA, 0.7837, 2.83, 0.376, 296, 250, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
2955, 4u45A, 0.7837, 2.78, 0.225, 289, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2956, 3zfxC, 0.7837, 1.95, 0.343, 248, 236, CRYSTAL STRUCTURE OF EPHB1
2957, 3ndmA, 0.7837, 2.71, 0.191, 383, 251, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2958, 3lm5A, 0.7837, 2.50, 0.224, 274, 246, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2959, 3ha6A, 0.7837, 2.86, 0.209, 263, 253, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
2960, 3f5pE, 0.7837, 3.25, 0.298, 299, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
2961, 3dogC, 0.7837, 2.69, 0.257, 267, 249, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2962, 2c5xC, 0.7837, 2.81, 0.254, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
2963, 1oiuC, 0.7837, 2.71, 0.257, 265, 249, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2964, 5w5oL, 0.7836, 2.33, 0.259, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2965, 3qriB, 0.7836, 2.58, 0.382, 262, 246, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
2966, 3qkkA, 0.7836, 2.75, 0.242, 326, 252, SPIROCHROMANE AKT INHIBITORS
2967, 3dogA, 0.7836, 2.81, 0.254, 297, 252, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2968, 2vagA, 0.7836, 2.93, 0.252, 330, 250, CRYSTAL STRUCTURE OF DI-PHOSPHORYLATED HUMAN CLK1 IN COMPLEX WITH A NOVEL SUBSTITUTED INDOLE INHIBITOR
2969, 2gmxB, 0.7836, 2.90, 0.198, 357, 253, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
2970, 2evaA, 0.7836, 2.28, 0.281, 295, 242, STRUCTURAL BASIS FOR THE INTERACTION OF TAK1 KINASE WITH ITS ACTIVATING PROTEIN TAB1
2971, 6babC, 0.7835, 2.32, 0.241, 284, 245, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2972, 5isoC, 0.7835, 2.69, 0.263, 429, 251, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2973, 5cyiA, 0.7835, 2.79, 0.254, 298, 252, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
2974, 3k2lA, 0.7835, 2.95, 0.248, 402, 250, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2)
2975, 2b9iA, 0.7835, 2.59, 0.235, 338, 247, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
2976, 4wunA, 0.7834, 2.60, 0.402, 282, 246, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
2977, 4azfA, 0.7834, 3.04, 0.241, 404, 253, HUMAN DYRK2 IN COMPLEX WITH LEUCETTINE L41
2978, 3a7jA, 0.7834, 2.91, 0.253, 286, 253, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
2979, 6c9dB, 0.7833, 2.70, 0.271, 422, 251, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
2980, 5uq0A, 0.7833, 2.37, 0.403, 266, 243, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
2981, 5i9wA, 0.7833, 2.25, 0.343, 267, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
2982, 3tt0B, 0.7833, 2.45, 0.400, 272, 245, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
2983, 3ccnA, 0.7833, 2.79, 0.340, 275, 247, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
2984, 5w5oF, 0.7832, 2.28, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2985, 5uorB, 0.7832, 2.53, 0.294, 262, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2986, 5lvmA, 0.7832, 2.78, 0.202, 283, 253, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
2987, 5ezrA, 0.7832, 2.97, 0.222, 803, 257, CRYSTAL STRUCTURE OF PVX_084705 BOUND TO COMPOUND
2988, 5cvfA, 0.7832, 2.89, 0.220, 325, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
2989, 4fmqA, 0.7832, 2.84, 0.226, 350, 252, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2990, 4eooA, 0.7832, 2.86, 0.253, 294, 253, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2991, 3tniA, 0.7832, 2.84, 0.231, 297, 251, STRUCTURE OF CDK9/CYCLIN T F241L
2992, 3tl8A, 0.7832, 2.80, 0.258, 300, 252, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
2993, 3ionA, 0.7832, 2.49, 0.211, 274, 246, PDK1 IN COMPLEX WITH COMPOUND 8H
2994, 2reiA, 0.7832, 2.47, 0.344, 277, 244, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
2995, 1urcC, 0.7832, 2.83, 0.250, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
2996, 1k9aD, 0.7832, 2.72, 0.319, 433, 248, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
2997, 6cd6D, 0.7831, 2.80, 0.241, 267, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2998, 5m4uA, 0.7831, 2.91, 0.215, 332, 256, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2999, 4ybjB, 0.7831, 2.01, 0.335, 253, 239, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
3000, 4qfgA, 0.7831, 2.63, 0.276, 365, 250, STRUCTURE OF AMPK IN COMPLEX WITH STAUROSPORINE INHIBITOR AND IN THE ABSENCE OF A SYNTHETIC ACTIVATOR
3001, 4nstA, 0.7831, 2.95, 0.242, 322, 256, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
3002, 3rhkB, 0.7831, 2.81, 0.305, 299, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
3003, 3gqlC, 0.7831, 2.56, 0.399, 275, 248, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3004, 3f3vA, 0.7831, 2.41, 0.335, 261, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3005, 2og8B, 0.7831, 2.30, 0.370, 249, 243, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
3006, 2h96A, 0.7831, 2.89, 0.198, 358, 253, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
3007, 2cciA, 0.7831, 2.82, 0.254, 296, 252, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
3008, 1oi9A, 0.7831, 2.80, 0.254, 295, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
3009, 5w5oP, 0.7830, 2.28, 0.260, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3010, 4qmwA, 0.7830, 2.91, 0.253, 286, 253, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
3011, 4ix5B, 0.7830, 3.18, 0.155, 350, 258, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
3012, 4ix4A, 0.7830, 3.17, 0.155, 346, 258, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
3013, 4cfnA, 0.7830, 2.87, 0.256, 296, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3014, 3f3wA, 0.7830, 2.30, 0.340, 261, 244, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3015, 5w5oC, 0.7829, 2.29, 0.260, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3016, 4kaoB, 0.7829, 2.49, 0.346, 254, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
3017, 3f3vB, 0.7829, 2.31, 0.336, 262, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3018, 2g9xA, 0.7829, 2.82, 0.258, 298, 252, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
3019, 2bpmA, 0.7829, 3.02, 0.246, 302, 256, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
3020, 6cd6A, 0.7828, 2.70, 0.246, 264, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3021, 5w5oB, 0.7828, 2.29, 0.264, 275, 242, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3022, 4v04A, 0.7828, 2.57, 0.390, 290, 246, FGFR1 IN COMPLEX WITH PONATINIB.
3023, 4pp7B, 0.7828, 2.83, 0.267, 274, 251, HIGHLY POTENT AND SELECTIVE 3-N-METHYLQUINAZOLINE-4(3H)-ONE BASED INHIBITORS OF B-RAFV600E KINASE
3024, 4eorC, 0.7828, 2.81, 0.259, 270, 251, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
3025, 3skcB, 0.7828, 2.75, 0.267, 276, 251, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
3026, 3h30B, 0.7828, 2.81, 0.213, 333, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
3027, 1pkdC, 0.7828, 2.82, 0.254, 296, 252, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
3028, 1h28A, 0.7828, 2.81, 0.254, 296, 252, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
3029, 5lqfD, 0.7827, 2.84, 0.256, 285, 250, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
3030, 5lqeA, 0.7827, 2.81, 0.254, 295, 252, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
3031, 4ix3B, 0.7827, 3.18, 0.155, 350, 258, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
3032, 3miyB, 0.7827, 1.91, 0.322, 240, 236, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
3033, 3kvwA, 0.7827, 2.82, 0.245, 403, 249, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2) IN COMPLEX WITH AN INDIRUBIN LIGAND
3034, 2oh4A, 0.7827, 2.67, 0.383, 297, 248, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
3035, 5nhoA, 0.7826, 3.10, 0.220, 343, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3036, 5jgbA, 0.7826, 2.37, 0.280, 295, 243, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 10
3037, 5bvnA, 0.7826, 2.72, 0.332, 278, 250, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3038, 3u6iA, 0.7826, 2.70, 0.314, 281, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
3039, 3orzA, 0.7826, 2.57, 0.210, 276, 248, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
3040, 3my5A, 0.7826, 2.86, 0.253, 296, 253, CDK2/CYCLINA IN COMPLEX WITH DRB
3041, 2y0aA, 0.7826, 2.94, 0.239, 300, 255, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
3042, 2g01B, 0.7826, 2.92, 0.198, 356, 253, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
3043, 1oiyA, 0.7826, 2.80, 0.254, 293, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
3044, 5mrdA, 0.7825, 2.79, 0.206, 283, 253, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
3045, 4nkaA, 0.7825, 2.56, 0.390, 279, 246, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
3046, 3orzC, 0.7825, 2.57, 0.210, 276, 248, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
3047, 3ddqC, 0.7825, 2.71, 0.257, 266, 249, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
3048, 2c5vA, 0.7825, 2.82, 0.250, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3049, 5mp8B, 0.7824, 2.90, 0.220, 323, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
3050, 5jfwA, 0.7824, 2.48, 0.389, 277, 244, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
3051, 4ra5B, 0.7824, 2.80, 0.210, 310, 252, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
3052, 4pmsA, 0.7824, 2.66, 0.379, 283, 248, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
3053, 4ix6B, 0.7824, 3.19, 0.155, 350, 258, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
3054, 2x0gA, 0.7824, 2.94, 0.224, 318, 254, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
3055, 2c5vC, 0.7824, 2.82, 0.254, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3056, 1h1qA, 0.7824, 2.81, 0.254, 296, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
3057, 5w5oI, 0.7823, 2.34, 0.259, 275, 243, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3058, 5uyjA, 0.7823, 2.90, 0.224, 281, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
3059, 5otlA, 0.7823, 2.81, 0.222, 320, 252, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
3060, 5nevA, 0.7823, 2.83, 0.258, 295, 252, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
3061, 4uy9A, 0.7823, 2.84, 0.312, 313, 250, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
3062, 3tz8A, 0.7823, 2.41, 0.335, 261, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
3063, 3sdjJ, 0.7823, 2.57, 0.210, 413, 248, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3064, 3o7lB, 0.7823, 2.78, 0.220, 326, 250, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
3065, 2iw9A, 0.7823, 2.81, 0.254, 293, 252, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
3066, 5v61A, 0.7822, 3.07, 0.231, 348, 255, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
3067, 5lxcB, 0.7822, 2.95, 0.235, 385, 251, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
3068, 5izjA, 0.7822, 2.84, 0.241, 328, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
3069, 5f0aA, 0.7822, 2.98, 0.222, 811, 257, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND 1-TERT-BUTYL-3-(3- CHLOROPHENOXY)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE INHIBITOR
3070, 2v5qB, 0.7822, 3.07, 0.259, 285, 255, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
3071, 2oibD, 0.7822, 3.09, 0.238, 288, 252, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3072, 5te0A, 0.7821, 2.73, 0.227, 316, 247, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
3073, 5bpyB, 0.7821, 2.39, 0.320, 247, 244, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
3074, 3tv4B, 0.7821, 2.77, 0.267, 276, 251, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
3075, 3bprB, 0.7821, 2.42, 0.347, 256, 242, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
3076, 2xzsA, 0.7821, 3.11, 0.226, 301, 257, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3077, 5fboA, 0.7820, 2.45, 0.309, 255, 246, BTK-INHIBITOR CO-STRUCTURE
3078, 4yzmA, 0.7820, 2.75, 0.282, 260, 248, HUMANIZED ROCO4 BOUND TO LRRK2-IN1
3079, 4bcoA, 0.7820, 2.83, 0.258, 298, 252, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3080, 4eqcA, 0.7819, 3.11, 0.210, 296, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
3081, 4cffA, 0.7819, 2.67, 0.264, 424, 250, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
3082, 4a07A, 0.7819, 2.79, 0.202, 282, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
3083, 3bprC, 0.7819, 2.40, 0.355, 259, 242, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
3084, 2no3B, 0.7819, 2.86, 0.198, 357, 252, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
3085, 2eu9A, 0.7819, 2.94, 0.223, 345, 251, CRYSTAL STRUCTURE OF CLK3
3086, 4yu2A, 0.7818, 3.03, 0.225, 348, 253, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
3087, 4ix5A, 0.7818, 3.19, 0.155, 346, 258, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
3088, 4eheB, 0.7818, 2.79, 0.267, 276, 251, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
3089, 4cfmA, 0.7818, 2.82, 0.254, 296, 252, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3090, 4bcpA, 0.7818, 2.83, 0.262, 298, 252, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3091, 3qd0A, 0.7818, 2.56, 0.211, 274, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
3092, 3i5nA, 0.7818, 2.99, 0.333, 280, 249, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
3093, 3bprD, 0.7818, 2.42, 0.355, 259, 242, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
3094, 2dwbA, 0.7818, 2.62, 0.234, 259, 248, AURORA-A KINASE COMPLEXED WITH AMPPNP
3095, 1h27C, 0.7818, 2.83, 0.258, 291, 252, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
3096, 5g1xA, 0.7817, 2.74, 0.231, 262, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH N-MYC
3097, 4rwjB, 0.7817, 2.74, 0.379, 282, 248, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
3098, 4nifB, 0.7817, 2.86, 0.226, 349, 252, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
3099, 3qrkA, 0.7817, 2.55, 0.382, 270, 246, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
3100, 3hrcA, 0.7817, 2.73, 0.203, 279, 251, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
3101, 3f66A, 0.7817, 2.87, 0.333, 288, 249, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
3102, 2c5oC, 0.7817, 2.84, 0.250, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3103, 1zwsE, 0.7817, 2.83, 0.213, 278, 254, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3104, 1uu3A, 0.7817, 2.61, 0.210, 276, 248, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
3105, 6cd6B, 0.7816, 2.84, 0.244, 266, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3106, 5t5tA, 0.7816, 2.66, 0.268, 368, 250, AMPK BOUND TO ALLOSTERIC ACTIVATOR
3107, 5os2A, 0.7816, 2.61, 0.234, 261, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3108, 5kmlA, 0.7816, 2.86, 0.376, 296, 250, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3109, 4pdoB, 0.7816, 2.22, 0.337, 261, 240, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3110, 4pdoA, 0.7816, 2.22, 0.337, 261, 240, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3111, 4nstC, 0.7816, 3.01, 0.250, 317, 256, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
3112, 4jr7A, 0.7816, 2.75, 0.203, 367, 251, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
3113, 3tz9A, 0.7816, 2.43, 0.335, 261, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
3114, 3eocA, 0.7816, 2.84, 0.254, 295, 252, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
3115, 2y9qA, 0.7816, 2.93, 0.230, 349, 252, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3116, 2no3A, 0.7816, 2.83, 0.198, 357, 252, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
3117, 1uv5A, 0.7816, 3.16, 0.230, 348, 256, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
3118, 6bleA, 0.7815, 2.87, 0.224, 265, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
3119, 5nhhA, 0.7815, 3.18, 0.234, 348, 256, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3120, 5lmkA, 0.7815, 2.84, 0.258, 296, 252, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
3121, 5dylA, 0.7815, 2.94, 0.223, 802, 256, CRYSTAL STRUCTURE OF PVX_084705
3122, 5autA, 0.7815, 2.74, 0.247, 274, 251, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
3123, 4ztmA, 0.7815, 3.00, 0.237, 287, 249, IRAK4-INHIBITOR CO-STRUCTURE
3124, 4twoA, 0.7815, 2.69, 0.313, 278, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
3125, 4nifE, 0.7815, 2.86, 0.226, 348, 252, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
3126, 4bcnA, 0.7815, 2.82, 0.254, 296, 252, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3127, 3ulzA, 0.7815, 2.87, 0.257, 291, 249, CRYSTAL STRUCTURE OF APO BAK1
3128, 3be2A, 0.7815, 2.41, 0.376, 290, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
3129, 2x6dA, 0.7815, 2.65, 0.233, 255, 249, AURORA-A BOUND TO AN INHIBITOR
3130, 2v22C, 0.7815, 2.86, 0.250, 296, 252, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
3131, 2fysA, 0.7815, 2.96, 0.217, 348, 254, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
3132, 2c5oA, 0.7815, 2.85, 0.250, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3133, 2bdwB, 0.7815, 2.75, 0.218, 309, 252, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
3134, 1h26A, 0.7815, 2.83, 0.254, 296, 252, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
3135, 5dfpA, 0.7814, 3.06, 0.211, 292, 256, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
3136, 5ar2A, 0.7814, 2.41, 0.267, 277, 243, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3137, 4mq2A, 0.7814, 2.99, 0.230, 343, 252, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
3138, 4ix3A, 0.7814, 3.19, 0.155, 346, 258, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
3139, 3ocbA, 0.7814, 2.81, 0.242, 315, 252, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
3140, 3f3tA, 0.7814, 2.41, 0.339, 261, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
3141, 2zoqB, 0.7814, 3.09, 0.216, 351, 255, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
3142, 2wu6A, 0.7814, 3.02, 0.222, 350, 252, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH DKI
3143, 6fyrA, 0.7813, 2.95, 0.223, 355, 251, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CPD-2 AT 1.42A 
3144, 5lpyA, 0.7813, 2.67, 0.231, 282, 247, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
3145, 4ix6A, 0.7813, 3.20, 0.155, 346, 258, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
3146, 4eorA, 0.7813, 2.85, 0.262, 293, 252, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
3147, 2wmbA, 0.7813, 2.83, 0.254, 296, 252, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
3148, 2bkzC, 0.7813, 2.88, 0.249, 298, 253, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
3149, 1u5rA, 0.7813, 2.85, 0.242, 308, 252, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
3150, 5nevC, 0.7812, 2.84, 0.258, 296, 252, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
3151, 5lihA, 0.7812, 2.79, 0.194, 324, 252, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
3152, 5cshB, 0.7812, 2.82, 0.222, 323, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
3153, 3nieA, 0.7812, 3.28, 0.187, 369, 257, CRYSTAL STRUCTURE OF PF11_0147
3154, 1yolB, 0.7812, 1.91, 0.333, 253, 237, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
3155, 1yhwA, 0.7812, 3.15, 0.202, 293, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
3156, 6d22A, 0.7811, 2.81, 0.376, 299, 250, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR 
3157, 5kmoA, 0.7811, 2.80, 0.378, 291, 249, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
3158, 4qfsA, 0.7811, 2.78, 0.267, 361, 251, STRUCTURE OF AMPK IN COMPLEX WITH BR2-A769662CORE ACTIVATOR AND STAUROSPORINE INHIBITOR
3159, 2yn8B, 0.7811, 2.36, 0.326, 260, 242, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3160, 1yomB, 0.7811, 2.26, 0.339, 261, 242, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
3161, 6cmjB, 0.7810, 2.89, 0.224, 284, 250, HUMAN CAMKK2 WITH GSK650393
3162, 5jgaA, 0.7810, 2.39, 0.280, 296, 243, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 11C
3163, 4ybjA, 0.7810, 2.05, 0.343, 255, 239, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
3164, 4qteA, 0.7810, 3.08, 0.231, 348, 255, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
3165, 4cffC, 0.7810, 2.67, 0.264, 422, 250, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
3166, 4cfeC, 0.7810, 2.67, 0.264, 403, 250, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
3167, 2wevA, 0.7810, 2.85, 0.250, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3168, 5ur1A, 0.7809, 2.53, 0.404, 278, 245, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
3169, 5unpB, 0.7809, 3.07, 0.210, 347, 252, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
3170, 5unpA, 0.7809, 3.07, 0.210, 347, 252, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
3171, 4yu2B, 0.7809, 2.87, 0.233, 347, 249, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
3172, 4e4xB, 0.7809, 2.78, 0.267, 274, 251, CRYSTAL STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH A DIHYDROPYRIDO[23-D]PYRIMIDINONE-BASED INHIBITOR
3173, 3ow4B, 0.7809, 2.79, 0.246, 317, 252, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
3174, 3el7A, 0.7809, 2.13, 0.347, 254, 239, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
3175, 1jktB, 0.7809, 2.80, 0.254, 276, 252, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3176, 6e4uA, 0.7808, 2.68, 0.272, 365, 250, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
3177, 6e4tA, 0.7808, 2.67, 0.268, 361, 250, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
3178, 5clpA, 0.7808, 2.79, 0.223, 322, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
3179, 4tygA, 0.7808, 2.86, 0.373, 293, 252, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3180, 4iz5D, 0.7808, 3.01, 0.220, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
3181, 3w8lA, 0.7808, 2.89, 0.213, 326, 253, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
3182, 3nayB, 0.7808, 2.59, 0.215, 278, 247, PDK1 IN COMPLEX WITH INHIBITOR MP6
3183, 2xzsB, 0.7808, 3.08, 0.223, 293, 256, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3184, 5f9eB, 0.7807, 2.88, 0.213, 293, 253, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
3185, 4yljA, 0.7807, 3.01, 0.230, 346, 252, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
3186, 4qnyA, 0.7807, 2.93, 0.237, 333, 253, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
3187, 4l52A, 0.7807, 2.46, 0.276, 295, 243, CRYSTAL STRUCTURE OF 1-(4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7-YL) FURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}PIPERIDIN-1-YL)ETHAN-1-ONE BOUND TO TAK1-TAB1
3188, 4kioB, 0.7807, 1.89, 0.319, 239, 235, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
3189, 4iz5C, 0.7807, 3.01, 0.220, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
3190, 4iz5A, 0.7807, 3.01, 0.220, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
3191, 3ow4A, 0.7807, 2.80, 0.246, 317, 252, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
3192, 3ddqA, 0.7807, 2.85, 0.258, 296, 252, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
3193, 6b1uC, 0.7806, 2.69, 0.260, 459, 250, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
3194, 5lqeC, 0.7806, 2.85, 0.254, 296, 252, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
3195, 5ia5A, 0.7806, 2.89, 0.320, 273, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
3196, 5ia1A, 0.7806, 2.31, 0.342, 261, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
3197, 5hkmA, 0.7806, 2.47, 0.212, 272, 245, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
3198, 5efqC, 0.7806, 2.92, 0.256, 325, 254, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
3199, 4yu2D, 0.7806, 2.82, 0.230, 346, 248, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
3200, 4mbjB, 0.7806, 2.79, 0.267, 276, 251, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
3201, 4iz5B, 0.7806, 3.01, 0.220, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
3202, 4gt5A, 0.7806, 2.76, 0.378, 290, 249, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
3203, 4eoqA, 0.7806, 2.89, 0.257, 295, 253, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
3204, 3nayA, 0.7806, 2.59, 0.215, 278, 247, PDK1 IN COMPLEX WITH INHIBITOR MP6
3205, 2xckA, 0.7806, 2.56, 0.206, 275, 247, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
3206, 2r7bA, 0.7806, 2.52, 0.211, 274, 246, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
3207, 2c5xA, 0.7806, 2.85, 0.250, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3208, 1fvvC, 0.7806, 2.86, 0.254, 298, 252, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
3209, 4zhxC, 0.7805, 2.68, 0.260, 452, 250, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
3210, 4yljD, 0.7805, 2.86, 0.225, 347, 249, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
3211, 3utoB, 0.7805, 3.07, 0.222, 566, 257, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
3212, 3d14A, 0.7805, 2.73, 0.228, 262, 250, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
3213, 2x4zA, 0.7805, 3.07, 0.195, 290, 256, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
3214, 1yhvA, 0.7805, 3.15, 0.202, 293, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
3215, 1unlA, 0.7805, 2.98, 0.217, 292, 253, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
3216, 5jfvA, 0.7804, 2.48, 0.385, 277, 244, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
3217, 4h3qA, 0.7804, 2.88, 0.226, 352, 252, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3218, 3fwqB, 0.7804, 3.01, 0.207, 334, 256, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
3219, 2uueC, 0.7804, 2.87, 0.250, 296, 252, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
3220, 1wvwA, 0.7804, 2.88, 0.252, 275, 254, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3221, 1h25C, 0.7804, 2.76, 0.260, 278, 250, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
3222, 6e4wA, 0.7803, 2.68, 0.268, 361, 250, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
3223, 6cmjA, 0.7803, 2.89, 0.224, 285, 250, HUMAN CAMKK2 WITH GSK650393
3224, 4fnzA, 0.7803, 2.47, 0.316, 287, 244, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
3225, 3ce3A, 0.7803, 2.89, 0.313, 293, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
3226, 5ezvC, 0.7802, 2.70, 0.260, 440, 250, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
3227, 3tz7A, 0.7802, 2.28, 0.337, 260, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL103
3228, 2x1nC, 0.7802, 2.87, 0.250, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3229, 2qobA, 0.7802, 2.80, 0.312, 279, 247, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
3230, 2g01A, 0.7802, 2.94, 0.202, 355, 253, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
3231, 5uq2A, 0.7801, 2.88, 0.254, 296, 252, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
3232, 5u94A, 0.7801, 2.47, 0.205, 263, 244, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
3233, 5nkaA, 0.7801, 2.59, 0.324, 271, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
3234, 5hvjA, 0.7801, 2.69, 0.270, 283, 248, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
3235, 4bicA, 0.7801, 2.62, 0.293, 260, 246, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3236, 3krlA, 0.7801, 2.63, 0.329, 281, 246, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
3237, 2wevC, 0.7801, 2.87, 0.258, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3238, 2jgzA, 0.7801, 2.77, 0.259, 288, 251, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
3239, 5vd3A, 0.7800, 3.01, 0.223, 293, 251, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (DE-PHOSPHORYLATED) IN COMPLEX WITH SARACATINIB
3240, 5j5sA, 0.7800, 2.11, 0.312, 258, 240, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
3241, 5bvoA, 0.7800, 2.67, 0.339, 276, 248, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3242, 4y83C, 0.7800, 2.79, 0.223, 293, 251, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
3243, 3nszA, 0.7800, 2.99, 0.219, 327, 256, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
3244, 3cs9B, 0.7800, 2.45, 0.360, 247, 242, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3245, 2qi8A, 0.7800, 2.22, 0.317, 255, 240, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
3246, 6fnhC, 0.7799, 2.47, 0.318, 270, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
3247, 4gs6A, 0.7799, 2.40, 0.277, 294, 242, IRREVERSIBLE INHIBITION OF TAK1 KINASE BY 5Z-7-OXOZEAENOL
3248, 4cfwA, 0.7799, 2.87, 0.257, 299, 253, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3249, 2wmaA, 0.7799, 2.84, 0.254, 296, 252, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
3250, 2rl5A, 0.7799, 2.74, 0.385, 294, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
3251, 2c6tC, 0.7799, 2.83, 0.255, 295, 251, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3252, 5v19B, 0.7798, 2.71, 0.287, 260, 247, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3253, 5ke0A, 0.7798, 3.11, 0.231, 340, 255, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
3254, 2wxvC, 0.7798, 2.90, 0.249, 299, 253, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
3255, 2oicD, 0.7798, 2.61, 0.242, 284, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
3256, 5otqA, 0.7797, 3.01, 0.227, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 33
3257, 5if1A, 0.7797, 2.86, 0.250, 298, 252, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
3258, 4qfrA, 0.7797, 2.67, 0.268, 361, 250, STRUCTURE OF AMPK IN COMPLEX WITH CL-A769662 ACTIVATOR AND STAUROSPORINE INHIBITOR
3259, 3eidA, 0.7797, 2.77, 0.252, 292, 250, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3260, 3a8xA, 0.7797, 2.96, 0.203, 334, 256, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3261, 1ol2C, 0.7797, 2.86, 0.250, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
3262, 6b2eA, 0.7796, 2.68, 0.264, 442, 250, STRUCTURE OF FULL LENGTH HUMAN AMPK (A2B2G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4. 
3263, 5fd2A, 0.7796, 2.85, 0.276, 264, 250, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
3264, 2uzdC, 0.7796, 2.83, 0.255, 295, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3265, 4azeA, 0.7795, 3.03, 0.222, 348, 252, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
3266, 2nruB, 0.7795, 2.99, 0.240, 294, 250, CRYSTAL STRUCTURE OF IRAK-4
3267, 2b9jA, 0.7795, 2.61, 0.236, 337, 246, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
3268, 1urcA, 0.7795, 2.86, 0.250, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
3269, 5kmjA, 0.7794, 2.83, 0.378, 300, 249, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
3270, 4yu2C, 0.7794, 2.88, 0.229, 346, 249, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
3271, 4yo6A, 0.7794, 3.01, 0.237, 286, 249, IRAK4-INHIBITOR CO-STRUCTURE
3272, 4yljC, 0.7794, 3.04, 0.226, 346, 252, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
3273, 4qnyB, 0.7794, 3.13, 0.238, 339, 256, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
3274, 4bcpC, 0.7794, 2.77, 0.257, 267, 249, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3275, 4azeC, 0.7794, 3.03, 0.222, 348, 252, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
3276, 4aw5A, 0.7794, 2.57, 0.296, 261, 243, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
3277, 3lijA, 0.7794, 3.00, 0.280, 465, 254, CRYSTAL STRUCTURE OF FULL LENGTH CPCDPK3 (CGD5_820) IN COMPLEX WITH CA2+ AND AMPPNP
3278, 2b9hA, 0.7794, 2.62, 0.244, 337, 246, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
3279, 1szmA, 0.7794, 2.85, 0.238, 317, 252, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
3280, 6g97A, 0.7793, 3.08, 0.232, 344, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3281, 5sysB, 0.7793, 2.15, 0.328, 258, 241, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
3282, 5mo4A, 0.7793, 2.40, 0.366, 429, 243, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
3283, 4xs2A, 0.7793, 3.05, 0.237, 283, 249, IRAK4-INHIBITOR CO-STRUCTURE
3284, 4agwA, 0.7793, 2.23, 0.336, 258, 241, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
3285, 3uimA, 0.7793, 2.91, 0.257, 291, 249, STRUCTURAL BASIS FOR THE IMPACT OF PHOSPHORYLATION ON PLANT RECEPTOR- LIKE KINASE BAK1 ACTIVATION
3286, 3tl8H, 0.7793, 2.67, 0.261, 303, 249, THE AVRPTOB-BAK1 COMPLEX REVEALS TWO STRUCTURALLY SIMILAR KINASEINTERACTING DOMAINS IN A SINGLE TYPE III EFFECTOR
3287, 3q52A, 0.7793, 3.18, 0.210, 292, 257, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
3288, 1tkiB, 0.7793, 2.90, 0.165, 321, 254, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
3289, 1tkiA, 0.7793, 2.90, 0.165, 321, 254, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
3290, 5t1sA, 0.7792, 3.02, 0.237, 280, 249, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3291, 4mq2D, 0.7792, 2.83, 0.226, 329, 248, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
3292, 4azeB, 0.7792, 3.03, 0.222, 345, 252, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
3293, 3tnwC, 0.7792, 2.75, 0.257, 291, 249, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
3294, 3cjfA, 0.7792, 2.52, 0.374, 276, 246, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
3295, 2bujA, 0.7792, 3.04, 0.228, 291, 254, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
3296, 1pyxA, 0.7792, 3.18, 0.227, 343, 256, GSK-3 BETA COMPLEXED WITH AMP-PNP
3297, 1ckjA, 0.7792, 3.23, 0.208, 296, 259, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3298, 6dkbA, 0.7791, 2.63, 0.385, 272, 247, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 10B. 
3299, 5vczA, 0.7791, 3.05, 0.218, 294, 252, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB ISOMER
3300, 5ufuA, 0.7791, 2.67, 0.268, 368, 250, STRUCTURE OF AMPK BOUND TO ACTIVATOR
3301, 6fnjA, 0.7790, 2.57, 0.314, 262, 245, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH AN ISOMER OF NVP-BHG712 
3302, 5lxcA, 0.7790, 2.89, 0.249, 383, 249, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
3303, 5lpwA, 0.7790, 2.75, 0.236, 280, 246, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
3304, 5ax9C, 0.7790, 2.69, 0.228, 282, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3305, 4o0rA, 0.7790, 3.09, 0.191, 293, 256, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3306, 4ebwA, 0.7790, 2.63, 0.367, 259, 245, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
3307, 3fztA, 0.7790, 2.58, 0.382, 259, 246, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
3308, 3ag9B, 0.7790, 2.80, 0.227, 317, 251, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
3309, 5uy6A, 0.7789, 2.96, 0.224, 282, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
3310, 4lueB, 0.7789, 2.17, 0.372, 417, 239, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
3311, 4f9bA, 0.7789, 3.18, 0.230, 318, 256, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
3312, 2c5nC, 0.7789, 2.89, 0.254, 296, 252, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3313, 1eh4A, 0.7789, 3.18, 0.174, 293, 259, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
3314, 4p5qA, 0.7788, 2.73, 0.329, 275, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3315, 4mq2C, 0.7788, 2.85, 0.230, 339, 248, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
3316, 4f65B, 0.7788, 2.76, 0.386, 279, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
3317, 4cfeA, 0.7788, 2.71, 0.264, 425, 250, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
3318, 3eqgA, 0.7788, 3.15, 0.238, 314, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
3319, 2gmxA, 0.7788, 2.91, 0.202, 357, 252, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
3320, 1yolA, 0.7788, 2.10, 0.336, 256, 238, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
3321, 6gt1B, 0.7787, 2.79, 0.245, 269, 249, NEK7 BOUND TO PURINE INHIBITOR 
3322, 6f3dB, 0.7787, 2.79, 0.241, 283, 245, IRAK4 IN COMPLEX WITH INHIBITOR 
3323, 5fetA, 0.7787, 2.94, 0.220, 802, 255, CRYSTAL STRUCTURE OF PVX_084705 IN PRESENCE OF COMPOUND 2
3324, 4cnhA, 0.7787, 2.60, 0.316, 285, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
3325, 2r7iA, 0.7787, 2.77, 0.219, 322, 251, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
3326, 2nryA, 0.7787, 2.98, 0.238, 286, 248, CRYSTAL STRUCTURE OF IRAK-4
3327, 2xh5A, 0.7786, 2.81, 0.242, 316, 252, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
3328, 1h24C, 0.7786, 2.88, 0.258, 293, 252, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
3329, 5hgiA, 0.7785, 2.85, 0.220, 395, 250, CRYSTAL STRUCTURE OF APO HUMAN IRE1 ALPHA
3330, 4pqnA, 0.7785, 1.99, 0.314, 240, 236, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
3331, 4i4fA, 0.7785, 2.53, 0.366, 255, 243, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
3332, 4f9aC, 0.7785, 3.14, 0.224, 317, 255, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
3333, 3u6hA, 0.7785, 2.72, 0.316, 280, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
3334, 3n9xB, 0.7785, 3.23, 0.203, 374, 256, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
3335, 3d5uA, 0.7785, 3.05, 0.244, 288, 254, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
3336, 3brbA, 0.7785, 2.51, 0.346, 260, 243, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH ADP
3337, 2x1nA, 0.7785, 2.90, 0.250, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3338, 2whbC, 0.7785, 2.88, 0.250, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3339, 1finA, 0.7785, 2.87, 0.258, 298, 252, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
3340, 5tehA, 0.7784, 2.28, 0.333, 261, 243, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
3341, 3lw0B, 0.7784, 2.92, 0.333, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3342, 2nruD, 0.7784, 2.96, 0.240, 293, 250, CRYSTAL STRUCTURE OF IRAK-4
3343, 1pkdA, 0.7784, 2.87, 0.254, 296, 252, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
3344, 5u6iA, 0.7783, 3.15, 0.231, 339, 255, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
3345, 5kmkA, 0.7783, 2.84, 0.378, 304, 249, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
3346, 5jgdA, 0.7783, 2.44, 0.280, 295, 243, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 12
3347, 1okwC, 0.7783, 2.89, 0.250, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
3348, 4f99A, 0.7782, 3.11, 0.224, 312, 255, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
3349, 3lw0C, 0.7782, 2.92, 0.333, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3350, 3lw0A, 0.7782, 2.92, 0.333, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3351, 2xbaA, 0.7782, 2.55, 0.313, 283, 243, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
3352, 2f57B, 0.7782, 3.12, 0.211, 299, 256, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
3353, 6fngA, 0.7781, 2.49, 0.340, 277, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AN ISOMER OF NVP-BHG712 
3354, 6bkuA, 0.7781, 2.92, 0.228, 267, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
3355, 5kq5A, 0.7781, 2.70, 0.272, 362, 250, AMPK BOUND TO ALLOSTERIC ACTIVATOR
3356, 5k0kA, 0.7781, 2.42, 0.344, 260, 241, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2434
3357, 5isoA, 0.7781, 2.77, 0.259, 453, 251, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
3358, 3o0gA, 0.7781, 2.95, 0.218, 289, 252, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
3359, 3lw0D, 0.7781, 2.92, 0.333, 292, 249, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
3360, 1p5eA, 0.7781, 2.88, 0.258, 296, 252, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
3361, 6fnjB, 0.7780, 2.59, 0.322, 262, 245, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH AN ISOMER OF NVP-BHG712 
3362, 4u44A, 0.7780, 2.69, 0.227, 286, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
3363, 4jnwA, 0.7780, 2.92, 0.165, 320, 254, BACTERIALLY EXPRESSED TITIN KINASE
3364, 4i4eA, 0.7780, 2.43, 0.339, 254, 242, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
3365, 6ft7B, 0.7779, 3.03, 0.223, 356, 251, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
3366, 4ub7A, 0.7779, 3.09, 0.207, 334, 256, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
3367, 4ianA, 0.7779, 2.98, 0.215, 321, 251, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
3368, 3nieB, 0.7779, 3.27, 0.187, 367, 256, CRYSTAL STRUCTURE OF PF11_0147
3369, 6fnlA, 0.7778, 2.66, 0.299, 262, 244, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE 
3370, 5uafA, 0.7778, 2.81, 0.343, 291, 245, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
3371, 5uadA, 0.7778, 2.81, 0.343, 291, 245, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
3372, 5kx7B, 0.7778, 2.91, 0.239, 286, 247, IRAK4-INHIBITOR CO-STRUCTURE
3373, 3tv6A, 0.7778, 2.90, 0.267, 268, 251, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
3374, 3f3wB, 0.7778, 2.40, 0.336, 260, 244, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3375, 2whbA, 0.7778, 2.89, 0.250, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3376, 1vywC, 0.7778, 2.93, 0.249, 299, 253, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
3377, 5vcyA, 0.7777, 3.09, 0.218, 296, 252, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
3378, 5j7bB, 0.7777, 2.42, 0.258, 281, 244, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3379, 4uy9B, 0.7777, 2.88, 0.316, 315, 250, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
3380, 5d11B, 0.7776, 2.20, 0.314, 255, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
3381, 4ianB, 0.7776, 2.99, 0.215, 319, 251, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
3382, 3bhyA, 0.7776, 2.52, 0.245, 268, 245, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
3383, 5ntjA, 0.7775, 2.85, 0.246, 346, 252, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUND RKP032 
3384, 3v8tA, 0.7775, 1.86, 0.322, 238, 233, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
3385, 2qokA, 0.7775, 2.67, 0.314, 281, 245, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
3386, 5p9lA, 0.7774, 2.67, 0.316, 252, 247, BTK1 IN COMPLEX WITH CC 292
3387, 5kmiA, 0.7774, 2.90, 0.378, 300, 249, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
3388, 5dt4A, 0.7774, 2.62, 0.235, 259, 247, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3389, 4ypsA, 0.7774, 2.70, 0.369, 280, 244, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3390, 4nttB, 0.7774, 2.89, 0.202, 339, 252, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
3391, 3d7uD, 0.7774, 2.21, 0.340, 248, 241, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3392, 1uwhA, 0.7774, 2.75, 0.267, 264, 247, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
3393, 5vd0A, 0.7773, 3.09, 0.219, 293, 251, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775
3394, 4eevA, 0.7773, 2.71, 0.333, 283, 246, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
3395, 4crsA, 0.7773, 2.71, 0.262, 331, 248, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
3396, 3dbeA, 0.7773, 3.04, 0.246, 284, 252, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 557
3397, 3d5wA, 0.7773, 2.99, 0.241, 284, 253, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
3398, 2jkoA, 0.7773, 2.44, 0.369, 256, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3399, 5y86A, 0.7772, 3.18, 0.236, 391, 254, CRYSTAL STRUCTURE OF KINASE 
3400, 5objA, 0.7772, 2.67, 0.234, 260, 248, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
3401, 4pp7A, 0.7772, 2.88, 0.267, 267, 251, HIGHLY POTENT AND SELECTIVE 3-N-METHYLQUINAZOLINE-4(3H)-ONE BASED INHIBITORS OF B-RAFV600E KINASE
3402, 4mq2B, 0.7772, 2.78, 0.231, 338, 247, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
3403, 3soaA, 0.7772, 2.78, 0.215, 436, 251, FULL-LENGTH HUMAN CAMKII
3404, 3a7gA, 0.7772, 2.98, 0.249, 289, 253, HUMAN MST3 KINASE
3405, 1k9aC, 0.7772, 2.73, 0.317, 438, 246, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3406, 6gt1A, 0.7771, 2.82, 0.245, 267, 249, NEK7 BOUND TO PURINE INHIBITOR 
3407, 3brbB, 0.7771, 2.61, 0.348, 271, 244, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH ADP
3408, 5nwzA, 0.7770, 2.54, 0.377, 271, 244, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
3409, 4mq1B, 0.7770, 2.87, 0.226, 340, 248, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
3410, 1gngB, 0.7770, 3.22, 0.226, 355, 257, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
3411, 1ckjB, 0.7770, 3.32, 0.193, 293, 259, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3412, 5oy4B, 0.7769, 3.32, 0.229, 353, 258, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
3413, 5nk0A, 0.7769, 2.59, 0.340, 273, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
3414, 4jnwB, 0.7769, 2.93, 0.165, 321, 254, BACTERIALLY EXPRESSED TITIN KINASE
3415, 4bhnB, 0.7769, 2.63, 0.291, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3416, 4agwB, 0.7769, 2.23, 0.336, 257, 241, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
3417, 2wpaC, 0.7769, 2.94, 0.253, 299, 253, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
3418, 2f2cB, 0.7769, 2.79, 0.258, 280, 248, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
3419, 4zs0A, 0.7768, 2.63, 0.235, 257, 247, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
3420, 4y73C, 0.7768, 2.94, 0.238, 290, 248, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3421, 4f9aA, 0.7768, 3.15, 0.224, 315, 255, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
3422, 3vidA, 0.7768, 2.57, 0.376, 299, 245, CRYSTAL STRUCTURE OF HUMAN VEGFR2 KINASE DOMAIN WITH COMPOUND A.
3423, 3utoA, 0.7768, 3.13, 0.222, 559, 257, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
3424, 4ztnA, 0.7767, 3.00, 0.238, 286, 248, IRAK4-INHIBITOR CO-STRUCTURE
3425, 4ysmB, 0.7767, 3.04, 0.242, 475, 256, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
3426, 4yljB, 0.7767, 2.83, 0.230, 347, 248, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
3427, 2nryB, 0.7767, 2.99, 0.238, 286, 248, CRYSTAL STRUCTURE OF IRAK-4
3428, 2nruC, 0.7767, 3.02, 0.240, 293, 250, CRYSTAL STRUCTURE OF IRAK-4
3429, 5nhlA, 0.7766, 3.25, 0.223, 345, 256, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3430, 5kmmA, 0.7766, 2.88, 0.378, 301, 249, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
3431, 4anbA, 0.7766, 3.06, 0.228, 282, 254, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
3432, 3cs9D, 0.7766, 2.75, 0.371, 263, 245, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3433, 2wmaC, 0.7766, 2.67, 0.258, 265, 248, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
3434, 6bfnA, 0.7765, 3.05, 0.238, 301, 252, CRYSTAL STRUCTURE OF HUMAN IRAK1
3435, 5opbA, 0.7765, 2.98, 0.249, 262, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
3436, 5nhpA, 0.7765, 3.17, 0.220, 338, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3437, 5k0xA, 0.7765, 2.38, 0.346, 258, 240, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2541
3438, 4l3pA, 0.7765, 2.44, 0.281, 295, 242, CRYSTAL STRUCTURE OF 2-(1-BENZOTHIOPHEN-7-YL)-4-[1-(PIPERIDIN-4-YL)- 1H-PYRAZOL-4-YL]FURO[23-C]PYRIDIN-7-AMINE BOUND TO TAK1-TAB1
3439, 1j1bB, 0.7765, 3.22, 0.227, 364, 256, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
3440, 5up3A, 0.7764, 2.55, 0.291, 258, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3441, 5drdA, 0.7764, 2.63, 0.235, 259, 247, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3442, 4qo9B, 0.7764, 3.00, 0.253, 285, 253, MST3 IN COMPLEX WITH DANUSERTIB
3443, 4gk2A, 0.7764, 2.64, 0.333, 265, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
3444, 3a7gB, 0.7764, 3.05, 0.248, 290, 254, HUMAN MST3 KINASE
3445, 2wfyC, 0.7764, 2.91, 0.254, 296, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3446, 1eh4B, 0.7764, 3.35, 0.176, 293, 261, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
3447, 5hhwA, 0.7763, 2.91, 0.323, 306, 251, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
3448, 2i0eA, 0.7763, 2.76, 0.245, 326, 249, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
3449, 6brcA, 0.7762, 2.94, 0.224, 265, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
3450, 5kbqA, 0.7762, 3.04, 0.188, 289, 255, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3451, 5if1C, 0.7762, 2.92, 0.254, 296, 252, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
3452, 5d12B, 0.7762, 2.16, 0.347, 253, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
3453, 5d11A, 0.7762, 2.18, 0.346, 254, 240, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
3454, 4ztlD, 0.7762, 2.92, 0.240, 285, 246, IRAK4-INHIBITOR CO-STRUCTURE
3455, 3v5qB, 0.7762, 2.62, 0.389, 265, 244, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
3456, 5mxxA, 0.7761, 3.33, 0.176, 361, 256, CRYSTAL STRUCTURE OF HUMAN SR PROTEIN KINASE 1 (SRPK1) IN COMPLEX WITH COMPOUND 1
3457, 5j5sB, 0.7761, 2.24, 0.329, 258, 240, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
3458, 4qtbB, 0.7761, 3.23, 0.219, 348, 256, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
3459, 4f9bC, 0.7761, 3.09, 0.220, 316, 254, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
3460, 2welA, 0.7761, 2.93, 0.209, 304, 253, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
3461, 2i40A, 0.7761, 2.77, 0.257, 291, 249, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
3462, 1q41A, 0.7761, 3.23, 0.223, 339, 256, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
3463, 5kx8A, 0.7760, 3.03, 0.238, 285, 248, IRAK4-INHIBITOR CO-STRUCTURE
3464, 4izaA, 0.7760, 3.07, 0.228, 346, 254, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3465, 4bidB, 0.7760, 2.69, 0.298, 258, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3466, 3uzpA, 0.7760, 3.35, 0.193, 292, 259, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
3467, 3otuA, 0.7760, 2.65, 0.206, 276, 248, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
3468, 5op2A, 0.7759, 3.06, 0.248, 263, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3469, 5i8aA, 0.7759, 2.45, 0.379, 269, 240, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
3470, 5dosA, 0.7759, 2.64, 0.235, 259, 247, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3471, 5deyA, 0.7759, 3.07, 0.208, 295, 255, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
3472, 5d7aA, 0.7759, 2.69, 0.228, 289, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
3473, 4u6rA, 0.7759, 3.05, 0.220, 403, 254, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC DOMAINS IN COMPLEX WITH A SULFONAMIDE INHIBITOR.
3474, 4mq1A, 0.7759, 2.92, 0.232, 345, 250, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
3475, 4cfmC, 0.7759, 2.70, 0.254, 266, 248, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3476, 2gphA, 0.7759, 3.13, 0.224, 345, 255, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
3477, 4u43A, 0.7758, 2.74, 0.224, 287, 246, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
3478, 4an2A, 0.7758, 3.00, 0.233, 282, 253, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
3479, 3d7tA, 0.7758, 2.19, 0.335, 249, 239, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
3480, 2clqB, 0.7758, 2.70, 0.289, 259, 246, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3481, 5t1sB, 0.7757, 2.99, 0.239, 282, 247, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3482, 4ptgB, 0.7757, 3.22, 0.223, 332, 256, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
3483, 3f5xC, 0.7757, 2.91, 0.258, 298, 252, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
3484, 3efkA, 0.7757, 2.47, 0.312, 276, 240, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
3485, 2x4fA, 0.7757, 2.98, 0.209, 289, 253, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3486, 2v22A, 0.7757, 2.92, 0.250, 296, 252, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
3487, 2i40C, 0.7757, 2.92, 0.250, 296, 252, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
3488, 1q5kB, 0.7757, 3.22, 0.219, 344, 256, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
3489, 1ol1A, 0.7757, 2.91, 0.250, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
3490, 4cfvC, 0.7756, 2.71, 0.255, 264, 247, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3491, 2vx3A, 0.7756, 2.96, 0.231, 346, 251, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
3492, 2r7iC, 0.7756, 2.77, 0.224, 321, 250, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
3493, 5f94B, 0.7755, 3.24, 0.227, 349, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3494, 4fzdB, 0.7755, 2.86, 0.261, 275, 249, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH WSF MOTIF
3495, 3zduA, 0.7755, 2.76, 0.233, 297, 245, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
3496, 2zoqA, 0.7755, 3.03, 0.209, 351, 253, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
3497, 2wipA, 0.7755, 2.94, 0.239, 297, 251, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
3498, 1h25A, 0.7755, 2.91, 0.254, 293, 252, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
3499, 4yo6D, 0.7754, 2.97, 0.239, 285, 247, IRAK4-INHIBITOR CO-STRUCTURE
3500, 4pteB, 0.7754, 3.24, 0.227, 347, 256, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
3501, 4mbjA, 0.7754, 2.84, 0.268, 269, 250, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
3502, 4bicB, 0.7754, 2.73, 0.297, 259, 246, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3503, 3tnwA, 0.7754, 2.90, 0.254, 295, 252, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
3504, 3ej1C, 0.7754, 2.92, 0.250, 294, 252, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3505, 2erkA, 0.7754, 2.88, 0.228, 351, 250, PHOSPHORYLATED MAP KINASE ERK2
3506, 2b9fA, 0.7754, 2.79, 0.237, 337, 249, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
3507, 4ysmA, 0.7753, 3.07, 0.238, 475, 256, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
3508, 4wunB, 0.7753, 2.65, 0.384, 268, 245, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
3509, 4twcA, 0.7753, 3.44, 0.195, 293, 261, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3510, 4nu1A, 0.7753, 3.22, 0.219, 356, 256, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N-TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
3511, 4ic7A, 0.7753, 3.02, 0.241, 355, 253, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
3512, 4e4xA, 0.7753, 2.83, 0.268, 267, 250, CRYSTAL STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH A DIHYDROPYRIDO[23-D]PYRIMIDINONE-BASED INHIBITOR
3513, 3tz9B, 0.7753, 2.34, 0.331, 259, 242, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
3514, 2vx3C, 0.7753, 2.88, 0.230, 338, 248, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
3515, 5ya5A, 0.7752, 2.92, 0.328, 273, 247, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NOVEL INHIBITOR 
3516, 5ia0A, 0.7752, 2.57, 0.336, 263, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
3517, 3pfqA, 0.7752, 2.71, 0.245, 520, 249, CRYSTAL STRUCTURE AND ALLOSTERIC ACTIVATION OF PROTEIN KINASE C BETA II
3518, 3eocC, 0.7752, 2.94, 0.250, 293, 252, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
3519, 3anqB, 0.7752, 2.94, 0.221, 343, 249, HUMAN DYRK1A/INHIBITOR COMPLEX
3520, 5y9mX, 0.7751, 2.89, 0.214, 319, 252, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
3521, 5oktA, 0.7751, 3.39, 0.204, 285, 260, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3522, 5kx8C, 0.7751, 2.92, 0.239, 287, 247, IRAK4-INHIBITOR CO-STRUCTURE
3523, 4ztnD, 0.7751, 2.97, 0.239, 285, 247, IRAK4-INHIBITOR CO-STRUCTURE
3524, 2ozoA, 0.7751, 2.96, 0.360, 545, 250, AUTOINHIBITED INTACT HUMAN ZAP-70
3525, 1q5kA, 0.7751, 3.26, 0.223, 345, 256, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
3526, 4ifcA, 0.7750, 3.00, 0.215, 327, 251, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
3527, 4dhfB, 0.7750, 2.66, 0.235, 258, 247, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3528, 1pyxB, 0.7750, 3.26, 0.227, 338, 256, GSK-3 BETA COMPLEXED WITH AMP-PNP
3529, 6bfnB, 0.7749, 3.00, 0.247, 294, 251, CRYSTAL STRUCTURE OF HUMAN IRAK1
3530, 5dt0A, 0.7749, 2.64, 0.235, 259, 247, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
3531, 4rfmA, 0.7749, 2.62, 0.299, 249, 244, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
3532, 4bhnA, 0.7749, 2.66, 0.292, 256, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3533, 3eqhA, 0.7749, 3.16, 0.239, 314, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
3534, 1h27A, 0.7749, 2.91, 0.254, 296, 252, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
3535, 6fylA, 0.7748, 3.07, 0.188, 340, 250, X-RAY STRUCTURE OF CLK2-KD(136-496)/CX-4945 AT 1.95A 
3536, 4zk5A, 0.7748, 2.91, 0.225, 286, 249, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
3537, 4ijpB, 0.7748, 2.99, 0.211, 333, 251, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
3538, 4an3A, 0.7748, 3.06, 0.228, 280, 254, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
3539, 3fxzA, 0.7748, 3.24, 0.206, 292, 257, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
3540, 3anqC, 0.7748, 2.94, 0.217, 340, 249, HUMAN DYRK1A/INHIBITOR COMPLEX
3541, 3a7hB, 0.7748, 3.08, 0.256, 290, 254, HUMAN MST3 KINASE IN COMPLEX WITH ATP
3542, 5to8A, 0.7747, 2.22, 0.381, 250, 239, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
3543, 5j7bA, 0.7747, 2.46, 0.263, 277, 243, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3544, 4bibB, 0.7747, 2.70, 0.294, 258, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3545, 3tz7B, 0.7747, 2.35, 0.337, 260, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL103
3546, 3a7hA, 0.7747, 3.00, 0.233, 289, 253, HUMAN MST3 KINASE IN COMPLEX WITH ATP
3547, 2yn8A, 0.7747, 2.17, 0.332, 253, 238, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3548, 2vwvA, 0.7747, 2.76, 0.303, 255, 244, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3549, 1okvC, 0.7747, 2.93, 0.254, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
3550, 4nksA, 0.7746, 2.59, 0.392, 265, 245, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
3551, 4ijpA, 0.7746, 3.00, 0.215, 330, 251, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
3552, 4ifcB, 0.7746, 2.96, 0.212, 329, 250, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
3553, 4dhfA, 0.7746, 2.66, 0.235, 258, 247, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3554, 3l1sA, 0.7746, 3.24, 0.227, 336, 256, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
3555, 2wfyA, 0.7746, 2.93, 0.246, 295, 252, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3556, 4h1mA, 0.7745, 2.57, 0.389, 256, 244, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
3557, 3octA, 0.7745, 2.30, 0.310, 244, 242, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
3558, 2wihC, 0.7745, 2.97, 0.253, 299, 253, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
3559, 2vx3D, 0.7745, 2.88, 0.226, 342, 248, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
3560, 1koaA, 0.7745, 3.19, 0.214, 447, 257, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
3561, 4yp8C, 0.7744, 2.94, 0.238, 287, 248, IRAK4-INHIBITOR CO-STRUCTURE
3562, 2uueA, 0.7744, 2.93, 0.250, 296, 252, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
3563, 2gsfA, 0.7744, 2.77, 0.314, 281, 245, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3564, 2cjmC, 0.7744, 2.83, 0.256, 294, 250, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
3565, 1j1cB, 0.7744, 3.24, 0.227, 364, 256, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
3566, 6bqqA, 0.7743, 2.95, 0.224, 271, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
3567, 5x17A, 0.7743, 3.35, 0.208, 290, 259, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3568, 4pmtA, 0.7743, 2.57, 0.349, 273, 241, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
3569, 4k2rA, 0.7743, 2.76, 0.360, 551, 247, STRUCTURAL BASIS FOR ACTIVATION OF ZAP-70 BY PHOSPHORYLATION OF THE SH2-KINASE LINKER
3570, 4fv7A, 0.7743, 3.08, 0.221, 342, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
3571, 3e8nA, 0.7743, 3.18, 0.235, 291, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
3572, 4obpA, 0.7742, 2.92, 0.225, 285, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
3573, 4mhaA, 0.7742, 2.26, 0.345, 256, 238, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1817
3574, 5uitB, 0.7741, 2.95, 0.240, 283, 246, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
3575, 4an9A, 0.7741, 3.07, 0.228, 281, 254, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
3576, 3vw6A, 0.7741, 2.62, 0.306, 255, 242, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3577, 3fwqA, 0.7741, 3.09, 0.203, 334, 256, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
3578, 3anrB, 0.7741, 2.94, 0.225, 342, 249, HUMAN DYRK1A/HARMINE COMPLEX
3579, 2henB, 0.7741, 2.54, 0.307, 259, 241, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
3580, 1ol2A, 0.7741, 2.94, 0.258, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
3581, 2henD, 0.7740, 2.54, 0.303, 259, 241, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
3582, 1p4fA, 0.7740, 2.62, 0.248, 269, 246, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
3583, 1kobB, 0.7740, 3.19, 0.206, 352, 257, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
3584, 6ft7A, 0.7739, 2.99, 0.197, 356, 249, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
3585, 5f94A, 0.7739, 3.27, 0.227, 346, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3586, 5dykA, 0.7739, 2.97, 0.193, 809, 254, CRYSTAL STRUCTURE OF PF3D7_1436600
3587, 3sayA, 0.7739, 3.23, 0.227, 347, 255, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
3588, 3nizA, 0.7739, 3.02, 0.246, 288, 252, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
3589, 3i4bA, 0.7739, 3.24, 0.223, 359, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
3590, 3eqcA, 0.7739, 3.16, 0.239, 312, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
3591, 2fumB, 0.7739, 2.52, 0.206, 262, 243, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3592, 1csnA, 0.7739, 3.29, 0.178, 293, 259, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
3593, 5uiqC, 0.7738, 2.90, 0.239, 280, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
3594, 5lvpD, 0.7738, 2.71, 0.210, 276, 248, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
3595, 4ptgA, 0.7738, 3.26, 0.227, 333, 256, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
3596, 3a8xB, 0.7738, 2.96, 0.197, 329, 254, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3597, 4ztnB, 0.7737, 2.95, 0.244, 282, 246, IRAK4-INHIBITOR CO-STRUCTURE
3598, 3dkfA, 0.7737, 2.87, 0.332, 294, 247, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
3599, 1s9iA, 0.7737, 3.27, 0.247, 303, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
3600, 5c03B, 0.7736, 2.49, 0.221, 260, 244, CRYSTAL STRUCTURE OF KINASE
3601, 3tubA, 0.7736, 2.58, 0.373, 253, 244, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
3602, 3db6A, 0.7736, 3.11, 0.244, 287, 254, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
3603, 1kobA, 0.7736, 3.26, 0.209, 352, 258, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
3604, 6cpeA, 0.7735, 2.59, 0.237, 256, 245, STRUCTURE OF APO; DEPHOSPHORYLATED AURORA A (122-403) IN AN ACTIVE CONFORMATION 
3605, 5ax9A, 0.7735, 2.68, 0.230, 282, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3606, 5ng3A, 0.7734, 2.86, 0.257, 283, 249, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
3607, 4mq1D, 0.7734, 2.86, 0.223, 336, 247, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
3608, 2wo6B, 0.7734, 2.91, 0.238, 339, 248, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
3609, 2fumA, 0.7734, 2.61, 0.205, 263, 244, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3610, 5xqxA, 0.7733, 2.97, 0.200, 340, 250, HUMAN CDK8-CYCC IN COMPLEX WITH COMPOUND 4: N-METHYL-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
3611, 4bieA, 0.7733, 2.60, 0.288, 257, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3612, 4aojB, 0.7733, 2.44, 0.387, 258, 243, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
3613, 3n9xA, 0.7733, 3.26, 0.196, 374, 255, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
3614, 3anqA, 0.7733, 2.87, 0.226, 342, 248, HUMAN DYRK1A/INHIBITOR COMPLEX
3615, 2o5kA, 0.7733, 3.29, 0.230, 350, 256, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
3616, 1vr2A, 0.7733, 2.66, 0.382, 275, 246, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
3617, 1q41B, 0.7733, 3.28, 0.227, 343, 256, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
3618, 5nkiA, 0.7732, 2.47, 0.339, 268, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
3619, 3piyA, 0.7732, 2.65, 0.325, 262, 246, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
3620, 3dlsD, 0.7732, 2.72, 0.228, 284, 246, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3621, 2qonA, 0.7732, 2.74, 0.311, 281, 244, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
3622, 1mruB, 0.7732, 2.46, 0.207, 271, 242, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3623, 6fyiA, 0.7731, 3.02, 0.204, 336, 250, X-RAY STRUCTURE OF CLK2-KD(130-496)/TG003 AT 2.6A 
3624, 5t1sD, 0.7731, 3.02, 0.240, 281, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3625, 5kx8D, 0.7731, 3.00, 0.240, 283, 246, IRAK4-INHIBITOR CO-STRUCTURE
3626, 5hesA, 0.7731, 2.75, 0.294, 287, 245, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
3627, 5a54B, 0.7731, 2.92, 0.226, 339, 248, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
3628, 4knbB, 0.7731, 2.77, 0.337, 256, 243, C-MET IN COMPLEX WITH OSI LIGAND
3629, 3orxG, 0.7731, 2.62, 0.215, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3630, 3efjA, 0.7731, 2.50, 0.308, 276, 240, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
3631, 1mqbA, 0.7731, 2.65, 0.311, 263, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3632, 5t1tD, 0.7730, 2.92, 0.240, 283, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3633, 5oy4A, 0.7730, 3.25, 0.227, 349, 255, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
3634, 5lvpC, 0.7730, 2.68, 0.211, 275, 247, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
3635, 4u7zA, 0.7730, 3.19, 0.239, 291, 255, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
3636, 4ptcB, 0.7730, 3.27, 0.227, 347, 256, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
3637, 3i4bB, 0.7730, 3.25, 0.223, 347, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
3638, 1okwA, 0.7730, 2.96, 0.242, 296, 252, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
3639, 1j1bA, 0.7730, 3.27, 0.227, 354, 256, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
3640, 6fu5B, 0.7729, 2.42, 0.252, 286, 242, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
3641, 4rzvA, 0.7729, 2.75, 0.279, 261, 247, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
3642, 2vx3B, 0.7729, 2.84, 0.239, 340, 247, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
3643, 5oq8A, 0.7728, 3.07, 0.253, 261, 249, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3644, 4ztmC, 0.7728, 3.04, 0.239, 282, 247, IRAK4-INHIBITOR CO-STRUCTURE
3645, 4nm3A, 0.7728, 3.26, 0.227, 357, 256, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N- TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
3646, 4dglC, 0.7728, 2.97, 0.213, 334, 253, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
3647, 3f5xA, 0.7728, 2.91, 0.259, 297, 251, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
3648, 3d15A, 0.7728, 2.63, 0.232, 256, 246, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
3649, 5w5oN, 0.7727, 2.34, 0.258, 272, 240, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3650, 5t1tC, 0.7727, 3.02, 0.238, 286, 248, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3651, 5jrsB, 0.7727, 2.32, 0.337, 240, 240, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
3652, 4rz7A, 0.7727, 2.99, 0.201, 801, 254, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND PCI32765
3653, 4mwiA, 0.7727, 2.48, 0.217, 266, 244, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
3654, 4mq1C, 0.7727, 2.89, 0.227, 328, 247, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
3655, 3iecB, 0.7727, 2.78, 0.249, 313, 249, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3656, 5m4iA, 0.7726, 3.07, 0.208, 331, 255, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
3657, 5fqdF, 0.7726, 3.35, 0.178, 294, 259, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3658, 3mblA, 0.7726, 3.17, 0.240, 290, 254, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
3659, 3eqfA, 0.7726, 3.27, 0.243, 314, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
3660, 6b8jA, 0.7725, 3.35, 0.229, 344, 258, CO-STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE BETA WITH A SELECTIVE (5-IMIDAZOL-2-YL-4-PHENYLPYRIMIDIN-2-YL)[2-(2-PYRIDYLAMINO) ETHYL]AMINE INHIBITOR
3661, 5y9mA, 0.7725, 3.00, 0.213, 320, 253, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
3662, 5acbC, 0.7725, 3.16, 0.241, 324, 257, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
3663, 5a4lB, 0.7725, 2.91, 0.226, 339, 248, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
3664, 4kbkB, 0.7725, 3.31, 0.198, 289, 258, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3665, 3pixA, 0.7725, 2.86, 0.301, 268, 249, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
3666, 3eqiA, 0.7725, 3.26, 0.243, 315, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
3667, 3dj7A, 0.7725, 2.68, 0.231, 257, 247, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
3668, 3anrA, 0.7725, 2.89, 0.238, 342, 248, HUMAN DYRK1A/HARMINE COMPLEX
3669, 1z9xC, 0.7725, 3.07, 0.216, 303, 255, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3670, 5vd1A, 0.7724, 2.90, 0.218, 295, 248, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3671, 5uabA, 0.7724, 2.76, 0.342, 288, 243, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
3672, 4wa9A, 0.7724, 2.31, 0.353, 246, 238, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
3673, 4nm7A, 0.7724, 3.26, 0.227, 355, 256, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
3674, 4nm5A, 0.7724, 3.27, 0.223, 361, 256, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
3675, 3pp1A, 0.7724, 3.16, 0.236, 291, 254, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
3676, 3anrC, 0.7724, 2.88, 0.226, 337, 248, HUMAN DYRK1A/HARMINE COMPLEX
3677, 6cthA, 0.7723, 2.85, 0.252, 295, 246, CRYSTAL STRUCTURE OF PATHOGENESIS-RELATED PROTEIN 1G (PR-1G) KINASE DOMAIN FROM CACAO 
3678, 5v5nA, 0.7723, 2.54, 0.284, 294, 243, CRYSTAL STRUCTURE OF TAKINIB BOUND TO TAK1
3679, 4pteA, 0.7723, 3.19, 0.228, 341, 254, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
3680, 4hnfB, 0.7723, 3.33, 0.205, 290, 259, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3681, 1zrzA, 0.7723, 2.86, 0.207, 310, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
3682, 1h24A, 0.7723, 2.95, 0.258, 293, 252, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
3683, 5x17B, 0.7722, 3.33, 0.194, 289, 258, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3684, 5vcwA, 0.7722, 2.95, 0.222, 285, 248, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
3685, 5lvpB, 0.7722, 2.73, 0.210, 276, 248, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
3686, 5hlnB, 0.7722, 3.32, 0.229, 346, 258, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
3687, 5f95B, 0.7722, 3.27, 0.227, 338, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3688, 5d7aB, 0.7722, 2.85, 0.231, 286, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
3689, 4zy4A, 0.7722, 3.05, 0.209, 288, 253, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
3690, 4ztlC, 0.7722, 3.08, 0.235, 282, 247, IRAK4-INHIBITOR CO-STRUCTURE
3691, 4iirA, 0.7722, 2.95, 0.213, 325, 249, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
3692, 4c2vA, 0.7722, 2.88, 0.200, 270, 250, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
3693, 3of0B, 0.7722, 2.17, 0.333, 251, 237, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
3694, 3cs9C, 0.7722, 2.46, 0.387, 243, 240, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3695, 5nhvA, 0.7721, 3.23, 0.224, 345, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3696, 4tyeA, 0.7721, 2.92, 0.386, 292, 251, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3697, 4qp8B, 0.7721, 2.82, 0.229, 337, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
3698, 4qp3B, 0.7721, 3.14, 0.209, 331, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
3699, 4fk3B, 0.7721, 2.62, 0.276, 257, 246, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
3700, 3vugA, 0.7721, 2.85, 0.205, 356, 249, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
3701, 3my0X, 0.7721, 2.68, 0.265, 257, 245, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3702, 3dlsF, 0.7721, 2.77, 0.228, 281, 246, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3703, 3c1xA, 0.7721, 2.61, 0.325, 290, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
3704, 2wo6A, 0.7721, 2.92, 0.242, 344, 248, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
3705, 1e9hA, 0.7721, 2.92, 0.255, 295, 251, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
3706, 6cz4A, 0.7720, 2.88, 0.316, 257, 247, STRUCTURE OF THE PTK6 KINASE DOMAIN BOUND TO A TYPE II INHIBITOR 2- {[(3R;4S)-3-FLUORO-1-{[4-(TRIFLUOROMETHOXY)PHENYL]ACETYL}PIPERIDIN-4- YL]OXY}-5-(1-METHYL-1H-IMIDAZOL-4-YL)PYRIDINE-3-CARBOXAMIDE 
3707, 6cz3A, 0.7720, 2.88, 0.340, 262, 247, STRUCTURE OF THE PTK6 KINASE DOMAIN BOUND TO A TYPE I INHIBITOR (3- FLUORO-4-{[6-METHYL-3-(1H-PYRAZOL-4-YL)IMIDAZO[1;2-A]PYRAZIN-8- YL]AMINO}PHENYL)(MORPHOLIN-4-YL)METHANONE 
3708, 6cpfA, 0.7720, 2.59, 0.237, 259, 245, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION 
3709, 5myvB, 0.7720, 3.36, 0.164, 349, 256, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
3710, 5gjfA, 0.7720, 2.55, 0.288, 298, 243, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 3
3711, 4lmnA, 0.7720, 3.24, 0.239, 292, 255, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
3712, 4iebA, 0.7720, 3.25, 0.242, 472, 256, CRYSTAL STRUCTURE OF A GLY128MET MUTANT OF THE TOXOPLASMA CDPK TGME49_101440
3713, 3zuvA, 0.7720, 3.09, 0.217, 357, 253, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
3714, 3iecD, 0.7720, 2.70, 0.247, 311, 247, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3715, 2xyuA, 0.7720, 2.64, 0.342, 260, 243, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
3716, 2i0eB, 0.7720, 2.82, 0.245, 300, 249, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
3717, 3iecC, 0.7719, 2.70, 0.251, 311, 247, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3718, 3hx4A, 0.7719, 3.19, 0.239, 467, 255, CRYSTAL STRUCTURE OF CDPK1 OF TOXOPLASMA GONDII TGME49_101440 IN PRESENCE OF CALCIUM
3719, 3amyA, 0.7719, 2.81, 0.202, 318, 248, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
3720, 5w84A, 0.7718, 2.91, 0.242, 279, 244, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
3721, 4yp8A, 0.7718, 3.03, 0.243, 284, 247, IRAK4-INHIBITOR CO-STRUCTURE
3722, 4ptcA, 0.7718, 3.30, 0.223, 342, 256, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
3723, 3zuvC, 0.7718, 3.16, 0.217, 357, 254, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
3724, 3orxH, 0.7718, 2.64, 0.215, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3725, 3orxE, 0.7718, 2.64, 0.215, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3726, 1o6yA, 0.7718, 2.44, 0.207, 260, 241, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
3727, 6gwrB, 0.7717, 3.09, 0.323, 285, 251, STRUCTURE OF THE KINASE DOMAIN OF HUMAN DDR1 IN COMPLEX WITH A POTENT AND SELECTIVE INHIBITOR OF DDR1 AND DDR2 
3728, 5t3qA, 0.7717, 2.65, 0.315, 278, 241, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
3729, 5dpvA, 0.7717, 2.64, 0.236, 257, 246, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
3730, 4zy5A, 0.7717, 3.11, 0.213, 283, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
3731, 3ii5A, 0.7717, 2.82, 0.266, 262, 248, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3732, 3dlsE, 0.7717, 2.89, 0.235, 282, 247, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3733, 2bpmC, 0.7717, 3.00, 0.253, 299, 253, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
3734, 4y73A, 0.7716, 2.95, 0.240, 289, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
3735, 3vudA, 0.7716, 2.84, 0.209, 355, 249, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
3736, 5hd7A, 0.7715, 3.30, 0.230, 347, 256, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
3737, 4f9cA, 0.7715, 3.19, 0.221, 306, 253, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND XL413
3738, 3zlsA, 0.7715, 3.22, 0.243, 315, 255, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
3739, 3uytC, 0.7715, 3.40, 0.204, 286, 260, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3740, 3uysC, 0.7715, 3.34, 0.194, 286, 258, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3741, 3m1sA, 0.7715, 3.28, 0.227, 348, 256, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
3742, 2csnA, 0.7715, 3.33, 0.174, 293, 259, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
3743, 1cmkE, 0.7715, 3.01, 0.214, 348, 252, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
3744, 5vamA, 0.7714, 2.84, 0.264, 269, 250, BRAF IN COMPLEX WITH RAF709
3745, 5m44A, 0.7714, 2.88, 0.211, 329, 251, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
3746, 5kziA, 0.7714, 2.64, 0.192, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
3747, 4i6fA, 0.7714, 3.26, 0.213, 285, 254, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3748, 3q3bA, 0.7714, 3.29, 0.223, 344, 256, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
3749, 3eqdA, 0.7714, 3.32, 0.238, 315, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
3750, 3dlsA, 0.7714, 2.84, 0.235, 285, 247, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3751, 2vgoB, 0.7714, 3.14, 0.197, 277, 254, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
3752, 5l6oA, 0.7713, 2.39, 0.324, 267, 238, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
3753, 5izjB, 0.7713, 2.98, 0.241, 325, 253, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
3754, 3zrkB, 0.7713, 3.37, 0.229, 348, 258, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
3755, 3orxF, 0.7713, 2.65, 0.215, 274, 246, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
3756, 3ornA, 0.7713, 3.08, 0.241, 280, 253, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4987655 AND MGAMP-PNP
3757, 3lltA, 0.7713, 2.90, 0.247, 341, 247, CRYSTAL STRUCTURE OF PF14_0431 KINASE DOMAIN.
3758, 3l1sB, 0.7713, 3.30, 0.227, 330, 256, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
3759, 5jsmA, 0.7712, 2.93, 0.274, 265, 248, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
3760, 5fqdC, 0.7712, 3.38, 0.178, 294, 259, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3761, 4l44A, 0.7712, 2.93, 0.261, 321, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
3762, 3zrkA, 0.7712, 3.39, 0.229, 345, 258, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
3763, 2oibC, 0.7712, 2.81, 0.238, 278, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3764, 5vcxA, 0.7711, 3.03, 0.213, 287, 249, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB
3765, 5lihB, 0.7711, 2.67, 0.199, 318, 246, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
3766, 5k76B, 0.7711, 2.95, 0.241, 281, 245, IRAK4 IN COMPLEX WITH COMPOUND 28
3767, 4yfiC, 0.7711, 2.72, 0.266, 269, 241, TNNI3K COMPLEXED WITH INHIBITOR 1
3768, 2qq7A, 0.7711, 2.14, 0.352, 251, 236, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
3769, 2jd5A, 0.7711, 2.86, 0.222, 353, 248, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
3770, 5t1sC, 0.7710, 3.04, 0.239, 284, 247, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3771, 4qtbA, 0.7710, 3.34, 0.202, 351, 257, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
3772, 4i6hA, 0.7710, 3.28, 0.213, 285, 254, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3773, 4g9cB, 0.7710, 2.82, 0.271, 264, 247, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
3774, 3vuhA, 0.7710, 2.86, 0.205, 355, 249, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
3775, 1q8zB, 0.7710, 3.20, 0.203, 364, 256, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
3776, 1h4lA, 0.7710, 2.76, 0.215, 278, 246, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
3777, 5t31A, 0.7709, 3.41, 0.233, 334, 258, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
3778, 4qo9A, 0.7709, 2.91, 0.267, 280, 251, MST3 IN COMPLEX WITH DANUSERTIB
3779, 4arkA, 0.7709, 3.20, 0.240, 291, 254, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
3780, 3ztxA, 0.7709, 2.99, 0.199, 269, 251, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
3781, 2nryC, 0.7709, 2.93, 0.241, 280, 245, CRYSTAL STRUCTURE OF IRAK-4
3782, 1ctpE, 0.7709, 3.02, 0.214, 332, 252, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
3783, 6ccfA, 0.7708, 2.94, 0.245, 260, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
3784, 5jznA, 0.7708, 2.74, 0.219, 268, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
3785, 5cs6B, 0.7708, 2.79, 0.222, 316, 248, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
3786, 4ztmD, 0.7708, 2.94, 0.241, 282, 245, IRAK4-INHIBITOR CO-STRUCTURE
3787, 4z7hA, 0.7708, 2.75, 0.215, 385, 246, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC KINASE-RNASE REGION - COMPLEX WITH IMIDAZOPYRIDINE COMPOUND 3
3788, 3zrmB, 0.7708, 3.39, 0.229, 347, 258, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
3789, 3sayB, 0.7708, 3.28, 0.227, 347, 255, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
3790, 2zv2A, 0.7708, 2.79, 0.224, 256, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
3791, 5w4wC, 0.7707, 3.37, 0.186, 284, 258, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3792, 5nwzB, 0.7707, 2.76, 0.363, 268, 245, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
3793, 5f95A, 0.7707, 3.30, 0.227, 345, 256, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3794, 5c01B, 0.7707, 2.49, 0.214, 260, 243, CRYSTAL STRUCTURE OF KINASE
3795, 5a4eB, 0.7707, 2.97, 0.226, 322, 248, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
3796, 4nm0A, 0.7707, 3.31, 0.227, 356, 256, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
3797, 3tucA, 0.7707, 2.67, 0.359, 257, 245, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
3798, 3fzsA, 0.7707, 2.50, 0.388, 254, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
3799, 3etaB, 0.7707, 2.87, 0.309, 292, 246, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
3800, 2y6oA, 0.7707, 2.65, 0.342, 263, 243, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
3801, 6fc8A, 0.7706, 3.14, 0.247, 269, 251, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
3802, 5gjdA, 0.7706, 2.61, 0.286, 292, 245, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 2
3803, 4ksqA, 0.7706, 2.59, 0.272, 258, 243, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR 5B
3804, 3fy0A, 0.7706, 3.23, 0.207, 292, 256, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
3805, 2nryD, 0.7706, 3.03, 0.244, 282, 246, CRYSTAL STRUCTURE OF IRAK-4
3806, 1unhB, 0.7706, 2.67, 0.209, 276, 244, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
3807, 4ehgA, 0.7705, 2.65, 0.272, 262, 246, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
3808, 4btjB, 0.7705, 3.21, 0.188, 293, 255, TTBK1 IN COMPLEX WITH ATP
3809, 3qupA, 0.7705, 2.25, 0.343, 241, 236, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
3810, 3efjB, 0.7705, 2.50, 0.310, 275, 239, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
3811, 5yf9B, 0.7704, 2.95, 0.211, 319, 251, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
3812, 5w4wB, 0.7704, 3.41, 0.190, 291, 258, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3813, 5a4qB, 0.7704, 2.95, 0.230, 335, 248, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
3814, 4o0wA, 0.7704, 2.66, 0.232, 259, 246, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3815, 4mygB, 0.7704, 2.86, 0.217, 335, 249, MAPK13 ACTIVE FORM
3816, 4i6bA, 0.7704, 3.31, 0.213, 285, 254, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3817, 4i5pA, 0.7704, 3.29, 0.213, 284, 254, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3818, 4eheA, 0.7704, 2.88, 0.269, 266, 249, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
3819, 2bfxA, 0.7704, 3.03, 0.198, 269, 252, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
3820, 4xj0B, 0.7703, 3.17, 0.236, 338, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
3821, 1j1cA, 0.7703, 3.31, 0.227, 354, 256, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
3822, 5vcwB, 0.7702, 3.06, 0.214, 285, 252, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
3823, 5uuuA, 0.7702, 3.22, 0.178, 414, 258, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
3824, 5c03A, 0.7702, 2.50, 0.222, 260, 243, CRYSTAL STRUCTURE OF KINASE
3825, 4c0tA, 0.7702, 3.17, 0.207, 290, 256, CANDIDA ALBICANS PKH KINASE DOMAIN
3826, 3zrlB, 0.7702, 3.40, 0.229, 347, 258, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
3827, 3vvhC, 0.7702, 3.15, 0.236, 283, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3828, 3krwA, 0.7702, 3.23, 0.208, 618, 259, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
3829, 3du8B, 0.7702, 3.30, 0.227, 339, 256, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
3830, 1q3wA, 0.7702, 3.31, 0.227, 344, 256, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
3831, 6g9aA, 0.7701, 3.21, 0.224, 341, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3832, 6fu5A, 0.7701, 2.43, 0.266, 282, 241, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
3833, 3zrmA, 0.7701, 3.41, 0.229, 344, 258, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
3834, 3du8A, 0.7701, 3.31, 0.227, 336, 256, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
3835, 1h4lB, 0.7701, 2.77, 0.215, 278, 246, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
3836, 5vamB, 0.7700, 2.62, 0.265, 260, 245, BRAF IN COMPLEX WITH RAF709
3837, 5t31B, 0.7700, 3.43, 0.233, 333, 258, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
3838, 5mqvC, 0.7700, 3.25, 0.199, 288, 256, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3839, 5ar4B, 0.7700, 2.66, 0.258, 279, 244, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3840, 3efkB, 0.7700, 2.47, 0.315, 272, 238, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
3841, 1q3wB, 0.7700, 3.34, 0.227, 341, 256, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
3842, 4yfiA, 0.7699, 2.70, 0.267, 268, 240, TNNI3K COMPLEXED WITH INHIBITOR 1
3843, 4xj0A, 0.7699, 3.07, 0.239, 345, 251, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
3844, 4kikB, 0.7699, 2.70, 0.255, 648, 247, HUMAN IKB KINASE BETA
3845, 4bckC, 0.7699, 3.00, 0.255, 293, 251, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3846, 3uytB, 0.7699, 3.29, 0.207, 286, 256, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3847, 3krxA, 0.7699, 3.22, 0.182, 618, 258, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
3848, 1mp8A, 0.7699, 2.54, 0.336, 252, 241, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
3849, 5hd4A, 0.7698, 3.27, 0.212, 347, 255, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
3850, 5dr9A, 0.7698, 2.63, 0.237, 257, 245, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
3851, 5cenA, 0.7698, 2.57, 0.316, 281, 244, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
3852, 5ceiA, 0.7698, 3.50, 0.187, 345, 257, CRYSTAL STRUCTURE OF CDK8:CYCLIN C COMPLEX WITH COMPOUND 22
3853, 4iirB, 0.7698, 2.95, 0.210, 327, 248, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
3854, 4ibmA, 0.7698, 3.04, 0.323, 301, 251, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
3855, 3eqbA, 0.7698, 3.13, 0.245, 289, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3856, 2wtkC, 0.7698, 2.94, 0.233, 285, 249, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3857, 2bfyA, 0.7698, 3.05, 0.198, 270, 252, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
3858, 6fckA, 0.7697, 3.17, 0.247, 269, 251, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
3859, 5oktB, 0.7697, 3.27, 0.195, 281, 256, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3860, 5k3yB, 0.7697, 3.15, 0.197, 277, 254, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
3861, 4ztmB, 0.7697, 2.80, 0.239, 280, 243, IRAK4-INHIBITOR CO-STRUCTURE
3862, 4acgA, 0.7697, 3.31, 0.223, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
3863, 3nczB, 0.7697, 2.77, 0.190, 379, 247, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
3864, 2wqbA, 0.7697, 2.73, 0.333, 289, 246, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
3865, 1howA, 0.7697, 2.91, 0.209, 346, 249, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
3866, 6brcB, 0.7696, 3.00, 0.225, 260, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
3867, 5k5nA, 0.7696, 3.18, 0.233, 331, 253, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
3868, 5d7aC, 0.7696, 2.83, 0.228, 286, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
3869, 4pnkA, 0.7696, 3.22, 0.182, 625, 258, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
3870, 3uqfB, 0.7696, 2.23, 0.342, 253, 237, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
3871, 2qi8B, 0.7696, 2.09, 0.336, 249, 235, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
3872, 2oibB, 0.7696, 2.97, 0.232, 278, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3873, 1q97B, 0.7696, 3.30, 0.187, 361, 256, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
3874, 6ccfB, 0.7695, 2.95, 0.245, 262, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
3875, 5w85B, 0.7695, 2.95, 0.233, 279, 245, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
3876, 5hlwA, 0.7695, 3.14, 0.329, 284, 249, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
3877, 4gcjA, 0.7695, 3.00, 0.254, 304, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
3878, 4bckA, 0.7695, 3.06, 0.257, 298, 253, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3879, 3vuiA, 0.7695, 2.89, 0.205, 355, 249, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
3880, 1okvA, 0.7695, 3.02, 0.242, 295, 252, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
3881, 6gwrA, 0.7694, 3.26, 0.324, 300, 253, STRUCTURE OF THE KINASE DOMAIN OF HUMAN DDR1 IN COMPLEX WITH A POTENT AND SELECTIVE INHIBITOR OF DDR1 AND DDR2 
3882, 5yf9X, 0.7694, 2.97, 0.215, 319, 251, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
3883, 5l8lA, 0.7694, 2.92, 0.191, 263, 251, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
3884, 5dr6A, 0.7694, 2.63, 0.237, 257, 245, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
3885, 3c4yB, 0.7694, 3.08, 0.202, 466, 253, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
3886, 2jd5B, 0.7694, 3.30, 0.203, 360, 256, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
3887, 4qp7A, 0.7693, 2.81, 0.218, 337, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
3888, 4gt4B, 0.7693, 2.78, 0.324, 273, 247, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
3889, 4cxaC, 0.7693, 3.17, 0.250, 330, 256, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
3890, 3zrlA, 0.7693, 3.43, 0.229, 345, 258, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
3891, 3m1sB, 0.7693, 3.32, 0.227, 349, 256, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
3892, 5ng3D, 0.7692, 2.87, 0.258, 278, 248, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
3893, 5myvC, 0.7692, 3.40, 0.164, 348, 256, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
3894, 5he0A, 0.7692, 3.27, 0.201, 621, 259, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
3895, 5a4eA, 0.7692, 2.80, 0.240, 341, 246, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
3896, 5a3xC, 0.7692, 3.00, 0.217, 333, 249, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
3897, 4qqcA, 0.7692, 2.73, 0.367, 273, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3898, 4qq5A, 0.7692, 2.79, 0.366, 275, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
3899, 3v3vA, 0.7692, 2.91, 0.209, 351, 249, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
3900, 6b16A, 0.7691, 3.08, 0.209, 285, 253, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
3901, 4tw9A, 0.7691, 3.36, 0.202, 290, 257, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3902, 3qlfA, 0.7691, 1.94, 0.342, 249, 234, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
3903, 5he2A, 0.7690, 3.25, 0.178, 628, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
3904, 5he1A, 0.7690, 3.28, 0.193, 618, 259, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
3905, 5dewA, 0.7690, 3.18, 0.208, 295, 255, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3906, 4xs2D, 0.7690, 2.89, 0.241, 277, 245, IRAK4-INHIBITOR CO-STRUCTURE
3907, 4at4A, 0.7690, 3.01, 0.371, 292, 248, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
3908, 1q99B, 0.7690, 3.13, 0.204, 364, 255, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
3909, 6g93A, 0.7689, 3.24, 0.236, 343, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3910, 6eqiC, 0.7689, 3.06, 0.200, 392, 255, STRUCTURE OF PINK1 BOUND TO UBIQUITIN
3911, 6cz2A, 0.7689, 2.85, 0.341, 261, 246, STRUCTURE OF THE PTK6 KINASE DOMAIN 
3912, 5t1tA, 0.7689, 3.00, 0.240, 283, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
3913, 5cwzA, 0.7689, 2.78, 0.229, 284, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3914, 4yo6C, 0.7689, 2.99, 0.243, 286, 247, IRAK4-INHIBITOR CO-STRUCTURE
3915, 4c57A, 0.7689, 3.13, 0.203, 310, 251, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
3916, 4bieB, 0.7689, 2.75, 0.299, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3917, 6dkwA, 0.7688, 2.59, 0.370, 284, 243, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 3. 
3918, 5ct7A, 0.7688, 2.59, 0.276, 257, 243, BRAF IN COMPLEX WITH RAF265
3919, 3vukA, 0.7688, 2.89, 0.205, 355, 249, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
3920, 1uwhB, 0.7688, 2.79, 0.272, 264, 246, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
3921, 5li9A, 0.7687, 2.80, 0.197, 329, 249, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
3922, 4ztnC, 0.7687, 3.07, 0.235, 284, 247, IRAK4-INHIBITOR CO-STRUCTURE
3923, 4nctD, 0.7687, 2.95, 0.222, 331, 248, HUMAN DYRK1A IN COMPLEX WITH PKC412
3924, 4j1rD, 0.7687, 3.44, 0.229, 345, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
3925, 4j1rB, 0.7687, 3.45, 0.229, 346, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
3926, 3zlyA, 0.7687, 3.25, 0.244, 310, 254, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
3927, 3zlxA, 0.7687, 3.29, 0.243, 312, 255, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
3928, 3my0K, 0.7687, 2.88, 0.252, 261, 246, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3929, 3iecA, 0.7687, 2.75, 0.251, 311, 247, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3930, 3f7zB, 0.7687, 3.40, 0.229, 339, 258, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
3931, 3etaA, 0.7687, 2.80, 0.310, 293, 245, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
3932, 3d2iA, 0.7687, 2.64, 0.233, 255, 245, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
3933, 2bfyB, 0.7687, 3.17, 0.201, 278, 254, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
3934, 1o9uA, 0.7687, 3.30, 0.231, 349, 255, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
3935, 1finC, 0.7687, 3.02, 0.250, 298, 252, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
3936, 4j1rA, 0.7686, 3.44, 0.229, 343, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
3937, 4bcqC, 0.7686, 2.92, 0.260, 292, 250, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3938, 3c4yA, 0.7686, 3.29, 0.205, 478, 259, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
3939, 6es0B, 0.7685, 2.79, 0.257, 287, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
3940, 5uitA, 0.7685, 2.79, 0.242, 284, 244, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
3941, 4kspA, 0.7685, 2.53, 0.269, 257, 242, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
3942, 1yxtA, 0.7685, 2.68, 0.188, 274, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
3943, 6gdqA, 0.7684, 3.23, 0.236, 339, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
3944, 5hlnA, 0.7684, 3.35, 0.229, 346, 258, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
3945, 5ar7B, 0.7684, 2.49, 0.264, 278, 242, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3946, 5a3xD, 0.7684, 2.96, 0.226, 331, 248, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
3947, 4qpaA, 0.7684, 3.18, 0.202, 331, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3948, 4qp1B, 0.7684, 3.20, 0.205, 343, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3949, 4q9sA, 0.7684, 2.44, 0.368, 252, 242, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
3950, 4j1rC, 0.7684, 3.45, 0.229, 344, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
3951, 4c2vB, 0.7684, 3.22, 0.197, 280, 254, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
3952, 4btmB, 0.7684, 3.24, 0.180, 293, 255, TTBK1 IN COMPLEX WITH INHIBITOR
3953, 4b8mB, 0.7684, 3.22, 0.197, 279, 254, AURORA B KINASE IN COMPLEX WITH VX-680
3954, 3skcA, 0.7684, 2.59, 0.266, 260, 244, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
3955, 3dv3A, 0.7684, 3.14, 0.242, 288, 252, MEK1 WITH PF-04622664 BOUND
3956, 2p2hA, 0.7684, 2.66, 0.380, 292, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
3957, 2oicB, 0.7684, 2.70, 0.241, 276, 241, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
3958, 2aypA, 0.7684, 3.13, 0.248, 268, 250, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
3959, 5nudA, 0.7683, 2.69, 0.393, 267, 244, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
3960, 5k7gD, 0.7683, 3.00, 0.241, 283, 245, IRAK4 IN COMPLEX WITH AZ3862
3961, 4achA, 0.7683, 3.34, 0.227, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
3962, 3dlsC, 0.7683, 2.93, 0.235, 281, 247, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3963, 1wzyA, 0.7683, 3.02, 0.231, 350, 251, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
3964, 5k5nB, 0.7682, 3.19, 0.233, 334, 253, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
3965, 4u80A, 0.7682, 3.21, 0.240, 286, 254, MEK 1 KINASE BOUND TO G799
3966, 4qp6B, 0.7682, 3.21, 0.213, 334, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
3967, 4qp2B, 0.7682, 3.21, 0.206, 329, 253, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
3968, 4itjB, 0.7682, 2.91, 0.269, 276, 245, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
3969, 4b8mA, 0.7682, 3.03, 0.199, 270, 251, AURORA B KINASE IN COMPLEX WITH VX-680
3970, 3vvhB, 0.7682, 3.20, 0.237, 290, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
3971, 3o7lD, 0.7682, 3.01, 0.210, 333, 252, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
3972, 3f69B, 0.7682, 2.98, 0.198, 282, 252, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3973, 3eb0A, 0.7682, 2.98, 0.226, 311, 248, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
3974, 2yerA, 0.7682, 3.19, 0.247, 268, 251, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
3975, 2wipC, 0.7682, 2.86, 0.242, 292, 248, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
3976, 2vrxA, 0.7682, 3.03, 0.199, 268, 251, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
3977, 1unhA, 0.7682, 2.86, 0.206, 276, 247, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
3978, 1ungA, 0.7682, 2.96, 0.209, 288, 249, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
3979, 1i09B, 0.7682, 3.35, 0.223, 341, 256, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
3980, 5bx0A, 0.7681, 3.30, 0.239, 315, 255, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
3981, 5a4qC, 0.7681, 2.94, 0.219, 332, 247, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
3982, 5a3xB, 0.7681, 2.98, 0.230, 340, 248, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
3983, 4j71A, 0.7681, 3.43, 0.229, 347, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
3984, 3f3zA, 0.7681, 2.97, 0.211, 271, 251, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
3985, 2jldA, 0.7681, 3.33, 0.227, 349, 256, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
3986, 1h8fB, 0.7681, 3.36, 0.227, 350, 256, GLYCOGEN SYNTHASE KINASE 3 BETA.
3987, 6f3dA, 0.7680, 2.87, 0.243, 277, 243, IRAK4 IN COMPLEX WITH INHIBITOR 
3988, 5w4wA, 0.7680, 3.46, 0.201, 291, 259, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3989, 5fdxA, 0.7680, 3.02, 0.333, 280, 249, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
3990, 4ty1A, 0.7680, 2.67, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
3991, 5h3qA, 0.7679, 2.97, 0.364, 302, 247, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
3992, 4mtaA, 0.7679, 2.69, 0.192, 273, 245, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
3993, 4mk0A, 0.7679, 3.28, 0.186, 631, 258, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH A A RATIONALLY DESIGNED PAROXETINE DERIVATIVE
3994, 4byiA, 0.7679, 2.61, 0.238, 254, 244, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3995, 4alwA, 0.7679, 2.62, 0.189, 273, 244, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3996, 3zu7A, 0.7679, 3.10, 0.230, 344, 252, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
3997, 1h8fA, 0.7679, 3.36, 0.223, 352, 256, GLYCOGEN SYNTHASE KINASE 3 BETA.
3998, 5cwzB, 0.7678, 2.80, 0.229, 284, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3999, 5aafA, 0.7678, 2.61, 0.238, 254, 244, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
4000, 5a54C, 0.7678, 2.95, 0.219, 332, 247, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
4001, 4qp9A, 0.7678, 2.84, 0.231, 335, 247, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
4002, 4h3pA, 0.7678, 3.08, 0.226, 342, 252, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
4003, 3qc4A, 0.7678, 2.87, 0.214, 276, 248, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
4004, 5e1sA, 0.7677, 2.68, 0.322, 284, 245, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
4005, 5a4tB, 0.7677, 2.97, 0.226, 339, 248, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
4006, 4nttA, 0.7677, 3.02, 0.210, 339, 252, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
4007, 4ntsB, 0.7677, 3.02, 0.210, 341, 252, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
4008, 4iq6A, 0.7677, 3.37, 0.227, 324, 256, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
4009, 4afjA, 0.7677, 3.28, 0.231, 342, 255, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
4010, 3v5qA, 0.7677, 2.65, 0.380, 263, 242, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
4011, 3begA, 0.7677, 3.36, 0.184, 348, 255, CRYSTAL STRUCTURE OF SR PROTEIN KINASE 1 COMPLEXED TO ITS SUBSTRATE ASF/SF2
4012, 2e9vA, 0.7677, 3.25, 0.255, 268, 251, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
4013, 5eykB, 0.7676, 3.17, 0.202, 275, 253, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
4014, 4y73B, 0.7676, 2.99, 0.237, 289, 245, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4015, 2vgoA, 0.7676, 3.04, 0.199, 268, 251, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
4016, 1q99A, 0.7676, 2.94, 0.213, 354, 249, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
4017, 6fniA, 0.7675, 2.89, 0.324, 261, 244, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH NVP-BHG712 
4018, 5l8kA, 0.7675, 3.04, 0.183, 266, 252, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
4019, 5buiA, 0.7675, 2.90, 0.234, 338, 248, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
4020, 4l46A, 0.7675, 2.97, 0.261, 317, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
4021, 3os3A, 0.7675, 2.84, 0.243, 272, 247, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4858061 AND MGATP
4022, 1i44A, 0.7675, 2.70, 0.333, 282, 246, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4023, 5hlpA, 0.7674, 3.45, 0.229, 337, 258, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
4024, 4u81A, 0.7674, 3.23, 0.240, 289, 254, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
4025, 4ic7D, 0.7674, 3.35, 0.207, 353, 256, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
4026, 3sd0B, 0.7674, 3.39, 0.227, 349, 256, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
4027, 2p55A, 0.7674, 3.22, 0.240, 289, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4028, 4yp8D, 0.7673, 2.99, 0.243, 285, 247, IRAK4-INHIBITOR CO-STRUCTURE
4029, 4xs2C, 0.7673, 2.96, 0.241, 281, 245, IRAK4-INHIBITOR CO-STRUCTURE
4030, 4ux9D, 0.7673, 2.82, 0.191, 344, 246, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4031, 4rmzA, 0.7673, 3.00, 0.240, 284, 246, CRYSTAL STRUCTURE OF IRAK-4
4032, 4qyyA, 0.7673, 3.32, 0.212, 337, 255, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
4033, 4ixpA, 0.7673, 3.02, 0.255, 334, 251, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
4034, 4afjB, 0.7673, 3.23, 0.232, 346, 254, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
4035, 3zlwA, 0.7673, 3.36, 0.234, 312, 256, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
4036, 3og7B, 0.7673, 2.54, 0.270, 254, 244, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
4037, 3gb2A, 0.7673, 3.42, 0.229, 340, 258, GSK3BETA INHIBITOR COMPLEX
4038, 5ar8B, 0.7672, 2.43, 0.261, 274, 241, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
4039, 5airB, 0.7672, 3.36, 0.223, 361, 256, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
4040, 5aadA, 0.7672, 2.54, 0.240, 252, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
4041, 3q3bB, 0.7672, 3.37, 0.227, 341, 256, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
4042, 2yexA, 0.7672, 3.30, 0.246, 269, 252, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
4043, 1gngA, 0.7672, 3.36, 0.230, 348, 257, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
4044, 5uiuB, 0.7671, 2.93, 0.245, 287, 245, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4045, 5k72A, 0.7671, 2.86, 0.243, 277, 243, IRAK4 IN COMPLEX WITH COMPOUND 21
4046, 4ztlA, 0.7671, 2.98, 0.239, 280, 243, IRAK4-INHIBITOR CO-STRUCTURE
4047, 4lgdB, 0.7671, 3.17, 0.205, 350, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4048, 3v01A, 0.7671, 3.22, 0.240, 289, 254, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
4049, 3sv0A, 0.7671, 3.38, 0.186, 294, 258, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
4050, 1mruA, 0.7671, 2.57, 0.207, 269, 242, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
4051, 1j3hB, 0.7671, 2.98, 0.211, 327, 251, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
4052, 6bskA, 0.7670, 2.69, 0.192, 273, 245, HUMAN PIM1 KINASE IN COMPLEX WITH COMPOUND 12B
4053, 5a4lC, 0.7670, 2.95, 0.219, 332, 247, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
4054, 4apcB, 0.7670, 2.97, 0.215, 296, 247, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
4055, 4acdB, 0.7670, 3.35, 0.227, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
4056, 3v04A, 0.7670, 3.22, 0.240, 289, 254, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
4057, 1i09A, 0.7670, 3.38, 0.227, 338, 256, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
4058, 4z7hB, 0.7669, 2.68, 0.226, 388, 243, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC KINASE-RNASE REGION - COMPLEX WITH IMIDAZOPYRIDINE COMPOUND 3
4059, 4yc3A, 0.7669, 2.98, 0.260, 295, 250, CDK1/CYCLINB1/CKS2 APO
4060, 4un0C, 0.7669, 3.17, 0.243, 308, 255, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
4061, 4qp4A, 0.7669, 2.85, 0.222, 337, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
4062, 4iq6B, 0.7669, 3.38, 0.227, 332, 256, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
4063, 4c57B, 0.7669, 3.15, 0.207, 308, 251, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
4064, 4alvA, 0.7669, 2.68, 0.188, 274, 245, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
4065, 2cguA, 0.7669, 3.10, 0.249, 263, 249, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4066, 1s9jA, 0.7669, 3.19, 0.240, 289, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4067, 5uisB, 0.7668, 3.00, 0.241, 274, 245, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4068, 5icpA, 0.7668, 3.51, 0.191, 343, 257, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (5-METHYL-IMIDAZO[51-B][134]THIADIAZOL-2-YL)-METHANONE
4069, 5airA, 0.7668, 3.37, 0.227, 353, 256, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
4070, 4c2wB, 0.7668, 3.24, 0.197, 277, 254, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
4071, 3c7qA, 0.7668, 2.70, 0.373, 286, 244, STRUCTURE OF VEGFR2 KINASE DOMAIN IN COMPLEX WITH BIBF1120
4072, 2y4iC, 0.7668, 3.17, 0.242, 313, 252, KSR2-MEK1 HETERODIMER
4073, 2np8A, 0.7668, 2.72, 0.236, 256, 246, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
4074, 2jldB, 0.7668, 3.35, 0.227, 349, 256, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
4075, 2cgxA, 0.7668, 3.07, 0.254, 265, 248, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4076, 1q4lA, 0.7668, 3.38, 0.215, 342, 256, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
4077, 4y73D, 0.7667, 2.98, 0.240, 288, 246, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4078, 4aszA, 0.7667, 3.01, 0.381, 289, 247, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
4079, 3zdiA, 0.7667, 3.36, 0.227, 348, 255, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND INHIBITOR 7D
4080, 2qoqA, 0.7667, 2.72, 0.314, 284, 242, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
4081, 1p4oA, 0.7667, 3.12, 0.313, 308, 249, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
4082, 5w5qA, 0.7666, 3.13, 0.223, 291, 251, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
4083, 5a4qA, 0.7666, 2.82, 0.240, 341, 246, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
4084, 4n70A, 0.7666, 2.70, 0.188, 274, 245, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
4085, 4k0yA, 0.7666, 2.70, 0.192, 274, 245, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
4086, 4f7sA, 0.7666, 3.38, 0.188, 339, 255, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
4087, 3zonA, 0.7666, 2.43, 0.228, 261, 241, HUMAN TYK2 PSEUDOKINASE DOMAIN BOUND TO A KINASE INHIBITOR
4088, 2vwuA, 0.7666, 2.64, 0.292, 253, 240, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4089, 2cgvA, 0.7666, 3.06, 0.254, 264, 248, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4090, 4lgdD, 0.7665, 3.16, 0.205, 338, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4091, 3r22A, 0.7665, 2.60, 0.230, 255, 244, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
4092, 3anqD, 0.7665, 2.97, 0.219, 334, 247, HUMAN DYRK1A/INHIBITOR COMPLEX
4093, 1p4oB, 0.7665, 3.13, 0.313, 314, 249, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
4094, 1jpaA, 0.7665, 2.51, 0.328, 273, 241, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4095, 5x5oA, 0.7664, 3.06, 0.291, 291, 247, CRYSTAL STRUCTURE OF ZAK IN COMPLEX WITH COMPOUND D2829
4096, 5diaA, 0.7664, 2.70, 0.192, 273, 245, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
4097, 5dhjA, 0.7664, 2.69, 0.188, 273, 245, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
4098, 5dgzA, 0.7664, 2.69, 0.184, 273, 245, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
4099, 5c01A, 0.7664, 2.49, 0.211, 258, 242, CRYSTAL STRUCTURE OF KINASE
4100, 5a4lA, 0.7664, 3.00, 0.226, 341, 248, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
4101, 4xhgA, 0.7664, 3.40, 0.159, 357, 258, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (FORMATE CONDITION)
4102, 1q8yA, 0.7664, 2.78, 0.224, 351, 246, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
4103, 1jpaB, 0.7664, 2.44, 0.331, 269, 239, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4104, 4twcB, 0.7663, 3.42, 0.202, 292, 258, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
4105, 4gt4A, 0.7663, 2.80, 0.324, 274, 247, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4106, 4bidA, 0.7663, 2.54, 0.300, 254, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4107, 4b7tA, 0.7663, 3.37, 0.227, 350, 256, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND LEUCETTINE L4
4108, 3pupB, 0.7663, 3.37, 0.227, 347, 256, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
4109, 2a1aB, 0.7663, 2.84, 0.256, 269, 246, PKR KINASE DOMAIN-EIF2ALPHA COMPLEX
4110, 5k7gC, 0.7662, 2.99, 0.241, 283, 245, IRAK4 IN COMPLEX WITH AZ3862
4111, 5g15A, 0.7662, 3.14, 0.190, 265, 253, STRUCTURE AURORA A (122-403) BOUND TO ACTIVATING MONOBODY MB1 AND AMPPCP
4112, 5aagA, 0.7662, 2.59, 0.239, 253, 243, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
4113, 4crlA, 0.7662, 3.34, 0.193, 339, 254, CRYSTAL STRUCTURE OF HUMAN CDK8-CYCLIN C IN COMPLEX WITH CORTISTATIN A
4114, 3r00A, 0.7662, 2.70, 0.188, 274, 245, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4115, 2vgpB, 0.7662, 3.26, 0.197, 277, 254, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
4116, 2bujB, 0.7662, 3.15, 0.228, 286, 254, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
4117, 1y6bA, 0.7662, 2.50, 0.376, 266, 242, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 2-ANILINO-5-ARYL-OXAZOLE INHIBITOR
4118, 1jowB, 0.7662, 2.62, 0.252, 277, 242, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
4119, 5kgdA, 0.7661, 2.70, 0.192, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
4120, 5a54A, 0.7661, 2.92, 0.223, 341, 247, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
4121, 4fc0A, 0.7661, 2.56, 0.269, 254, 242, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
4122, 4bibA, 0.7661, 2.54, 0.296, 254, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4123, 4achB, 0.7661, 3.37, 0.227, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
4124, 3tv4A, 0.7661, 2.87, 0.271, 264, 247, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
4125, 1q97A, 0.7661, 2.79, 0.224, 351, 246, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
4126, 5uiqB, 0.7660, 2.84, 0.243, 272, 243, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4127, 5jznB, 0.7660, 2.88, 0.238, 266, 248, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
4128, 5hlpB, 0.7660, 3.48, 0.229, 335, 258, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
4129, 5a4tC, 0.7660, 2.97, 0.219, 332, 247, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
4130, 4wt6A, 0.7660, 2.70, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
4131, 4wrsA, 0.7660, 2.70, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
4132, 4tn6A, 0.7660, 3.31, 0.191, 292, 257, CK1D IN COMPLEX WITH INHIBITOR
4133, 2y6mA, 0.7660, 2.67, 0.343, 262, 242, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
4134, 2vwwA, 0.7660, 2.66, 0.307, 253, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4135, 2c3kA, 0.7660, 3.11, 0.250, 262, 248, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4136, 3pvuA, 0.7659, 3.28, 0.182, 609, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
4137, 3a8wA, 0.7659, 2.98, 0.202, 326, 252, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
4138, 2xj2A, 0.7659, 2.66, 0.189, 273, 244, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4139, 6gn1B, 0.7658, 3.34, 0.227, 339, 255, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
4140, 5nk8A, 0.7658, 2.50, 0.324, 266, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
4141, 4wovA, 0.7658, 2.48, 0.227, 258, 242, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
4142, 4j71B, 0.7658, 3.47, 0.229, 347, 258, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
4143, 3pupA, 0.7658, 3.38, 0.227, 346, 256, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
4144, 1q8zA, 0.7658, 2.96, 0.209, 354, 249, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
4145, 5v82A, 0.7657, 2.66, 0.193, 273, 244, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
4146, 5hvjB, 0.7657, 2.85, 0.264, 284, 246, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
4147, 5ebzJ, 0.7657, 3.07, 0.241, 655, 253, CRYSTAL STRUCTURE OF HUMAN IKK1
4148, 4nctA, 0.7657, 3.02, 0.222, 341, 248, HUMAN DYRK1A IN COMPLEX WITH PKC412
4149, 3slsB, 0.7657, 3.06, 0.243, 294, 251, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4150, 2e9oA, 0.7657, 3.21, 0.252, 269, 250, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
4151, 2cjmA, 0.7657, 3.01, 0.260, 285, 250, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
4152, 5jrqA, 0.7656, 2.92, 0.274, 258, 248, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
4153, 4c8bA, 0.7656, 2.27, 0.262, 279, 237, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
4154, 4accB, 0.7656, 3.37, 0.227, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
4155, 3vc4A, 0.7656, 2.70, 0.184, 274, 245, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4156, 3mygA, 0.7656, 2.55, 0.244, 252, 242, AURORA A KINASE COMPLEXED WITH SCH 1473759
4157, 3eidC, 0.7656, 2.98, 0.256, 290, 250, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
4158, 3dlsB, 0.7656, 2.93, 0.236, 280, 246, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
4159, 5idpA, 0.7655, 3.48, 0.187, 342, 257, CDK8-CYCC IN COMPLEX WITH (3-AMINO-1H-INDAZOL-5-YL)-[(S)-2-(4-FLUORO- PHENYL)-PIPERIDIN-1-YL]-METHANONE
4160, 5hnbA, 0.7655, 3.43, 0.188, 342, 255, CDK8-CYCC IN COMPLEX WITH [6-HYDROXY-3-(3-METHYL-BENZYL)-1H-INDAZOL-5- YL]-((S)-3-HYDROXY-PYRROLIDIN-1-YL)-METHANONE
4161, 4dtkA, 0.7655, 2.71, 0.188, 273, 245, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
4162, 4acdA, 0.7655, 3.38, 0.227, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
4163, 2o64A, 0.7655, 2.71, 0.188, 274, 245, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
4164, 2e9vB, 0.7655, 3.18, 0.256, 268, 250, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
4165, 2chlA, 0.7655, 3.50, 0.169, 298, 260, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
4166, 6c2yA, 0.7654, 3.21, 0.180, 617, 256, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257142 
4167, 5op7A, 0.7654, 3.10, 0.246, 261, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
4168, 5jzjA, 0.7654, 2.81, 0.215, 271, 246, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
4169, 2xj1A, 0.7654, 2.68, 0.189, 273, 244, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
4170, 2bfxB, 0.7654, 3.11, 0.199, 275, 251, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
4171, 1r0pA, 0.7654, 3.07, 0.312, 301, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
4172, 5kplB, 0.7653, 3.37, 0.227, 339, 255, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
4173, 5ipjA, 0.7653, 2.71, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
4174, 5eolA, 0.7653, 2.71, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
4175, 3f2aA, 0.7653, 2.73, 0.192, 276, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
4176, 2p0cA, 0.7653, 2.31, 0.352, 249, 236, CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER
4177, 5uoxB, 0.7652, 2.69, 0.303, 252, 241, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4178, 5lvpA, 0.7652, 2.79, 0.206, 275, 247, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
4179, 4n6zA, 0.7652, 2.67, 0.184, 272, 244, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
4180, 4mh7B, 0.7652, 2.46, 0.340, 255, 238, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1896
4181, 4dbnA, 0.7652, 2.65, 0.272, 257, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4182, 4c8bB, 0.7652, 2.45, 0.258, 281, 240, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
4183, 4b9dB, 0.7652, 3.09, 0.218, 295, 248, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
4184, 4acgB, 0.7652, 3.37, 0.223, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
4185, 2xj0A, 0.7652, 2.71, 0.188, 274, 245, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4186, 2x7gA, 0.7652, 3.40, 0.169, 344, 255, STRUCTURE OF HUMAN SERINE-ARGININE-RICH PROTEIN-SPECIFIC KINASE 2 (SRPK2) BOUND TO PURVALANOL B
4187, 5w4wD, 0.7651, 3.30, 0.188, 287, 255, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4188, 5u6cB, 0.7651, 2.33, 0.343, 257, 236, CRYSTAL STRUCTURE OF THE MER KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4189, 5hieC, 0.7651, 2.68, 0.280, 253, 243, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4190, 4mblA, 0.7651, 2.71, 0.184, 274, 245, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
4191, 4ehgB, 0.7651, 2.63, 0.275, 260, 244, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
4192, 3f88A, 0.7651, 3.46, 0.229, 340, 258, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
4193, 2rfnA, 0.7651, 2.41, 0.314, 268, 236, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4194, 5uiuA, 0.7650, 2.92, 0.242, 286, 244, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4195, 5ar4A, 0.7650, 2.47, 0.262, 274, 240, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
4196, 4mygA, 0.7650, 2.89, 0.218, 335, 248, MAPK13 ACTIVE FORM
4197, 3vbqA, 0.7650, 2.63, 0.189, 271, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4198, 3qtiA, 0.7650, 3.00, 0.331, 292, 245, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4199, 3f88B, 0.7650, 3.45, 0.229, 340, 258, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
4200, 2ywpA, 0.7650, 3.17, 0.253, 269, 249, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
4201, 6groA, 0.7649, 3.50, 0.169, 293, 260, HUMAN CSNK1G3 BOUND TO SB-223133 
4202, 4wo5B, 0.7649, 2.59, 0.281, 257, 242, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
4203, 4r6vA, 0.7649, 2.83, 0.367, 273, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4204, 6f3gA, 0.7648, 2.92, 0.236, 274, 242, IRAK4 IN COMPLEX WITH INHIBITOR 
4205, 5v80A, 0.7648, 2.71, 0.184, 273, 245, PIM1 KINASE IN COMPLEX WITH CPD1 (1-METHYL-4-(3-(6-(PIPERAZIN-1-YL) PYRIDIN-2-YL)-1H-PYRAZOLO[3;4-C]PYRIDIN-5-YL)PIPERAZIN-2-ONE) 
4206, 5a4tD, 0.7648, 2.98, 0.223, 332, 247, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
4207, 4wsyA, 0.7648, 2.72, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
4208, 4prjA, 0.7648, 2.53, 0.232, 251, 241, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
4209, 4nctB, 0.7648, 3.03, 0.222, 333, 248, HUMAN DYRK1A IN COMPLEX WITH PKC412
4210, 4hyhA, 0.7648, 3.10, 0.246, 263, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
4211, 2objA, 0.7648, 2.67, 0.184, 272, 244, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
4212, 6gt1C, 0.7647, 2.57, 0.244, 257, 242, NEK7 BOUND TO PURINE INHIBITOR 
4213, 5uvcA, 0.7647, 3.30, 0.190, 457, 258, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
4214, 5jsmB, 0.7647, 3.05, 0.274, 263, 248, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4215, 4p5zA, 0.7647, 2.72, 0.324, 267, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4216, 4jx7A, 0.7647, 2.71, 0.188, 274, 245, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
4217, 4aluA, 0.7647, 2.71, 0.184, 274, 245, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
4218, 3c4eD, 0.7647, 2.72, 0.192, 273, 245, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4219, 3bhhD, 0.7647, 2.67, 0.208, 286, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
4220, 2rfnB, 0.7647, 2.49, 0.316, 269, 237, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
4221, 5iisA, 0.7646, 2.72, 0.188, 273, 245, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
4222, 4accA, 0.7646, 3.39, 0.227, 350, 256, GSK3B IN COMPLEX WITH INHIBITOR
4223, 3zm4A, 0.7646, 3.29, 0.245, 309, 253, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
4224, 1yxxA, 0.7646, 2.72, 0.188, 274, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
4225, 1q4lB, 0.7646, 3.42, 0.219, 337, 256, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
4226, 5fdpA, 0.7645, 3.21, 0.319, 285, 251, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
4227, 4k1bA, 0.7645, 2.70, 0.184, 273, 245, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
4228, 3vw6B, 0.7644, 2.63, 0.304, 253, 240, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4229, 3cy2A, 0.7644, 2.71, 0.188, 271, 245, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND II
4230, 1uwjA, 0.7644, 2.76, 0.275, 264, 244, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4231, 3jxwA, 0.7643, 2.71, 0.188, 274, 245, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
4232, 2oi4X, 0.7643, 2.77, 0.183, 275, 246, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
4233, 2hwoA, 0.7643, 2.19, 0.345, 251, 235, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
4234, 2f57A, 0.7643, 3.26, 0.181, 297, 254, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
4235, 1zysA, 0.7643, 3.25, 0.260, 271, 250, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
4236, 1jstA, 0.7643, 3.00, 0.259, 297, 251, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
4237, 5w85A, 0.7642, 2.99, 0.243, 278, 243, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 9)
4238, 5uiqA, 0.7642, 2.90, 0.244, 268, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4239, 3w55A, 0.7642, 2.88, 0.232, 335, 246, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
4240, 3pvwA, 0.7642, 3.30, 0.178, 613, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
4241, 6cqhB, 0.7641, 3.47, 0.169, 316, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
4242, 5ng3B, 0.7641, 2.80, 0.261, 275, 245, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4243, 5mqvA, 0.7641, 3.24, 0.201, 286, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4244, 4rmzB, 0.7641, 3.01, 0.246, 282, 244, CRYSTAL STRUCTURE OF IRAK-4
4245, 4k18A, 0.7641, 2.76, 0.187, 277, 246, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
4246, 4g9cA, 0.7641, 2.66, 0.262, 265, 244, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
4247, 2pk9A, 0.7641, 3.11, 0.247, 287, 251, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
4248, 2gdoA, 0.7641, 3.40, 0.250, 269, 252, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
4249, 5kgiA, 0.7640, 2.72, 0.188, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
4250, 5k3yA, 0.7640, 2.98, 0.197, 267, 249, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
4251, 5he3A, 0.7640, 3.30, 0.186, 623, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
4252, 5a3xA, 0.7640, 2.90, 0.239, 342, 247, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
4253, 4zy6A, 0.7640, 3.12, 0.210, 284, 252, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
4254, 4xhkB, 0.7640, 2.73, 0.188, 269, 245, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
4255, 4nctC, 0.7640, 2.97, 0.223, 339, 247, HUMAN DYRK1A IN COMPLEX WITH PKC412
4256, 4k9yA, 0.7640, 3.14, 0.332, 271, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
4257, 4g9rA, 0.7640, 2.80, 0.269, 262, 245, B-RAF V600E KINASE DOMAIN BOUND TO A TYPE II DIHYDROQUINAZOLINE INHIBITOR
4258, 3tcpA, 0.7640, 2.43, 0.338, 256, 237, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC569
4259, 3pj2A, 0.7640, 2.31, 0.322, 248, 239, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
4260, 3o71A, 0.7640, 3.16, 0.217, 340, 253, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
4261, 3cxwA, 0.7640, 2.71, 0.188, 272, 245, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND I
4262, 3cqeA, 0.7640, 2.81, 0.200, 258, 245, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
4263, 2xruA, 0.7640, 2.62, 0.247, 253, 243, AURORA-A T288E COMPLEXED WITH PHA-828300
4264, 5oq7A, 0.7639, 3.04, 0.260, 259, 246, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4265, 5kplA, 0.7639, 3.41, 0.227, 339, 255, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
4266, 5hieA, 0.7639, 3.06, 0.278, 258, 248, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4267, 5a4eD, 0.7639, 2.94, 0.227, 331, 247, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
4268, 1ckiA, 0.7639, 3.20, 0.213, 292, 253, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
4269, 5ur1B, 0.7638, 2.74, 0.400, 265, 245, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4270, 5ih5A, 0.7638, 3.34, 0.208, 286, 255, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
4271, 5dwrA, 0.7638, 2.68, 0.184, 273, 244, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
4272, 4o91A, 0.7638, 2.57, 0.281, 293, 242, CRYSTAL STRUCTURE OF TYPE II INHIBITOR NG25 BOUND TO TAK1-TAB1
4273, 4c2wA, 0.7638, 3.04, 0.200, 268, 250, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
4274, 3v5wA, 0.7638, 3.30, 0.167, 623, 258, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
4275, 5o21A, 0.7637, 3.10, 0.261, 272, 249, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
4276, 5o0yA, 0.7637, 3.25, 0.200, 288, 255, TLK2 KINASE DOMAIN FROM HUMAN 
4277, 5kggA, 0.7637, 2.73, 0.188, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
4278, 5itaA, 0.7637, 2.53, 0.282, 250, 241, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4279, 5hbhA, 0.7637, 3.19, 0.179, 336, 251, CDK8-CYCC IN COMPLEX WITH 5-{5-CHLORO-4-[1-(2-METHOXY-ETHYL)-18- DIAZA-SPIRO[4.5]DEC-8-YL]-PYRIDIN-3-YL}-1-METHYL-13-DIHYDRO- BENZO[C]ISOTHIAZOLE 22-DIOXIDE
4280, 4hgsA, 0.7637, 3.54, 0.169, 302, 260, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
4281, 3r01A, 0.7637, 2.73, 0.188, 274, 245, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4282, 2xngA, 0.7637, 2.59, 0.240, 253, 242, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
4283, 5ukmA, 0.7636, 3.34, 0.182, 621, 258, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
4284, 5k7gA, 0.7636, 2.90, 0.244, 277, 242, IRAK4 IN COMPLEX WITH AZ3862
4285, 5k75B, 0.7636, 3.08, 0.240, 274, 246, IRAK4 IN COMPLEX WITH COMPOUND 1
4286, 5hieB, 0.7636, 2.99, 0.274, 259, 248, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4287, 4g17A, 0.7636, 3.53, 0.169, 302, 260, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
4288, 4ae6A, 0.7636, 3.06, 0.218, 319, 252, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
4289, 2henA, 0.7636, 2.78, 0.302, 259, 242, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4290, 5t1tB, 0.7635, 2.90, 0.243, 280, 243, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4291, 5ebzE, 0.7635, 3.04, 0.246, 655, 252, CRYSTAL STRUCTURE OF HUMAN IKK1
4292, 4g16A, 0.7635, 3.53, 0.169, 302, 260, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
4293, 5kgeA, 0.7634, 2.73, 0.188, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
4294, 5ebzD, 0.7634, 3.03, 0.238, 655, 252, CRYSTAL STRUCTURE OF HUMAN IKK1
4295, 4n6yA, 0.7634, 2.74, 0.184, 273, 245, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
4296, 4m69A, 0.7634, 2.88, 0.269, 284, 245, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
4297, 4bznA, 0.7634, 2.70, 0.189, 272, 244, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
4298, 3qf9A, 0.7634, 2.79, 0.183, 274, 246, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A FURAN- THIAZOLIDINEDIONE LIGAND
4299, 3naxA, 0.7634, 2.89, 0.214, 278, 248, PDK1 IN COMPLEX WITH INHIBITOR MP7
4300, 2hxlA, 0.7634, 3.24, 0.248, 272, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
4301, 2f9gA, 0.7634, 2.74, 0.242, 332, 244, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
4302, 2bcjA, 0.7634, 3.33, 0.186, 624, 258, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
4303, 1ywnA, 0.7634, 2.83, 0.371, 279, 245, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
4304, 5n4vA, 0.7633, 2.74, 0.184, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 2-CYCLOPROPYL-45- DIMETHYLTHIENO[54-D]PYRIMIDINE-6-CARBOXYLIC ACID
4305, 5jsmC, 0.7633, 2.84, 0.279, 262, 244, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4306, 2ojgA, 0.7633, 3.29, 0.213, 337, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
4307, 2e9uA, 0.7633, 3.20, 0.253, 269, 249, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
4308, 6gn1A, 0.7632, 3.50, 0.229, 339, 258, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
4309, 4ditA, 0.7632, 3.25, 0.231, 328, 251, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
4310, 3sd0A, 0.7632, 3.43, 0.227, 350, 256, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
4311, 3qtwA, 0.7632, 3.05, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
4312, 2oibA, 0.7632, 3.07, 0.230, 280, 243, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4313, 1yxuD, 0.7632, 2.75, 0.188, 273, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
4314, 1p14A, 0.7632, 2.74, 0.324, 287, 244, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4315, 1m7nB, 0.7632, 3.13, 0.302, 299, 248, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4316, 5ih6A, 0.7631, 3.37, 0.208, 286, 255, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
4317, 5aikB, 0.7631, 2.99, 0.238, 342, 248, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
4318, 5a4qD, 0.7631, 2.91, 0.224, 334, 246, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
4319, 3kk8A, 0.7631, 3.22, 0.213, 283, 253, CAMKII SUBSTRATE COMPLEX A
4320, 5aikA, 0.7630, 2.99, 0.230, 344, 248, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
4321, 4jbpA, 0.7630, 2.63, 0.239, 255, 243, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
4322, 3rk5A, 0.7630, 3.05, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
4323, 3p08A, 0.7630, 2.93, 0.317, 252, 243, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
4324, 3kk9A, 0.7630, 3.13, 0.214, 275, 252, CAMKII SUBSTRATE COMPLEX B
4325, 2ydiA, 0.7630, 3.24, 0.256, 279, 250, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4326, 2x8dA, 0.7630, 3.24, 0.252, 279, 250, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4327, 2w1gA, 0.7630, 2.65, 0.218, 254, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4328, 2oicA, 0.7630, 2.73, 0.246, 276, 240, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4329, 1tvoA, 0.7630, 3.33, 0.227, 350, 255, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
4330, 1pxpA, 0.7630, 3.08, 0.257, 294, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
4331, 5ukkA, 0.7629, 3.35, 0.193, 613, 259, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
4332, 5l4qB, 0.7629, 2.42, 0.237, 287, 236, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4333, 5k75C, 0.7629, 3.06, 0.240, 282, 246, IRAK4 IN COMPLEX WITH COMPOUND 1
4334, 5ar7A, 0.7629, 2.67, 0.263, 278, 243, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
4335, 3slsA, 0.7629, 3.00, 0.237, 292, 249, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4336, 3jpvA, 0.7629, 2.75, 0.192, 273, 245, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
4337, 2bzhB, 0.7629, 2.79, 0.183, 275, 246, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4338, 1xqzA, 0.7629, 2.78, 0.183, 277, 246, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
4339, 5vi9A, 0.7628, 2.88, 0.227, 306, 247, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
4340, 5l4qA, 0.7628, 2.43, 0.237, 293, 236, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4341, 5aikD, 0.7628, 3.04, 0.226, 342, 248, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
4342, 3cikA, 0.7628, 3.34, 0.182, 619, 258, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
4343, 3bgqA, 0.7628, 2.70, 0.189, 272, 244, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
4344, 4e7wA, 0.7627, 3.37, 0.205, 359, 254, STRUCTURE OF GSK3 FROM USTILAGO MAYDIS
4345, 3r21A, 0.7627, 2.64, 0.239, 254, 243, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
4346, 3eb0C, 0.7627, 2.97, 0.224, 310, 246, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
4347, 2ojiA, 0.7627, 3.32, 0.201, 344, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
4348, 6b2qB, 0.7626, 2.80, 0.253, 266, 245, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4349, 5ax9B, 0.7626, 2.67, 0.232, 274, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
4350, 4qp1A, 0.7626, 3.22, 0.209, 342, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
4351, 3dzqA, 0.7626, 2.87, 0.317, 268, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
4352, 2xizA, 0.7626, 2.71, 0.184, 273, 244, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4353, 6dcgA, 0.7625, 3.19, 0.211, 326, 251, DISCOVERY OF MK-8353: AN ORALLY BIOAVAILABLE DUAL MECHANISM ERK INHIBITOR FOR ONCOLOGY 
4354, 5o21B, 0.7625, 3.12, 0.269, 273, 249, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
4355, 5a4tA, 0.7625, 2.95, 0.227, 341, 247, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
4356, 5a4lD, 0.7625, 2.93, 0.224, 334, 246, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
4357, 4yllA, 0.7625, 3.08, 0.230, 340, 248, CRYSTAL STRUCTURE OF DYRK1AA IN COMPLEX WITH 10-BROMO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5T
4358, 3unjA, 0.7625, 3.04, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
4359, 3py1A, 0.7625, 3.20, 0.245, 302, 249, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
4360, 1s9iB, 0.7625, 3.21, 0.247, 291, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
4361, 6f3gB, 0.7624, 3.09, 0.241, 277, 245, IRAK4 IN COMPLEX WITH INHIBITOR 
4362, 5ebzC, 0.7624, 3.15, 0.249, 655, 253, CRYSTAL STRUCTURE OF HUMAN IKK1
4363, 4lgdA, 0.7624, 3.25, 0.193, 350, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4364, 3f7zA, 0.7624, 3.50, 0.229, 339, 258, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
4365, 3bgpA, 0.7624, 2.71, 0.184, 272, 244, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
4366, 5telA, 0.7623, 2.74, 0.188, 273, 245, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4367, 5k4iA, 0.7623, 2.72, 0.230, 336, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
4368, 5j95A, 0.7623, 2.99, 0.224, 284, 246, MAP4K4 IN COMPLEX WITH INHIBITOR
4369, 5ih4A, 0.7623, 3.34, 0.197, 286, 254, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
4370, 4xh6A, 0.7623, 2.74, 0.188, 273, 245, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
4371, 4ficA, 0.7623, 2.17, 0.350, 251, 234, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
4372, 4bf2A, 0.7623, 2.54, 0.301, 253, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4373, 3r02A, 0.7623, 2.67, 0.189, 271, 243, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4374, 3ctjA, 0.7623, 2.86, 0.324, 289, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
4375, 3anrD, 0.7623, 2.93, 0.232, 340, 246, HUMAN DYRK1A/HARMINE COMPLEX
4376, 2henC, 0.7623, 2.72, 0.303, 259, 241, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4377, 1zltA, 0.7623, 3.27, 0.252, 272, 250, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
4378, 1pxnA, 0.7623, 3.05, 0.261, 294, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
4379, 5vcvA, 0.7622, 3.08, 0.213, 287, 249, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH DASATINIB
4380, 4ylkA, 0.7622, 3.03, 0.194, 341, 248, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-CHLORO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5S
4381, 3qc4B, 0.7622, 2.86, 0.220, 278, 246, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
4382, 3p1aA, 0.7622, 3.00, 0.219, 281, 247, STRUCTURE OF HUMAN MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE- SPECIFIC CDC2-INHIBITORY KINASE MYT1 (PKMYT1)
4383, 6bqlA, 0.7621, 3.12, 0.220, 278, 250, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
4384, 5hbjA, 0.7621, 3.40, 0.193, 342, 254, CDK8-CYCC IN COMPLEX WITH 8-[2-AMINO-3-CHLORO-5-(1-METHYL-1H-INDAZOL- 5-YL)-PYRIDIN-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
4385, 4lghB, 0.7621, 1.97, 0.352, 247, 233, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4386, 3hkoA, 0.7621, 3.35, 0.192, 319, 255, CRYSTAL STRUCTURE OF A CDPK KINASE DOMAIN FROM CRYPTOSPORIDIUM PARVUM CGD7_40
4387, 2wtwA, 0.7621, 2.75, 0.216, 256, 245, AURORA-A INHIBITOR STRUCTURE (2ND CRYSTAL FORM)
4388, 1yxvA, 0.7621, 2.74, 0.188, 274, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
4389, 6f3eB, 0.7620, 3.13, 0.244, 282, 246, IRAK4 IN COMPLEX WITH INHIBITOR 
4390, 5oq5A, 0.7620, 3.20, 0.256, 265, 250, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4391, 5nguA, 0.7620, 3.38, 0.224, 339, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
4392, 5kpmA, 0.7620, 3.51, 0.229, 344, 258, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
4393, 5k0xB, 0.7620, 2.28, 0.343, 254, 233, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2541
4394, 4qpaB, 0.7620, 3.24, 0.209, 345, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
4395, 4m67A, 0.7620, 2.47, 0.220, 264, 241, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
4396, 3qu0A, 0.7620, 3.08, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
4397, 2xmyA, 0.7620, 3.08, 0.253, 295, 249, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
4398, 2vrxB, 0.7620, 3.12, 0.200, 274, 250, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
4399, 2e9nA, 0.7620, 3.24, 0.248, 269, 250, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
4400, 6b8uA, 0.7619, 2.68, 0.276, 253, 243, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4401, 5uiqD, 0.7619, 2.68, 0.243, 271, 239, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4402, 5mqvF, 0.7619, 3.27, 0.201, 286, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4403, 5kpkB, 0.7619, 3.53, 0.221, 344, 258, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
4404, 5ebzK, 0.7619, 3.18, 0.249, 655, 253, CRYSTAL STRUCTURE OF HUMAN IKK1
4405, 5aikC, 0.7619, 3.02, 0.238, 342, 248, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
4406, 5aaeA, 0.7619, 2.60, 0.240, 252, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
4407, 4o0uA, 0.7619, 2.73, 0.196, 259, 245, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
4408, 4bzoA, 0.7619, 2.70, 0.184, 272, 244, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
4409, 3dcvA, 0.7619, 2.78, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
4410, 3bgzA, 0.7619, 2.72, 0.189, 267, 244, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
4411, 1ym7D, 0.7619, 3.34, 0.190, 599, 258, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4412, 5uq0B, 0.7618, 2.57, 0.404, 256, 240, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4413, 5hzeA, 0.7618, 3.32, 0.241, 305, 253, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
4414, 5ct7B, 0.7618, 2.45, 0.267, 254, 240, BRAF IN COMPLEX WITH RAF265
4415, 4hglA, 0.7618, 3.55, 0.165, 302, 260, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
4416, 2j2iB, 0.7618, 2.73, 0.184, 273, 245, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
4417, 2hxqA, 0.7618, 3.21, 0.253, 272, 249, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
4418, 1q8yB, 0.7618, 3.28, 0.194, 357, 253, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
4419, 5uklA, 0.7617, 3.35, 0.171, 630, 258, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
4420, 5ko1A, 0.7617, 2.63, 0.218, 265, 243, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
4421, 5hbeA, 0.7617, 3.51, 0.187, 344, 256, CDK8-CYCC IN COMPLEX WITH 8-[3-CHLORO-5-(1-METHYL-22-DIOXO-2 3- DIHYDRO-1H-2L6-BENZO[C]ISOTHIAZOL-5-YL)-PYRIDIN- 4-YL]-1-OXA-38- DIAZA-SPIRO[4.5]DECAN-2-ONE
4422, 5ebzG, 0.7617, 2.98, 0.247, 655, 251, CRYSTAL STRUCTURE OF HUMAN IKK1
4423, 4kbcA, 0.7617, 3.38, 0.195, 288, 256, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
4424, 2ojjA, 0.7617, 3.39, 0.212, 344, 255, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
4425, 5vt1A, 0.7616, 3.06, 0.213, 265, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
4426, 5ebzL, 0.7616, 3.18, 0.252, 655, 254, CRYSTAL STRUCTURE OF HUMAN IKK1
4427, 5c1qB, 0.7616, 2.73, 0.188, 273, 245, SERINE/THREONINE-PROTEIN KINASE PIM-1
4428, 4ux9A, 0.7616, 2.87, 0.215, 343, 246, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4429, 3od6X, 0.7616, 3.18, 0.219, 344, 251, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
4430, 2yiyA, 0.7616, 2.58, 0.277, 293, 242, CRYSTAL STRUCTURE OF COMPOUND 8 BOUND TO TAK1-TAB
4431, 1ym7C, 0.7616, 3.33, 0.186, 607, 258, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4432, 1yi3A, 0.7616, 2.67, 0.185, 267, 243, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
4433, 1x8bA, 0.7616, 2.76, 0.197, 259, 244, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
4434, 6g9hA, 0.7615, 3.35, 0.213, 343, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4435, 5a54D, 0.7615, 2.93, 0.224, 334, 246, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
4436, 4s33A, 0.7615, 3.33, 0.201, 347, 254, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
4437, 4gw8A, 0.7615, 2.75, 0.188, 273, 245, HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND LEUCETTINE L41
4438, 3wigA, 0.7615, 3.14, 0.235, 278, 251, HUMAN MEK1 KINASE IN COMPLEX WITH CH5126766 AND MGAMP-PNP
4439, 3qtuA, 0.7615, 3.11, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
4440, 3py0A, 0.7615, 3.06, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR SU9516
4441, 3pizA, 0.7615, 2.44, 0.315, 245, 238, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH (5-AMINO-1-O- TOLYL-1H-PYRAZOL-4-YL)-[3-(1-METHANESULFONYL-PIPERIDIN-4-YL)-PHENYL]- METHANONE
4442, 3jyaA, 0.7615, 2.76, 0.188, 274, 245, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
4443, 2o3pA, 0.7615, 2.76, 0.188, 274, 245, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
4444, 5uirB, 0.7614, 2.80, 0.244, 273, 242, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 11
4445, 5n4rA, 0.7614, 2.77, 0.184, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(AZEPAN-1-YL)-1-(1H-INDOL-3-YL) PROPAN-1-ONE
4446, 5kpkA, 0.7614, 3.55, 0.221, 346, 258, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
4447, 5kcxA, 0.7614, 2.73, 0.184, 272, 244, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
4448, 5imeA, 0.7614, 2.80, 0.208, 280, 245, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
4449, 4neuB, 0.7614, 2.17, 0.297, 268, 236, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
4450, 3pscA, 0.7614, 3.35, 0.190, 614, 258, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
4451, 1m7nA, 0.7614, 2.96, 0.305, 299, 246, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4452, 5kpmB, 0.7613, 3.52, 0.229, 345, 258, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
4453, 4hgtA, 0.7613, 3.24, 0.198, 283, 252, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
4454, 3fdnA, 0.7613, 2.72, 0.233, 261, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
4455, 1ym7A, 0.7613, 3.35, 0.190, 608, 258, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4456, 5n4xA, 0.7612, 2.76, 0.188, 272, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 45-DIBROMOTHIOPHENE-2- CARBOHYDRAZIDE
4457, 4wovB, 0.7612, 2.41, 0.234, 256, 239, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
4458, 4fv1A, 0.7612, 3.27, 0.213, 342, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
4459, 4btjA, 0.7612, 3.22, 0.178, 292, 253, TTBK1 IN COMPLEX WITH ATP
4460, 3uytA, 0.7612, 3.42, 0.202, 287, 258, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4461, 3rk7A, 0.7612, 3.09, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
4462, 3qtzA, 0.7612, 3.09, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
4463, 3k5uA, 0.7612, 2.68, 0.202, 260, 243, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
4464, 2x7fB, 0.7612, 2.77, 0.230, 288, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4465, 1v0oA, 0.7612, 3.00, 0.236, 276, 246, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
4466, 6es0A, 0.7611, 2.75, 0.260, 288, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
4467, 5wg4A, 0.7611, 3.27, 0.180, 621, 256, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257284
4468, 5obrA, 0.7611, 2.66, 0.235, 255, 243, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
4469, 3teiA, 0.7611, 2.77, 0.229, 339, 245, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
4470, 3r9dA, 0.7611, 3.10, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
4471, 1ym7B, 0.7611, 3.35, 0.190, 608, 258, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4472, 4xs2B, 0.7610, 3.01, 0.239, 278, 243, IRAK4-INHIBITOR CO-STRUCTURE
4473, 2xiyA, 0.7610, 2.73, 0.189, 273, 244, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4474, 5jsmD, 0.7609, 3.05, 0.275, 259, 247, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
4475, 5i5zA, 0.7609, 3.53, 0.188, 345, 255, CDK8-CYCC IN COMPLEX WITH 8-(1-METHYL-22-DIOXO-23-DIHYDRO-1H-2L6- BENZO[C]ISOTHIAZOL-5-YL)-[16]NAPHTHYRIDINE-2-CARBOXYLIC ACID METHYLAMIDE
4476, 4u40A, 0.7609, 3.22, 0.227, 295, 251, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
4477, 3j4rE, 0.7609, 3.17, 0.217, 325, 253, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
4478, 3j4rD, 0.7609, 3.17, 0.217, 325, 253, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
4479, 3j4qE, 0.7609, 3.17, 0.217, 325, 253, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
4480, 3j4qD, 0.7609, 3.17, 0.217, 325, 253, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
4481, 3a8wB, 0.7609, 2.96, 0.200, 327, 250, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
4482, 2ow3B, 0.7609, 3.45, 0.227, 351, 255, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
4483, 2in6A, 0.7609, 2.77, 0.197, 256, 244, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
4484, 2a0cX, 0.7609, 3.11, 0.261, 294, 249, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
4485, 5vuaB, 0.7608, 2.63, 0.190, 270, 242, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
4486, 3qtiB, 0.7608, 2.84, 0.335, 280, 242, C-MET KINASE IN COMPLEX WITH NVP-BVU972
4487, 1wakA, 0.7608, 3.42, 0.173, 353, 254, X-RAY STRUCTURE OF SRPK1
4488, 5xyzB, 0.7607, 1.96, 0.315, 234, 232, THE STRUCTURE OF HUMAN BTK KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR 
4489, 4kbkC, 0.7607, 3.37, 0.188, 280, 255, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4490, 4kbaB, 0.7607, 3.36, 0.197, 285, 254, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4491, 3rpvA, 0.7607, 3.09, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
4492, 1uwjB, 0.7607, 2.95, 0.264, 263, 246, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4493, 5k7iA, 0.7606, 2.83, 0.246, 272, 240, IRAK4 IN COMPLEX WITH AZ3864
4494, 5hidB, 0.7606, 2.96, 0.282, 269, 248, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
4495, 4jbqA, 0.7606, 2.69, 0.234, 257, 244, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
4496, 4btmA, 0.7606, 3.22, 0.182, 292, 253, TTBK1 IN COMPLEX WITH INHIBITOR
4497, 4as0A, 0.7606, 2.75, 0.184, 273, 245, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
4498, 2z2wA, 0.7606, 2.78, 0.193, 260, 244, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
4499, 1ia8A, 0.7606, 3.27, 0.248, 272, 250, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
4500, 5di1A, 0.7605, 3.02, 0.224, 285, 246, MAP4K4 IN COMPLEX WITH AN INHIBITOR
4501, 3ti1A, 0.7605, 3.13, 0.261, 294, 249, CDK2 IN COMPLEX WITH SUNITINIB
4502, 1r0eB, 0.7605, 3.44, 0.227, 344, 256, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
4503, 1cm8B, 0.7605, 2.74, 0.201, 327, 244, PHOSPHORYLATED MAP KINASE P38-GAMMA
4504, 1cm8A, 0.7605, 2.74, 0.201, 327, 244, PHOSPHORYLATED MAP KINASE P38-GAMMA
4505, 1ckiB, 0.7605, 3.34, 0.209, 286, 254, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
4506, 5mqvB, 0.7604, 3.32, 0.201, 287, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4507, 5kgkA, 0.7604, 2.75, 0.184, 273, 245, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
4508, 5ebzF, 0.7604, 3.10, 0.246, 655, 252, CRYSTAL STRUCTURE OF HUMAN IKK1
4509, 4yffA, 0.7604, 2.76, 0.267, 264, 240, TNNI3K COMPLEXED WITH INHIBITOR 2
4510, 4tthB, 0.7604, 2.75, 0.260, 256, 242, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
4511, 4rpvA, 0.7604, 2.76, 0.184, 273, 245, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
4512, 3qzfA, 0.7604, 3.08, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
4513, 3qtxA, 0.7604, 3.09, 0.249, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
4514, 3qqkA, 0.7604, 3.12, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L4
4515, 2ydkA, 0.7604, 3.26, 0.248, 263, 250, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4516, 2qg5A, 0.7604, 3.32, 0.217, 284, 253, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4517, 2fysB, 0.7604, 2.85, 0.224, 338, 246, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
4518, 1y6aA, 0.7604, 2.59, 0.367, 261, 240, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 2-ANILINO-5-ARYL-OXAZOLE INHIBITOR
4519, 3qruA, 0.7603, 3.10, 0.257, 295, 249, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
4520, 3d5xA, 0.7603, 3.09, 0.250, 279, 248, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
4521, 2iztA, 0.7603, 3.41, 0.171, 296, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4522, 5jzjB, 0.7602, 2.83, 0.241, 261, 245, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
4523, 4jx3A, 0.7602, 2.77, 0.184, 274, 245, CRYSTAL STRUCTURE OF PIM1 KINASE
4524, 3tcpB, 0.7602, 2.17, 0.342, 250, 231, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC569
4525, 3qxpA, 0.7602, 3.05, 0.247, 294, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
4526, 2bzjA, 0.7602, 2.77, 0.188, 273, 245, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
4527, 6cpwA, 0.7601, 3.16, 0.204, 328, 250, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
4528, 5ndtA, 0.7601, 2.77, 0.184, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(2-(THIOPHEN-2-YL)VINYL)-3; 4-DIHYDROQUINOXALIN-2(1H)-ONE 
4529, 5mqvD, 0.7601, 3.36, 0.200, 287, 255, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4530, 5k75D, 0.7601, 3.03, 0.238, 280, 244, IRAK4 IN COMPLEX WITH COMPOUND 1
4531, 4mbiA, 0.7601, 2.78, 0.188, 274, 245, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
4532, 4l43A, 0.7601, 2.99, 0.264, 316, 246, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
4533, 4a7cA, 0.7601, 2.81, 0.188, 273, 245, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
4534, 2xnbA, 0.7601, 3.14, 0.261, 296, 249, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
4535, 1yxuC, 0.7601, 2.72, 0.184, 272, 244, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
4536, 5turA, 0.7600, 2.74, 0.189, 270, 244, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4537, 5k72D, 0.7600, 2.96, 0.244, 276, 242, IRAK4 IN COMPLEX WITH COMPOUND 21
4538, 4rc4A, 0.7600, 2.72, 0.189, 272, 244, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
4539, 4ll5A, 0.7600, 2.72, 0.184, 268, 244, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4540, 4ae9A, 0.7600, 3.06, 0.219, 321, 251, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
4541, 3vvhA, 0.7600, 3.25, 0.242, 287, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4542, 3vbvA, 0.7600, 2.70, 0.189, 268, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4543, 3q4zA, 0.7600, 2.92, 0.206, 282, 247, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4544, 3o23A, 0.7600, 3.09, 0.331, 293, 248, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
4545, 3m11A, 0.7600, 2.64, 0.207, 256, 242, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
4546, 2w1fA, 0.7600, 2.65, 0.219, 253, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4547, 2qo7A, 0.7600, 2.63, 0.318, 278, 239, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
4548, 2ow3A, 0.7600, 3.58, 0.229, 346, 258, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
4549, 5vucB, 0.7599, 2.60, 0.187, 269, 241, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
4550, 5uq1A, 0.7599, 2.96, 0.247, 288, 247, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
4551, 5ng3C, 0.7599, 3.02, 0.261, 272, 245, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4552, 5n4yA, 0.7599, 2.78, 0.184, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 25-DIHYDRO-1H-ISOTHIOCHROMENO[3 4-D]PYRAZOL-3-ONE
4553, 4erkA, 0.7599, 3.36, 0.209, 350, 254, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
4554, 4d4rB, 0.7599, 3.28, 0.337, 270, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4555, 2ghgA, 0.7599, 3.27, 0.248, 269, 250, H-CHK1 COMPLEXED WITH A431994
4556, 6g9mA, 0.7598, 3.31, 0.236, 341, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4557, 5toeA, 0.7598, 2.74, 0.189, 272, 244, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4558, 5n4uA, 0.7598, 2.74, 0.184, 272, 244, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 5-(2-AMINO-13-THIAZOL-4- YL)-13-DIHYDROBENZIMIDAZOL-2-ONE
4559, 5m5aA, 0.7598, 2.42, 0.277, 315, 238, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4560, 5l6pA, 0.7598, 2.65, 0.328, 274, 241, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
4561, 5kkrC, 0.7598, 3.31, 0.242, 309, 252, KSR2:MEK1 COMPLEX BOUND TO THE SMALL MOLECULE APS-2-79
4562, 3rk9A, 0.7598, 3.12, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
4563, 3lokA, 0.7598, 2.17, 0.348, 248, 233, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
4564, 3erkA, 0.7598, 3.25, 0.231, 350, 251, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
4565, 3cy3A, 0.7598, 2.75, 0.189, 270, 244, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND THE JNK INHIBITOR V
4566, 1xr1A, 0.7598, 2.88, 0.183, 277, 246, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
4567, 1r0eA, 0.7598, 3.45, 0.227, 344, 256, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
4568, 5jt2B, 0.7597, 2.67, 0.290, 251, 241, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
4569, 5ebzH, 0.7597, 3.06, 0.250, 655, 252, CRYSTAL STRUCTURE OF HUMAN IKK1
4570, 5ebzB, 0.7597, 3.11, 0.246, 655, 252, CRYSTAL STRUCTURE OF HUMAN IKK1
4571, 4l3lA, 0.7597, 3.09, 0.258, 291, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
4572, 4i41A, 0.7597, 2.73, 0.189, 272, 244, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
4573, 4fv3A, 0.7597, 3.28, 0.213, 346, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
4574, 4fv2A, 0.7597, 3.29, 0.213, 344, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
4575, 3vbtA, 0.7597, 2.71, 0.189, 267, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4576, 2x8iA, 0.7597, 3.17, 0.250, 261, 248, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4577, 2broA, 0.7597, 3.44, 0.222, 272, 252, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4578, 1jqhA, 0.7597, 3.26, 0.296, 291, 253, IGF-1 RECEPTOR KINASE DOMAIN
4579, 4s32A, 0.7596, 3.36, 0.220, 346, 255, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
4580, 4rvtA, 0.7596, 2.94, 0.224, 281, 245, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
4581, 3rniA, 0.7596, 3.11, 0.265, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
4582, 3r04A, 0.7596, 2.70, 0.189, 271, 243, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4583, 3ekkA, 0.7596, 2.82, 0.322, 285, 245, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
4584, 1yxuB, 0.7596, 2.79, 0.188, 273, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
4585, 6g9dA, 0.7595, 3.32, 0.202, 345, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4586, 6g8xA, 0.7595, 3.33, 0.202, 338, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4587, 5mahA, 0.7595, 2.47, 0.276, 316, 239, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4588, 5ebzA, 0.7595, 3.16, 0.253, 655, 253, CRYSTAL STRUCTURE OF HUMAN IKK1
4589, 4ez3A, 0.7595, 3.04, 0.255, 294, 247, CDK2 IN COMPLEX WITH NSC 134199
4590, 3bwfA, 0.7595, 2.78, 0.188, 273, 245, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
4591, 5vd4A, 0.7594, 2.99, 0.202, 261, 248, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 016 A MK1775 ANALOUGUE
4592, 5v5yA, 0.7594, 2.89, 0.203, 259, 246, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
4593, 4zp5A, 0.7594, 3.04, 0.224, 284, 246, MAP4K4 IN COMPLEX WITH INHIBITOR
4594, 4rc2A, 0.7594, 2.74, 0.189, 272, 244, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
4595, 4j7bA, 0.7594, 3.02, 0.244, 284, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
4596, 4apcA, 0.7594, 3.12, 0.215, 293, 247, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
4597, 1q3dA, 0.7594, 3.48, 0.227, 339, 256, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
4598, 5n50A, 0.7593, 2.78, 0.184, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(4-CHLOROPHENYL) SULFANYLACETOHYDRAZIDE
4599, 5mqvE, 0.7593, 3.31, 0.201, 287, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4600, 4qyhB, 0.7593, 3.19, 0.255, 264, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
4601, 3r8zA, 0.7593, 3.20, 0.261, 290, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
4602, 3q96A, 0.7593, 2.64, 0.274, 253, 241, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4603, 3lj1A, 0.7593, 2.52, 0.214, 404, 238, IRE1 COMPLEXED WITH CDK1/2 INHIBITOR III
4604, 3jy0A, 0.7593, 2.75, 0.184, 275, 244, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
4605, 1q3dB, 0.7593, 3.47, 0.227, 339, 256, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
4606, 6g91A, 0.7592, 3.33, 0.217, 344, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4607, 5n4zA, 0.7592, 2.74, 0.184, 272, 244, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-4-(4-HYDROXYPHENYL)BUT-3-EN-2- ONE
4608, 4nt4A, 0.7592, 3.36, 0.184, 300, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
4609, 4b9dA, 0.7592, 3.12, 0.227, 290, 247, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
4610, 2izsA, 0.7592, 3.59, 0.165, 298, 260, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4611, 6c3eA, 0.7591, 2.86, 0.257, 258, 241, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
4612, 5vubB, 0.7591, 2.62, 0.187, 269, 241, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
4613, 5tvtA, 0.7591, 2.60, 0.274, 321, 241, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4614, 4wuaA, 0.7591, 3.49, 0.180, 344, 255, CRYSTAL STRUCTURE OF HUMAN SRPK1 COMPLEXED TO AN INHIBITOR SRPIN340
4615, 3uysD, 0.7591, 3.30, 0.186, 284, 253, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4616, 3unkA, 0.7591, 3.10, 0.253, 295, 249, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
4617, 2bilB, 0.7591, 2.79, 0.184, 274, 245, THE HUMAN PROTEIN KINASE PIM1 IN COMPLEX WITH ITS CONSENSUS PEPTIDE PIMTIDE
4618, 5k72C, 0.7590, 2.99, 0.244, 277, 242, IRAK4 IN COMPLEX WITH COMPOUND 21
4619, 5ebzI, 0.7590, 3.20, 0.249, 655, 253, CRYSTAL STRUCTURE OF HUMAN IKK1
4620, 2qo2A, 0.7590, 2.72, 0.317, 282, 240, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
4621, 1yxuA, 0.7590, 2.80, 0.184, 273, 245, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
4622, 1jqhC, 0.7590, 3.27, 0.296, 291, 253, IGF-1 RECEPTOR KINASE DOMAIN
4623, 5tc0B, 0.7589, 2.33, 0.333, 250, 234, STRUCTURE-BASED OPTIMIZATION OF 1H-IMIDAZOLE-2-CARBOXAMIDES AS AXL KINASE INHIBITORS UTILIZING A MER MUTANT SURROGATE
4624, 4fuxA, 0.7589, 3.34, 0.213, 342, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
4625, 4aguA, 0.7589, 2.62, 0.213, 277, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4626, 2vgpA, 0.7589, 2.99, 0.206, 265, 247, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
4627, 2oidD, 0.7589, 2.89, 0.246, 274, 240, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4628, 3uokB, 0.7588, 2.80, 0.239, 265, 243, AURORA A IN COMPLEX WITH YL5-81-1
4629, 3umwA, 0.7588, 2.62, 0.191, 264, 241, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
4630, 5nhfA, 0.7587, 3.34, 0.209, 339, 254, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
4631, 4nfnA, 0.7587, 3.36, 0.180, 293, 255, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
4632, 4mneE, 0.7587, 3.28, 0.237, 286, 253, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4633, 3ztxB, 0.7587, 3.13, 0.201, 272, 249, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
4634, 2f49A, 0.7587, 2.93, 0.199, 335, 246, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
4635, 2cgwA, 0.7587, 3.19, 0.254, 262, 248, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4636, 5n5lA, 0.7586, 2.76, 0.184, 271, 244, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND [2-OXO-2-(1H-PYRROL-2-YL)ETHYL] 5-BROMO-1H- INDOLE-3-CARBOXYLATE
4637, 4fkuA, 0.7586, 3.13, 0.266, 293, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4638, 4bcqA, 0.7586, 3.05, 0.245, 292, 249, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
4639, 3qd2B, 0.7586, 2.97, 0.206, 271, 247, CRSYTAL STRUCTURE OF MOUSE PERK KINASE DOMAIN
4640, 3lj1B, 0.7586, 2.54, 0.214, 404, 238, IRE1 COMPLEXED WITH CDK1/2 INHIBITOR III
4641, 3idpA, 0.7586, 2.82, 0.275, 255, 244, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4642, 3cr0A, 0.7586, 2.86, 0.188, 257, 245, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
4643, 6bwkA, 0.7585, 2.58, 0.222, 263, 243, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN T357E/S358E MUTANT 
4644, 5x18A, 0.7585, 3.62, 0.131, 294, 260, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
4645, 5opuA, 0.7585, 3.11, 0.252, 261, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4646, 5flfE, 0.7585, 2.77, 0.388, 258, 242, DISEASE LINKED MUTATION IN FGFR
4647, 4l45A, 0.7585, 2.99, 0.264, 317, 246, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
4648, 4ez7A, 0.7585, 3.24, 0.247, 302, 251, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
4649, 3rjcA, 0.7585, 3.14, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L4-12
4650, 3qqjA, 0.7585, 3.10, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L2
4651, 2qvsE, 0.7585, 3.16, 0.218, 323, 252, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
4652, 1j3hA, 0.7585, 3.09, 0.200, 329, 250, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
4653, 4xp2A, 0.7584, 3.34, 0.220, 337, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4654, 4hyiA, 0.7584, 3.31, 0.260, 269, 250, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
4655, 4g6lA, 0.7584, 3.32, 0.191, 336, 251, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
4656, 3qqgA, 0.7584, 3.07, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L2-5
4657, 3mvjB, 0.7584, 3.15, 0.195, 320, 251, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
4658, 2izuA, 0.7584, 3.47, 0.171, 297, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4659, 5uirA, 0.7583, 2.63, 0.248, 270, 238, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 11
4660, 5o13A, 0.7583, 2.68, 0.190, 270, 242, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4661, 4p4cA, 0.7583, 2.79, 0.328, 266, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4662, 3r8lA, 0.7583, 3.12, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L3-4
4663, 3dkoA, 0.7583, 2.74, 0.331, 275, 242, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
4664, 3c4eB, 0.7583, 2.80, 0.184, 273, 245, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4665, 3bi6A, 0.7583, 2.88, 0.200, 258, 245, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
4666, 2brnA, 0.7583, 3.24, 0.217, 268, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4667, 2a19B, 0.7583, 3.00, 0.248, 263, 246, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
4668, 1yhsA, 0.7583, 2.72, 0.189, 267, 243, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
4669, 5wg5A, 0.7582, 3.26, 0.180, 617, 255, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224061
4670, 5vd5A, 0.7582, 2.96, 0.202, 260, 248, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 050 A MK1775 ANALOUGUE
4671, 4u9aA, 0.7582, 2.97, 0.237, 272, 241, SULPHUR ANOMALOUS CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4672, 6f3iB, 0.7581, 3.16, 0.245, 279, 245, IRAK4 IN COMPLEX WITH INHIBITOR 
4673, 5oq7B, 0.7581, 3.03, 0.262, 256, 244, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4674, 4twnA, 0.7581, 3.08, 0.333, 276, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
4675, 3vbxA, 0.7581, 2.73, 0.189, 268, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4676, 6g92A, 0.7580, 3.35, 0.220, 343, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4677, 4enxA, 0.7580, 2.64, 0.195, 266, 241, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
4678, 3qxoA, 0.7580, 3.10, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
4679, 3ql8A, 0.7580, 3.11, 0.249, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
4680, 3nlbA, 0.7580, 3.29, 0.250, 261, 248, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
4681, 2xixA, 0.7580, 2.72, 0.185, 272, 243, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4682, 2b54A, 0.7580, 3.08, 0.254, 298, 248, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
4683, 4zzmA, 0.7579, 3.34, 0.225, 344, 253, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
4684, 4qygA, 0.7579, 3.36, 0.249, 264, 249, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
4685, 4iz7A, 0.7579, 3.10, 0.208, 344, 250, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
4686, 3vbyA, 0.7579, 2.73, 0.189, 267, 243, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4687, 3c9wA, 0.7579, 2.88, 0.234, 336, 244, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
4688, 5lcjA, 0.7578, 3.35, 0.220, 345, 254, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
4689, 4xrlA, 0.7578, 3.40, 0.205, 337, 254, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4690, 4j7bD, 0.7578, 2.99, 0.241, 281, 245, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
4691, 3uokA, 0.7578, 2.82, 0.239, 265, 243, AURORA A IN COMPLEX WITH YL5-81-1
4692, 6gdmA, 0.7577, 3.27, 0.214, 341, 252, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4693, 4s34A, 0.7577, 3.38, 0.220, 343, 255, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
4694, 2x8eA, 0.7577, 3.04, 0.253, 259, 245, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4695, 1irkA, 0.7577, 3.07, 0.325, 303, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
4696, 6bu6A, 0.7576, 3.52, 0.154, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4697, 5acbD, 0.7576, 3.23, 0.244, 319, 254, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
4698, 4lmuA, 0.7576, 2.68, 0.186, 265, 242, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
4699, 3py3A, 0.7576, 3.25, 0.207, 355, 251, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
4700, 3pxyA, 0.7576, 3.09, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR JWS648
4701, 3c51B, 0.7576, 2.75, 0.221, 461, 244, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
4702, 3bhhC, 0.7576, 2.80, 0.212, 285, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
4703, 5oktC, 0.7575, 3.37, 0.193, 285, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
4704, 5es1A, 0.7575, 2.43, 0.273, 304, 238, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
4705, 4u97A, 0.7575, 2.66, 0.239, 272, 238, CRYSTAL STRUCTURE OF ASYMMETRIC IRAK4 DIMER
4706, 4bgqA, 0.7575, 2.83, 0.234, 276, 244, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
4707, 3tizA, 0.7575, 3.08, 0.258, 293, 248, CDK2 IN COMPLEX WITH NSC 111848
4708, 3qtqA, 0.7575, 3.15, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
4709, 3c4eC, 0.7575, 2.77, 0.180, 272, 244, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4710, 2oidB, 0.7575, 3.03, 0.236, 272, 242, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH AMPPNP
4711, 6g9nA, 0.7574, 3.33, 0.213, 344, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4712, 6b2pA, 0.7574, 2.46, 0.198, 255, 237, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4713, 5vd8A, 0.7574, 2.90, 0.198, 260, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 099 A MK1775 ANALOGUE
4714, 5n4nA, 0.7574, 2.80, 0.188, 273, 245, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIMETHYL-5-(1H-124-TRIAZOL- 3-YL)THIOPHENE-2-CARBONITRILE
4715, 4xp3A, 0.7574, 3.45, 0.220, 339, 255, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4716, 3c4eA, 0.7574, 2.82, 0.180, 273, 245, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4717, 2exmA, 0.7574, 3.11, 0.265, 298, 249, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
4718, 1pxoA, 0.7574, 3.18, 0.257, 294, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
4719, 5vd7A, 0.7573, 2.88, 0.202, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 098 A MK1775 ANALOGUE
4720, 5umoA, 0.7573, 3.28, 0.203, 347, 251, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
4721, 4qygB, 0.7573, 3.22, 0.255, 264, 247, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
4722, 3qqhA, 0.7573, 3.09, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L2-2
4723, 2c6oA, 0.7573, 3.09, 0.254, 290, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4724, 5vc4A, 0.7572, 2.92, 0.198, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
4725, 4zzoA, 0.7572, 3.46, 0.220, 339, 255, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
4726, 4yo6B, 0.7572, 2.94, 0.241, 277, 241, IRAK4-INHIBITOR CO-STRUCTURE
4727, 2clxA, 0.7572, 3.13, 0.257, 293, 249, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
4728, 1ykrA, 0.7572, 3.17, 0.257, 298, 249, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
4729, 1hckA, 0.7572, 3.18, 0.261, 294, 249, HUMAN CYCLIN-DEPENDENT KINASE 2
4730, 5vd9A, 0.7571, 2.93, 0.202, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 097 A MK1775 ANALOGUE
4731, 5n5mA, 0.7571, 2.77, 0.184, 272, 244, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND (R)-3-(2-((ISOQUINOLIN-5-YLMETHYL)(METHYL) CARBAMOYL)PHENYL)PYRROLIDIN-1-IUM
4732, 5fdxB, 0.7571, 2.96, 0.328, 274, 244, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
4733, 4yffB, 0.7571, 2.77, 0.268, 264, 239, TNNI3K COMPLEXED WITH INHIBITOR 2
4734, 4lg4C, 0.7571, 3.21, 0.223, 288, 251, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4735, 4aguC, 0.7571, 2.65, 0.218, 278, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4736, 3uliA, 0.7571, 3.19, 0.258, 286, 248, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
4737, 3dy7A, 0.7571, 3.21, 0.236, 260, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4738, 2br1A, 0.7571, 3.32, 0.220, 272, 250, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4739, 1xwsA, 0.7571, 2.79, 0.184, 273, 245, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
4740, 5mafA, 0.7570, 2.50, 0.276, 315, 239, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4741, 5hesB, 0.7570, 2.65, 0.298, 278, 238, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
4742, 4umpD, 0.7570, 3.03, 0.247, 321, 247, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4743, 4tn6B, 0.7570, 3.37, 0.189, 285, 254, CK1D IN COMPLEX WITH INHIBITOR
4744, 4kb8B, 0.7570, 3.44, 0.208, 285, 255, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4745, 3rkbA, 0.7570, 3.23, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
4746, 2uzoA, 0.7570, 3.09, 0.262, 290, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
4747, 2bziB, 0.7570, 2.77, 0.189, 272, 244, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
4748, 6fdyU, 0.7569, 3.16, 0.268, 261, 250, UNC-51-LIKE KINASE 3 (ULK3) IN COMPLEX WITH BOSUTINIB 
4749, 6bruA, 0.7569, 3.52, 0.158, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4750, 4qyhA, 0.7569, 3.31, 0.250, 264, 248, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
4751, 3p86A, 0.7569, 2.47, 0.314, 250, 239, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4752, 5ootA, 0.7568, 3.18, 0.247, 260, 247, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4753, 4mneA, 0.7568, 3.38, 0.245, 286, 253, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4754, 3tiyA, 0.7568, 3.13, 0.262, 293, 248, CDK2 IN COMPLEX WITH NSC 35676
4755, 3r9hA, 0.7568, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
4756, 2qg5D, 0.7568, 3.43, 0.213, 283, 253, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
4757, 1golA, 0.7568, 3.40, 0.209, 357, 254, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
4758, 6ge0A, 0.7567, 3.27, 0.214, 343, 252, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4759, 5uisA, 0.7567, 2.58, 0.246, 269, 236, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4760, 5iexA, 0.7567, 3.02, 0.260, 285, 246, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
4761, 4s31A, 0.7567, 3.41, 0.201, 347, 254, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
4762, 3lj2B, 0.7567, 2.45, 0.211, 404, 237, IRE1 COMPLEXED WITH JAK INHIBITOR I
4763, 5itaB, 0.7566, 2.49, 0.272, 252, 239, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4764, 4lm5A, 0.7566, 2.69, 0.190, 264, 242, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
4765, 3r1qA, 0.7566, 3.10, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
4766, 3i60A, 0.7566, 2.83, 0.230, 335, 243, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
4767, 3c4cA, 0.7566, 2.76, 0.272, 258, 243, B-RAF KINASE IN COMPLEX WITH PLX4720
4768, 2qoiA, 0.7566, 2.70, 0.314, 274, 239, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
4769, 1omwA, 0.7566, 3.41, 0.190, 614, 258, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
4770, 5texA, 0.7565, 2.83, 0.184, 274, 245, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4771, 5hieD, 0.7565, 2.80, 0.280, 253, 243, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4772, 4jvgD, 0.7565, 2.78, 0.283, 262, 244, B-RAF KINASE IN COMPLEX WITH BIRB796
4773, 4g9rB, 0.7565, 2.96, 0.269, 261, 245, B-RAF V600E KINASE DOMAIN BOUND TO A TYPE II DIHYDROQUINAZOLINE INHIBITOR
4774, 3rm7A, 0.7565, 3.13, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
4775, 3qzgA, 0.7565, 3.12, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
4776, 3lj2A, 0.7565, 2.46, 0.219, 404, 237, IRE1 COMPLEXED WITH JAK INHIBITOR I
4777, 2xneA, 0.7565, 2.69, 0.236, 246, 242, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
4778, 2x7fC, 0.7565, 2.73, 0.236, 285, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4779, 2qlqB, 0.7565, 2.14, 0.348, 248, 233, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
4780, 2p0cB, 0.7565, 2.42, 0.349, 248, 235, CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER
4781, 2brbA, 0.7565, 3.29, 0.257, 272, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4782, 1yxsA, 0.7565, 2.83, 0.180, 274, 245, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
4783, 6bu6D, 0.7564, 3.46, 0.163, 318, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4784, 5uorA, 0.7564, 2.45, 0.306, 249, 235, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4785, 4hokM, 0.7564, 3.54, 0.181, 291, 259, CRYSTAL STRUCTURE OF APO CK1E
4786, 3qzhA, 0.7564, 3.11, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
4787, 2qodA, 0.7564, 2.84, 0.328, 274, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
4788, 6b2qC, 0.7563, 2.77, 0.252, 264, 242, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4789, 5x3fB, 0.7563, 3.19, 0.191, 348, 251, CRYSTAL STRUCTURE OF THE YGJG-PROTEIN A-ZPA963-PKA CATALYTIC DOMAIN
4790, 5w7tA, 0.7563, 3.10, 0.267, 276, 247, STRUCTURE OF PHOSPHORYLATED WNK1 
4791, 5nzzE, 0.7563, 3.24, 0.217, 343, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4792, 5my8A, 0.7563, 3.54, 0.176, 355, 255, CRYSTAL STRUCTURE OF SRPK1 IN COMPLEX WITH SPHINX31
4793, 4gt3A, 0.7563, 3.27, 0.227, 347, 251, ATP-BOUND FORM OF THE ERK2 KINASE
4794, 5kx8B, 0.7562, 3.02, 0.241, 278, 241, IRAK4-INHIBITOR CO-STRUCTURE
4795, 4xv1B, 0.7562, 2.44, 0.277, 249, 238, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7904
4796, 4lv8A, 0.7562, 3.40, 0.163, 360, 257, MURINE IRGA6 BOUND TO TOXOPLASMA ROP5C A PSEUDOKINASE GDI
4797, 4ksqB, 0.7562, 2.62, 0.274, 255, 241, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR 5B
4798, 3c9wB, 0.7562, 2.92, 0.230, 336, 244, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
4799, 2izrA, 0.7562, 3.60, 0.162, 298, 259, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4800, 1erkA, 0.7562, 3.42, 0.201, 357, 254, STRUCTURE OF SIGNAL-REGULATED KINASE
4801, 6gt1D, 0.7561, 2.74, 0.236, 260, 242, NEK7 BOUND TO PURINE INHIBITOR 
4802, 5xv7A, 0.7561, 3.54, 0.180, 350, 255, SRPK1 IN COMPLEX WITH ALECTINIB
4803, 4qp8A, 0.7561, 2.79, 0.226, 335, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
4804, 4nfmA, 0.7561, 3.40, 0.180, 293, 255, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
4805, 4hnfA, 0.7561, 3.49, 0.187, 289, 257, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
4806, 4xhlA, 0.7560, 3.32, 0.162, 330, 253, STRUCTURE OF S. CEREVISIAE HRR25 1-394 (K38R MUTANT)
4807, 4l42A, 0.7560, 3.12, 0.258, 299, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
4808, 4kb8C, 0.7560, 3.32, 0.198, 277, 252, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4809, 3ii5B, 0.7560, 2.76, 0.272, 257, 243, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
4810, 3a99A, 0.7560, 2.87, 0.188, 273, 245, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
4811, 5k76A, 0.7559, 2.93, 0.233, 270, 240, IRAK4 IN COMPLEX WITH COMPOUND 28
4812, 5csxA, 0.7559, 3.00, 0.280, 261, 246, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
4813, 4mh7A, 0.7559, 2.16, 0.352, 248, 230, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1896
4814, 3s00A, 0.7559, 3.15, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L4-14
4815, 3r28A, 0.7559, 3.09, 0.265, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
4816, 6aydA, 0.7558, 2.80, 0.184, 272, 244, PIM1 COMPLEXED WITH N-(6-(4-HYDROXYPHENYL)-1H-INDAZOL-3-YL) CYCLOPROPANECARBOXAMIDE
4817, 4hniA, 0.7558, 3.30, 0.194, 284, 253, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
4818, 4aguB, 0.7558, 2.62, 0.214, 276, 238, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
4819, 3vn9A, 0.7558, 3.21, 0.249, 291, 253, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
4820, 3r1sA, 0.7558, 3.15, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
4821, 2i6lA, 0.7558, 2.75, 0.212, 292, 241, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
4822, 1pxlA, 0.7558, 3.02, 0.264, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
4823, 5oopA, 0.7557, 3.23, 0.226, 261, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
4824, 5l2qC, 0.7557, 2.67, 0.202, 282, 243, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
4825, 4kbaC, 0.7557, 3.36, 0.209, 277, 253, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4826, 2qlqA, 0.7557, 2.05, 0.343, 245, 230, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
4827, 2c6iA, 0.7557, 3.13, 0.262, 292, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4828, 1ywvA, 0.7557, 2.83, 0.180, 274, 245, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
4829, 5ieyA, 0.7556, 3.06, 0.260, 286, 246, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
4830, 4zznA, 0.7556, 3.37, 0.220, 338, 254, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
4831, 4medA, 0.7556, 2.79, 0.189, 272, 244, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
4832, 4kspB, 0.7556, 2.73, 0.273, 256, 242, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4833, 4jvgA, 0.7556, 2.80, 0.279, 262, 244, B-RAF KINASE IN COMPLEX WITH BIRB796
4834, 4fv6A, 0.7556, 2.85, 0.236, 332, 242, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
4835, 3we8A, 0.7556, 2.83, 0.188, 273, 245, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
4836, 2qofA, 0.7556, 2.72, 0.314, 280, 239, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
4837, 1wbpA, 0.7556, 3.39, 0.174, 350, 253, SRPK1 BOUND TO 9MER DOCKING MOTIF PEPTIDE
4838, 1jqhB, 0.7556, 3.38, 0.296, 287, 253, IGF-1 RECEPTOR KINASE DOMAIN
4839, 5op4A, 0.7555, 3.11, 0.249, 259, 245, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
4840, 4ntsA, 0.7555, 3.12, 0.192, 341, 250, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
4841, 3royA, 0.7555, 3.13, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
4842, 3r6xA, 0.7555, 3.14, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
4843, 2brmA, 0.7555, 3.17, 0.219, 263, 247, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4844, 5bnjA, 0.7554, 3.45, 0.190, 343, 253, CDK8/CYCC IN COMPLEX WITH 8-{3-CHLORO-5-[4-(1-METHYL-1H-PYRAZOL-4-YL)- PHENYL]-PYRIDIN- 4-YL}-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
4845, 4xneA, 0.7554, 3.37, 0.202, 344, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4846, 4xh0A, 0.7553, 3.29, 0.159, 350, 252, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (SO4 CONDITION)
4847, 4bf2B, 0.7553, 2.71, 0.305, 252, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4848, 3p08B, 0.7553, 2.98, 0.318, 258, 242, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
4849, 5v24A, 0.7552, 2.67, 0.307, 249, 238, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4850, 5v19A, 0.7552, 2.58, 0.300, 250, 237, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4851, 5n4oA, 0.7552, 2.76, 0.181, 271, 243, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE (E)-3-(P-TOLYL)ACRYLIC ACID
4852, 5k0kB, 0.7552, 2.10, 0.349, 248, 229, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2434
4853, 5idnA, 0.7552, 3.12, 0.198, 336, 247, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (3-METHYL-1H-PYRAZOLO[34-B]PYRIDIN-5-YL)-METHANONE
4854, 4rc3A, 0.7552, 2.75, 0.189, 271, 243, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
4855, 4l3jA, 0.7552, 3.00, 0.260, 291, 246, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
4856, 4kd1A, 0.7552, 3.16, 0.261, 298, 249, CDK2 IN COMPLEX WITH DINACICLIB
4857, 3r73A, 0.7552, 3.15, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
4858, 3qyzA, 0.7552, 3.39, 0.220, 339, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4859, 3qywA, 0.7552, 3.40, 0.220, 340, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4860, 3my0J, 0.7552, 2.27, 0.274, 252, 234, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4861, 2qooA, 0.7552, 2.86, 0.324, 273, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
4862, 4jvgB, 0.7551, 2.80, 0.284, 259, 243, B-RAF KINASE IN COMPLEX WITH BIRB796
4863, 4fv8A, 0.7551, 2.74, 0.232, 333, 241, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
4864, 3r8uA, 0.7551, 3.18, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
4865, 3r7vA, 0.7551, 3.15, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
4866, 3pj1A, 0.7551, 2.30, 0.331, 241, 236, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 3-(26-DICHLORO- PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-1-METHYL-34- DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
4867, 5wngB, 0.7550, 2.82, 0.198, 365, 243, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
4868, 4r5yB, 0.7550, 2.83, 0.276, 254, 243, THE COMPLEX STRUCTURE OF BRAF V600E KINASE DOMAIN WITH A NOVEL BRAF INHIBITOR
4869, 6cnxA, 0.7549, 3.58, 0.158, 322, 260, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
4870, 5vc6A, 0.7549, 2.92, 0.199, 259, 246, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
4871, 5tkxA, 0.7549, 3.60, 0.139, 315, 259, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
4872, 4tw9B, 0.7549, 3.44, 0.204, 289, 255, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
4873, 4bkyA, 0.7549, 2.45, 0.278, 311, 237, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH PYRROLOPYRAZOLE INHIBITOR
4874, 3uohB, 0.7549, 2.81, 0.240, 264, 242, AURORA A IN COMPLEX WITH RPM1722
4875, 3uohA, 0.7549, 2.81, 0.240, 264, 242, AURORA A IN COMPLEX WITH RPM1722
4876, 4fsuA, 0.7548, 3.22, 0.256, 260, 246, CRYSTAL STRUCTURE OF THE CHK1
4877, 4erwA, 0.7548, 3.18, 0.262, 292, 248, CDK2 IN COMPLEX WITH STAUROSPORINE
4878, 4enyA, 0.7548, 2.64, 0.196, 261, 240, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
4879, 5ukfA, 0.7547, 3.63, 0.149, 322, 262, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4880, 4lggB, 0.7547, 2.01, 0.326, 245, 230, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4881, 4h3pD, 0.7547, 2.98, 0.220, 338, 246, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
4882, 4g6nA, 0.7547, 3.39, 0.220, 341, 254, CRYSTAL STRUCTURE OF THE ERK2
4883, 3r63A, 0.7547, 3.46, 0.220, 347, 255, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
4884, 1y8yA, 0.7547, 3.11, 0.258, 292, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
4885, 6b5jB, 0.7546, 2.79, 0.268, 264, 239, TNNI3K COMPLEXED WITH A 46-DIAMINOPYRIMIDINE
4886, 6b5jA, 0.7546, 2.76, 0.265, 263, 238, TNNI3K COMPLEXED WITH A 46-DIAMINOPYRIMIDINE
4887, 5w7tB, 0.7546, 3.20, 0.262, 276, 248, STRUCTURE OF PHOSPHORYLATED WNK1 
4888, 5lckA, 0.7546, 3.35, 0.221, 345, 253, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
4889, 4yp8B, 0.7546, 2.97, 0.245, 278, 241, IRAK4-INHIBITOR CO-STRUCTURE
4890, 3r1yA, 0.7546, 3.18, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
4891, 3dtcA, 0.7546, 2.36, 0.342, 245, 234, CRYSTAL STRUCTURE OF MIXED-LINEAGE KINASE MLK1 COMPLEXED WITH COMPOUND 16
4892, 2o63A, 0.7546, 2.85, 0.184, 274, 245, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
4893, 2j4zA, 0.7546, 2.88, 0.221, 263, 244, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
4894, 1pxmA, 0.7546, 3.05, 0.260, 290, 246, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
4895, 1pxjA, 0.7546, 3.17, 0.257, 294, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
4896, 6b2qA, 0.7545, 2.73, 0.257, 261, 241, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4897, 5c9cA, 0.7545, 2.83, 0.272, 254, 243, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4898, 4ficB, 0.7545, 1.97, 0.348, 245, 230, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
4899, 3uo6A, 0.7545, 2.73, 0.241, 264, 241, AURORA A IN COMPLEX WITH YL5-083
4900, 3r8vA, 0.7545, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
4901, 3r7eA, 0.7545, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
4902, 3qx4A, 0.7545, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
4903, 3qqfA, 0.7545, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR L1
4904, 3comB, 0.7545, 3.40, 0.193, 279, 254, CRYSTAL STRUCTURE OF MST1 KINASE
4905, 2z7lA, 0.7545, 3.31, 0.211, 329, 251, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
4906, 2w1eA, 0.7545, 2.68, 0.220, 252, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4907, 2c3jA, 0.7545, 3.08, 0.250, 257, 244, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4908, 1yi4A, 0.7545, 2.77, 0.185, 267, 243, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
4909, 5o2cA, 0.7544, 3.20, 0.276, 368, 250, CRYSTAL STRUCTURE OF WNK3 KINASE AND CCT1 DIDOMAIN IN A UNPHOSPHORYLATED STATE
4910, 3uo6B, 0.7544, 2.73, 0.241, 264, 241, AURORA A IN COMPLEX WITH YL5-083
4911, 3s0oA, 0.7544, 3.08, 0.247, 293, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
4912, 4rvkA, 0.7543, 3.26, 0.263, 264, 247, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
4913, 4ftiA, 0.7543, 3.26, 0.259, 270, 247, CRYSTAL STRUCTURE OF THE CHK1
4914, 3nw6A, 0.7543, 3.14, 0.302, 301, 248, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
4915, 3h0zA, 0.7543, 2.50, 0.244, 248, 238, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4916, 4qp3A, 0.7542, 3.13, 0.206, 339, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
4917, 4q5jA, 0.7542, 2.69, 0.235, 282, 238, CRYSTAL STRUCTURE OF SEMET DERIVATIVE BRI1 IN COMPLEX WITH BKI1
4918, 3tkiA, 0.7542, 3.25, 0.255, 272, 247, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
4919, 3en7A, 0.7542, 2.15, 0.351, 247, 231, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
4920, 5oorA, 0.7541, 3.16, 0.252, 273, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
4921, 4rvmA, 0.7541, 3.26, 0.255, 264, 247, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
4922, 4fk3A, 0.7541, 2.72, 0.277, 251, 242, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4923, 3r8mA, 0.7541, 2.99, 0.256, 286, 246, CDK2 IN COMPLEX WITH INHIBITOR L3-3
4924, 4ibmB, 0.7540, 3.07, 0.325, 294, 249, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
4925, 4c3rA, 0.7540, 2.69, 0.199, 252, 241, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
4926, 3rpoA, 0.7540, 3.17, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
4927, 3qwjA, 0.7540, 3.16, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
4928, 2c47D, 0.7540, 3.31, 0.190, 290, 253, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4929, 6g9kA, 0.7539, 3.34, 0.206, 343, 252, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4930, 5uu1A, 0.7538, 3.53, 0.140, 315, 258, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
4931, 4ux9C, 0.7538, 2.86, 0.213, 333, 244, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4932, 3raiA, 0.7538, 3.17, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
4933, 3pxfA, 0.7538, 3.51, 0.253, 302, 253, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
4934, 6g9jA, 0.7537, 3.30, 0.227, 347, 251, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4935, 5wg3A, 0.7537, 3.22, 0.186, 618, 253, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG258748
4936, 5uisC, 0.7537, 2.78, 0.244, 270, 238, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 12
4937, 5oprA, 0.7537, 3.08, 0.254, 258, 244, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
4938, 4ithB, 0.7537, 2.77, 0.252, 270, 238, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
4939, 4fsnA, 0.7537, 3.23, 0.256, 270, 246, CRYSTAL STRUCTURE OF THE CHK1
4940, 3uixA, 0.7537, 2.70, 0.187, 266, 241, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4941, 3lj0A, 0.7537, 2.65, 0.218, 404, 239, IRE1 COMPLEXED WITH ADP AND QUERCETIN
4942, 1pf8A, 0.7537, 3.07, 0.253, 298, 245, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
4943, 3k54A, 0.7536, 2.46, 0.312, 243, 237, STRUCTURES OF HUMAN BRUTON S TYROSINE KINASE IN ACTIVE AND INACTIVE CONFORMATIONS SUGGESTS A MECHANISM OF ACTIVATION FOR TEC FAMILY KINASES.
4944, 5j8iA, 0.7535, 2.47, 0.266, 288, 237, CRYSTAL STRUCTURE OF TL11-113 BOUND TO TAK1-TAB1
4945, 4yffD, 0.7535, 2.71, 0.256, 257, 238, TNNI3K COMPLEXED WITH INHIBITOR 2
4946, 4yffC, 0.7535, 2.71, 0.256, 258, 238, TNNI3K COMPLEXED WITH INHIBITOR 2
4947, 4x7qB, 0.7535, 2.43, 0.208, 243, 236, PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
4948, 4kaoA, 0.7535, 2.71, 0.342, 252, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4949, 4h58C, 0.7535, 2.86, 0.262, 272, 244, BRAF IN COMPLEX WITH COMPOUND 3
4950, 3qx2A, 0.7535, 3.17, 0.253, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
4951, 3c4cB, 0.7535, 2.64, 0.274, 257, 241, B-RAF KINASE IN COMPLEX WITH PLX4720
4952, 2c6mA, 0.7535, 3.15, 0.262, 290, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4953, 5op5A, 0.7534, 3.18, 0.248, 259, 246, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
4954, 5o26A, 0.7534, 3.26, 0.255, 271, 251, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
4955, 5o11A, 0.7534, 2.66, 0.183, 268, 240, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4956, 4qp7B, 0.7534, 2.78, 0.215, 335, 242, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
4957, 3q96B, 0.7534, 2.76, 0.277, 262, 242, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4958, 2e9pA, 0.7534, 3.34, 0.225, 269, 249, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
4959, 2c6kA, 0.7534, 3.13, 0.262, 292, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4960, 4xv9A, 0.7533, 2.75, 0.272, 261, 243, B-RAF KINASE DOMAIN IN COMPLEX WITH PLX5568
4961, 4g6oA, 0.7533, 3.40, 0.218, 339, 252, CRYSTAL STRUCTURE OF THE ERK2
4962, 4bl1A, 0.7533, 2.54, 0.277, 312, 238, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH AMP-PNP
4963, 3qwkA, 0.7533, 3.20, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
4964, 3pxzA, 0.7533, 3.52, 0.253, 302, 253, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
4965, 2x7fA, 0.7533, 2.70, 0.237, 276, 240, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4966, 2v0dA, 0.7533, 3.14, 0.262, 292, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
4967, 3repA, 0.7532, 3.10, 0.265, 268, 249, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
4968, 3pj3A, 0.7532, 2.19, 0.322, 240, 233, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-METHYL-5-[(E)- (3-PHENYL-ACRYLOYL)AMINO]-N-(2-PHENYL-3H-IMIDAZO[45-B]PYRIDIN-6-YL)- BENZAMIDE
4969, 2o65A, 0.7532, 2.88, 0.184, 274, 245, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
4970, 2bikB, 0.7532, 2.80, 0.184, 272, 244, HUMAN PIM1 PHOSPHORYLATED ON SER261
4971, 5vc5A, 0.7531, 2.97, 0.198, 261, 247, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
4972, 5valB, 0.7531, 2.77, 0.260, 254, 242, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4973, 5myvA, 0.7531, 3.52, 0.165, 352, 254, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
4974, 5ievA, 0.7531, 3.05, 0.261, 284, 245, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
4975, 5byyA, 0.7531, 3.20, 0.239, 338, 251, ERK5 IN COMPLEX WITH SMALL MOLECULE
4976, 3zhpC, 0.7531, 2.98, 0.244, 272, 246, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
4977, 3pxrA, 0.7531, 3.17, 0.261, 294, 249, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
4978, 3lj0B, 0.7531, 2.57, 0.214, 399, 238, IRE1 COMPLEXED WITH ADP AND QUERCETIN
4979, 4kbkA, 0.7530, 3.46, 0.206, 283, 253, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4980, 4jvgC, 0.7530, 2.78, 0.281, 258, 242, B-RAF KINASE IN COMPLEX WITH BIRB796
4981, 4iaaA, 0.7530, 2.81, 0.189, 272, 244, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
4982, 4fuyA, 0.7530, 3.19, 0.226, 329, 248, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
4983, 3twjB, 0.7530, 2.95, 0.201, 395, 244, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
4984, 2w1dA, 0.7530, 2.66, 0.221, 251, 240, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4985, 1v0oB, 0.7530, 2.94, 0.243, 274, 243, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
4986, 6cmmB, 0.7529, 3.43, 0.156, 310, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
4987, 5nudB, 0.7529, 2.88, 0.385, 271, 244, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
4988, 4xrjA, 0.7529, 3.25, 0.197, 344, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
4989, 4s2zA, 0.7529, 3.55, 0.219, 346, 256, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
4990, 3we4A, 0.7529, 3.06, 0.260, 286, 246, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
4991, 3nw7A, 0.7529, 3.15, 0.304, 297, 247, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
4992, 4umpB, 0.7528, 3.05, 0.252, 324, 246, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4993, 4aotA, 0.7528, 3.04, 0.260, 278, 242, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
4994, 3r7yA, 0.7528, 3.21, 0.261, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
4995, 3qrtA, 0.7528, 3.19, 0.257, 294, 249, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
4996, 3kmwA, 0.7528, 3.11, 0.265, 268, 249, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
4997, 2oj9A, 0.7528, 3.30, 0.293, 295, 249, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
4998, 5osmA, 0.7527, 3.22, 0.261, 292, 249, CDK2(F80C C177A) WITH COVALENT ADDUCT AT C80
4999, 5nzzF, 0.7527, 2.99, 0.216, 341, 245, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
5000, 5gjgA, 0.7527, 2.70, 0.282, 289, 241, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 4
